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Humans are exposed throughout their entire life to multitude of diverse xenobiotic 
compounds, such as industrial chemicals and pharmaceuticals. This exposure is either 
intended, e.g. when prescribed as drug, or unintended, e.g. as contaminants in food or the 
environment. Xenobiotic exposure may pose health risks; when a hazardous concentration 
is reached adverse biological effects may occur. Toxicological research aims to identify 
these adverse health effects (hazard) and compare hazard threshold levels with real-life 
exposure levels to estimate the risk associated with actual exposure. The liver is one of the 
major targets of toxicological effects, because it is the first organ to be encountered after 
absorption from the gastro-intestinal tract, and it is therefore important to assess hepatotoxic 
properties of xenobiotics that humans are exposed to1. Traditionally hepatotoxicity is 
studied mainly in animal studies, but observations in animal exposure studies appeared 
to be not fully predictive for the effects in humans2. The predictivity of animal studies is 
limited mainly by physiological differences between species, leading to differences in 
toxicokinetic fate, i.e. absorption, distribution, metabolism, and excretion of the xenobiotic, 
and differences in sensitivity of target cells2. These differences are the cause of uncertainties 
associated with extrapolation from animal to man and from short-term to long-term 
exposure. Thus, effects that occur in humans may remain undetected in animals. Therefore, 
there is an imperative need to improve toxicological testing, and develop strategies that 
do not rely on traditional testing in rodents. Development of new screening methods 
should build on new in silico and in vitro methods, which can also help to implement the 
3R strategy to Replace, Reduce and Refine the use of animals. An approach is to analyze 
the molecular mechanisms that underlay toxicological effects facilitating comparison across 
models and species, through the use of ‘omics-technologies’. A promising alternative 
testing model is the zebrafish embryo, which we evaluate here for its application in 
hepatotoxicity testing through the use of several toxicogenomics tools. 
The liver as critical target organ for toxicity 
The liver is an important target for adverse effects of xenobiotics, as it is the first organ to 
pass after enteric absorption, positioned between the gastro-intestinal tract and systemic 
circulation. The liver has metabolic activity, which allows deactivation or detoxication of 
xenobiotics, thereby facilitating their excretion. This process is called biotransformation, 
which is a multistep process including Phase I and Phase II metabolism. Phase I metabolism 
can be divided into by three steps including modification, oxidation and reduction 
preparing the xenobiotics for Phase II metabolism. In Phase II metabolism, the xenobiotics 
are conjugated resulting in clearance3. Due to the position of the liver and its metabolic 
function, it serves as a ‘first pass’ organ resulting in relatively high concentrations of 
xenobiotics that depend on oral uptake. This may lead to toxic activity of the xenobiotic 
and thereby to the induction of liver injury1,4–6. 
The liver consists of several cell types. Hepatocytes are the most predominant cell type, 









Furthermore, all of these compounds are frequently used in in vivo and in vitro studies to 
induce cholestasis1,12,15–17. 
Several studies have shown that these model compounds are able to induce cholestasis 
in a wide variety of models including in vivo mouse and rats, and also in vitro mouse liver 
slices, primary hepatocytes and many more. 
Steatosis. Fat metabolism is another important function of the liver, specifically through 
fatty acid synthesis and promoting lipid circulation by lipoprotein synthesis1,3. Changes in 
fat metabolism may result from an increase in uptake of lipids, elevation of the de novo 
synthesis of fatty acids, an impairment of lipoprotein synthesis/secretion, and/or a 
reduction in fatty acid oxidation19. The accumulation of cytoplasmic fatty acids in the 
form of lipid droplets is known as steatosis11,19. Disrupted fat metabolism is manifested as 
Furthermore, they express a wide scale of circulating plasma proteins including albumin1,3,7. 
Less than 40% of the liver is comprised of sinusoid endothelial cells, Kuppfer cells, and 
stellate cells1,3,7. Sinusoidal endothelial cells are the largest group of non-parenchymal cells 
compromising around 19% of the total liver cell mass. These cells are a physical barrier for 
blood circulation allowing the interchange of nutrients, toxicants, hormones and other 
molecules from the plasma to the hepatotocytes. In addition, these cells play an important 
role in the inflammatory reactions7,8. Kuppfer cells compromise 15% of the total liver mass 
and in healthy situations these cells are present as resting macrophages. However, upon 
activation, for example due to liver damage, these cells will excrete pro-inflammatory 
cytokines potentially aggravating the damage in the hepatocytes and promoting the 
pro-apoptotic responses7,9,10. Stellate cells are the smallest non-parenchymal cells in the 
liver, only compromising 6% of the total liver mass. Their function in the liver is to store 
vitamin A, however, under toxic stress these cells have various other functions including 
the secretion of chemokines and activation of natural killer cells7. This shows that 
hepatotoxicity may occur through interaction of a xenobiotic with various cell types 
within the liver. Depending on the toxic functions and pathways that are activated, 
xenobiotic interaction may lead to a variety of liver pathologies including cholestasis 
(intra- or extracellular bile accumulation), steatosis (fatty liver), and necrosis (cell death)1,4,6,11. 
These specific toxic phenotypes are explained below in more detail, together with actions 
of some reference toxicants. 
Cholestasis. Cholestasis is one of the main xenobiotic-induced liver pathologies resulting 
from either impairment in bile secretion or obstruction in bile flow12–14. Bile and bile acids 
are not only important for the digestion of fat from the diet, but also for the clearance 
of xenobiotics from the liver1. Cholestasis occurs when there is either an impaired bile 
transport or an inhibition of bile transporters12. Several drugs are known to induce 
cholestasis via different molecular mechanisms. 
First, 17α-ethinylestradiol (EE2), a synthetic estrogen derivative, is used in combined oral 
contraceptive pills, which reduces bile flow by inhibiting bile acid active transporters at 
the hepatic canalicular membrane. EE2 also increases the permeability of cells in the bile 
ductules elevating the reabsorption of bile components1,15. 
Second, cyclosporine A (CsA) is widely used as an immunosuppressant in organ transplantation 
to avoid rejection. In humans, it induces cholestasis by interacting with and inhibiting the 
bile transporter, also known as the bile salt export pump (BSEP)12.
Third, chlorpromazine (CPZ) is used to treat acute and chronic psychoses16. CPZ induces 
cholestasis by directly acting at the intracellular membrane thereby decreasing bile 
acid-dependent bile flow resulting in a loss of bile acids via defective bile canaliculi. 
In addition, the Na+/K+ pump and hydroxylation of cholesterol to bile acids are inhibited 
by CPZ16. 
Figure 1  Toxicity pathway of cholestasis. 
Cyclosporine A (CsA) and 17α-ethinylestradiol (EE2) block the transporters regulating bile flow from 
hepatocyte to bile duct (bile salt pump (BSEP) and multidrug resistance protein 1 (MDR1)), resulting 
in accumulation of bile in the hepatocyte. Chlorpromazine (CPZ) and EE2 act on the uptake 
transporters Na+-dependent taurocholic cotransporting polypeptide (NTCP) and organic anion- 
transporting polypeptide (OATP), but also inhibit the excretion transporters BSEP and MDR1. This 
inhibition of bile acid excretion leads to accumulation of intracellular bile acids. Cholesterol is known 
to be converted to bile acids by cytochrome P450 CYP7A1 into bile acids, which in turn activate 
pregnane X receptor (PXR) leading to an increase in expression of MDR1 and OATP (Adapted from 























regulating the peroxisome proliferator activated receptors (PPARs), which are involved in 
the development of steatosis through their important role in lipid deposition21,22. 
Valproic acid (VPA) is an antiepileptic agent, used to treat specific types of seizures. VPA 
hepatotoxicity is believed to be mediated by either an inhibitory effect on the mitochondrial 
β-oxidation pathway, which gives rise to microvesicular steatosis, or by metabolic effects 
which promote weight gain and insulin resistance giving rise to macrovesicular steatosis 
and steatohepatitis23. 
Studies have shown that VPA and TET induce steatosis in mice through an increase in 
cholesterol and triglyceride biosynthesis and a decrease in fatty acid oxidation22,24,25. 
Furthermore, AMD has been found to promote steatosis in mice through altering lipid 
homeostasis in the liver20. 
Necrosis. Necrosis, or cell death, is caused by severe metabolic perturbations resulting in 
ATP depletion. Diminished levels of ATP breakdown and cytoskeleton integrity, which 
results in the characteristic morphology of cell swelling accompanied by membrane 
blebbing11. Furthermore, mitochondrial permeability transition (MPT) plays an important 
role in necrosis. MPT is known to lead to either necrosis or apoptosis after mitochondrial 
oxidative stress7,27. Known drugs or compounds that induce necrosis are acetaminophen 
(APAP), paraquat (PQ) and thioacetamide (TAA). 
Acetaminophen (paracetamol; APAP) is an analgesic and antipyretic, which is considered 
safe at therapeutic doses. In this setting, APAP is inactivated by sulfation and glucuronida-
tion. However, when therapeutic doses are exceeded, APAP causes hepatic damage and 
may eventually lead to liver failure. APAP toxicity is due to its active metabolic conversion 
by CYP2E1 to the highly toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). In 
normal situations, NAPQI is conjugated to reduced glutathione and is excreted the bile. 
However, when therapeutic doses are exceeded, NAPQI concentrations increase due to 
saturation of the sulfation and glucuronidation pathways. Hepatotoxicity occurs when 
NAPQI binds to macromolecules, for example in the mitochondria, which leads to 
mitochondrial dysfunction and DNA damage11,28,29. 
Paraquat (PQ), a contact herbicide, is a dehydrate and defoliant used for harvesting cotton, 
potatoes, and soy beans. PQ is a bipyridyl derivative, which can be taken up by the redox 
cycle leading to the release of active oxygen radicals, which in turn can induce damage to 
the hepatocyte30. 
Thioacetamide (TAA) was formerly used as a fungicide. The underlying mechanism of 
hepatotoxicity of this compound appears to be its metabolism via CYP2E1. TAA is 
metabolized to di-S-oxide (CH3-C(SO2)NH2), which is a reactive intermediate that 
covalently binds to hepatic macromolecules resulting in necrosis31
either microvesicular (multiple small vacuoles in the hepatocytes) or macrovesicular 
steatosis (larger vacuoles that dislocate the nucleus from the center of the cell). Several 
drugs and chemicals are known to induce steatosis in humans including amiodarone 
(AM), tetracycline (TET), and valproic acid (VPA). 
Amiodarone (2-butyl-3-benzofuranyl 4-[2-(diethylamino)etoxcy]-3,5-diiodophenyl ketone; 
AM) is a frequently prescribed antiarrythmic agent, to prevent atrial fibrillation. AM induces 
steatosis in humans, and also in rodent models, probably through inhibiting mitochondrial 
β-oxidation of long-, medium-, and short-chain fatty acids. Furthermore, this compound 
inhibits carnitine palmitoyltransferase-I (CPTI)-dependent transport of long-chain fatty acids 
across the mitochondrial membrane 20 resulting in fatty acid accumulation in hepatocytes.
Tetracycline is a frequently used antibiotic, to fight infections with both gram-positive and 
gram-negative bacteria. Tetracycline induces microvesicular steatosis in the liver by down- 
Figure 2  Toxicity pathway of steatosis. 
Sources of fatty acids (FA) are triacylglycerol (TAG) and chylomicrons (CM). TAG is exported out of the 
hepatocytes in the form of very low density lipoproteins (VLDL). Tetracycline (TET) induces steatosis 
by downregulation of nuclear receptors including liver X receptor (LXR) and peroxisome proliferator 
receptors (PPARs) and their target genes sterol regulatory element-binding protein 1c (SREBP-1c) and 
carbohydrate response element-binding protein (chREBP); this in turn leads to an increase in fatty 
acids (FA) level. Valproic acid (VPA) and amiodarone (AM) inhibit the β-oxidation cycle resulting in 
decreased metabolism of fatty acids, which then accumulate in the hepatocyte (Adapted from 























of xenobiotics. Currently, multiple alternatives are available for hepatotoxicity testing, including 
single liver cell systems, liver slices and whole organisms7,11. 
The in vitro cell system of primary hepatocytes is one of the most prominent models for 
studying hepatotoxicity and allows for easy interspecies comparison7,11,37. Generally, these 
cells maintain expression of Phase I and Phase II metabolic enzyme activities for longer 
periods of time, however, they are not fully representative of the in vivo liver due to a loss 
of original cell shape and a deviating gene expression response to xenobiotics7,11,37. 
Alternatively, several permanent, immortalized cell models are available for toxicity 
screening. Of these, the frequently used human hepatocarcinoma derived HepG2 cell line 
has a long history in xenobiotics testing. The advantage of this cell line is that it provides 
an infinite reservoir of identical cells7,11,37. HepG2 cells show activity of several Phase I and 
Phase II metabolic enzymes, however, not all metabolizing enzymes are present and 
otherwise the expression level is generally much lower than in the in vivo situation or 
primary human hepatocyes, leading to a different response after compound exposure7,11,37. 
However, recent advances allowed to improve the expression of Phase I enzymes in the 
HepG2 cells constructing Adv-HepG2 cell line38.
Hepatotoxicity testing
Traditionally, rodent studies are used to predict the hepatotoxic effects of xenobiotics. 
As introduced above, an important scientific argument against the use of rodent studies 
is that the obtained effects are not always fully predictive for the effects in humans2. 
In general, animal studies are helpful to identify human toxicants, but particularly in the 
case of hepatotoxicity, the identification remains low due to a poor correlation between 
human and animals2,7,11. Missed hepatotoxic effects in traditional screening assays is a 
major cause of the high attrition rate in drug development and therewith associated with 
high cost1,4,6. From the perspective of animal welfare it is unfavorable that animals need 
to be exposed to high doses of compounds for extended periods of time. Therefore, there 
is an imperative need to develop alternative models to assay the hepatotoxic potential 
Figure 3  Toxicity pathway of hepatic necrosis.
Necrosis is the consequence of induction of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), which eventually leads to a decrease of glutathione (GSH). GSH depletion eventually 
leads excess of ROS/RNS, oxidative damage and hence to cell death. Acetaminophen (APAP) induces 
ROS/RNS through its toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) to which it is 
converted by cytochrome P450 (CYP) enzymes. Thioacetamide (TAA) is also metabolised by CYP 
enzymes to a reactive metabolite which increases the ROS production. Mechanism of paraquat (PQ) 
is not completely understood, but it probably also induces an increase in ROS production. One 
important damaging action of ROS/RNS is the decrease of mitochondrial permeability transition 
(MPT) leading to loss of ATP, which contributes to cell death. Kupffer cells secrete cytokines which 
may aggravate ROS/RNS production leading to cell death (Adapted from Hinson et al. (2010) and 
Jaeschke et al. (2012) 32,33)
Table 1  Reference compounds and phenotypes.
Phenotype Compound Proposed mechanism of action References
Cholestasis 17α-ethinylestradiol Inhibition of bile acid transporters Wagner et al.,12,34
Cyclosporine A Inhibition of BSEP Antherieu et al.,12
Chlorpromazine Decreases bile acid dependent  
bile flow
Yamamoto et al,.16
Steatosis Amiodarone Inhibition of mitochondrial 
β-oxidation and CPTI  
dependent transport
Anderson and Borlak19
Tetracycline Down-regulation of PPARs which 
play a role in lipid desposition
Yin et al.,21,22
Valproic acid Inhibition of mitochondrial 
β-oxidation
Silva et al.,23
Necrosis Acetaminophen CYP2E1 metabolism releasing 
NAPQI (toxic metabolite) inducing 
mitochondrial dysfunction
McGill et al.35
Paraquat Taken up by redox cycle inducing 
release of active oxygen radicals
Burk et al., and Bus  
and Gordon30,36
Thioacetamide Metabolism via CYP2E1 resulting  
in reactive intermediate
Hunter et al.,31
































The zebrafish embryo and hepatotoxicity testing. While most of the important 
cytochromes are present in the zebrafish embryo, this model might be suitable to detect 
hepatotoxicity. Some studies showed that zebrafish embryos are suitable to detect hepa-
totoxicants. In a study by Jones et al., the whole zebrafish embryo model was evaluated 
through morphological endpoints after exposure to a set of compounds, including falsely 
classified DILI drugs by HepG2 cells. In this study, the whole zebrafish embryo model 
successfully detected hepatotoxicants with higher specificity than the HepG2 cells49. In 
another study, Amali et al., carried out histopathological, molecular and biochemical 
analysis in zebrafish embryos exposed to a single dose of thioacetamide and showed that 
the whole zebrafish embryo model is suitable to detect steatohepatitis57. These studies 
indicate the potential of the zebrafish embryo as a model for hepatotoxicity testing at the 
level of the phenotype, but they provide limited insights into the underlying mechanisms 
of toxicity58. Toxicogenomics is hypothesized to contribute understanding of the 
underlying mechanisms of hepatotoxicity and discrimination between various hepatotoxic 
phenotypes, such as cholestasis, steatosis and necrosis.
Toxicogenomics
For drug development, understanding the mechanism of toxicity is imperative, not only 
to compare between reference toxicants and test compounds, but also to differentiate 
between toxic and targeted effects, and to develop relevant markers of toxicity. The 
method to analyze and describe mechanisms of toxicity comprises a set of tools, which 
generally involves toxicogenomics61. 
Traditionally, hepatotoxic properties of chemicals and compounds are determined using 
rodent studies which rely on different toxicity endpoints including body and organ weight, 
death rate, serum toxicity biomarkers and histopathological changes11. Although these 
phenotypical endpoints give an indication of toxicity, they do, however, not provide insight into 
the underlying molecular mechanisms of hepatotoxicity. By applying molecular techniques, 
such as transcriptomics, proteomics and next generation sequencing, in the toxicology setting 
will provide an insight into the underlying molecular mechanisms61–63. The assumption is that 
changes in for example toxicity markers and histopathology are preceded by changes on 
gene and/or protein level after exposure to compounds. The changes in genes and/or proteins 
will provide us with a more detailed view on the onset of the toxic events. 
Transcriptomics analysis can be implemented in different ways including the use of micro 
arrays and the more recent technique next generation sequencing. Next generation 
sequencing provides multiple advantages over the traditionally used mRNA microarrays. 
In contrast to microarrays, NGS does not rely on the probe design and probe selection, 
thus enabling detection of non-predefined transcripts, including diverse splicing variants 
of a single gene.
Another advantage of the implementation of molecular techniques in toxicology research 
is that it allows the researcher to extrapolate the findings to other organisms. In the area of 
Other hepatocyte cell lines are also used, and HepaRG is an example of a recently isolated 
and cultured hepatoma cell line. Several studies have shown the presence of xenobiotic 
metabolizing enzymes, much similar to the primary hepatocytes, enabling them to be 
suitable in assessing the xenobiotic compounds hepatotoxicity potential39–41. Another 
recent advancement is use of 3D cell culture systems. HepG2 cells cultured in 3D stopped 
proliferating, self-organize and differentiate to form multiple polarized spheroids acquiring 
hepatotocyte functions including glycogen storage, transportation of bile salts and the 
formation of structures resembling bile canaliculi42. 
The isolated perfused liver and liver slices are considered to be the system closest related 
to the in vivo condition, because these systems maintain 3D-architecture including bile 
flow and cell-cell interactions. Furthermore, these systems contain the non-parenchymal 
cells which have an important role in mediating the toxicity7,43. A downside of these systems 
is the relative short period of viability, limiting these models to test only compounds which 
are expected to have an effect within a few hours7,43. 
Toxicological science is in need of a model that combines these advantages and overcomes 
the drawbacks of these systems. In this respect, the zebrafish embryo could be considered 
as a complementary alternative model to screen for potential hepatotoxic compounds 
and to investigate the mechanisms by which chemicals induce liver injury44–49.
The zebrafish embryo
The zebrafish (Danio rerio) is a diploid minnow of the teleost family Cyprinidae and was 
introduced several decades ago to study development and neurobiology. Thereof, the 
zebrafish emerged as a powerful model to study human disease and the effects of 
chemical exposure45,50–53. Several features make the zebrafish embryo attractive as an 
experimental model, among which are the potential for use in a high-throughput 
screening setting and the small size of both the adult zebrafish and zebrafish embryo. 
Furthermore, maintenance in large stocks is easy due to their high fecundity. In the 
embryo, direct observation and experimental manipulation of tissue and organs is 
relatively simple due to the transparency and the rapid development. As a result of the 
rapid development, most organs become fully functional between three and five days 
post fertilization50. In addition, during the earliest developmental stages (until 
independent, free-feeding) the zebrafish embryo is not a protected animal under present 
European legislation (Directive 2010/63/EU) and can therefore be considered as an 
alternative to animal experimentation54. A fully functional liver is present in the zebrafish 
embryo by three days post fertilization, at which time it is perfused with blood. In terms of 
xenobiotic biotransformation capacity, zebrafish embryos express 94 cyps, which occur in 
the same 18 gene families as in humans, and most of them are human cyp orthologs. The 
cyp1-4 families are mainly involved in metabolizing xenobiotics, similar to humans. Most 
important is the presence of the human CYP3A4 ortholog, cyp3a65, because this cyp 









hepatotoxicity, several studies have shown that toxicogenomics can be applied to 
investigate the underlying molecular mechanisms leading to toxicity61,64. Mostly, these 
toxicogenomics techniques are applied in traditionally used models for hepatotoxicity 
including mice, rats and in vitro models64,65. With regards to the ZFE, several recent studies 
show that toxicogenomics can be applied to investigate the underlying mechanisms of 
toxicity. For example, the study of Yang et al., showed that the ZFE allows for the robust 
identification of genes to distinguish between toxicants53. More specifically, several 
 transcriptomics studies identified the underlying mechanisms of teratogenicity66–70 of 
compounds showing the suitability of applying toxicogenomics in the ZFE. Few studies 
have been performed with toxicogenomics in ZFE with regard to hepatotoxicity46,49,57. 
Nevertheless, these transcriptomics studies show that the zebrafish embryo model is 
suitable for detecting differences between chemical classes illustrating the possibilities of 
this model. Several proteomics studies have been performed in other models, such as 
in vitro and in vivo systems, to gain further insight into the differences in proteomes after 
exposure to hepatotoxicants17,71,72. These studies show the potential of this technique to 
assess the molecular mechanisms of hepatotoxicity. 
With regard to the ZFE, proteomics studies have been performed, but are mainly targeted 
at the differences between proteomes during different life-stages. Less is known about 
Table 2  Testing models for hepatotoxicity.
Model Strength Weakness
Liver slices Fairly high throughput
Retain liver structure; contain all 
cell types
Functional bile canaliculi
Good in vitro/in vivo correlation 
of xenobiotic metabolism
Maintain zone-specific CYP 
activity; maintain toxicity 
mechanisms
Stability of phase II enzymes, 
albumin production, 
gluconeogenesisis for 20-96 
hours
Cellular necrosis after 48-72 hours
CYP levels quickly decrease (6-72 hours)
Poor concordance with liver for intrinsic 
clearance rates and Km values
Diffusion-limited gradient of the exposure 




Throughput depends on 
application
Unlimited amount of cells 
available
Some cell lines retain expression 
of many liver-specific functions
Lacking most phenotypic and functional 





Better estimate of internal 
clearance than monolayer 
cultures
Retain high level of enzyme 
functionality (close to in vivo)
Loss of cell-cell interactions
Loss of cell-matrix interactions
Limited viability allows short-term use only 
(<4 hours)





Throughput depends on the 
application
Cells can re-establish cell-cell 
interactions and polarity
Cells retain some morphology 
and liver specific functionality in 
short-term cultures (2-4 days)
Induction/inhibition of the 
metabolizing enzymes can be 
studied
Inability to maintain in vivo liver-specific 
functionality for long-term culture
Quick reduction in functionality and 
phenotype (24-48 hours)





Throughput depends on the 
application 
Restores in vivo polygonal 
morphology
Better maintains liver-specific 
functionality
Prevents loss of viability
Functional bile canaliculi
Loss of liver-specific functionality, 
morphology and phenotype in long-term 
cultures
Decline in metabolic enzyme activity in 
long-term culture




Functional activities remain 
stable for long time period
Enzyme activity can be 
modulated allowing to more 
closely mimic inter-individual 
variations in xenobiotics 
metabolizing enzymes
Loss of cell-cell interactions




Ex vivo development and optical 
clarity of the embryo
Embryogenesis is completed at 
72 hpf, liver is fully functional
Biological complexity of in vivo 
models
Easy to handle and cheap
Genome of the zebrafish is 
sequenced. Molecular biology 
tools are available for genetic 
manipulation
High-throughput screening
Developmental stage of the hepatocytes
Extrapolation to human
First pass effect
Teleost fish possess two copies of many 
mammalian genes due to gene duplication 
events









UniProt (Universal Protein database) provides a freely accessible resource of protein 
sequence and functional information78,79. 
The implementation of toxicogenomics in the area of hepatotoxicity testing has advanced 
the understanding of the underlying molecular mechanisms of the different hepatotoxic 
classes65. In addition, this technique allows to extrapolate the findings to the human 
situation. 
Aim and outline of this thesis
Aim of this thesis. The hepatotoxic potential of compounds and chemicals are traditionally 
assessed using in vivo rodent studies. Since these in vivo rodents studies are associated 
with scientific issues (limited predictivity for effects in humans), economical (high costs 
due to high doses and long experimental periods), and ethical (large numbers of animals 
to be exposed), there is a need to develop and validate alternative approaches. As such, 
the zebrafish embryo is presented as an alternative test model that may replace or support 
the traditional in vivo rodent studies. This zebrafish embryo model combines the benefits 
of an in vivo model, namely biological complexity including interactions between tissues 
and cells49,54,95, with the advantages of in vitro models, that is, the ability for medium to 
high throughput testing. Therefore, the objective of this thesis is to evaluate the whole 
zebrafish embryo as an alternative model system to screen for the hepatotoxic potential of 
compounds using different “-omics” technologies including next-generation sequencing, 
 transcriptomics, and proteomics, thereby improving the prediction for effects in humans. 
To achieve this objective, a dedicated set of approaches was applied in the studies schematically 
represented in Fig. 4 and outlined below.
Outline of this thesis. First, we evaluated whether the whole zebrafish embryo can be 
used for the determination of hepatotoxicity. In Chapter 2, we determined whether 
hepatotoxicity-associated gene expression was detectable in whole zebrafish embryos 
using next-generation sequencing. 
To unravel the underlying molecular mechanisms, we investigated in Chapter 3 whether 
gene expression analysis after hepatotoxicant exposure could produce a limited set of 
informative biomarkers for human hepatotoxicity. To characterize the model even further, 
we applied proteomics in Chapter 4, to strengthen the applicability of the model. 
To assess the additonal value of the zebrafish embryo as a model for hepatotoxicity, we 
performed a meta-analysis based on gene-expression changes including different species 
in Chapter 5. 
A general discussion and possible future perspectives are discussed in Chapter 6 
including discussion on the implementation of a better toxicokinetics characterization of 
the model, while a summary is provided in Chapter 7.
the changes occurring after exposure to hepatotoxicants. The most practical way to study 
hepatic gene expression in ZFE is to use whole ZFE RNA extract for analysis, instead of liver 
extracts, but this may result in masking of signals or lowering the signal/noise ratio of the 
regulated genes. Although available, sophisticated methods such as micro-dissection to 
study hepatic gene expression in small organism hinder the throughput of the system73.
Toxicogenomics data analysis. The amount of data generated by applying these 
molecular techniques in such a toxicology experiment is enormous, and it is therefore 
imperative that the proper methods are applied which might translate to biological 
conclusions. For all the “omics-techniques” analysis, the data needs to be corrected for the 
background and normalized after the samples are either hybridized to the array 
(transcriptome) or measured by mass spectrometry (proteome). Background corrections 
are applied to improve the signal of the measurements, and thus adjust for artifacts, 
including non-specific hybridizations of the samples on the arrays or peak distributions in 
proteins74. After background correction, the data is routinely log-transformed. This 
improves the characteristics of the data distribution and enables the use of classical 
parametric statistics75,76. In the next step, the gene expression data is normalized, which 
corrects for the systematic difference between the arrays. After the preprocessing phase, 
the analysis of the data is continued by identifying the genes/proteins which differ from 
the control situation. This is mostly achieved by a selection based on significance level 
using p-values, or false discovery rate (FDR) combined with a fold change (FC). Genes/
proteins fitting the selection criteria can be visualized using different methods including 
biplots, PCA and hierarchical clustering methods. By using these available tools, it is 
possible to identify the mode-of-action of compounds. In this case, certain groups of 
compounds are used to establish a ‘fingerprint’ for certain classes of toxicity. A new 
compound can thus be identified as toxic based on the basis of overlap based on the 
fingerprint of the toxicity classes, thereby contributing to the predictive toxicology. 
To compare the results from the experiments with the literature, several databases are 
available, for example Gene Ontology77, UniProt78,79, National Center for Biotechnology 
Information (NCBI)80, comparative toxicology database81, and specific for the zebrafish is 
the Zebrafish Model Organism Database from the Zebrafish Information Network (ZFIN)82. 
Identification of genes which differ from the control situation is not enough to improve 
the understanding of the molecular mechanism behind the toxic event. Therefore, the 
genes are tested for overrepresentation in certain biological processes (Gene Ontology77) 
or pathways (KEGG, Wikipathways, MetaCore, Tox-Profiler, DAVID)83–89. Also for proteomic 
expression several databases exist to compare the results to literature. The analysis for 
proteomics expression can be done using Trans Proteomic Pipeline (TPP) which is a 
completely open-source analysis method for MS/MS-based proteomics90. For example, 
STITCH, UNIPROT, and again DAVID. STITCH is a resource to explore known and predicted 









Figure 4  Schematic representation of experiments in this thesis.
Embryos	  in	  a	  micro-tre	  plate	  
	  +/-­‐	  compound	  exposure	  








Next	  genera-on	  sequencing	  
and	  Affymetrix	  microarrays	  
Proteomics	  
Chapter	  4	  
Mass	  spectrometry	  and	  
FTICR	  analysis	  
Cross	  species	  analysis	  
Mul-species-­‐comparison	  using	  in	  vivo	  
systems	  (mouse,	  rat)	  and	  in	  vitro	  systems	  
(HepG2	  and	  primary	  hepatocytes)	  
Chapter	  5	  
Zebrafish	  
Chapter	  2	  -­‐	  5	  
Selec6on	  of	  biomarkers	  for	  
hepatotoxicity	  
Exploring the Zebrafish Embryo  
as an alternative Model for  
the Evaluation of Liver Toxicity by  
Histopathology and Expression Profiling
Marja Driessen, Anne S. Kienhuis, Jeroen L.A. Pennings, Tessa E. Pronk, Evert-Jan van den Brandhof, 
Marianne Roodbergen, Herman P. Spaink, Bob van de Water, Leo T.M. van der Ven
Archives of Toxicology (2013) May;87(5):807-23
2
CALVIN AND HOBBES © 1989 Watterson. Reprinted with permission of UNIVERSAL UCLICK. All rights reserved.
28








The liver is a critical target for xenobiotic-induced toxicity, and drug-induced liver injury is 
a major contributor in attrition of drugs in pre-clinical development. A first factor in hepatic 
susceptibility is that active hepatic processing leads to high intracellular concentrations of 
xenobiotics. Secondly, hepatocellular biotransformation of xenobiotics, which normally 
protects against the direct-acting toxicity through inactivation and facilitation of excretion, 
may also lead to reactive metabolites that are more toxic than the parent compound, 
resulting in liver cell injury4. Xenobiotic-induced hepatotoxicity occurs through different 
mechanisms associated with distinct histopathological and clinical phenotypes, including 
cholestasis, steatosis and necrosis, which will be further referred to as nominal phenotypes. 
These pathological conditions represent the consequences of respectively impaired 
hepatocellular bile excretion, triglyceride accumulation resulting from disruption of 
fatty-acid oxidation, and hepatocellular cell death4. Traditionally, histopathology and 
clinical chemistry are used to detect hepatotoxic properties of chemicals in in vivo rodent 
studies. Such studies require high numbers of animals, interfere with animal welfare, and 
are associated with high costs and are not always predictive for the human situation. 
Therefore, alternative test systems are needed to improve predictivity, and to contribute 
to reduction, refinement and replacement of in vivo rodent studies.
Following this necessity, several alternative methods to monitor liver injury have been proposed, 
including liver slices96, cultured primary hepatocytes97,98, and continuous cell lines, particularly 
the human hepatoma derived HepG2 line99,100 and the more recently derived human 
hepatocyte HepaRG line40. However, these in vitro systems each have their limitations related 
to their reductionistic nature and to loss of functionality compared to the liver in vivo101.
The zebrafish (Danio rerio) is a widely used model organism to study human biology and 
pathology, because physiological and molecular functions at the organ and cell level are 
highly comparable between the zebrafish and humans44. Consequently its value in the 
area of toxicology testing as well as drug discovery has also been recognized, making it a 
potentially important alternative for in vivo testing in rodents102. The zebrafish has several 
experimental advantages such as its short life cycle, accessibility and availability, and the 
power to generate high numbers of embryos easily, which makes the model suitable for 
high throughput testing. Moreover, the zebrafish genome is completely sequenced and a 
wide variety of genetic, molecular and cellular manipulation tools are available103.
As a particular refinement, the use of the whole zebrafish embryo (ZFE) is advantageous 
since the early embryo is considered not to perceive pain or otherwise discomfort. 
According to legislation104, whole ZFE can be considered as an alternative model system 
and it is already applied for studying chemical toxicity using developmental and lethality 
endpoints47,66. In contrast to in vitro cell cultures, in vivo cell type and organ interactions 
are maintained in the whole zebrafish embryo. These aspects may contribute to a better 
representation of hepatotoxic responses that occur in vivo.
Abstract
The whole zebrafish embryo model (ZFE) has proven its applicability in developmental 
toxicity testing. Since functional hepatocytes are already present from 36-hours post 
fertilization (hpf) onwards, whole zebrafish embryo have been proposed as an attractive 
alternative to mammalian in vivo models in hepatotoxicity testing. The goal of the present 
study is to further underpin the applicability of whole zebrafish embryo for hepatotoxicity 
testing by combining histopathology and next generation sequencing-based gene 
expression profiling. To this aim, whole zebrafish embryo and adult zebrafish were exposed 
to a set of hepatotoxic reference compounds. Histopathology revealed compound and 
life-stage specific effects indicative of toxic injury in livers of whole zebrafish embryo and 
adult zebrafish. Next generation sequencing (NGS) was used to compare transcript 
profiles in pooled individual RNA samples of whole zebrafish embryo and livers of 
adult zebrafish. This revealed that hepatotoxicity-associated expression can be detected 
beyond the overall transcription noise in the whole embryo. In situ hybridization verified 
liver specificity of selected highly expressed markers in whole zebrafish embryo. Finally, 
cyclosporine A (CsA) was used as an illustrative case to support applicability of zebrafish 
embryo in hepatotoxicity testing by comparing CsA-induced gene expression between 
zebrafish embryo, in vivo mouse liver, and HepaRG cells on the levels of single genes, 
pathways and transcription factors. While there was no clear overlap on single gene level 
between the whole zebrafish embryo and in vivo mouse liver, strong similarities were 
observed between whole zebrafish embryo and in vivo mouse liver in regulated pathways 
related to hepatotoxicity, as well as in relevant overrepresented transcription factors. 
In conclusion, both the use of NGS of pooled RNA extracts analysis combined with 
histopathology, as well as traditional microarray in single case showed the potential to 
detect liver-related genes and processes within the transcriptome of a whole zebrafish 
embryo. This supports the applicability of the whole zebrafish embryo model for  compound- 
induced hepatotoxicity screening.
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embryo data was compared with available data from in vivo mouse liver and from the 
HepaRG cell line, at the levels of single genes, pathways, and transcription factors. Pathway 
and transcription factor-based analyses attractively leveled out differences between 
models due to species variation, model sensitivity and power.
Altogether, using pooled RNA extracts in NGS analysis combined with histopathology, 
followed by case-directed traditional microarray, we supportively demonstrate the 
applicability of the whole zebrafish embryo model for toxicogenomics-based compound- 
induced hepatotoxicity screening.
Materials and Methods
Materials. Exposure studies were performed with reference compounds known to 
induce nominal hepatotoxic phenotypes in humans (cholestasis, steatosis and necrosis; 
Table 1). All test chemicals were purchased from Sigma Aldrich (Zwijndrecht, the 
Netherlands), and included acetaminophen or paracetamol (N-actyl-para-aminophenol; 
APAP, CAS no.103-90- 2), paraquat (1,1’-Dimethyl-4,4’-bipyridinium dichloride, PQ, CAS 
no.1910-42-5), thioacetamide((CH3-C(S)NH2); TA, CAS no.62-55-5), amiodarone hydrochloride 
(2-butyl- 3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride; 
AM, CAS no.19774-82-4), valproic acid (2-propylpentanoic acid sodium; VPA, CAS no.1069-66- 5), 
tetracycline (TET, CAS no.64-75-5), cyclosporine A (CsA, CAS no.59865-13-3),17α- ethinyl-
estradiol (17α-Ethinyl-1,3,5(10)-estratriene-3,17β-diol; EE2, CAS no.57-63-6) and chlorpromazine 
(2-Chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride; CPZ, CAS no.69-09-0), 
tricaine methansulfonate (MS-222; CAS no. 886-86-2). Dimethylsulfoxide (DMSO, CAS no. 
67-68-5) was ordered from Fisher-Scientific. The RNeasy MinElute Cleanup kit (Cat. No. 
74204) and the QIAzol Lysis reagent (Cat. No. 79306) were obtained from Qiagen Benelux 
B.V. (Venlo, the Netherlands). Phase-lock Gel Heavy (Cat. No. 2302870) and the metal micro 
pestle (P985.1) were purchased from VWR International B.V. (Amsterdam, the Netherlands).
Zebrafish. Wild-type zebrafish (Danio rerio) were originally obtained as commercially 
bred Singapore import (Ruinemans Aquarium BV, Montfoort, The Netherlands), which 
were maintained and bred in our facilities for more than 5 generations. Adult zebrafish 
(aZF) used in this study were approximately 14 months of age. For generation of zebrafish 
embryos, two male and two female adulte zebrafish were set together one day before 
spawning, after a period of four day separation to improve egg production. The breeding 
tank was constructed to prevent egg predation and after spawning, a glass siphon 
was used to collect the eggs. All eggs were checked for fertility and thereafter pooled in 
a single petri dish containing Dutch Standard Water (DSW; demineralized water 
supplemented with NaHCO3 (100 mg/l), KHCO3 (20 mg/l), CaCl2 · 2H2O (200 mg/l), and 
MgSO4 · 7H2O (180 mg/l) aerated for 24h at 27°C) until the start of the exposure.
From a hepatotoxicity testing perspective, the liver in the zebrafish embryo is fully 
functioning with active drug metabolism at 72-hpf105. A few promising studies showed 
that zebrafish embryos are suitable to detect human hepatotoxicants. In a study by Jones 
et al., the whole zebrafish embryo model was evaluated through morphological endpoints 
after exposure to a set of compounds including drugs which were falsely identified by the 
HepG2 cells. In this design, whole zebrafish embryo successfully detected more hepato-
toxicants with higher specificity than the HepG2 cells49. In another study, Amali et al. 
carried out histopathological, molecular and biochemical analysis in zebrafish embryo 
exposed to a single dose of thioacetamide and showed that the whole zebrafish embryo 
model is suitable to detect steatohepatitis57. These descriptive studies certainly indicate 
the potential of the whole zebrafish embryo model for hepatotoxicity testing, but further 
validation of the model is needed. A potential addition in this perspective is toxicogenomics, 
as it enables detailed analysis of the underlying mechanisms of cellular responses upon 
xenobiotics exposure. The most practical way to study hepatic gene expression in 
zebrafish embryo is to use whole zebrafish embryo RNA extract for analysis, instead of liver 
extracts, but this may result in masking of signals or lowering the signal/noise ratio of the 
regulated genes. Although available, sophisticated methods such as micro-dissection to 
study hepatic gene expression in small organism hinder the throughput of the system73.
The main objective of this study was to further substantiate the applicability of whole 
zebrafish embryo as a model for testing hepatotoxicity by combining histopathology with 
toxicogenomics, by means of next generation sequencing (NGS)-based gene expression 
profiling. To this end, histopathology in the zebrafish embryo and adult zebrafish liver 
was studied after exposure to a set of hepatotoxic reference compounds to confirm 
hepatocellular pathology and to extrapolate between developmental stages. Subsequently, 
induction of hepatoxicity relevant genes was analyzed in a single RNA pool composed 
from a set of whole zebrafish embryo and adult zebrafish liver, individually exposed to one 
out of a range of reference hepatotoxicants, using NGS. The use of such a single combined 
pool of RNA is a cost-effective way to obtain robustly expressed transcripts after treatment 
with compounds of a similar toxicity class106. The advantage of NGS is that, in contrast to 
expression arrays, it does not build on sequence- specific probe hybridization and does 
not suffer from background and cross-hybridization problems. Furthermore, it provides an 
absolute measure of all transcripts, not just the relative abundance in an array selection, 
enabling to assess the whole transcriptome107. The zebrafish embryo and adult zebrafish 
liver transcriptomes were then compared to reveal whether hepatotoxicity associated 
signals, as present in the overlap between zebrafish embryo and adult liver, can be 
detected in the noise of other tissues that contribute to the whole zebrafish embryo RNA. 
Highly expressed markers in zebrafish embryo were confirmed for liver specificity through 
in situ hybridization. Further analysis of the transcriptome was on regulation of pathways 
related to liver toxicity. General conclusions on hepatotoxic responses in the zebrafish 
embryo were verified in a dedicated case, i.e. cyclosporine A (CsA), where zebrafish 
32







group consisted of four male zebrafish. Test concentrations and exposure duration were 
as for zebrafish embryo (except CPZ; Table 1). After the exposure, the zebrafish were 
euthanized with a solution of 100 mg/l MS-222 buffered with sodium bicarbonate. 
Following decapitation, the fish were slit ventrally from heart to anus and livers were 
dissected and snap frozen in liquid nitrogen zebrafish embryo and aZFL samples were 
stored at -80°C until RNA extraction.
Experiments with adult zebrafish were approved by the RIVM Animal Experimentation 
Ethical Committee and carried out in accordance with relevant Dutch national legislation, 
including the 1997 Dutch Act on Animal Experimentation.
Histopathology. For histopathology, zebrafish embryo were sampled from three highest 
concentrations without mortality or teratogenicity of the concentration range finding 
study and adult zebrafish livers were dissected from adult fish exposed in the expression 
study. Whole zebrafish embryo and aZFL were fixed in 4% paraformaldehyde for 24 hrs, 
then transferred and stored in 70% ethanol until use. Samples were first embedded in a 
specially designed 1% agarose mold for adequate positioning of the embryos108,109, and 
then transferred to paraffin, whereafter 4 µm sections were routinely stained with 
hematoxylin and eosin (H& E) and covered with a glass coverslip. Additional cryosections 
from AM, VPA and TET were stained with Oil Red O to determine fatty droplet accumulation 
in zebrafish embryo and aZFL. Furthermore, in aZFL, additional sections from CPZ, EE2 and 
CsA were stained with Fouchet staining to detect bile accumulation. For the aZFL only 
one replicate per compound was included. As for the zebrafish embryo, approximately 12 
replicates were included per compound.
RNA isolation and processing.  Total RNA was isolated using the MinElute Clean up kit 
according to the protocol of de Jong et al.,110. RNA concentration was measured spectro-
photometrically (ND1000; NanoDrop technologies, Wilmington, DE) and RNA integrity 
was assessed using Bioanalyzer 2100 (Agilent Technologies, Amstelveen, the Netherlands). 
All samples contained intact total RNA with RNA Integrity Number (RIN) > 8. To reduce 
cost of NGS, RNA extracts of all zebrafish embryo of the highest exposure concentration 
of each compound were combined to a single pool. This is justified because our primary 
interest was in responsiveness potency of the zebrafish embryo, not in effects of single 
compounds, and pooling of samples has analytical advantages (see Discussion). We 
added control samples to be able to pick up any transcripts that are highly expressed in 
control conditions and down regulated in samples treated with liver toxicants, although, 
these transcripts may be harder to detect because they now have their highest expression 
level only in a minority of the pooled samples (2 control samples versus 9 hepatotoxi-
cants). A pool contained 500 ng/µl RNA, with equal quantities derived from approximately 
45 embryos per compound (Fig.1). A similar RNA pool was prepared from three adult 
zebrafish livers per compound at the same concentration.
Exposure conditions. All zebrafish embryo exposures started at 3 days post fertilization 
(3dpf) with embryos which were randomly derived from at least 2 spawning units. 
Exposures were performed in 48-well plates (BD Biosciences) containing 1 ml of test 
medium per well. Exposures were performed in an incubator at 26.5 ± 1°C in a static way, 
and lasted for 48 hrs. Concentrations for the expression study were defined in a range 
finding study conducted with zebrafish embryo, where respectively 6 and 7 exposures 
were tested for DMSO and water diluted compounds, with 12 zebrafish embryos per 
condition, each embryo in a single well. The exposures in the expression study were 
conducted with three concentrations (Table1), where the highest concentration was 
defined as the no effect concentration in zebrafish embryo (no mortality or teratogenicity) 
in the range finding study. Each concentration was performed in five replicate units, 
where each unit had 15 embryos (three wells each with five embryos). Each plate was set 
up to have 6 vehicle control wells. After exposure, the 15 embryos of each replicate unit 
were sampled in a single tube and snap frozen in liquid nitrogen.
aZF were transferred to the static test system 3 days prior to testing for acclimatization, 
and this consisted of full-glass aquaria containing three liters of DSW covered by a glass 
plate. The water was continuously aerated and ambient conditions were daily monitored. 
The temperature was kept at 27 ± 2 °C, pH between 7.4 to 9.0, and oxygen > 7.10 mg/l at 
all times. The light/dark cycle was 14 hours light and 10 hours dark. Each experimental 







Chlorpromazin (CPZ) Cholestasis 3 - 1 - 0.32 DMSO3
Cyclosporin A (CsA) Cholestasis 6 - 2 - 0.7 DMSO
17α-ethynylestradiol (EE2) Cholestasis 3.5 - 1.2 - 0.4 DMSO
Amiodarone (AM) Steatosis 10 - 3.3 - 1.1 DMSO
Valproic acid (VPA) Steatosis 600 - 200 - 67 DSW4
Tetracycline (TET) Steatosis 200 - 66.7 - 22.2 DMSO
Acetaminophen (APAP) Necrosis 660 - 220 - 73.3 DMSO
Paraquat (PQ) Necrosis 3,000 - 1,000  - 330 DSW
Thioacetamide (TA) Necrosis 10,000 - 3,333 - 1,111 DSW
1  Test concentrations of the reference compounds for transcriptomics and histopathology
2  aZF were exposed to a different range of CPZ, i.e. 1 - 0.3 μM - 0.1 μM.
3   Compounds initially dissolved in DMSO and diluted further in DSW with a final DMSO concentration of 
0.2% v/v. DSW and DMSO 0.2% v/v were included as vehicle controls.
4   Dutch Standard Water, demineralized water supplemented with NaHCO3 (100 mg/l), KHCO3 (20 mg/l), 
CaCl2•2H2O (200 mg/l), and MgSO4•7H2O (180 mg/l) aerated for 24h at 27 °C.
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GeneChip hybridization. For control and CsA , RNA samples were used as produced for 
the RNA NGS sequencing (Fig. 1). Sample labeling and hybridization to Affymetrix 
GeneChip zebrafish ST Genome Arrays were performed by ServiceXS B.V. (Leiden, the 
Netherlands). The Ambion WT Expression kit (#4411974) was used to synthesize labeled 
sense stranded cDNA starting from 100 ng total RNA. The minimal yield of the cRNA 
product is 10 µg. The Affymetrix Terminal Labeling Kit (901524) was used to perform the 
fragmentation and terminal labeling step using 5.5 µg of the ss cDNA. The concentration 
and the quality of the cRNA and fragmented ss cDNA samples were assessed using the 
Nanodrop and the BioAnalyzer. A total amount of 2.9 µg (25 ng/µl) fragmented ss cDNA 
was finally utilized for the hybridization on the Affymetrix Zebrafish ST Array. The Ambion 
WT Wash and Stain Kit for GeneTitan Hybridization (#901622) was used for the hybridization, 
washing, staining and scanning of the chips. The entire experimental procedure was 
carried out according to ServiceXS Standard Operating Procedures (SOPs) which have 
been validated for use with the Affymetrix kits and GeneChips and Array Plates and are 
completely compatible with the Affymetrix protocols.
The software program Affymetrix GeneChip Command Console (v3.2) was used for fully 
automated operation of the Affymetrix fluidics stations, which process the washing and 
staining of the cartridges. After scanning, the array images (DAT files) as well as the correct 
alignment of the grid were inspected using the program Affymetrix Command Console 
Viewer software.
Data analysis. In the NGS output file, transcripts were quantified to reads per kilobase of 
exon model per million mapped reads (RPKM) values, which are expression values 
corrected for library size and transcript length. These RPKM values were calculated with 
the CLC Genomics Workbench software111. Previous RNA NGS studies of zebrafish embryos 
indicated that this technique is extremely sensitive and can even detect gene expression 
at levels that are hard to detect with other high density technologies such as micro-
arrays112–114. On the other hand, at extremely low expression levels, exact quantification 
and reproducibility are often impaired. We therefore used a filter level to exclude unreliable 
values. Based on previous experience (unpublished results), this filter level was set at an 
RPKM of 0.12 and only genes with a higher RPKM value were included in the analyses. 
Statistical analyses were carried out using the R statistical software environment (http://
www.r-project.org). To investigate the expression of genes associated with hepatotoxicity, 
gene lists were made using a text-mining tool (Anni2.1, April, 2010)115. This tool provides an 
interface to Medline and retrieves associations for several classes of biomedical concepts. 
For determining the relevance to the applied search term, every concept is given a 
concept weight. The used search terms were ‘hepatotoxicity’ and ‘heart-, eye-, brain 
development’, and were based on human data. As a specificity threshold, the maximum 
value of the multiple search terms combined should exceed 0.01. Functional overrepre-
sentation analysis was performed using the software program PathVisio2 (2.0.11, February, 
RNA NGS sequencing. NGS sequencing was performed by BaseClear B.V. (Leiden, the 
Netherlands) using the Illumina GAII instrument. RNA seq libraries were made from 10 µg 
total RNA for each pool using the Illumina mRNA-Seq Sample Preparation Kit according to 
manufacturer’s instructions (Illumina, Inc., San Diego). In brief, this included purification of 
the RNA, fragmentation through divalent cations under elevated temperatures, followed 
by cDNA synthesis. Next, adaptors were ligated and the product was again purified and 
then amplified. A quantity of 4 pmol of each library was transferred to a flow cell, there 
again amplified to produce clusters of fragment copies, which were then paired end 
sequenced with a read length of 51 nucleotides. Fragments in a cluster were sequenced 
twice (forward and reverse), ensuring highly accurate alignment of the reads. Paired end 
sequences can be considered as technical duplicates, to control for reliability of the 
procedure. The Illumuna system is based on fluorometric image analysis, in which base 
calling and tag counting were performed using the Illumina pipeline. The sequence reads 
were mapped to the reference genome (Ensemble, Zv8, Release 59, August 2010) using 
the CLC Genomics Workbench (version 4.0.3., October 28, 2010).
Figure 1  Study design for next generation sequencing analysis.
Each pool contained 500ng/μl total RNA, consisting of equal absolute quantities of total RNA from 
each exposure to the highest concentration of each compound
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included in the CsA case study. 
** Embryos for histopathology were sampled from the concentra�on range finding study. 
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RNA probes. Anti-sense RNA probes were designed using Primer-BLAST from the NCBI 
website122 based on the complete RefSeq sequence of the gene of interest. Primers were 
ordered by Invitrogen (Life Technologies, Breda, the Netherlands) and are summarized in 
Table 2. Primers were used for an RT-PCR with the Titan One Tube RT- PCR System (Roche 
Applied Science). This PCR product was purified with the QIAquick PCR purification kit 
(Qiagen, Venlo, the Netherlands) and a nested PCR was then conducted to amplify the 
PCR product. A synthesis step using T3 and T7 polymerase promoters was then performed 
to generate DIG-labeled RNA probes.
In situ hybridization. Whole mount in situ hybridization was performed following a 
protocol adapted from Thisse et al.124. ZFEs were collected at 5-dpf and fixed overnight in 
4% paraformaldehyde. After fixation zebrafish embryos were washed 2 times in 1x PBS, 
bleached in 3% H2O2/0.5% KOH solution to remove pigment and washed in 1x PBS. 
Following bleaching, the zebrafish embryos were dehydrated in a graded methanol/PBS 
series and stored in 100% methanol at -20°C. Before in situ hybridization zebrafish embryos 
were rehydrated with 50/50 PBS/MeOH for 5 min, washed 4 times for 5 min with PTW 
2011)116. A pathway was considered ‘overrepresented’ when the Z score was greater than 
two and the minimally required number of changed genes was set at two. Pathways were 
retrieved from Curated collection of Pathways117, Kyoto Encyclopedia of Genes and 
Genomes (KEGG), and manually curated collection of Pathways (MC). BLAST was employed 
to search for homologs of the hypothetical transcripts against the NCBI Non-Redundant 
database. This procedure was used to assign hypothetical transcripts with a functional 
annotation, based on protein sequence similarity.
All Affymetrix Cell Intensity Files (*.cel) generated for each Genechip using the Affymetrix 
GeneChip Command Console (v3.0) software were normalized using the Robust Multichip 
Average (RMA) algorithm. For all systems, the data was annotated with a MBNI custom 
CDF specifically designed for the chips (http://brainarray.mbni.med.umich.edu/Brainarray/
Database/CustomCDF/CDF/)118. Mouse liver expression data were obtained from an 
exposure study of Kienhuis et al.119, where the mice were exposed to a dose of 26.6 mg/kg 
b.w. of CsA for 11 days. Expression data of HepaRG cells exposed for 12 hrs to 300 μM was 
obtained from Jennen et al.120, EBI ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/) 
with accession number E-MEXP-2458. All gene expression signals were Log2 transformed 
before calculations were performed.
In the CsA case study, comparisons were performed on the level of single significantly 
expressed genes, pathways and enriched motifs for transcription factors. Significantly 
expressed genes were selected in whole zebrafish embryo, in vivo mouse liver, and the in 
vitro cell line using ANOVA performed over different exposure conditions (concentrations, 
doses, time- points) with an FDR cut-off of 0.05, 0.1, and 0.01, respectively. Comparison of 
regulated pathways between the whole zebrafish embryo, mouse in vivo and the cell line 
was done using the T-Profiler software, which enables a threshold and parameter free 
analysis of genome-wide expression patterns83. The input for T-Profiler consisted of 
individual samples of the three models. After pathway calculation the enrichment score, 
that is the t-value, was averaged per condition per model. Heatmaps are produced using 
the GeneMaths XT Software (Version, Applied Maths NV). Transcription factor enrichment 
analysis was performed using the significant genes in whole zebrafish embryo, in vivo 
mouse liver and the in vitro cell line.
Transcription factor binding motifs associated with the significant genes were determined 
using the C3 dataset, which contains transcription factor binding motifs found 2kB up- or 
downstream of target genes121. For optimal retrieval, the zebrafish and mouse gene IDs 
were converted to their human homologues by using the homologene dataset of the 
NCBI. To determine which transcription factors binding motifs were present significantly 
more than random in the gene sets, a random permutation test was applied using a 
cut-off value of p < 0.01. As an additional criterium the transcription factor binding motifs 
should be found by at least four genes in the set. To calculate the probability of overlap of 
the transcription factor binding motifs between models, the phyper package in R was 
used.
Table 2  Primer sequences for in situ hybridization.
Primer Strand PCR Sequence
fabp10 Forward 1st PCR AGCGGGACGTGGCAGGTTTAC
fabp10 Reverse 1st PCR CCTCCGACTGTCAGCGTCTCCAC
fabp10 Forward Nested PCR CTCAGAGCCATCTCTCTGCCAGA
fabp10 Reverse Nested PCR CCTGGATGTGGGAGAATCGGTCA
pparγ Forward 1st PCR GACGTTTGGCTGGCCCGTGG
pparγ Reverse 1st PCR CAGGAACAGCGCCATGTCGCA
pparγ* Forward Nested PCR GAAGATCCGTCTTCATCCTCAC
pparγ* Reverse Nested PCR GATCTGTCCGTAGGAGATCAGG
zgc:193613 Forward 1st PCR TGGGCACAGGAATGGCCCGT
zgc:193613 Reverse 1st PCR TGGACACACAGCTGTCAGATTGGT
zgc:193613 Forward Nested PCR TCAAGAGGCTTGTCAATGCTTGGG
zgc:193613 Reverse Nested PCR TTCCCTGGGGCAGTACGGTGT
wu:fj16a03 Forward 1st PCR TTCCAACTTGCTGAACATCCGTGAA
wu:fj16a03 Reverse 1st PCR ATGTTGCTGCATTGCTGTCGGAT
wu:fj16a03 Forward Nested PCR TGTTCCTGCTGCTGCCTGTCTG
wu:fj16a03 Reverse Nested PCR AGCATTTCCAGCCTTTCTTCTCGC
* Primer set from literature123
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(1x PBS, 0.1 % Tween20) followed by 40 min incubation in 5µg/ml proteinase K in PTW at 
37°C. Embryos were fixated again in 4% paraformaldehyde, followed by 5 times 5 min 
wash in PTW. Until here, all the washing steps were performed in 24-well plates using 
small baskets made from 15 ml tubes with a nylon mesh melted to its opened bottom 
end. After this, the embryos were transferred to transparent 4 ml screw cap vials and 
prehybridized in hybridization buffer (50% deionized formamide; 5x SSC; 500 µg/ml tRNA; 
50 µg/ml heparin; 0.1% Tween20; pH 6.0 with 1M citric acid) for 3 hrs at 70°C. The buffer 
was then replaced by fresh hybridization buffer (pre-heated for 5-10 min at 70°C) 
containing digoxigenin labelled RNA probe and incubated overnight at 70°C. After 
hybridization the embryos were washed twice at 70°C for 20 min with respectively 50% 
hybridization buffer (without tRNA and heparin)/50% 2xSSC; and 2xSSC. Then the zebrafish 
embryo were washed twice with 0.2xSSC for 60 min, followed by 5 min washes at room 
temperature with 50% PBT (PTW with 2% sheep serum and 0.2% BSA)/50% 0.2xSSC and 
finally 100% PBT. The embryos were incubated at room temperature while shaking with 
PBT for 3 hrs, followed by incubation overnight at 4°C with anti-DIG antibody solution 
diluted at 1/2000 with PBT under gentle agitation. The embryos were subsequently 
washed 6 times 15 min each with PBT at room temperature. Embryos were transferred to 
a 24-wells plate and washed 4 times for 20 min with staining buffer (100 mM Tris pH 9.5, 50 
mM MgCl2, 100 mM NaCl, 0.1% Tween 20, 5 mM levamisole). The first of these washing 
steps was done with staining buffer without MgCl2. Embryos were stained with 20mL/ml 
NBT/BCIP staining buffer until an optimal signal was obtained. The staining reaction was 
stopped by three washes in 0.5 ml PTW, followed by overnight fixation in 4% paraformal-
dehyde at 4°C. Embryos were subsequently washed 3 times in 0.5 ml PTW and transferred 
to 100% glycerol, placed on a rocker and agitated gently overnight at room temperature 
in the dark, mounted in 100% glycerol and observed and photographed microscopically. 
Results
Hepatotoxicant-specific liver pathology in zebrafish embryo and adult zebrafish liver. 
Histopathological examination in the whole zebrafish embryo and aZFL was conducted 
after 48 hrs of exposure to the model compounds. In H&E staining, hepatocytes of the control 
adult zebrafish showed a similar morphology as mammalian hepatocytes (Fig. 2a-b). 
Although the liver as a whole did not show the obvious lobular structure which is present 
in mammals, substructures such as bile canaliculi could be discerned (Fig. 2b, arrow). 
Hepatocytes in the control embryos showed a more open cytoplasm, although with 
varying degrees, indicative of varying levels of glycogen contents (Fig. 3a-b). After 48 hrs 
of exposure, cholestasis was a remarkably frequent observation in aZFL, with a high 
incidence in nominal cholestatic compounds (CPZ, EE2, CsA), but also with most of the 
non-cholestatic compounds (Table 3). Cholestasis appeared as intracellular and intra- 
Figure 2  Microphotographs illustrating of various observations.
Reference histology in control (a); arrowhead indicates bile canaliculus. Cholestasis is shown in H&E 
(b-d) and Fouchet staining (e-h). Arrowheads in b, c intracellular cholestasis, in d, intracanalicular 
cholestasis. Corresponding intracellular and intracanalicular cholestasis with Fouchet staining are 
shown in f and g, respectively; additional intranuclear cholestasis in h. Steatosis is shown with Oil red 
O staining in j, absence of OrO is shown in i. Cell death is indicated by chromatin condensation and 
eosinophilic cytoplasm (arrowheads in k). Arrowheads in l, chromophobic vacuolization, arrowheads 
in m, eosinophilic cytoplasm inclusions; n, basophilic cytoplasm. Compound abbreviations are 
explained in Table 1. Size bar refers to all microphotographs.
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canalicular brown pigment accumulation in H&E staining (Fig. 2c-e), and these subtypes 
were confirmed by Fouchet staining (Fig. 2g-h, compared with control in 2f). In addition, 
with TAA, Fouchet staining was confined to the nuclei (Fig. 2i). Cholestasis was not 
observed in zebrafish embryo. Lipid vacuoles as a mark of steatosis were not observed in 
aZFL, but well discernible in zebrafish embryo with two of the nominal steatotic 
compounds and one nominal cholestatic compound (Fig. 3c-e). However, Oil Red O 
staining also revealed lipid droplets in aZFL, with nominal steatotic compounds (illustrated 
for TET in Fig. 2k, compare with control in 2j). Necrosis did not show in either aZFL or 
zebrafish embryo, i.e. not in a zonal pattern as can be observed in mammal liver. On the 
other hand, marks of cell death, particularly chromatin condensation and cytoplasmic 
eosinophilia, were observed in both aZFL (Fig. 2l) and zebrafish embryo with some 
compounds, although without much consistency between life stages and clearly more 
compound than class specific. Additional observations were chromophobic and 
eosinophilic vacuolization, which occurred in aZFL and zebrafish embryo (Fig. 2m-n, Fig. 3f-h), 
mainly coinciding with nominal cholestatic and necrotic compounds (Table 3); and 
cytoplasm basophilia, in aZFL only observed with EE2 (Fig. 2o) and in zebrafish embryo 
with CPZ (Fig. 3c).
Overall assessment of all exposed animals indicated that simple histopathological effects 
were mainly observed with nominal steatotic compounds, and that complex histopathology 
effects were present in most nominal cholestatic and necrotic compounds (Table 3). 
Furthermore, serial sections of the whole zebrafish embryo revealed additional histo- 
pathology in the intestinal epithelium, which showed vacuolization after exposure to CPZ, 
EE2 and APAP (Table 3). Histopathological observations are summarized in Table 3, without 
considering the xenobiotic concentration conditions.
Next generation sequencing of the whole zebrafish embryo and adult zebrafish liver 
transcriptomes. Next-generation RNA sequencing was used to compare the transcriptomes 
of adult zebrafish liver and whole zebrafish embryo. A number of 21914 transcripts were 
sequenced from zebrafish embryo (Fig. 4a, blue and yellow area) and 16459 transcripts 
from the adult zebrafish liver (Fig.4a, blue and green area). There were 15801 overlapping 
transcripts (Fig. 4a, blue area). These three areas can also be distinguished when comparing 
relative expression (RPKM values) between zebrafish embryo and adult zebrafish liver 
(Fig. 4b). Here, the grey diagonal (Fig.4b) separates transcripts that are more highly expressed 
in the whole zebrafish embryo (above) from those that are more highly expressed in the 
adult zebrafish liver (below).
PathVisio2 was used to identify overrepresented biological pathways and processes from 
the uniquely expressed transcripts in zebrafish embryo (6113 transcripts, Fig.4a-b, yellow 
area) and adult zebrafish liver (658 transcripts, Fig.4a-b, green area). zebrafish embryo thus 


































































































































































































































































































































































































































































































































































pathways not obviously related to the liver. In adult zebrafish liver, overrepresented 
pathways were mainly found in the immune and intracellular processes (Table 4). It should 
be noted that due to nature of the experimental setup and the pooling of all individual 
samples that regulation of neither adaptive or toxicity pathways nor of transcription 
factors can be attributed to any individual of our hepatoxicants.
Hepatotoxicity-associated gene expression in the exposed zebrafish transcriptomes. 
Next, to discover whether transcripts related to either human hepatotoxicity or development 
were expressed in exposed whole zebrafish embryo or adult zebrafish liver, we performed 
text mining using an automated search strategy (Supplementary Table 1 for hepatotoxicity, 
supplementary Table 2 for development).
Transcripts specific for hepatotoxicity were evenly distributed in both pooled zebrafish 
embryo and adult zebrafish liver samples and mainly located in the set of overlapping 
genes (Fig. 4b, red squares, n=127, and explained in supplementary Table 3). Furthermore, 
Figure 4   Expression comparison of hepatotoxicity-associated genes and development 
specific genes for the adult zebrafish liver and zebrafish embryo.
a. Venn diagram showing the number of expressed transcripts per experimental pool and the 
overlap of these expressed transcripts after exposure to a set of model hepatotoxicants. b. Black 
circles represent genes that were neither related to hepatotoxicity nor involved in development of 
heart, eye and brain based on the results of the text-mining. Grey circles represent genes that were 
not included in the analysis due to their RPKM expression below 0.12. Green diamonds indicate 
genes associated with development, red squares indicate genes associated with hepatotoxicity. 
Colored areas indicate model specificity of transcripts: green area only expressed in adult zebrafish 
liver (658), yellow area only expressed in whole zebrafish embryo (6,113), blue area expressed in both 
model systems (15,801). White shaded area indicate transcripts not involved in analysis (color figure 
online).
Distribution of assembled transcripts
6113 15801 658
a.





























Figure 3  Hepatotoxicant-specific liver pathology in whole zebrafish embryo.
Microphotographs are illustrations of various observations recorded in Table 3. Reference histology 
in controls (a,b); arrowhead indicates irregular unstained area indicitive of glycogen storage. Lipid 
vacuoles of varying sizes (arrowheads) as observed in H\&E are illustrated in c-e (small in c-d, larger 
in e). Arrowheads in f and g indicated chromophobic vacuolization, and eosinophilic inclusions in h.
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transcripts related to development were predominantly present in the whole zebrafish 
embryo (Fig. 4b, green diamonds, n= 324, and explained in supplementary Table 4). 
Several hepatotoxicity associated genes (red squares) were uniquely present in zebrafish 
embryo, namely, aanat1, cyp1b1, fabp10a, hgfa, npy, otc, pomca, and, si:dkey- 22d17.3. In adult 
zebrafish liver, the uniquely expressed hepatotoxicity related gene was faslg and the 
uniquely expressed genes for development were amh and bmp10. 
Validation of liver specific gene expression by in situ hybridization. Genes which by 
text-mining were associated with hepatotoxicity and also were highly expressed in both 
whole zebrafish embryo and adult zebrafish liver, were selected to verify liver-specificity of 
the expression using in situ hybridization in whole zebrafish embryo. This set included 
three known genes, i.e. fatty acid binding protein 10a (fabp10a), peroxisome proliferator 
activated receptor gamma (pparγ), and apolipoprotein A2 (apoa2) and one unannotated 
hypothetical gene, wu:fj16a03. All four genes thus showed expression in the liver region, 
whereas pparγ and wu:fj16a03 showed additional staining in the brain and gut (Fig.5). For 
fabp10a, pparγ, and apoa2 the sense probes were negative, while for wu:fj16a03 the sense 
probe stained the same areas as the antisense probe, cautioning for conclusiveness of the 
wu:fj16a03 antisense signal. Still, the in situ hybridization confirmed the liver specificity as 
concluded from NGS in at least three of the four analyzed expression markers.






ECM-Receptor Interaction 3.1 -
Cell Adhesion Molecules (CAMs) 3.6 -
Immune Phagosome - 1.8
Prostaglandin Signaling 2.7 -
NOD Pathway - 2.6
Cytokine-cytokine Receptor Iinteraction - 3.0
Other ACE Inhibitor Pathway 2.3 -
Phototransduction 5.8 -
SIDS Susceptibility Pathways 4.5 -
Oocyte Meiosis - 2.9
Ovarian Infertility Genes - 5.3
Analysis is based on 6113 unique transcripts in zebrafish embryo and 658 unique transcripts in adult zebrafish 
liver (Fig. 4). - pathway is not overrepresented
Table 4   Biological pathways and processes in the subset of uniquely expressed 
transcripts in ZFE and aZFL. Pathways were “overrepresented” when the  




Development Neural Crest Development 10.8 -
Canonical wnt - zebrafish 6.9 -
Noncanonical wnt Pathway 5.0 -
Wnt Signaling Pathway 2.6 -
Endochondral Ossification 2.0 -
Hedgehog Signaling Pathway 3.9 2.0
Melanogenesis 4.8 -
BMP Signaling Pathway 2.8 -
Muscle Systems Vascular Smooth Muscle Contraction 2.0 -
Calcium Regulation in the Cardiac Cell 6.4 -
Striated Muscle Contraction 3.1 -
Cardiac Muscle Contraction 4.7 -
Metabolism Glycosphingolipid Biosynthesis - Ganglio Series 2.1 -
Taurine and Hypotaurine Metabolism 2.3 -
Biogenic Amine Synthesis 3.8 -
Nitrogen metabolism - 5.3






Nodal Signaling Pathway 3.7 -
Peptide GPCRs 3.8 -
GPCRs, Class C Metabotropic Glutamate, Pheromone 2.4 -
Monoamine GPCRs 2.3 -
MAPK Signaling Pathway 3.8 -
ERK1 - ERK2 MAPK Cascade 2.8 -
FGF Signaling Pathway 5.0 -
Myometrial Relaxation and Contraction Pathways 3.3 -
Calcium Signaling Pathway 8.2 2.1
Neuroactive Ligand-Receptor Interaction 14.8 2.9
GnRH Signaling Pathway (signaling) 2.2 -
Proteasome - 2.4
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The high concordance in hepatotoxicity pathways between zebrafish embryo and mouse 
liver is indicative for similar regulation at the level of transcription factors. To verify this we 
started out with only those genes which were significantly regulated and liver specific in 
the zebrafish embryo, that is, present in the overlapping genes in the NGS comparison 
Case study cyclosporine A. As a next step, we performed a comparative study using the 
widely studied hepatotoxicant cyclosporine A (CsA). Here, CsA-regulated gene sets, 
pathways and transcription factors in zebrafish embryo were compared with existing data 
from studies of CsA treated in vivo mouse livers and HepaRG cells. Statistical analysis of 
Affymetrix microarray data revealed 72 significantly regulated liver associated genes for 
the whole zebrafish embryo model. In comparison, 115 significantly regulated genes were 
observed in the in vivo mouse liver; and 262 significantly regulated genes in the HepaRG 
cell line. On single gene level, there was no overlap observed between the significant CsA 
induced transcripts of the in vivo mouse liver and whole zebrafish embryo, which can be 
understood from the low number of significant transcripts in each model. For the human 
HepaRG cell line, 3 transcripts overlapped with the in vivo mouse liver. Pathway analysis 
using all genes is therefore a more informative approach, and when aligning all regulated 
pathways in the three models in a cluster analysis, this showed good comparability 
between whole zebrafish embryo and mouse liver in vivo (Fig. 6). 
These two models had 15 of the 26 regulated pathways regulated in the same direction, 
whereas the HepaRG cell line showed a deviating regulation of the these 15 pathways, 
and only 5 pathways regulated in the same direction as compared to mouse. Concordance 
between mouse liver and the cell line was similar to that between zebrafish embryo and 
the cell line. While most corresponding pathways between whole zebrafish embryo and 
mouse in vivo included hepatotoxicity related pathways (Fig.6, italics), the pathways that 
showed overlap between whole the zebrafish embryo and the liver cells included cell 
cycle-related pathways, which is related to the active proliferation in these two models. 
Importantly, cholesterol biosynthesis was down regulated in all models.
Figure 5  Validation of liver specific gene expression by in situ hybridization.
Representative in situ hydrization microphotographs for fabp10a, pparγ, apoa2, and wu:fj16a03 
mRNAs in 5-dpf zebrafish embryo. mRNA staining is dark blue. fabp10a shows intensely in the liver, 
and an additional small area in the hindbrain, pparγ and wu:fj16a03 are observed in the liver, gut, and 
brain, and apoa2 intensely in liver with additional staining in the yolk sac
Figure 6  Heatmap of pathway responses upon cyclosporine A exposure.
Pathways regulated in mouse liver in vivo, whole zebrafish embryo and the cell line HepaRG. The 
cluster of pathways that are upregulated in both whole zebrafish embryo and mouse liver in vivo is 
clearly enriched for hepatotoxicity related pathways (indicated in italics). The color scale indicates 
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The zebrafish is a powerful vertebrate model for human biology and disease, and zebrafish 
liver resembles the mammalian liver on the morphological and functional level125. 
In zebrafish embryo, hepatocytes are present from 36-hpf, and at 72-hpf the liver is fully 
functioning, including functional activity of the cytochrome P450 system, which is 
important for metabolizing xenobiotics105. Therefore hepatic responses can be expected 
after exposure to hepatotoxicants in zebrafish embryo. In this paper, we investigated the 
applicability of the zebrafish embryo as an alternative model system for hepatotoxicity 
testing. To this aim, we compared hepatotoxic effects induced by a set of reference 
compounds (Table 1), reflected by histopathology and gene expression profiling, in the 
whole zebrafish embryo and adult zebrafish liver.
Histopathology indicated that the adult zebrafish liver is particularly sensitive for 
development of cholestasis, after exposure with both typical and non-typical cholestatic 
compounds (Table 3). Cholestasis could not be detected in zebrafish embryos. This is 
probably due to underdevelopment of bile production mechanisms, in line with the 
observation that genes involved in the formation of bile ducts are first expressed at 
48-hpf126 and that the onset of fully operational bile production in the embryo is only 
from 5-dpf onwards44. On the other hand, comparable para-cholestatic events were 
present at both life stages reflected by vacuolization observed in both zebrafish embryo 
and aZF and induced by nominal cholestatic compounds, although vacuolization was a 
rather generalized observation in zebrafish embryo. Vacuolization might therefore be a 
non-specific response in zebrafish embryo hepatocytes, e.g. resulting from induction of 
metabolic activity or as an inhibiting effect on the mitochondrial energy production127. 
The steatotic compounds (AM, VPA and TET) induced an effect that was consistent with 
the nominal phenotype in both zebrafish life stages, that is lipid accumulation as observed 
with Oil Red O staining, but lipid accumulation was also present with CPZ in zebrafish 
embryo. All three necrotic compounds (TAA, PQ and APAP) induced hepatocellular 
vacuoles at both life stages, with the exception of APAP in adult zebrafish liver, but no 
apparent apoptosis or necrosis.
There was also additional, mixed effects. Taken together, the nominal phenotypes of the 
tested compound classes were not simply reproduced in adult zebrafish liver and zebrafish 
embryo. The final morphology of hepatotoxic effects were related to life stage dependent 
capability of hepatocytes, and hepatotoxic responses could lead to mixed histopathology. 
Still, all of the tested hepatotoxicants do induce specific histopathological effects in the 
liver, which could be interpreted as a different expression of similar mechanisms of 
hepatotoxicity compared to humans. Since the design of our study aimed at qualitative 
assessment of histopathological effects, the information on relation to exposure concentration 
is limited.
between whole zebrafish embryo and adult zebrafish liver (Fig. 4, blue area). Transcription 
enrichment analysis thus resulted in 45 enriched transcription factor binding motifs (Fig. 7). 
In mouse liver, using the whole set of significantly regulated genes, 58 enriched transcription 
factors were found, and 19 enriched transcription factors in the HepaRG cell line. The 
overlap between the whole zebrafish embryo and in vivo mouse liver was significant 
(p-value < 0.001, hypergeometric test) and showed eight overlapping transcription factor 
binding motifs, which were Runx2, Ets2, Atf1, Mef2, microRNA 137, microRNA 181, microRNA 
182, microRNA 527. The overlap between the cell line HepaRG and in vivo mouse liver was 
5 transcription factor binding motifs, which were Meis 1, Usf2, microRNA 145, microRNA 
181, and Ddit3. The overlap between zebrafish embryo, in vivo mouse liver and HepaRG 
cells was one transcription factor binding motif, which was microRNA 181.
Figure 7   Venn diagram of the enriched transcription factor motifs enriched after CsA 
exposure.
Venn diagram showing the number of enriched transcription factor motifs in the in vivo mouse liver, 
whole zebrafish embryo model and the two cell lines exposed to CsA. Enrichement of transcription 
factors is based on the significant genes per system after exposure to CsA using an ANOVA analysis. 
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The overall aim of the NGS analysis was to confirm that transcripts associated with 
hepatotoxicity are expressed in the whole zebrafish embryo (by comparison with adult 
zebrafish liver), and that hepatotoxicity specific signals are detectable over the noise of 
other tissues. To achieve this aim, NGS provides multiple advantages over mRNA 
microarrays. In contrast to microarrays, NGS does not rely on the probe design and probe 
selection, thus enabling detection of non-predefined transcripts, including diverse 
splicing variants of a single gene. The high expenses that come with NGS in a traditional 
toxicogenomics study set-up could in our case be avoided by the use of pooled samples. 
This was justified because this would sufficiently reveal the liver specific response 
capability of the zebrafish embryo. Working with pools even has a specific advantage, 
because it eliminates the blur of non or low-responding individuals and of non or 
less-active compounds106. On the other hand, good transcript counts depend on a 
sufficient number of response-evoking compounds, and information on individual 
compounds is lost. This was however not considered as a weakness, because com-
pound-specific activity was not the focus here. Nevertheless, hepatotoxicity-associated 
gene expression could have been too low to support general conclusions on the 
applicability of the zebrafish embryo model with a specific transcriptional response in 
only a limited number of compounds.
Bioinformatics-based text mining showed that hepatotoxicity-associated transcripts are 
detectable in zebrafish embryo as well as adult zebrafish liver, and that they were evenly 
distributed between the two models (Figure 4, red squares). This indicates that similar 
processes are active in whole zebrafish embryo and adult zebrafish liver, in spite of the 
immature hepatocyte morphology in zebrafish embryo, and in spite of a different 
histopathology between the two models. Apparently, initial cellular responses do overlap 
as reflectec in similar gene expression changes, but the downstream biological outcomes 
differ, depending on the developmental stage of the organism.
Besides a major overlap in the NGS transcripts, unique transcripts were found for both 
zebrafish embryo and adult zebrafish liver conditions. These transcripts were analyzed for 
underlying pathways and processes. Unique transcripts in zebrafish embryo were mostly 
related to developmental processes, which is an expected result considering the 
developmental stage of the embryo. The specific transcripts in adult zebrafish liver were 
predominantly involved in immune response pathways. Such responses are not likely to 
happen in zebrafish embryo in view of the immaturity of the immune function at that 
stage128. The gene expression showed that some hepatotoxicity-associated genes were 
only present in whole zebrafish embryo. These genes were arylalkylamine N-acetyltrans-
ferase 1 (aanat1), cytochrome P450, family 1, subfamily B, polypeptide 1 (cyp1b1), fatty acid 
binding protein 1a (fabp1a), neuropeptide Y (npy), ornithine carbamoyltransferase (otc) 
and carbamoyl-phosphate synthase 1, mitochondrial (cps1, former si:dkey-225d17.3) and are 
highly expressed in other tissues than liver82. The absence of these genes in adult zebrafish 
liver is either because gene expression is below the RPKM cut-off value or transcripts are 
in zebrafish embryo expressed in other tissues than the liver. The ability to identify these 
off-target gene expressions can be interpreted as an advantage of the zebrafish embryo 
model as it may still contribute to the hepatotoxic response. Cyp1b1, for example, is an 
enzyme for biotransformation of compounds and is highly expressed in the gills of 
zebrafish129. Like the gut in mammals, the gill represents the first-pass organ in fish and its 
cross-talk with the liver is important for biotransformation of compounds130. Such 
interaction between organs is important for assessment of hepatotoxicity and an 
advantage of whole zebrafish embryo model. Moreover, the zebrafish embryo model 
allows for identification of toxic responses in organs outside the liver, shown in the 
affected intestinal epithelium after exposure to CPZ, EE2 and APAP (Table 3). One 
hepatotoxicity related gene was uniquely expressed in the adult zebrafish liver, faslg, 
which is known to be present only in the adult stages82. The major conclusion from the 
comparison ZFE-aZF liver is that using whole zebrafish embryo RNA extract allows for 
detection of important transcripts for hepatotoxicity, either in the liver or in other tissues.
Moreover, none of the important hepatotoxicity pathways as expressed in aZF livers were 
missed in whole zebrafish embryo exposed to reference hepatotoxicants, providing a 
promising perspective for use of the whole zebrafish embryo model for (toxicogenomics- 
based) hepatotoxicity testing.
The liver expression of key hepatotoxicity related genes identified in the whole zebrafish 
embryo was confirmed by in situ hybridization. Liver expression of fapb10a, pparγ, and 
apoa2 was also observed by others44,131. Neither function nor site-specificity of the highly 
expressed hypothetical gene wu:fj16a03 has been described. The closest observation is 
that BLAST analysis indicates that this gene has a strong sequence similarity to the toxin-1 
gene, which is found in rainbow trout (Oncorhynchus mykiss). In trout, expression of this 
particular gene is found in the liver, spleen and brain, which is similar to our observations 
in whole zebrafish embryos82. Some off-liver expression sites were detected for some of 
the genes, e.g. the wu:fj16a03 transcript is rather prominent in the head region and in the 
gut. To further validate the applicability of the zebrafish embryo as a suitable alternative 
for hepatotoxicity testing, pathways regulated by CsA, which is known to induce 
cholestasis in humans6, were compared between our zebrafish embryo model, a mouse 
model 119 and one in vitro model, the HepaRG cell lines120. Although CsA doses/
concentrations and exposure duration differed between models, they were all selected to 
optimally induce hepatotoxicity, reflected by clinical chemistry (mouse in vivo119), 
histopathology (whole zebrafish embryo) and cytotoxicity (in vitro cell line120) and 
therefore allowed for comparison. Pathway and transcription factor based analyses 
attractively level out differences between models due to species variation, and model 
sensitivity and power, which can hamper model comparison based on single gene level. 
Transcription factors are key players in the regulation of a wide variety of cellular processes 
in health and disease. They play an important role in the development of toxic responses, 
and transcription factor analysis is therefore an attractive way to interpret gene was 
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observed in affected significantly different genes between the whole zebrafish embryo 
and in vivo mouse liver. Nevertheless, pathway analysis showed that there is an overlap in 
regulation of the affected pathways. It appeared that the cluster of pathways showing the 
same direction of regulation of gene expression was highly enriched for pathways relevant 
for liver toxicity. The one pathway that was down-regulated in all model systems, the 
cholesterol biosynthesis pathway, corresponds with the inhibiting effect of CsA on 
cholesterol 7α-hydroxylase, which is the rate-limiting step in cholesterol conversion to bile 
acids132. In addition, a significant overlap in transcription factors was found between 
whole zebrafish embryo and in vivo mouse liver. These transcription factors (Runx2, Ets2, 
Atf1 and Mef2) regulate immune processes, which can be understood from the immuno-
suppressant function of CsA. For the three microRNAs, not enough information is available 
to link them to the CsA effects. The overlapping transcription factors between hepaRG 
cells and in vivo exposed mouse liver are mainly involved in wide range of processes which 
can be linked to DNA binding (Ddit3, Usf2) and development (Meis1). The absence of 
immune cells in the HepaRG model can explain the absence of immune-function related 
transcription factors.
Overall, these results indicate that there is more similarity of responses between the 
zebrafish embryo and in vivo mouse liver after CsA exposure than between HepaRG cells 
and in vivo mouse liver, particularly on the level of pathways and transcription factors. This 
supports the notion that the whole zebrafish embryo is a better proxy for the traditional 
in vivo model than the human cell line in vitro model.
In conclusion, we confirmed that the zebrafish embryo is a promising alternative model 
for hepatotoxicity testing, as indicated by hepatotoxicant-induced liver histopathology 
and by induction of hepatotoxicity-associated gene expression. NGS appeared a powerful 
tool allowing sensitive and specific quantitative comparison of transcripts between 
zebrafish embryo and adult zebrafish liver. While due to high costs we had to apply NGS 
on pooled samples from multiple experiments, comparison of gene expression from a 
single hepatotoxicant experiment between zebrafish embryo, in vivo mouse liver, and 
HepaRG cells further supported the potential of zebrafish embryo in hepatotoxicity 
testing.
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The zebrafish embryo (ZFE) is a promising non-rodent model in toxicology, and initial studies 
suggested its applicability in detecting hepatotoxic responses. Here, we hypothesize that 
the detailed analysis of underlying mechanisms of hepatotoxicity in ZFE contributes to 
the improved identification of hepatotoxic properties of new compounds and to the 
reduction of rodents used for screening. ZFEs were exposed to nine reference hepa - 
to toxicants, targeted at induction of cholestasis, steatosis and necrosis, and two non- 
hepatotoxic controls. Histopathology revealed various specific morphological changes 
in the ZFE hepatocytes indicative of cell injury. Gene expression profiles of the individual 
compounds were generated using microarrays. Regulation of single genes and of pathways 
could be linked to hepatotoxic responses in general, but phenotype-specific responses 
could not be distinguished. Hepatotoxicity-associated pathways included xenobiotic 
metabolism and oxidoreduction related pathways. Overall analysis of gene expression 
identified a limited set of potential biomarkers specific for a common hepatotoxicity 
response. This set included several cytochrome P450 genes (cyp2k19, cyp4v7, cyp2aa3), 
genes related to liver development (pklr) and genes important in oxidoreduction 
processes (zgc:163022, zgc:158614, zgc:101858 and sqrdl). In conclusion, the ZFE model allows 
for identification of hepatotoxicants, without discrimination into specific phenotypes.
Introduction 
The liver has a central role in the metabolism of xenobiotic substances in an organism, 
which includes biotransformation targeted at inactivation of toxic parent compounds. 
However, this biotransformation may also produce toxic reactive metabolites, leading to 
xenobiotic-induced liver injury4,6. Various underlying mechanisms can result in a wide 
range of xenobiotic-induced liver toxic phenotypes, of which cholestasis, steatosis and 
necrosis are most frequently observed. Cholestasis is a chronic condition and is 
phenotypically characterized by bile accumulation as a result of changes in intra- or 
extracellular bile flow or bile composition34. Steatosis may occur chronically as well and is 
characterized as an increase in cellular lipid content due to an increase in de novo synthesis 
of fatty acids or reduced lipid secretion or oxidation19. Necrosis is an acute condition and 
is characterized by cell death due to oxidative stress4,33. 
A challenge in toxicology is to predict the hepatotoxic potential of compounds to which 
humans are exposed. In mammals, and particularly for oral uptake, many compounds 
provoke first signs of toxicity in the liver (due to the first path effect and activation in liver 
cells), and therefore hepatotoxicity is an important aspect of adverse drug effects and 
adverse effects of chemicals. To this end, there is an urging need to develop and validate 
alternative approaches, since traditional in vivo animal studies are associated with ethical 
(large numbers of animals exposed), economical (high costs and long experimental 
periods), and scientific issues (not fully predictive for effects in humans). As such, the 
zebrafish embryo is an alternative screening model with the potential of reducing 
traditional in vivo rodent studies. It combines the benefits of an in vivo model, namely 
complete biological complexity including interaction between tissues and cells49,54,95, 
with the advantages of an in vitro model, that is, reduced animal discomfort and the ability 
for medium to high throughput testing. The structure and function of the adult zebrafish 
liver is similar to the mammalian liver46,55, and fully functional liver tissue is present in the 
zebrafish embryo at 72 hours post fertilization (hpf), which is therefore a suitable time 
point to start hepatotoxicity testing. There is also high genetic conservation between 
humans and zebrafish, including genes functioning in biotransformation46,55. Zebrafish 
embryos express 94 cytochrome P450 enzymes (CYPs), which occur in the same 18 gene 
families as in humans. Furthermore, the CYP1-4 families, which are involved in metabolizing 
xenobiotics, are very similar between the two species, and an ortholog of the human 
CYP3A4, which catalyzes the majority of known drug-metabolizing reactions, is present in 
zebrafish as well, namely, cyp3a6546,55. 
In a previous study, we showed that the zebrafish embryo can be used to identify human 
hepatotoxic responses using histopathology and analysis of hepatotoxicity-associated 
transcripts by next-generation sequencing (NGS)133.  In that study, we showed that the 
induced phenotype in zebrafish embryos (summarized in Table 1) differs from histo-
pathology in humans and rodents, partly due to species differences, and partly due 
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to immaturity of embryonic hepatocytes. The phenotype in humans and rodents is 
therefore defined as ‘nominal’, and that in zebrafish embryos as ‘observed’. Our NGS results 
demonstrated that hepatotoxicity-associated gene expression responses remain detectable 
even in case of a non-tissue specific analysis in whole body homogenates and are distinct 
from developmental toxicity processes. Furthermore, our initial microarray study with 
cyclosporin A (CsA) showed that changes in gene expression were reflective of mechanisms 
underlying the onset of cholestasis133. 
Building on these premises, the hypothesis of the present study was that detailed analysis 
of mechanisms of hepatotoxicity may contribute to a better description of hepatotoxic 
responses and to the development of expression markers predictive for hepatotoxicity in 
humans. The specific objective was to analyze hepatotoxicity related gene expression 
responses and derive transcriptomics markers. To allow for the comparison of phenotypic 
responses between zebrafish embryos and humans and for the deduction of tran-
scriptional responses underlying these phenotypes in the zebrafish embryos, we selected 
nine reference hepatotoxicants based on established major hepatotoxic phenotypes in 
humans and/or the classical rodent testing models, namely cholestasis (cyclosporine A, 
chlorpromazine and 17α-ethinylestradiol)1,15,134,135, steatosis (amiodarone, tetracycline and 
valproic acid)23,136,137 and necrosis (acetaminophen, paraquat and thioacetamide)1,4,138. 
Zebrafish embryos were treated with these compounds for 48 hours starting at three days 
post fertilization. Transcriptional analysis was performed using microarrays followed by 
both gene and pathway level analysis. The individual gene analysis approach is particularly 
useful to derive predictive markers for hepatotoxicity, whereas the analysis on the pathway 
and process level provides more integrative information into the underlying molecular 
mechanism of hepatotoxicity61. 
Materials and methods
Chemicals. All tested chemicals (purity >95%), were purchased from Sigma Aldrich 
(Zwijndrecht, the Netherlands), and included acetaminophen (N-actyl-para-aminophenol; 
paracetamol; APAP, CAS no.103-90-2; 660 µM), paraquat (1,1’-Dimethyl-4,4’-bipyridinium 
dichloride; PQ, CAS no.1910-42-5; 3000 µM), thioacetamide (CH3-C(S)NH2); TA, CAS 
no.62-55-5; 10000 µM), amiodarone hydrochloride (2-butyl-3-benzofuranyl-4-[2-(diethyl-
amino)ethoxy]-3,5-diiodophenyl ketone hydrochloride; AM, CAS no.19774-82-4; 10 µM), 
valproic acid (2-propylpentanoic acid sodium; VPA, CAS no.1069-66-5; 600 µM), tetracycline 
(TET, CAS no.64-75-5; 200 µM), cyclosporine A (CsA, CAS no.59865-13-3; 6 µM),17α-ethinyl-
estradiol (17α-Ethinyl-1,3,5(10)-estratriene-3,17β-diol; EE2, CAS no.57-63-6; 3.5 µM), 
chlorpromazine (2-Chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride; 
CPZ, CAS no.69-09-0; 3 µM), D-Mannitol (Mannite; DM, CAS no. 69-65-8; 3000 µM), lithium 
carbonate (Carbonic acid lithium salt; Li2CO3, CAS no. 554-13-2; 1100 µM) and tricaine 
methanesulfonate (MS-222, CAS no. 886-86-2). Dimethylsulfoxide (DMSO, CAS no. 67-68-5; 
0.2%) was ordered from Fisher-Scientific. 
Fish treatment. Wild-type zebrafish (Danio Rerio) were originally obtained as commercially 
bred Singapore import (Ruinemans Aquarium BV, Montfoort, The Netherlands), which was 
maintained and bred in our facilities for more than 5 generations. Egg production was 
optimized by separation of the male and female fish before spawning, and female 
zebrafish were fed only thawed Artemia Naupli prior to spawning. Egg predation was 
prevented by using a breeding tank with a perforated bottom, in which male and female 
zebrafish were paired in a 2:2 ratio before spawning. Spawning was triggered by morning 
light and was usually completed within 30 minutes. After spawning, the eggs were 
collected using a glass siphon and debris was removed to rinse the fertilized batches at 
least three times in Dutch Standard Water (DSW; demineralized water supplemented with 
NaHCO3 (100 mg/l), KHCO3 (20 mg/l), CaCl2 · 2H2O (200 mg/l), and MgSO4 · 7H2O (180 
mg/l) aerated for 24h at 27°C). After rinsing, the fertilized eggs from different batches were 
pooled and placed in a petri dish in an incubator at 26.5 ± 1°C with a photoperiod of 14 
hours light/10 hours dark. The used concentration for all compounds including the 
negative compounds was the highest subtoxic concentration in a range-finding study, i.e. 
the highest concentration that had no observable morphological or teratological effects 
and no mortality (See Table 1 for histopathological changes). After 72 hours, hatched 
embryos were randomly distributed over 48-well plates in a density of 5 embryos per well 
in 1 ml test or control medium. Each test compound had at least four statistical replicates, 
which consisting of 3 wells (15 embryos) per replicate. In total, 13 conditions were tested 
including the 9 reference hepatotoxicants, two vehicle controls and two non-hepatotoxi-
cants. At 120 hpf, the embryos were evaluated under a Leica Labovert FS microscope for 
altered normal development (e.g. delay in development, teratogenic effects) and 
indications of toxicity (e.g. abnormal swimming behaviour) and snap frozen in liquid 
nitrogen for microarray analysis. Although we did not analyze compound concentrations 
during the 48 h exposure period, all compounds were indicated to be relatively stable in 
the indicated time period according to the NLM Hazardous Substances Database (http://
toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB).
All procedures were done under licensed conditions for studies with laboratory animals, 
according to European and Dutch legislation.
Microarray hybridization and quality control. The RNeasy MinElute Cleanup kit (Cat. 
No. 74204) and the QIAzol Lysis reagent (Cat. No. 79306) were obtained from Qiagen 
Benelux B.V. (Venlo, the Netherlands). Phase-lock Gel Heavy (Cat. No. 2302870) and the 
metal micro pestle (P985.1) were purchased from VWR International B.V. (Amsterdam, the 
Netherlands). For microarray analysis, samples consisting of 15 embryos per concentration 
per compound were snap frozen in liquid nitrogen. Total RNA was isolated using the 
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MinElute Cleanup Kit110. RNA concentration was measured spectrophotometrically 
(ND-1000, NanoDrop Technologies Inc., Wilmington, DE) and RNA integrity was assessed 
by automated gel electrophoresis using the RNA 6000 Nano Chip Kit (Bioanalyzer 2100, 
Agilent technologies, Amstelveen, The Netherlands). Total RNA samples with an RNA 
Integrity Number (RIN) > 7 were used for further analysis. 
Technical handling of the microarrays (GeneChip hybridization) was outsourced to 
ServiceXS BV (Leiden, the Netherlands). RNA quality control, hybridisation, microarray 
quality check and data processing were performed as described previously133.
For data processing and quality control, affymetrix Cell Intensity Files (*.cel) were normalized 
using the Robust Multichip Average (RMA) algorithm 76 and the MBNI custom CDF version 15 
(http://brainarray.mnbi.medumich.edu/Brainarray/Database/CustomCDF)118. RMA normalized 
data was Log2 transformed and the quality of micro array images was inspected visually 
(http://arrayanalysis.org, BiGCaT Maastricht University). Four out of 192 arrays were 
eliminated from further analysis because they did not meet the quality criteria. Affymetrix 
internal controls ID were not used in further analyses, leaving a total of 23,758 probe sets 
corresponding to unique Entrez GeneIDs. R software (Version 2.15.0 R Foundation for 
Statistical Computing, Vienna, Austria) was used to correct the Log2-transformed data for 
the median of the vehicle controls.
Gene expression analysis. Following our hypothesis, the basis for gene expression 
analysis was histopathological clustering. Clusters were based either on the phenotype as 
observed in humans after compound exposure (referred to as nominal phenotype) or on 
actually observed histopathology (observed phenotype, Table 1). The nominal phenotype 
clusters included three classes, namely cholestasis (CPZ, CsA and EE2), steatosis (AM, TET 
and VPA) and necrosis (APAP, PQ and TAA). The observed phenotype consisted of four 
clusters; (1) lipid vacuolization (AM, CPZ and VPA), (2) chromatin condensation (CPZ, EE2 
and PQ), (3) chromophobic vacuolization (CsA, EE2, PQ and TAA) and (4) eosinophilic 
vacuolization (CPZ, CsA, TET and APAP). Processes and pathways regulated after exposure, 
were determined using T-Profiler. T-Profiler allows genome-wide expression analysis 
without applying cut-offs on single gene level resulting in the use of all the genes on the 
array83. Compound-specific pathways were identified using the highest concentration of 
each compound and by averaging the replicates. Pathways were considered significant 
when the absolute T-value was >3 and the E-value < 0.05 (a Bonferoni corrected two-tailed 
P-value) in at least one reference hepatotoxicant. Compound specific effects on pathway 
level were determined using the top-3 up and down regulated pathways per compound. 
Pathways were included in the top-3 if they had at least an absolute T-value > 4. Next, to 
assess which pathways were phenotype specific, a two-group comparison was performed 
using Qlucore Omics Explorer (Qlucore AB, Lund, Sweden). Phenotypic clusters were 
based on either nominal phenotype, observed phenotype and common hepatotoxicity 
phenotype. Phenotype-specific pathways were counted as those with a p-value <0.05. 
Finally, to detect commonly induced genes between hepatotoxic compounds, the gene 
expression values for the highest concentration of each compound were analyzed by 
one-way ANOVA with an FDR<0.05. Genes with an absolute FC > 1.2 were considered to be 
differentially expressed and were ranked on the number of compounds regulating the gene. 
Results
Hepatotoxicity-associated pathways. T-Profiler was used to identify the significantly 
regulated pathways per compound to confirm a compound’s ability to induce hepatotoxicity- 
associated pathways/processes in the zebrafish embryo. A biological pathway/process 
with an absolute T-value > 4 and E-value < 0.05 in one of the compounds was considered 
significant and a heatmap separating up- and down-regulated pathways and processes was 
generated (Fig. 1). The compounds were clustered using an unsupervised Euclidian distance 
with Ward linkage clustering method, which revealed that most hepatotoxicants cluster 
together, with exception of TAA and CPZ, which cluster with the non-hepatotoxicants DM 
and Li2CO3 for the up-regulated pathways. For the down-regulated pathways, a different 
clustering of the compounds was observed. Here, all hepatotoxicants formed a cluster, 
whereas the negative compounds, DM and Li2CO3, formed a distinct cluster. Distinctive 
functions can be identified between the up-regulated and down-regulated pathways/
processes. Up-regulated pathways/processes were associated with oxidative stress 
(including oxidoreductase activity, oxidation reduction related pathways/processes) and 
xenobiotic metabolism (including glutathione metabolism, glutathione transferase activity, 
metabolism of xenobiotics by cytochrome P450 and drug metabolism-cytochrome P450). 
Down-regulated pathways/processes were mainly involved in ribosome, protein kinase 
activity and regulation of transcription. Without considering statistical significance, directions 
of responses of the regulated pathways/processes were highly concordant between 
hepatotoxic compounds. Listing of the three most highly up- and down-regulated 
pathways/processes per compound (Table 2) showed that the most up-regulated pathways 
over all compounds included oxidoreductase activity, oxidation reduction, heme binding, 
and iron ion binding. The most down-regulated pathways were involved in ribosome and 
cytoplasmic ribosomal proteins related processes. CPZ had only 3 significantly regulated 
pathways/processes, one up-regulated (signal transducer activity) and two down-regulated 
pathways, which overlapped with other compounds in the set. TAA did not have any 
significant pathways/processes in either direction.
Phenotype directed clustering of processes and pathways at the transcriptome 
level. To determine whether the phenotypes, nominal or observed, specifically defined 
pathways/processes, a phenotype-directed analysis was performed using a two-group 
comparison, i.e. phenotype-related compounds versus all other compounds in the set. 
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Figure 1  Hepatotoxicant regulated pathways.
Significantly regulated pathways per compound were analyzed using T-Profiler, with significance 
criteria T-value > 4 and E-value > 0.05, so each pathway has a significant occurrence in at least one 
compound. _go, _kegg, _wiki indicates pathway origin from The Gene Ontology (GO), Kyoto 
Encyclopedia of Genes and Genomes (KEGG), and Wikipathways (WIKI). Color shades in the heatmap 
represent corresponding T-value (see color scale). Left panel: upregulated pathways, right panel 
downregulated pathways. Pathways and compounds are unsupervisedly clustered using Euclidian 
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Figure 2   Heatmap of all pathways specific for the nominal, observed and common 
hepatotoxic phenotype.
Significantly regulated pathways per phenotypic observation based on T-Profiler output and a 2-group 
comparison in Qlucore. Nominal phenotype indicates the phenotypes as observed in humans, 
observed phenotype indicates what is seen in ZFE and common hepatotoxicity pathways indicate the 
response on pathway level without discriminating between phenotypes. _go, _kegg, _wiki indicates 
pathway origin from The Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and 
Wikipathways (WIKI). Color shades in the heatmap represent corresponding T-value (see color scale). 
Pathways and compounds are clustered using euclidian distance with Ward linkage
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Figure 2   Continued.


























protein amino cid ph sphorylation_go
pr tei  serine/threonine kinase activity_go
transcription_go
regulati  of transcription, DNA-dependent_go









































































































structural c nstituent of ribosome_go






Progester ne-mediated ocyte maturation_kegg
postsynaptic membrane_go
synapse_go
extr c llular-glutam te-gated ion channel activity_go
ionot opic glut mate receptor activity_go





serine-typ  endopeptidase activity_go
serin -type peptidase activity_go
oxidoreductase activity
Cell adhesion molecules (CAMs)_kegg
Glycerolipid metabolism_kegg
cartilage development_go




transferas  activit , transferring glycosyl groups_go
transferas  activity, transferring hexosyl groups_go
extracellular region_go





























































DNA phot lyase activity_go



























c rbohyd at  metabolic process_go
Glycerophospholipid metabolism_kegg
carbohydrate transport_go
hydrolase activity, hydrolyzing O-glycosyl compounds_go
Golgi apparatus_go
endoplasmic reticulum_go































Nominal henotypes Observed henotypes Common hepatotoxicity
-10 -5 0 5 10
66







The nominal classification followed the selection of reference compounds, i.e. cholestasis 
(CPZ, EE2, CsA), steatosis (AM, TET, VPA) and necrosis (APAP, PQ, TAA). The observed differed 
from the nominal phenotypes, probably due to life-stage and species specificity of 
responses, and the major observed classes were chromatin condensation (CPZ, EE2, PQ), 
chromophobic condensation (CsA, EE2, PQ, TAA), eosinophilic vacuolization (CPZ, CsA, 
TET, APAP) and lipid vacuolization (AM, CPZ, VPA); see Driessen et al. for further details133. 
This analysis did not reveal unique phenotype-specific patterns for either the nominal 
(Fig. 2, left) or observed (Fig. 2, middle) phenotypes. Since phenotype-specific pathways/
processes could not be identified and the pathway/process listing (Table 2) suggested 
that there was a more common hepatotoxic response, it was assessed whether common 
hepatotoxicity pathways/processes could be confirmed using a comparison between 
all hepatotoxicants and controls (Fig. 2, right). Seven out of the nine compounds showed 
a uniform response for 39 different pathways/processes, where 19 pathways were 
up-regulated and 20 down-regulated. Common down-regulated pathways included, for 
example, translation, DNA replication and mRNA processing. Common up-regulated 
pathways included, for example, oxidoreductase activity, transferase activity and carboxy-
peptidase activity. In line with per compound analysis, CPZ and TAA showed a distinctive 
and less active pattern of regulated pathways/processes.  
Identification of common hepatotoxicity marker genes. As described above, analysis 
on pathway and process level revealed a uniform response for most of the compounds. 
To determine marker genes for common hepatotoxicity, a one-way ANOVA with ten 
groups was performed, i.e. all hepatotoxicants as one group against the controls, which 
resulted in 732 significantly regulated genes (Fig. 3A; Supplementary Table 1). These 
significant genes were then ranked by the number of compounds that regulated the 
specific gene and the following criteria, absolute fold change (FC) > 1.2 and regulation by 
at least three compounds, were applied to identify the best possible informative marker 
for a common hepatotoxic response. The 20 best performing up-regulated and 
down-regulated genes were then selected (Fig. 3B). The top up-regulated genes included 
several cytochrome P450s (cyp2k19, cyp4v7, cyp19a1b, cyp24a1 and cyp2aa3), genes involved 
in oxidoreduction processes (zgc:163022, zgc:158614, zgc:101858 and sqrdl), and a gene in 
the drug metabolism pathways (impdh1b). The top-10 down-regulated genes were related 
to liver development (zgc:77778), glucose transport (slc2a9l2), and glycolysis/gluconeo-
genesis (pklr). Three  uncharacterized genes were identified, which were LOC100003115, 
LOC100538043, and LOC100330229. Furthermore, three genes were involved in neuropeptide 
signaling (scg5), peptidase activity (zgc:154142), thrombospondin-1-like (LOC100535166), 
and heart development (tcap). It was further assessed whether these marker genes were 
also present in the significant pathways/processes observed after the phenotype-directed 
analysis, and this could be confirmed for 10 of the 20 marker genes (Fig. 3B, genes with 
asterixs). These ten marker genes are listed in Table 3, which also shows that most of the 
Figure 3   Selection of the proposed marker genes.
3A. Depiction of steps in the analysis leading to marker genes for the prediction of human 
hepatotoxicity. After one-way ANOVA with 10 groups resulted in 732 significant genes with 
significance criteria FDR < 0.05 and corrected for the negative compounds. 3B. Heatmap of the 
proposed marker genes to predict human hepatotoxicity. Proposed markers for the prediction of 
human hepatotoxicity using a ranked approach on the number of compounds inducing the gene. 
Color shades in the heatmap represent corresponding fold change, where green represents down 
regulation and red presents up regulation (see color scale). Compounds are clustered using Euclidian 








































































0 0.5 1 1.5 2
B.A.
23 877 probe sets 





Ranking on fold change
and number of compounds
regulating the gene
20











genes were derived from the common hepatotoxic response pathways (Fig. 2, right), and 
specifically from the oxidoreductase activity pathway therein, whereas only the genes 
tcap and pklr were present in the observed and/or nominal phenotypic specific pathways 
(Fig. 2, left and middle).  
Discussion
In this study, we analyzed the transcriptional changes on single gene as well as on pathway 
level in the zebrafish embryo after exposure to reference hepatotoxicants to verify 
whether mechanistic information can contribute to the applicability of this model in 
screening for hepatotoxic potential of compounds. The ultimate objective was to derive 
predictive markers for hepatotoxicity.
Histopathological analysis showed that the hepatotoxic observed phenotypes differ from 
those know from mammalian studies. However, specific morphological changes were 
observed in the zebrafish embryo, which were different from those observed in adult 
zebrafish liver, the latter more resembling histopathology common in livers of humans 
and model rodents133. This difference indicated that the developmental stage affects the 
final phenotypical outcome, and the early life stage of the zebrafish embryo, with 
premature hepatocytes, may lack the modes of action leading to expression of a mature 
hepatotoxic phenotype. Although, the observed histopathological changes confirmed 
the responsiveness of the zebrafish embryo to the hepatotoxicants suggesting that 
initiating mechanisms are already active in the early embryo. We observed that hepato-
toxicity-associated gene expression was present in the zebrafish embryo supporting that 
mechanisms of hepatotoxicity are similar between the embryonic and adult stages. The 
zebrafish embryo is therefore a potentially suitable model to identify hepatotoxic markers. 
In the present study, gene expression analysis was performed at the compound level to 
investigate whether the molecular changes induced by the reference hepatotoxicants in 
zebrafish embryos may reflect hepatotoxicity in humans and/or classical rodents to which 
these reference hepatotoxicants refer.
In the pathway analysis that was based on the compound specific transcriptomes, 
responses of the significant pathways appeared very similar between compounds in 
terms of directionality (up- or down-regulated), independent of the phenotype class, but 
with a few exceptions. The most abundant up-regulated pathways were related to 
xenobiotic metabolism and oxidoreduction processes. The induction of the cytochrome 
P450 system confirms the capability of the embryos to carry out this important function 
Table 3   Overview of the ten hepatotoxicity associated markers present in the  
phenotype directed analysis.
GeneName GeneID AM APAP CPZ CsA EE2 PQ TAA TET VPA DM Li2CO3 Phenotype Pathway
zgc:163022 100038777 1.82 1.76 1.28 1.29 1.38 7.89 1.39 2.1 1.47 0.98 0.76 Fig. 3, common oxidoreductase activity
zgc:158614 791218 1.28 1.13 1.21 1.12 1.32 3.79 1.39 1.5 1.45 0.98 1.04 Fig. 3, common oxidoreductase activity
zgc:101858 449555 1.25 1.15 1.34 1.29 1.33 0.97 0.74 1.32 1.39 0.87 0.83 Fig. 3, common oxidoreductase activity
sqrdl 550580 1.45 0.92 0.89 1.16 1.14 4.37 1.24 1.13 1.31 0.93 1.09 Fig. 3, common oxidoreductase activity
cyp19a1b 60640 2.11 1.48 1.71 0.96 4.07 1.16 1.35 1.04 1.21 0.93 0.94 Fig. 3, common oxidoreductase activity
impdh1b 338306 0.98 1.16 1.3 0.97 1.31 0.95 1.08 1.14 1.45 1.02 1.13 Fig. 3, common oxidoreductase activity
zgc:77778 406484 0.54 0.68 0.56 0.52 0.81 0.74 0.74 0.64 0.6 0.83 0.94 Fig. 3, common extracellular region_go
zgc:154142 555481 0.62 0.95 0.62 1.33 0.54 0.61 0.51 0.97 0.49 0.88 0.85 Fig. 3, common peptidase activity_go
tcap 556258 0.65 0.64 0.6 1.6 0.52 1.18 1.07 0.62 0.65 0.99 0.85 Fig. 3, observed Striated Muscle Contraction_wiki
pklr 114551 0.46 0.78 0.63 0.55 0.67 0.73 0.7 0.9 0.71 1.04 0.92 Fig. 3, nominal and observed transferase activity_go
The 20 proposed markers were assessed for their presence in the phenotype-directed analysis, where ten of 
these markers were found. Values indicate the fold change per compound, the column phenotype indicates 
from which phenotype-directed analysis the gene is derived (see Fig. 3) The column pathway indicates in 
which significantly regulated pathway the gene is present (Fig.2 and/or Table 2).
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in the detoxification of xenobiotics4. The presence of this key function of detoxification is 
further supported by the high induction of glutathione-related pathways, including 
glutathione metabolism and glutathione transferase activity139. The metabolism-related 
pathways in our model differ from CYP related processes in zebrafish embryos analyzed 
for mechanisms of developmental toxicity67, and are therefore considered to be hepa-
totoxicity specific. This conclusion is further supported when comparing the regulated 
pathways between these two models for the same compound: exposure to VPA in the 
developmental toxicity assay of Hermsen et al. 67, using a more development-sensitive 
exposure time window, shows no overlap of pathways with those identified in our model. 
CPZ and TAA up-regulated the same pathways as all other hepatotoxicants, albeit to a 
lesser extent forcing them to cluster with the negative controls. Others showed that TAA57 
and CPZ105 are active in the zebrafish embryo, excluding low absorption as a cause of this 
less active regulation of processes. The same references indicate that the effects of TAA 
and CPZ may be induced acutely, i.e. within a shorter time span than the 48 hours used in 
our study, and this provides a good explanation for the low activity at our measurement 
point.
In the down-regulated pathways/processes, a more differentiated response was observed 
and three clusters were formed. Here, APAP and CPZ clustered together, as did VPA, EE2, 
TAA, CsA, AM, and PQ, and a third cluster consisted of the negative controls. APAP and CPZ 
down-regulated the same pathways as all other hepatotoxicants, although to a lesser 
extent, forcing them to cluster separately. Again, the same reasoning as proposed for the 
up-regulated pathways could apply to the down-regulated pathways in the case of CPZ 
exposure. Although APAP was chosen for inducing necrosis, a relative acute condition, 
regenerative events will also be activated and may even take over140,141. The up-regulated 
pathways have higher t-values than the down-regulated pathways suggesting that the 
up-regulated pathways are more significant when compared to the down-regulated 
pathways. Furthermore, these up-regulated pathways could more easily be linked to 
hepatotoxicity than the down-regulated pathways.
The negative controls have no known hepatotoxic activity, but are linked to nephrotoxicity 
in rodents142. Because the gene expression is measured in the whole embryo, a slight, 
non-significant, induction of similar pathways could follow from this nephrotoxic activity. 
Downregulation of pathways related to transcription and ribosomal activity by these 
controls could represent an adaptive response to cell stress. It is known that stalling of the 
transcription process occurs in response to DNA damage which was observed in cells 
after exposure to cisplatin143. Our observations of gene expression dependent regulation 
of pathways and processes in zebrafish embryos are in line with those in the rat, as far as 
available from in vitro and in vivo studies. AM exposure in rats showed highly enriched 
pathways related to oxidative stress144. For VPA, the pathway amino sugar and nucleotide 
sugar metabolism23, and for PQ, an increase in glutathione metabolism was observed 
which can be correlated to its toxic mechanism. PQ is reduced to a superoxide anion by a 







zgc:163022 100038777 oxidoreductase activity
cyp2k19 562304 members of this xenobiotic CYP family
no known function
no human homolog
zgc:158614 791218 cell redox homeostasis
zgc:101858 449555 oxidoreductase activity 
sqrdl 550580 oxidoreductase activity
cyp4v7 562008 members of this xenobiotic CYP family
less involvement in xenobiotic metabolism 
shares synteny with their human counterparts 
cyp19a1b 60640 important in synthesis of cholesterol, steroids and other lipids
important in estrogen biosynthesis
human counterpart
cyp24a1 100004700 important in synthesis of cholesterol, steroids and other lipids
important in vitamin D regulation
part of the nuclear receptor in toxicity pathway
human counterpart
impdh1b 338306 IMP dehydrogenase activity
cyp2aa3 386638 members of this xenobiotic CYP family
induced by PXR agonists which are cytochrome P450 inducers 
to protect the body 
no human homolog
zgc:77778 406484 liver development
slc2a9l2 798023 glucose transporter 
LOC100003115 100003115 unknown function
human homolog gene is member of the Fc-receptor like 
family
LOC100535166 100535166 unknown function
pklr 114551 gluconeogenesis and glycolysis
scg5 393699 neuropeptide signaling 
LOC100330229 100330229 unknown function
LOC100538043 100538043 unknown function
zgc:154142 555481 catalytic activity
tcap 556258 T-tubule organization
* Gene information was retrieved from NCBI PubMed Gene80 and ZFIN82
Bold italic gene names indicate association with liver-specific processes
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variety of enzymes leading to the production of reactive oxygen species (in vitro 
observation)145.
Each compound was able to induce pathways relevant for hepatotoxicity. A caveat in our 
approach is that although producing specific hepatotoxicity, the selected exposure 
concentration may not be optimally represent the underlying mechanisms. However, the 
reference compounds were selected for their ability to induce specific phenotypical 
changes. Therefore, compounds were clustered by nominal (cholestasis, steatosis, necrosis) 
or by observed histopathological changes, (chromophobic, eosinophilic, and lipid 
vacuolization, and chromatin condensation). Neither of these two approaches produced 
overrepresented pathways. Grouping based on all hepatotoxicants versus non-hepato-
toxicants revealed discriminative pathways, which overlapped with pathways that resulted 
from the gene expression analysis per compound. Based on the distinction between 
 hepatotoxicants and non-hepatotoxicants, we aimed to identify a set of key genes for 
common hepatotoxicity that could be used for the prediction of the hepatotoxic potential of a 
compound. Ten up-regulated and ten down-regulated genes were identified as sensitive 
to toxicity based on a gene list ranked on fold change and the number of compounds 
inducing the gene  (Fig. 3B). Functions of these genes and details per gene are summarized 
in Table 4. Although these genes were associated with hepatotoxicant exposure at 
concentrations inducing liver histopathology, this does not define their dysregulated 
expression as adverse per se. Some examples of detected genes that can be linked to 
adversity are pklr, which is a known marker for acute hepatotoxicity146, and zgc:77778, 
which in case of downregulation (as observed) results in maldevelopment of the liver147. 
Furthermore, many detected genese are associated with oxidoreductase activity, which 
upon upregulation may cause oxidative stress and thus lead to cell injury. A link to adversity 
may not be obvious for all individual detected genes, but through these examples of 
adversity, the set as a whole may be considered as pathognomonic for liver injury.
In conclusion, our exposure study with known hepatotoxicants identified a set of marker 
genes that could be linked to pathways and processes involved in toxic responses in the 
liver. These markers and pathways/processes were associated with a general hepatotoxic 
response, whereas specific hepatotoxic phenotypes or classes could not be distinguished. 
The identified markers are suitable candidates to predict human hepatotoxicity, because 
they were anchored in responses induced by known hepatotoxicants in humans and/or 
traditional rodent models for human hepatotoxicity. 
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The zebrafish embryo (ZFE) is a promising non-rodent model in toxicology, and initial 
studies suggested its applicability in detecting hepatotoxic responses. Here, we 
hypothesize that detailed analysis of underlying mechanisms of hepatotoxicity in ZFE 
contributes to the improved identification of hepatotoxic properties of new compounds 
and to the reduction of rodents used for hepatotoxicity assessment. ZFEs were exposed 
to nine reference hepatotoxicants, targeted at induction of cholestasis, steatosis and 
necrosis and two non-hepatotoxic controls. Protein profiles of the individual compounds 
were generated using LC-MS/MS. Regulation of single genes and pathways could be 
linked to hepatotoxic responses in general, but phenotype-specific responses could not 
be distinguished. While overrepresented processes were mainly associated with cellular 
adaptive stress-responses, individual proteins could be linked to hepatotoxicity-associated 
processes. This resulted in a set of possible protein markers, especially glud1b, hspe1 and 
anxa1c, for the detection of hepatotoxicity in a high-throughput manner. 
Introduction
The liver has a central role in the metabolism of xenobiotic substances in an organism, 
which includes biotransformation targeted at inactivation of toxic parent compounds. 
However, this biotransformation may also produce toxic reactive metabolites, leading to 
xenobiotic-induced liver injury4,6. Various underlying mechanisms can result in a wide 
range of xenobiotic-induced liver toxic phenotypes, of which cholestasis, steatosis and 
necrosis are most frequently observed. Cholestasis is a chronic condition and is 
phenotypically characterized by bile accumulation as a result of changes in intra- or 
extracellular bile flow or bile composition34. Steatosis may occur chronically as well and is 
characterized as an increase in cellular lipid content due to an increase in de novo synthesis 
of fatty acids or reduced lipid secretion or oxidation19. Necrosis is an acute condition and 
is characterized by cell death typically due to oxidative stress4,33. 
A challenge in toxicology is to predict hepatotoxic potential of compounds to which 
humans are exposed. There is an urging need to develop and validate alternative 
approaches, since the traditional in vivo rodent studies are associated with ethical (large 
numbers of animals need to be exposed), economical (high costs due to high doses and 
long experimental periods), and scientific issues (the obtained results might not be fully 
predictive for the effects in humans). As such, the ZFE is an alternative test model that may 
replace or support the traditional in vivo rodent studies. This model combines the benefits 
of an in vivo model, namely complete biological complexity including interactions 
between tissues and cells49,54,95, with the advantages of in vitro model, that is, the ability 
for medium to high throughput testing. 
The structure and the function of the liver in the adult zebrafish is similar to the mammalian 
liver46, and a functional liver is present in the ZFE at three days post fertilization, which is 
therefore a suitable time point to start hepatotoxicity testing in this model. Furthermore, 
there is high genetic conservation between humans and zebrafish, including genes 
important for hepatotoxicity and biotransformation46,55. ZFEs express several cytochrome 
P450 enzymes, CYPs, which are grouped into the same families when compared to 
humans. In the zebrafish, the CYP families 1-4 are important for metabolizing xenobiotics, 
and these families are similar between the two species. In humans, the most important 
CYP responsible for catalyzing the majority of known drug-metabolizing reactions, 
namely CYP3A4, has an ortholog in the zebrafish, namely, cyp3a6546,55.
In previous studies, we showed that the ZFE not only can be used to identify hepatotoxic 
responses using histopathology hepatotoxic-associated transcripts by next-generation 
sequencing (NGS)133, but is also suitable for the identification of possible biomarkers for 
general hepatotoxicity by gene expression analysis133. Although gene expression analysis 
resulted in a possible list of biomarkers to predict hepatotoxicity in a high-through put 
manner, it does not allow to predict the protein concentration or activity from the 
measurement of mRNA levels148. Therefore proteomics analysis has become an additional 
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tool in understanding the underlying molecular mechanisms of hepatotoxicity while it 
provides quantitative information of molecular events at a more functional level. Therefore, 
to obtain full insight into the underlying mechanisms of hepatotoxicity, the proteomic 
changes are imperative information herein. Proteomics is frequently applied in the ZFE, 
but is mainly targeted at unraveling the developing proteome. The objective of this study 
was to identify proteomic signatures which describe hepatotoxic events in the ZFE. 
Specifically, it is hypothesized that distinct phenotypical classes of interest including 
cholestasis, steatosis and necrosis can be discerned by a specifically altered proteomics 
profile. Finally, we assessed whether we can define hepatotoxicity-associated proteomics 
markers to complement the changes as observed with gene expression after exposure to 
nine reference hepatotoxicants. These reference hepatotoxicants were confirmed to show 
hepatotoxic phenotypes in humans and rodent studies, namely cholestasis (cyclosporine 
A, chlorpromazine and 17α-ethinylestradiol)1,15,134,135, steatosis (amiodarone, tetracycline 
and valproic acid)23,136,137, and necrosis (acetaminophen, paraquat and thioacetamide)1,4,33. 
ZFEs were treated with the nine reference hepatotoxicants for 48 hours starting from 
three days post fertilization. Gene expression was performed as described previously149 
and the proteomics profiling was done by using liquid chromatography coupled with 
tandem mass spectometry. 
Materials and methods
Chemicals. All tested chemicals (purity >95%), were purchased from Sigma Aldrich 
(Zwijndrecht, the Netherlands), and included acetaminophen (N-actyl-para-aminophenol; 
paracetamol; APAP, CAS no.103-90-2; 660 µM), paraquat (1,1'-Dimethyl-4,4'-bipyridinium 
dichloride; PQ, CAS no.1910-42-5; 3 mM), thioacetamide (CH3-C(S)NH2); TA, CAS no.62-55-5; 
10 mM), amiodarone hydrochloride (2-butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-
3,5-diiodophenyl ketone hydrochloride; AM, CAS no.19774-82-4; 10 µM), valproic acid 
(2-propylpentanoic acid sodium; VPA, CAS no.1069-66-5; 600 µM), tetracycline (TET, CAS 
no.64-75-5; 200 µM), cyclosporine A (CsA, CAS no.59865-13-3; 6 µM),17α- ethinylestradiol 
(17α-Ethinyl-1,3,5(10)-estratriene-3,17β-diol; EE2, CAS no.57-63-6; 3.5 µM), chlorpromazine 
(2-Chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride; CPZ, CAS no.69-09-0; 
3 µM), D-Mannitol (Mannite; DM, CAS no. 69-65-8; 3 mM), Lithium Carbonate (Carbonic 
acid lithium salt; Li2CO3, CAS no. 554-13-2; 1.1 mM) and tricaine methanesulfonate (MS-222, 
CAS no. 886-86-2). Dimethylsulfoxide (DMSO, CAS no. 67-68-5; 0.2%) was ordered from 
Fisher-Scientific. 
Fish treatment. Wild-type zebrafish (Danio rerio) were originally obtained as commercially 
bred Singapore import (Ruinemans Aquarium BV, Montfoort, The Netherlands), which was 
maintained and bred in our facilities for more than 5 generations. Egg production was 
optimized by separation of the male and female fish before spawning, and female 
zebrafish were fed only thawed Artemia naupli prior to spawning. Egg predation was 
prevented by using a breeding tank with a perforated bottom, in which male and female 
zebrafish were paired in a 2:2 ratio before spawning. Spawning was triggered by morning light 
and was usually completed within 30 minutes. After spawning, the eggs were collected using a 
glass siphon and debris was removed to rinse the fertilized batches of eggs at least three 
times in Dutch Standard Water (DSW; demineralized water supplemented with NaHCO3 
(100 mg/l), KHCO3 (20 mg/l), CaCl2·2H2O (200 mg/l), and MgSO4·7H2O (180 mg/l) which was 
then aerated for 24 h at 27°C). After rinsing, the fertilized eggs from different batches were 
pooled and placed in a petri dish in an incubator at 26.5 ± 1°C with a photoperiod of 14 
hours light/10 hours dark. After 72 hours, hatched embryos were randomly distributed over 
48-well plates in a density of 5 embryos per well in 1 ml test or control medium. Three 
concentrations per test compounds in at least three statistical replicates per concentration 
consisting of 2 wells (10 embryos) per replicate were used. In total, 12 conditions were 
tested including 9 human hepatotoxicants, two vehicle controls and one non-hepato-
toxicant (Fig.1). The highest concentration that had no observed morphological or 
teratological effects and no mortality was used. At 120 hpf, the embryos were evaluated 
under a Leica Labovert FS microscope for deviations from normal development (e.g. delay 
in development, teratogenic effects) and indications of toxicity (e.g. abnormal swimming 
behavior) and snap frozen in liquid nitrogen to be used for proteomic analysis. Compound 
concentration during the 48 hours of exposure period was not analyzed, however, all 
compounds were indicated to be relatively stable according to NLM Hazardous Substances 
Database (http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB). 
All procedures were done under licensed conditions for studies with laboratory animals, 
according to European and Dutch legislation. 
Protein extraction and digestion. Protein extraction and digestion was adapted from 
Van der Plas-Duijvesteijn et al.150 with some modifications. In short, at 120 hpf, 10 embryos 
from each control and treated groups were homogenized using 0.5 mm zirconium oxide 
beads and the Bullet Blender (Next Advance, New York, United States) and their proteomes 
were extracted using a lysis buffer containing 8 M urea, 75 mM NaCL, 50 mM Tris-HCl pH 
8.2, 50 U/ml benzonase (E1014-5KU, Sigma-Aldrich), 2mM MgCl2, and protease inhibitors 
(Complete ULTRA Tablets, mini, EDTA-free, Roche). The lysate was kept at 4°C for 30 
minutes, after which it was centrifuged for 30 minutes at maximum speed (16,000×g) for 
another 30 minutes at 4°C. Total protein concentration was estimated by the use of a BCA 
assay (Product #23235, Bio-Rad) based on a bovine serum albumin as standard. In solution 
digest of the proteins was performed by adding 60 mM DTT to the protein lysate and 
incubated for 45 min at 56°C for cystines reduction. For alkylation and protection of the 
cystitis, 100 mM iodoacetamide was added to the sample and incubated for one hour at 
room temperature in the dark. Then, the protein mixture was diluted by adding 50 mM 
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ammonium bicarbonate. Next, the volume of the samples was reduced to 30 µl by 
centrifuging at room temperature for 30 minutes at 14000×g using the Millipore Amicon 
Centrifugal Filter ultra 0.5 (3,000 Da MWCO). The samples were collected by reversing the 
column in a new tube and centrifuging at 1000×g for 2 minutes. After this, sequenc-
ing-grade trypsin which specifically cleaves at the carboxylic side of lysine and arginine 
residues, was added to each sample to initiate digestion, and after overnight incubation, 
10% TFA was added to quench the digestion producing peptides that are readily identified 
by mass spectometry. Samples were centrifuged at 2,500×g for 10 minutes at room 
temperature; where after, supernatant was transferred to a fresh tube. Peptide digests 
were stored at -80°C until further analysis.  
Liquid chromatography - Tandem Mass Spectrometry. As previously described, two 
μl of each sample was loaded and desalted on a C18 PepMap 300 μm, 5 mm-i.d., 300 Å 
precolumn (Thermo Scientific) and separated by reversed-phase liquid chromatography 
using two identical 150 mm 0.3 mm–i.d. ChromXP C18CL, 120 Å columns (Eksigent, Dublin, 
CA, USA) coupled parallel and connected to a split less NanoLC-Ultra 2D plus system 
(Eksigent) with a linear 90-minute gradient from 4% to 35% acetonitrile in 0.05% formic 
acid and a constant (4 μL/minute) flow rate. The LC system was coupled to an amaZon 
speed ETD ion trap (Bruker Daltonics, Bremen, Germany) equipped with an Apollo II ESI 
source. After each MS scan, up to 10 abundant multiply charged species in m/z 300-1300 
were selected for MS/MS and actively excluded for one minute after having been selected 
twice. Each individual scan or tandem mass spectrum was saved to the hard drive. The LC 
system was controlled by HyStar 3.2 and the ion trap by trapControl 7.1. 
Data analysis
Data processing. Raw LC-MS/MS data were converted to line spectra mzXML151 files with 
the Bruker compassXport tool version 3.05. All further data processing was done with the 
Trans-Proteomic Pipeline 4.6 rev 390,152. Database search was performed with X!Tandem 
(2009.10.01.1)90,153 using the following parameters: precursor mass tolerance window was 
set between -2.0 and 4.0 Da, while fragment tolerance was set to 0.4 Da, modifications 
were set for carbamidomethylation of cysteine and oxidation of methionine, k-scoring 
was enabled, maximum missed cleavages was set to 2 and scoring was done for b and y 
ions. The X!Tandem output files were converted to pepXML file format with tandem2xml 
without applying any cut-offs. X!Tandem pepXML files were merged into PeptideProphet 
and analyzed with the decoy option enabled154. The resulting posterior probabilities for 
the peptide spectrum matches were further refined by iProphet 155. Finally, ProteinProphet 
was used to compute a probability that each protein was present in the sample and to 
estimate a global false discovery rate (FDR). ProteinProphet output was filtered using the 
probability threshold that corresponded to an FDR < 1% and proteins with an individual 
probability of zero were discarded. Filtered protein lists were combined90,153.
Protein expression analysis. Following our hypothesis, the basis for protein expression 
analysis was histopathological clustering. Clusters were based either on the phenotype as 
observed in humans after compound exposure (referred to as nominal phenotype) or on 
actual observed histopathology (observed phenotype) (detailed information can be 
found in Driessen et al.133,149. The nominal phenotype clusters included three classes, 
namely cholestasis (CPZ, CsA and EE2), steatosis (AM, TET and VPA) and necrosis (APAP, PQ 
and TAA). The observed phenotypes consisted of four clusters; (1) lipid vacuolization (AM, 
CPZ and VPA), (2) chromatin condensation (CPZ, EE2, and PQ), (3) chromophobic 
vacuolization (CsA, EE2, PQ and TAA) and (4) eosinophilic vacuolization (CPZ, CsA, TET and 
APAP). Overrepresented proteins were determined using a two group-comparison with a 
p < 0.05 in QluCore Omics Explorer (Qlucore AB, Lund, Sweden). Phenotypic clusters were 
based on either nominal phenotype or observed phenotype and overrepresented 
pathways per cluster were determined using STITCH with FDR < 0.0591–94 (Table 1). 
Marker protein selection. To detect commonly induced proteins between hepatotoxic 
compounds, the protein expression values for the highest concentration of each 
compound were analysed by correcting for negative controls. Proteins with an apparent 
absolute FC > 1.5 were considered to be differentially expressed and were ranked on the 
number of compounds regulating the proteins. General hepatotoxicity markers were 
defined as proteins induced by at least six compounds and FC > 1.5.
Match of transcript and protein expression. Gene expression was obtained from a previous 
study149 and matched with the observed proteins in this study. Protein names from 
UniProt were matched against the microarray transcripts gene IDs156. This resulted in a set 
of 402 proteins/genes. Next, the expression between the gene-protein was matched, 
whereby the protein should have a FC > 1.5. 
Results
Basic proteomics observations. In the present study in total we identified 287,000 Pep-
tide-Spectrum Matches (PSMs) corresponding to 3,461 unique peptides and 1,258 unique 
proteins with 1% FDR. From these 1,258 proteins identified, 1,012 proteins were present in 
at least two samples.
Hepatotoxicity-associated pathways. A general view of the enriched pathways based 
on the 1012 identified proteins revealed enrichment in many biological processes including 
translation, gene expression and cellular metabolic process (Table 1). The enriched biological 
processes shared similarities based on single protein levels, whereas for example the protein 
rpl4 is present in 18 different biological processes.  
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Table 1   Description of the marker genes.
Phenotype GO_id Term Number of 
Genes
p-value p-value_fdr p-value_ 
bonferroni
necrosis GO:0006412 translation 13 4,34E-14 2,54E-10 2,54E-10
GO:0044267 cellular protein metabolic process 17 1,09E-07 3,17E-04 6,34E-04
GO:0010467 gene expression 17 4,96E-07 8,04E-04 2,90E-03
GO:0044249 cellular biosynthetic process 16 7,03E-07 8,04E-04 4,10E-03
GO:0034645 cellular macromolecule biosynthetic process 14 9,19E-07 8,04E-04 5,36E-03
GO:1901576 organic substance biosynthetic process 16 9,34E-07 8,04E-04 5,45E-03
GO:0009059 macromolecule biosynthetic process 14 9,64E-07 8,04E-04 5,63E-03
GO:0009058 biosynthetic process 16 1,58E-06 1,16E-03 9,24E-03
GO:0019538 protein metabolic process 17 3,83E-06 2,48E-03 2,23E-02
GO:0008152 metabolic process 26 1,33E-05 7,76E-03 7,76E-02
GO:0044237 cellular metabolic process 22 2,66E-05 1,41E-02 1,55E-01
GO:0044260 cellular macromolecule metabolic process 18 6,42E-05 3,13E-02 3,75E-01
GO:0044238 primary metabolic process 22 9,21E-05 4,13E-02 5,37E-01
cholestasis GO:0006412 translation 10 1,94E-11 1,13E-07 1,13E-07
GO:0044249 cellular biosynthetic process 13 1,50E-06 2,78E-03 8,77E-03
GO:0044267 cellular protein metabolic process 13 1,54E-06 2,78E-03 9,00E-03
GO:1901576 organic substance biosynthetic process 13 1,91E-06 2,78E-03 1,11E-02
GO:0009058 biosynthetic process 13 2,98E-06 3,48E-03 1,74E-02
GO:0034645 cellular macromolecule biosynthetic process 11 5,21E-06 4,52E-03 3,04E-02
GO:0009059 macromolecule biosynthetic process 11 5,42E-06 4,52E-03 3,16E-02
GO:0019538 protein metabolic process 13 2,49E-05 1,74E-02 1,45E-01
GO:0006189 ‘de novo’ IMP biosynthetic process 2 2,93E-05 1,74E-02 1,71E-01
GO:0008152 metabolic process 20 3,01E-05 1,74E-02 1,75E-01
GO:0010467 gene expression 12 3,27E-05 1,74E-02 1,91E-01
Steatosis GO:0006412 translation 12 3,86E-13 2,25E-09 2,25E-09
GO:0034645 cellular macromolecule biosynthetic process 13 1,90E-06 3,87E-03 1,11E-02
GO:0009059 macromolecule biosynthetic process 13 1,99E-06 3,87E-03 1,16E-02
GO:0010467 gene expression 15 4,27E-06 6,24E-03 2,49E-02
GO:0044249 cellular biosynthetic process 14 6,86E-06 8,01E-03 4,01E-02
Lipid  
Vacuolization
GO:0006412 translation 11 3,42E-12 2,00E-08 2,00E-08
GO:0010467 gene expression 18 1,54E-09 4,49E-06 8,99E-06
GO:0044267 cellular protein metabolic process 15 2,38E-07 4,58E-04 1,39E-03
GO:0044260 cellular macromolecule metabolic process 19 3,34E-07 4,58E-04 1,95E-03
GO:0034645 cellular macromolecule biosynthetic process 13 5,11E-07 4,58E-04 2,98E-03
GO:0009059 macromolecule biosynthetic process 13 5,34E-07 4,58E-04 3,12E-03
GO:0043170 macromolecule metabolic process 20 5,50E-07 4,58E-04 3,21E-03
GO:0019538 protein metabolic process 16 9,31E-07 6,79E-04 5,43E-03
GO:0044237 cellular metabolic process 21 1,66E-06 1,08E-03 9,71E-03
GO:0009058 biosynthetic process 14 3,51E-06 2,05E-03 2,05E-02
GO:0044238 primary metabolic process 21 6,13E-06 3,26E-03 3,58E-02
GO:0008152 metabolic process 23 8,16E-06 3,97E-03 4,76E-02
GO:0071704 organic substance metabolic process 21 9,18E-06 4,12E-03 5,36E-02
GO:0044249 cellular biosynthetic process 13 1,11E-05 4,62E-03 6,47E-02
GO:1901576 organic substance biosynthetic process 13 1,39E-05 5,42E-03 8,13E-02
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Phenotype clustering. The basis for our current protein expression analysis was the 
association with histopathological clustering. Clusters were based either on the phenotype 
as observed in humans after compound exposure (referred to as nominal phenotype) or 
on actual observed histopathology (observed phenotype). To determine whether the 
phenotypes, nominal or observed, specifically defined processes, a phenotype-directed 
analysis was performed. For each specific cluster, a set of discriminating proteins was 
identified and this set was used for the determination of enriched processes. For the 
nominal phenotypes, the cluster necrosis resulted in 13 enriched biological processes, 
steatosis only in 5 biological processes and cholestasis resulted in 11 enriched biological 
processes. For the observed phenotypes, chromatin condensation resulted in one 
enriched biological process, whereas lipid vacuolization, eosinophilic vacuolization and 
chromophobic condensation resulted in 15, 18, and 9 enriched biological process, respectively 
(see Table 1). It should be noted that much overlap was present in the enriched biological 
processes, for example the biological process “translation” was enriched in each cluster 
Table 1   Continued.
Phenotype GO_id Term Number of 
Genes




GO:0030163 protein catabolic process 8 1,26E-09 7,38E-06 7,38E-06
GO:1901575 organic substance catabolic process 11 5,44E-09 1,52E-05 3,17E-05
GO:0009056 catabolic process 11 1,18E-08 1,52E-05 6,91E-05
GO:0051603 proteolysis involved in cellular protein catabolic process 7 1,35E-08 1,52E-05 7,88E-05
GO:0044257 cellular protein catabolic process 7 1,52E-08 1,52E-05 8,86E-05
GO:0009057 macromolecule catabolic process 8 1,56E-08 1,52E-05 9,11E-05
GO:0044265 cellular macromolecule catabolic process 7 9,62E-08 8,03E-05 5,62E-04
GO:0044248 cellular catabolic process 9 2,78E-07 2,03E-04 1,62E-03
GO:0044238 primary metabolic process 21 2,56E-06 1,66E-03 1,49E-02
GO:0009117 nucleotide metabolic process 7 3,17E-06 1,77E-03 1,85E-02
GO:0006753 nucleoside phosphate metabolic process 7 3,33E-06 1,77E-03 1,94E-02
GO:0071704 organic substance metabolic process 21 3,86E-06 1,88E-03 2,26E-02
GO:0044237 cellular metabolic process 20 4,26E-06 1,91E-03 2,49E-02
GO:0009150 purine ribonucleotide metabolic process 6 4,85E-06 2,02E-03 2,83E-02
GO:0006163 purine nucleotide metabolic process 6 5,50E-06 2,14E-03 3,21E-02
GO:0019693 ribose phosphate metabolic process 6 6,81E-06 2,34E-03 3,97E-02
GO:0009259 ribonucleotide metabolic process 6 6,81E-06 2,34E-03 3,97E-02
GO:0055086 nucleobase-containing small molecule metabolic process 7 7,34E-06 2,38E-03 4,29E-02
Chromophobic 
condensation
GO:0006412 translation 10 1,31E-14 7,67E-11 7,67E-11
GO:0034645 cellular macromolecule biosynthetic process 10 5,33E-08 1,08E-04 3,11E-04
GO:0009059 macromolecule biosynthetic process 10 5,54E-08 1,08E-04 3,23E-04
GO:0010467 gene expression 11 1,26E-07 1,84E-04 7,37E-04
GO:0019538 protein metabolic process 11 5,64E-07 6,07E-04 3,29E-03
GO:0044249 cellular biosynthetic process 10 7,12E-07 6,07E-04 4,16E-03
GO:0044267 cellular protein metabolic process 10 7,27E-07 6,07E-04 4,25E-03
GO:1901576 organic substance biosynthetic process 10 8,67E-07 6,32E-04 5,06E-03
GO:0009058 biosynthetic process 10 1,25E-06 8,11E-04 7,30E-03
Chromatin  
condensation
GO:0006412 translation 7 1,49E-07 8,68E-04 8,68E-04
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except eosinophilic vacuolization (Table 1). The phenotype steatosis completely overlapped 
with the phenotypes necrosis and cholestasis based on enriched processes, whereas 
there were three necrosis specific processes and one for steatosis. For the observed 
phenotypes, eosinophilic vacuolization had 15 specific enriched processes and only 
shared 3 processes with lipid vacuolization phenotype. The other three observed 
phenotypes overlap based on the enriched processes (Fig.1) indicating that the ZFE is 
not able to discriminate between the different hepatotoxic classes using proteomics. 
Overlap phenotypes/common hepatotoxicity. Since phenotype-specific processes 
could not be identified due to large overlap of enriched processes, all hepatotoxicants 
were grouped together, corrected for the negative controls, and ranked on FC and the 
number of compounds inducing the protein to identify markers for general hepatotoxicity. 
This resulted in 427 proteins of the total of 1258 proteins detected having a FC > 1.5 and 
being modulated by 6 or more compounds. Using these 427 proteins, enriched processes 
were determined and resulted in 15 up-regulated processes and 10 down-regulated 
processes. The common up-regulated biological processes included, for example, some 
relevant processes including translation, gene expression and metabolic processes. 
Common down-regulated processes included, for example, translation and protein 
folding (See Table 2) (Supplementary tables 1 and 2 for individual proteins per process). 
Identification of common hepatotoxicity marker proteins. Next, we determined 
marker proteins for common hepatotoxicity. The 427 proteins related to general hepato- 
toxicity were ranked on FC and the number of compounds inducing the specific protein. 
A cluster analysis separated proteins into two groups, first CsA and PQ in one group and 
all the others in the second group (Fig. 2) suggesting that CsA and PQ induce the common 
proteins to a lesser extent.  For the upregulated proteins, two proteins were regulated by 
all 9 compounds which included pcnxl3 and si:ch211-212n6.8. There were 19 proteins 
induced by eight compounds and these proteins were mylpfa, zgc:163069, rpsa, psap, 
psma8, si:ch211-93f2.1, snrpa1, epb41b, msi2a , glud1b, nbeal2, naps, zgc:165571, col1a1a, eno1a, 
znf143, still, cirbp and fdx1 (Fig.2, table 3).
For the downregulated proteins, 13 proteins were induced by nine compounds and 41 
were induced by eight compounds. The 13 proteins induced by nine compounds included 
murc, ttnb, srsf3a, paics, si:ch1073-349o24.2, anxa1c, hspe1, zgc:86599, kat6b, rps14, tnw, ldhba , 
and psma6b (Fig.2, table 3). Figure 1   Ranking of the regulated proteins.
Heatmap - regulated proteins per compound were determine using FC > 1.5 and regulation of the 
protein by at least 6 compounds. Table -  indicates the number of proteins regulated by the number 
of compounds. 
#"compounds #"of"proteins Regula4on 
9 13 DOWN 
8 41 DOWN 
7 77 DOWN 
6 94 DOWN 
6 102 UP 
7 54 UP 
8 19 UP 
9 2 UP 
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Figure 2   STRING network representation of the down regulated proteins.
STRING network representation of the 402 proteins identified as having a FC > 1.5 and by regulated 
by more than 6 compounds. Blue lines indicate connects between the proteins.
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AM APAP CPZ CsA EE2 PQ TAA TET VPA Sum down Sum Up
A1L260 552940 murc cell differentiation, muscle organ development, regulation of 
transcription DNA dependent, transcription DNA dependent
NA -2,23756 -0,66 -0,77 -2,52 -1,42 -1,58 -2,65 -1,07 -1,40 9 0
B0S6Y0 100333283 ttnb titin b NA -2,00178 -1,29 -0,98 -1,77 -1,30 -3,33 -0,36 -0,43 -0,80 9 0
Q801U3 368925 srsf3a nucleic acid binding NA -1,88251 -1,01 -1,67 -2,55 -2,52 -2,27 -1,34 -0,31 -1,24 9 0
Q7ZUN6 321193 paics phosphoribosylaminoimidazole carboxylase, phosphoribosy-
laminoimidazole succinocarboxamide synthetase
10606 PAICS -1,72851 -1,98 -3,05 -3,41 -1,57 -0,38 -0,36 -0,75 -0,19 9 0
E9QCL0 100333283 si:ch1073-349o24.2 255101 CCDC108 -1,22398 -0,16 -0,51 -1,93 -2,21 -1,17 -0,80 -0,40 -0,08 9 0
Q804H0 494158 anxa1c annexin A1c NA -1,17645 -1,99 -2,24 -1,10 -1,49 -1,48 -0,39 -0,92 -0,86 9 0
Q6IQI7 58041 hspe1 heat shock 10 protein 1 (chaperonin 10) 3336 HSPE1 -0,89881 -1,72 -1,19 -1,20 -1,97 -1,69 -2,38 -0,91 -1,73 9 0
F1RCH5 415253 zgc:86599 zgc:86599 1329 COX5B -0,78497 -1,80 -3,29 -0,16 -0,76 -1,18 -0,98 -0,64 -0,59 9 0
B7ZD47 568932 kat6b nucleosome assembly, nucleosome, nucleus, DNA binding, 
zinc ion binding
23522 KAT6B -0,77977 -1,35 -3,21 -0,73 -2,27 -1,01 -0,19 -1,57 -0,69 9 0
Q6PBW3 336687 rps14 ribosomal protein S14 6208 RPS14 -0,66654 -1,05 -1,20 -0,01 -1,06 -1,62 -0,49 -0,96 -0,12 9 0
B0S6K6 30234 tnw ECM-Receptor interaction, Focal adhesion NA -0,61845 -0,45 -3,22 -1,26 -1,06 -1,66 -0,41 -0,06 -0,48 9 0
Q9PVK4 30497 ldhba Cellular carbohydrate metabolic process, glycolysis, cytoplasm, 
L-lactate dehydrogenase activity
NA -0,35410 -0,57 -0,79 -1,53 -1,16 -1,24 -1,66 -0,40 -1,81 9 0
Q6DGY8 436862 psma6b proteasome (prosome, macropain) subunit, alpha type, 6b 5687 PSMA6 -0,33796 -1,02 -1,77 -0,59 -2,49 -4,01 -0,66 -0,75 -0,96 9 0
Q800A1 360209 pvalb9 parvalbumin 9 654231 OCM -2,71063 -2,01 -2,35 -3,33 -2,92 -1,66 -0,57 1,51 -1,10 8 1
E7F4A4 100004231 wu:fa03e10 NA -2,53285 -1,41 -1,03 -2,77 -2,40 -2,22 1,01 -0,44 -1,09 8 1
Q66I42 286739 msna blood vessel lumenization, endoderm development, 
 cytoplasm, cytoskeleton, extrinsic to membrane
4478 MSN -2,35953 0,45 -1,00 -0,76 -0,12 -0,69 -0,56 -0,33 -0,95 8 1
F1QCB3 494042 slc43a2b integral to membrane, L-amino acid transmembrane 
 transporter activity
124935 SLC43A2 -2,03292 -1,30 -1,28 -3,29 -2,13 -1,73 1,11 -2,03 -0,33 8 1
F1R1J9 559276 ahnak oxidoreductase activity 79026 AHNAK -2,00947 -0,17 -2,99 -2,90 0,30 -2,55 -2,31 -0,03 -1,35 8 1
E7F366 324479 bptf zinc ion binding 2186 BPTF -1,93982 -1,13 -1,41 0,44 -0,81 -1,30 -1,88 -0,42 -0,09 8 1
Q7SY53 334082 tdo2b tryptophan 2,3-dioxygenase b NA -1,90317 -0,95 -0,85 -2,71 -1,32 -2,69 -1,37 0,44 -0,37 8 1
F1RA03 572200 LOC572200 similar to vimentin NA -1,87826 -0,94 -1,28 -3,23 -1,40 -1,94 -0,56 0,46 -1,08 8 1
B8JL29 641484 hmgb2a 3148 HMGB2 -1,50086 -0,74 -1,78 -1,45 -1,66 -2,43 -0,05 0,15 -1,25 8 1
Q6GMJ1 566132 ces2 hydrolase activity 8824 CES2 -1,44611 -0,12 -0,29 -1,30 -0,95 -2,03 -1,18 0,69 -1,46 8 1
F1QD81 447889 pnp5b nucleoside metabolic process, purine-nucleoside 
 phosphorylase activity
NA -1,42661 -0,92 0,66 -1,49 -1,39 -1,55 -0,12 -2,61 -0,08 8 1
F8W4A8 567855 si:ch73-50f9.1 integral to membrane NA -1,38696 0,27 -1,97 -1,03 -0,17 -1,50 -0,71 -0,35 -0,04 8 1
Q6DHB6 445051 zgc:92533 zgc:92533 3872 KRT17 -1,35638 -0,45 -1,30 -2,07 -2,35 -1,47 0,06 -0,96 -1,58 8 1
Q6IQ59 322549 uqcrc2b proteolysis, metal ion binding, metalloendopeptidase activity 7385 UQCRC2 -1,33726 -1,12 -0,84 -2,45 -1,15 -2,17 -1,08 0,63 -1,27 8 1
Q7T3L3 386590 hsp90b1 heat shock protein 90, beta (grp94), member 1 7184 HSP90B1 -1,31686 -0,45 -0,88 -2,02 -1,16 -0,94 -0,72 -0,10 0,30 8 1
F1R1Z6 335842 tsc22d1 zgc:85857 8848 TSC22D1 -1,30107 0,52 -0,26 -1,56 -0,51 -2,07 -0,58 -0,61 -1,47 8 1
Q802D5 394235 pfn2 profilin 2 5217 PFN2 -1,28425 -1,05 -0,45 -2,42 -0,80 -1,63 -0,46 -1,15 0,22 8 1
A3FKT8 100005083 icn2 ictacalcin 2 6275 S100A4 -1,25978 -0,53 -1,30 -0,74 -0,97 -0,28 -1,29 0,12 -0,33 8 1
Q503C7 553655 pygma carbohydrate metabolic process, glycogen phosphorylase 
activity, pyridoxal phosphate binding
5837 PYGM -1,24654 -0,25 -0,99 -2,11 -1,33 -2,48 0,36 -0,83 -0,75 8 1
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AM APAP CPZ CsA EE2 PQ TAA TET VPA Sum down Sum Up
F8W4M7 322670 aco2 aconitase 2, mitochondrial 50 ACO2 -1,16415 -1,46 -1,62 -0,10 -1,58 -1,89 0,06 -0,57 -0,83 8 1
F1QXH7 327500 zgc:66474 zgc:66474 NA -1,11214 -0,75 -3,03 -2,52 -0,94 -1,12 0,63 -0,48 -1,86 8 1
H9GX84 100003906 zgc:112265 3700 ITIH4 -1,04245 -0,61 0,11 -1,12 -0,53 -2,37 -0,95 -1,44 -0,37 8 1
Q6IQJ2 767806 zgc:55461 zgc:55461; zgc:123194; zgc:153264; zgc:123292; tubulin, beta 
2c; zgc:153426
NA -0,99582 -0,59 -0,22 2,65 -0,04 -1,69 -1,90 -1,89 -0,07 8 1
I3NI77 449864 grin2da ionotropic glutamate receptor signaling pathway, cell junction, 
integral to membrane, outer membrane-bounded periplas-
mic space, plasma membrane, postsynaptic membrane, 
extracellular-glutamate-gated ion channel activity, ionotropic 
glutamate receptor activity
2906 GRIN2D -0,92925 -0,67 -1,86 -2,17 -0,21 -0,60 -0,58 0,92 -2,08 8 1
Q7ZYZ4 30601 hbae3 hemoglobin alpha embryonic-3 NA -0,91220 -0,07 0,12 -0,14 -0,44 -0,94 -1,50 -0,44 -0,94 8 1
F1QW57 100331557 LOC100331557 0 NA -0,89687 -2,25 -3,14 1,20 -3,15 -1,95 -0,23 -0,34 -0,87 8 1
A8E5I2 393540 zgc:77517 zgc:77517 3875 KRT18 -0,79947 -0,75 -0,36 -0,75 -0,79 -2,38 -1,33 0,39 -0,89 8 1
E7EYE1 565428 CR847973.1 NA -0,76208 0,85 -0,96 -0,10 -0,02 -2,16 -0,55 -0,37 -0,09 8 1
Q8AWD0 322126 vdac2 voltage-dependent anion channel 2 7417 VDAC2 -0,75896 -1,56 -0,52 -1,31 -1,17 -0,54 0,60 -1,40 -0,90 8 1
Q803M1 373076 tpm3 7170 TPM3 -0,70343 0,65 -0,00 -1,49 -1,94 -1,73 -0,20 -0,96 -0,78 8 1
Q6NXA9 322073 ubxn1 negative regulation of proteasomal ubiquitin-dependent 
protein catabolic process, negative regulation of protein ubi-
quitination, cytoplasm, K6 linked polyubiquitin binding
51035 UBXN1 -0,64131 0,97 -0,22 -1,92 -1,02 -0,62 -0,56 -0,90 -0,19 8 1
Q6XG62 336655 icn ictacalcin 6275 S100A4 -0,61938 -0,83 -1,29 -1,39 -0,56 -1,00 -0,12 0,33 -0,45 8 1
Q6PH46 393555 cct4 chaperonin containing TCP1, subunit 4 (delta) 10575 CCT4 -0,56944 -1,07 -1,76 -1,35 -1,06 -0,11 0,28 -0,33 -0,29 8 1
Q5BLF6 30596 hbbe3 hemoglobin beta embryonic-3 3046 HBE1 -0,56314 -0,67 -2,49 -0,85 0,35 -1,76 -0,48 -0,25 -1,43 8 1
Q66I73 447930 mylpfb calcium ion binding 29895 MYLPF -0,53469 -0,19 -0,66 -1,13 -0,68 0,51 -0,59 -1,07 -0,83 8 1
F1QS28 323529 hnrnpa0a nucleic acid binding, nucleotide binding 10949 HNRNPA0 -0,41444 -0,11 -0,45 -0,39 -0,71 -1,48 -0,06 0,00 -0,16 8 1
E7F8W3 797132 sirt1 cell migration involved in sprouting angiogenesis, NAD+ 
binding
23411 SIRT1 -0,34615 -1,03 -1,80 -1,87 -1,29 -1,41 0,94 -0,73 -0,38 8 1
Q7T2J4 402841 adh8b alcohol dehydrogenase 8a; alcohol dehydrogenase 8b NA -0,15260 -0,07 -0,54 0,32 -0,27 -1,82 -0,35 -0,38 -0,90 8 1
H9GYZ0 100536006 LOC100536006 NA 0,15408 -2,22 -2,70 -2,13 -1,57 -1,27 -0,55 -0,46 -1,12 8 1
Q08CK7 558182 igf2bp1 insulin-like growth factor 2 mRNA binding protein 1 10642 IGF2BP1 0,28011 -2,02 -1,73 -4,29 -2,39 -0,71 -1,03 -1,37 -0,68 8 1
A2BID5 405756 veph brain development, ear morphogenesis, plasma membrane, 
phospholipid binding
79674 VEPH1 1,39680 -2,32 -2,62 -1,22 -1,88 -1,91 -2,05 -0,15 -3,04 8 1
O93409 30429 mylpfa calcium ion binding 29895 MYLPF 0,05979 0,58 1,83 0,23 0,27 0,81 0,72 -0,54 0,34 1 8
F1R2V7 100038785 zgc:163069 zgc:163069; wu:fj55c09; zgc:111961 NA 0,22677 0,02 0,60 0,91 0,41 0,46 0,30 -0,59 0,81 1 8
Q803F6 394027 rpsa ribosomal protein SA 3921 RPSA 0,24968 1,50 3,35 0,68 2,12 0,03 -0,73 1,01 1,10 1 8
F1QMF5 140811 psap sphingolipid metabolic process, lysosome 5660 PSAP 0,27516 0,41 0,52 0,20 0,37 -0,60 0,35 2,43 0,90 1 8
Q6P0I2 406445 psma8 proteasome (prosome, macropain) subunit, alpha type, 8 143471 PSMA8 0,36309 1,81 2,61 2,14 0,68 -0,36 2,10 1,15 2,40 1 8
F1QLQ9 561967 si:ch211-93f2.1 carboxylesterase activity NA 0,42594 1,65 1,91 0,29 1,05 -2,18 0,23 1,67 0,56 1 8
F1R300 492511 snrpa1 6627 SNRPA1 0,43642 1,31 1,63 1,31 0,25 -0,87 0,17 2,15 0,63 1 8
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Proteins are linked to hepatotoxicity-associated pathways. We then determined for 
each of the marker proteins to which processes they belong. The proteins up-regulated by 
eight or more compounds could be linked to the enriched processes/pathways including 
zinc ion binding, calcium ion binding, heat shock proteins, but also liver-associated pathways, 
i.e. carbohydrate metabolism, oxidoreductase activity and alcohol dehydrogenase activation 
(Fig.3, Table 3). 
Proteins downregulated by eight or more compounds were linked to enriched processes/
pathways including calcium ion binding, glycolysis and cytoskeleton related processes 
(Fig. 2, Table 3).  
Match transcripts and proteins. In addition, we matched the direction of expression 
between gene and protein expression, while it is assumed that gene expression levels 
correlate with protein levels over time. Gene expression data were based on the same 
time point and published by us before149. Analysis was based on the availability of 
matching protein-gene combinations resulting in a total of 403 direct mRNA-protein 
comparisons. Matching of direction can be divided into four up-down combinations. This 
analysis revealed that CsA, EE2, PQ, TAA and VPA were overrepresented in group ‘protein 
– gene down’ (Fig 4.). For the other compounds the directionality of expression between 
protein and gene expression did not match very well. PQ showed the highest correlation 
(0.82), and the most enriched GO biological processes in the protein – gene down cluster 
were glutamate receptor signaling pathway, synaptic transmission, translation, cell-cell 
signaling, nucleosome organization and protein-DNA complex subunit organization 
(Table 4). 











AM APAP CPZ CsA EE2 PQ TAA TET VPA Sum down Sum Up
Q8JG61 326287 epb41b cortical actin cytoskeleton organization, embryonic hemo-
poiesis, erythrocyte differentiation, cytoplasm, cytoskeleton, 
extrinsic to plasma membrane, calmodulin binding
NA 0,63215 1,88 1,01 0,26 0,61 -0,70 0,65 1,24 0,87 1 8
Q7ZW10 100002680 msi2a musashi homolog 2a (Drosophila) 124540 MSI2 0,65499 1,56 1,48 0,04 0,96 -0,68 1,19 0,82 1,14 1 8
Q6P3L9 373092 glud1b zgc:192851; glutamate dehydrogenase 1b 2747 GLUD2 0,71978 1,51 1,78 0,14 0,97 -0,87 0,84 1,58 0,53 1 8
E7FAW3 100330830 nbeal2 endoplasmic reticulum 23218 NBEAL2 0,85297 1,10 1,55 1,63 0,91 -0,14 1,11 0,33 0,95 1 8
F1QNE0 799570 nasp nuclear autoantigenic sperm protein (histone-binding) 4678 NASP 0,86559 1,74 2,13 0,61 0,24 -1,61 0,41 1,44 0,39 1 8
F1Q8B0 335309 zgc:165571 NA 0,89473 1,67 0,83 2,25 0,59 -1,16 0,47 0,62 0,20 1 8
F1QJC9 337158 col1a1a collagen, type I, alpha 1 1277 COL1A1 1,09770 2,49 0,94 1,72 0,73 -0,16 2,39 0,29 0,58 1 8
Q6PC12 334116 eno1a glycolysis, phosphopyruvate hydratase complex, magnesium 
ion binding, phosphopyruvate hydratase activity
NA 1,62171 1,19 0,32 1,94 1,56 -0,08 1,01 1,36 0,40 1 8
Q1LYE3 393954 znf143 zinc finger protein 143 7702 ZNF143 2,13124 1,55 0,80 -1,24 3,16 0,77 0,77 0,09 1,94 1 8
Q8JGS1 192317 stil body morphogenesis, mitotic spindle organization, multi-
cellular organismal development, neuron homeostasism 
smoothened signaling pathway, spindle assembly, cytoplasm
6491 STIL 2,40272 0,10 3,16 2,00 1,40 0,18 1,14 -1,44 0,91 1 8
F1R6L4 678563 cirbp nucleic acid binding, nucleotide binding 1153 CIRBP 2,68568 1,40 1,47 4,09 0,65 0,96 2,06 0,06 -0,13 1 8
E7F7J1 100126232 fdx1 2 iron 2 sulfur cluster binding, electron carrier activity, metal 
ion binding
2230 FDX1 3,20284 2,24 4,08 2,61 0,88 -0,65 0,91 2,04 0,80 1 8
E7FBX3 100333869 pcnxl3 integral to membrane NA 0,55653 1,38 1,63 0,74 0,36 0,13 1,54 0,79 1,75 0 9
A6H8Q4 100329887 si:ch211-212n6.8 NA 1,66097 2,06 1,12 1,66 0,76 0,37 1,87 1,43 1,85 0 9
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Figure 3   STRING network representation of the up regulated proteins.
STRING network representation of the 402 proteins identified as having a FC > 1.5 and by regulated 
by more than 6 compounds. Blue lines indicate connects between the proteins.
Table 4   Description of the marker genes.






GO:0035235 ionotropic glutamate receptor 
signaling pathway
7 2,58E-11 8,46E-08 1,50E-07
GO:0007215 glutamate receptor signaling 
pathway
7 4,35E-11 8,46E-08 2,54E-07
GO:0035249 synaptic transmission, 
 glutamatergic
7 4,35E-11 8,46E-08 2,54E-07
GO:0007268 synaptic transmission 8 1,79E-07 2,09E-04 1,04E-03
GO:0006412 translation 12 2,67E-07 2,60E-04 1,56E-03
GO:0007267 cell-cell signaling 8 1,99E-06 1,66E-03 1,16E-02
Figure 4   Correlation between gene and protein expression per compound.
Representation of the matched directionality of corresponding gene – protein pair. Directionality of 
each pair can be placed into four catergories including gene up – protein up, gene up – protein 
down, gene down – protein down, gene down – protein up. Each color represents a different 
reference hepatotoxicant.
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In this study, we analysed the regulation of protein expression in ZFEs after exposure to 9 
reference hepatotoxicants, to improve mechanistic understanding of processes underlying 
hepatotoxicity and derive predictive biomarkers hereof. Furthermore, we compared gene 
and protein expression to detect interrelations between these levels in the dynamics of 
liver toxicity. 
To investigate whether the significantly expressed proteins underlined the histopatholog-
ical changes defining phenotypical clusters, overrepresented pathway analysis was 
performed using STITCH91–94. This enrichment analysis showed that the proteomic 
responses appeared very similar between the phenotypical clusters, resulting in shared 
pathways and/or processes.  One such a shared biological process is “translation”, which is 
known to be disrupted in in global stress responses157.  “Translation” was highly enriched 
for both up- and down -regulated proteins, which were mainly characterized by rps and 
rpl proteins, respectively. Other detected shared processes, such as the extremely broad 
“cellular protein metabolic process”, “gene expression” and “metabolic process” are also 
known to be influenced in a general stress response. Altogether, proteome profiling in the 
ZFE after hepatotoxicant exposure tends to detect a more general stress response which 
may be linked to oxidative stress, and the large overlap of enriched processes between 
the phenotypical clusters suggests that this type of broad analysis in the ZFE is not suitable 
to discriminate between the histopathological phenotypes.  
An extended analysis based on common hepatotoxicity produced “translation”, “gene 
expression” and “protein folding” as highly overrepresented processes. The down-regulated 
process “protein folding” is associated with a stress response involving the endoplasmic 
reticulum (ER), and a prolonged stress response will eventually lead to apoptosis158. The 
unfolded protein stress response has been found as important for drug induced liver 
injury (DILI)159. The strong upregulation of translation processes indicates that the ZFE is 
adapting to the stress caused by the xenobiotics157. A general stress response thus appears 
to emerge as an importantly regulated protein expression process after hepatotoxicant 
exposure. 
While there was a large overlap between the phenotypical clusters on pathway and/or 
process level, we identified a set of predictive key proteins for common hepatotoxicity. For 
the upregulated proteins, pcnx l3 and si:ch211-212n6.8 were regulated by all 9 reference 
compounds. The first protein, pcnxl3, is involved in membrane composition80. The other 
protein is recently annotated as crygm2d19, which is a crystallin. Crystallins play an 
important role in the development of the lens of the eye, but have recently also been 
observed in other areas of the body, where they might play a role in calcium ion binding80. 
This could be relevant in hepatotoxic processes in view of the role of calcium as an 
important second messenger in response to stress80. In addition, crystallins are found to 
be regulated after toxic stress in PFOS treated zebrafish larvae160,161. 
Also proteins that were induced by only 8 of the 9 compounds (Table 3) could be linked to 
hepatotoxic processes. For example, the protein glud1b (glutamate dehydrogenase 1b) 
plays a key role in nitrogen and glutamate metabolism, and also in the energy 
homeostasis80. The human ortholog GLUD1 is a serum marker for hepatotoxicity along 
with ALT and AST162. The si:ch211-93f2.1 protein is a carboxyl esterase which in humans is 
known to be involved in the hydrolysis of xenobiotics80. The eno1a protein is involved in 
glycolysis and was previously reported to be differentially expressed in ZFE after exposure 
to CsA163, supporting a role in hepatotoxicity. The mitochondrial 10 kDa heat shock 
protein, hspe1, was upregulated in our ZFEs after exposure to the hepatotoxicants 
suggesting the occurrence of oxidative stress. This is in contrast to the observed 
downregulation in mouse liver slices after CsA exposure, which, however, might be an 
artifact of exposure duration164. Heat-shock proteins are involved in folding/unfolding of 
proteins and protein translocation. The ER stress after CsA exposure negatively affects the 
function of heat-shock proteins164. Another protein, anxa1c, is known to influence 
hepatocyte differentation80, and anxa1c also appears to play a functional role in the 
modulation of hepatotoxic inflammation linked to steatosis165. In summary, although the 
regulated processes and/or pathways point towards more general stress and oxidative 
stress responses, analysis of individual genes/proteins also reveal more hepatotoxicity-as-
sociated changes. This supports that protein expression changes can identify hepatotox-
icity-specific responses in the ZFE. 
An underlying assumption in many biological studies is the concordance of transcripts 
and protein level166. Comparison of protein expression signatures with their corresponding 
gene expression149 revealed the best correlation in the cluster were both are down-
regulated, with the highest correlation for the compound PQ. The overrepresented GO 
biological processes for this compound include cell-cell signaling and glutamate receptor 
signaling, which are suggestive for an oxidative stress response in the cell. This is in line 
with the known mode-of-action of this compound as observed in multiple species30,145. 
Difficulties in correlating mRNA and protein expression are generally acknowledged, and 
relate to post-transcriptional processing, different half-lives between mRNAs and proteins, 
and the noise in both mRNA and protein expression measurements, preventing an easy 
mechanistic interpretation166.  Some of this the lack of correlation between mRNA and 
protein expression in ZFEs was recently shown to derive from three important categories: 
ribosomal proteins, histones and vitellogenins156. The specific noise in our analyses relates 
to the selective counting of the number of genes and/or proteins being regulated. 
Furthermore, because mRNA and protein data were derived from the same time point, 
the different expression kinetics between mRNAs and proteins will also reduce the degree 
of correlation or even result in negative correlation, particularly for transiently induced 
genes with slow protein turnover. Despite, or perhaps because of these limitations, 
mRNA-protein sets with matching expression clusters support the use of these entities as 
markers for hepatotoxicity, as they suggest non-transiently up- or downregulated gene 
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expression with a corresponding and rapid change in protein abundance.
In conclusion, our exposure study with a set of reference hepatotoxicants in ZFEs identified 
proteomics markers for enriched biological processes associated with general hepa-
totoxicity. The most prominent process was stress response, as indicated by translation, 
gene expression and metabolic synthetic processes. The identified protein markers, 
particularly glud1b, hspe1 and anxa1c, are potentially suitable candidates for the prediction 
of human hepatotoxicants. Such markers could be further developed into high throughput 
screening using more dedicated methods such as Western blots or ELISA assays. 
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The zebrafish embryo (ZFE) is a promising alternative, non-rodent model in toxicology, 
which has an advantage over the traditionally used models as it contains complete 
biological complexity, and provides a medium to high-throughput setting. Here, we 
assess how the ZFE compares to the traditionally used models for liver toxicity testing, i.e. 
in vivo mouse and rat liver, in vitro mouse and rat hepatocytes, and primary human 
hepatocytes. For this comparison we analyzed gene expression changes induced by 
three model compounds for cholestasis, steatosis, and necrosis. The three compounds, 
cyclosporine A, amiodarone, and acetaminophen, were chosen because of their relevance 
to human toxicity and these compounds displayed hepatotoxic-specific changes in the 
mouse in vivo data. Compound induced expression changes in the ZFE model shared 
similarity with both in vivo and in vitro. Comparison on single gene level revealed the 
presence of model specific changes and no clear concordance across models. However, 
concordance was identified on the pathway level. Specifically the pathway “Regulation of 
metabolism – bile acids regulation of glucose and lipid metabolism via FXR” was affected 
across all models and compounds. In conclusion, our study with three hepatotoxic model 
compounds shows that the ZFE model is at least as comparable to traditional models in 
identifying hepatotoxic activity, and has the potential for use as a pre-screen to determine 
hepatotoxic potential of compounds.
Introduction
A challenge in toxicology is to predict the hepatotoxic potential of compounds to which 
humans are exposed. In mammals and particularly for xenobiotics that rely on oral uptake, 
many compounds provoke first signs of toxicity in the liver. This is mainly due to the 
location of the liver (first pass effect) and liver cell activation. Therefore, hepatotoxicity is 
an important target to study, particularly in the context of adverse xenobiotic effects. 
Hepatotoxicity is the result of various xenobiotic-induced underlying molecular 
mechanisms, which produce different liver toxic phenotypes, of which cholestasis, 
steatosis and necrosis are most frequently observed. Cholestasis is a chronic condition and 
is phenotypically characterized by bile accumulation as a result of changes in intra- or 
extracellular bile flow or bile composition34. Steatosis may occur chronically as well and is 
characterized as an increase in cellular lipid content due to an increase in de novo synthesis 
of fatty acids or reduced lipid secretion or oxidation19. Necrosis is an acute condition and 
is characterized by cell death due to oxidative stress4,33. 
Traditionally, these hepatotoxic properties of xenobiotics are determined using different 
in vivo and in vitro models. Detection of hepatotoxicity in in vivo studies is based on 
histopathology and clinical chemistry. However, these studies require high numbers of 
animals, interfere with animal welfare, and are associated with high costs and are not 
always predictive for the human situation. In vitro systems have limitations related to their 
reductionistic nature and to their loss of functionality compared to the liver in vivo101. In 
the effort to improve screening for hepatotoxicity regarding predictivity for humans and 
throughput and in the same time reduce animal experimentation, the development of 
alternative models has gained attention. As such, the zebrafish embryo is an alternative 
screening model with the potential to reduce animal experimentation. It combines the 
benefits of an in vivo model, namely complete biological complexity including interaction 
between tissues and cells49,54,95, with the advantages of an in vitro model, that is reduced 
animal discomfort and the ability for median to high throughput testing. The structure 
and function of the adult zebrafish liver is similar to the mammalian liver46,55, and fully 
functional liver tissue is present in the zebrafish embryo at 72 hours post fertilization (hpf), 
which is therefore a suitable time point to start hepatotoxicity testing. There is also high 
genetic conservation between humans and zebrafish, including genes functioning in 
 biotransformation46,55. Previous studies showed that the zebrafish embryo could be used 
to identify human hepatotoxic responses using histopathology and gene expression 
analysis149. These studies have demonstrated that hepatotoxicity-associated gene expression 
remains detectable in the noise of other tissues and are distinct from developmental 
toxicity processes149. 
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Although the above mentioned studies have shown promise for the zebrafish embryo as 
an alternative model, it still does not identify how comparable the obtained results are to 
the traditionally used models. Our anticipation is that the zebrafish embryo model shares 
commonalities with in vivo and in vitro models. To this end, we compared the ZFE to the in vivo 
mouse and rat liver, in vitro mouse and rat hepatocytes, and primary human hepatocytes using 
gene expression changes from existing experiments using a model compound for each 
hepatotoxic phenotype. 
Three compounds, cyclosporine A (CsA), amiodarone (AMD), and acetaminophen (APAP), 
were chosen for the comparison because of their relevance to human toxicity and the 
availability of reference data in all of the selected models. The model compound CsA 
induces cholestasis. CsA competitively inhibits the bile salt export protein, which is the 
primary transporter involved in the biliary efflux of conjugated bile acids across the 
canalicular membrane134,135. AMD, an antiarrhythmic agent, induces steatosis in humans137 
by altering lipid homeostasis in the liver. Finally, necrosis is induced by APAP, an analgesic 
and antipyretic, which is considered safe at therapeutic doses. In this setting, APAP is 
inactivated by sulfation and glucuronidation. However, when the therapeutic doses are 
exceeded, APAP causes hepatic damage and may eventually lead to liver failure1,138.
Although the zebrafish embryo model cannot distinguish between human hepatotoxicity 
phenotypes using transcriptomics or proteomics, mechanisms of general hepatotoxicity 
can be identified and these might overlap with those induced in the traditional models 
for which data is available (Fig. 1). Our current data suggest overlap in the activation of 
pathways of toxicity between ZFE and other models. Therefore, the zebrafish embryo may 
well serve as a preferred quick and accurate first round testing of new compounds. 
Materials and methods
This study utilized data from multiple sources. In house (in vivo ZFE and mouse) and 
externally available data (in vivo rat and in vitro mouse, rat and human) were combined to 
assess the predictivity of the zebrafish embryo as a model for hepatotoxicity testing. In 
total, 161 treatment groups or conditions including a total of 161 Affymetrix CEL files with 
up to four replicates per conditions, were included in the analyses and an overview of 
each model is shown in Table 1 (Supplementary Table 1). 
Zebrafish embryo model (ZFE). The studies on zebrafish embryos were conducted by 
the National Institute for Public Health and the Environment (RIVM) as described earlier133. 
Briefly, 72 hours old hatched embryos were randomly distributed over 48-well plates in a 
density of 5 embryos per well in 1 ml test or control medium. Following treatment, using 
previously described procedures110,133,149, total RNA was isolated from the zebrafish 
embryo (1 sample consisted of 15 ZFE embryos) and used for gene expression analyses on 
Affymetrix Zebrafish Gene ST Array. At least 4 biological replicates were conducted. The 
expression data set is publicly available at the Gene Expression Omnibus (GEO) database, 
(http://www.ncbi.nlm.nih.gov/geo/), accession number GSE55618 (full dataset). 
Mouse in vivo (MIV). The in vivo mouse liver studies were conducted by the RIVM as 
described previously119,141,167.  Briefly, male C57BL/6JIco mice, aged 10 weeks, were treated 
with a low, medium, and high dose of CsA and AMD for 1, 4, and 11 days, and for APAP, 
mice were given a single treatment at a low, medium, and high dose and assayed 1 and 2 
days later. RNA from liver tissue was isolated and used for gene expression analysis by 
hybridizing to the Affymetrix HT Mouse Genome 430 PM Array. The expression data set is 
publicly available at the Gene Expression Omnibus (GEO) database, (http://www.ncbi.nlm.
nih.gov/geo/), accession number GSE31540 (CsA), GSE48126 (AMD) and GSE51969  (APAP). 
At least 4 biological replicates were conducted.
Figure 1   Concordance model for toxicogenomics-based extrapolation.
Central overlap represents species- and model-independent robust toxicity pathways or genes that 
are predictive for pathways/genes related to hepatotoxicity in humans. Solid red and blue lines, 
toxicity pathways/genes measured in in vivo models; large spaced dotted red, green, and blue lines, 
toxicity pathways/genes measured in in vitro models; small spaced dotted green line, the human in 
vivo toxicity pathways/genes to be predicted; red line, the zebrafish embryo toxicity pathways/gene 
contribution sharing similarity with in vitro as well as in vivo (adapted from Kienhuis et al.5).
108







Primary mouse hepatocytes (MPH). Samples were from a previous transcriptomics 
study from Maastricht University (UM) on mouse primary hepatocytes (MPH) treated with 
AMD, APAP and CsA168. In short, primary hepatocytes were isolated from adult male 
C57Bl/6 mice and brought into culture in a collagen-collagen sandwich formation. 
Following treatment, using previously published procedures169, total RNA was isolated 
from cultured mouse hepatocytes and used for gene expression analyses on high-density 
oligonucleotide gene chips (Affymetrix Mouse Genome 430 2.0 GeneChip arrays). Three 
independent biological replicates were conducted.
Rat in vivo and in vitro rat and human. Experimental study designs for AMD, CsA and 
APAP for rat primary hepatocytes (RPH), rat in vivo repeated dosing (RIVR), rat in vivo single 
dosing (RIVS) and human primary hepatocytes (HPH) performed in the Japanese 
Toxicogenomics Project and Toxicogenomics Informatics Project (TGP) (Open TG-GATEs; 
http://toxico.nibio.go.jp)170,171. These studies can be obtained from ArrayExpress (https://
www.ebi.ac.uk/arrayexpress/) under accession numbers E-MTAB-797 (rat primary 
hepatocytes), E-MTAB-798 (human primary hepatocytes), E-MTAB-799 (in vivo rat single 
dose) and E-MTAB-800 (in vivo rat repeated dose). 
Data preprocessing and quality control. For all systems, the data was annotated with 
a MBNI custom CDF specifically designed for the chips (http://brainarray.mbni.med.umich.
edu/Brainarray/Database/CustomCDF/CDF/)118 and RMA normalized using the Robust 
Multichip Average algorithm76. RMA normalized data was Log2 transformed and the 
quality of the micro array images was inspected visually (http://arrayanalysis.org, BiGCaT 
Maastricht University)172.  
Homolog conversion. The unique Entrez GeneIDs for each species was converted to 
human homologs by downloading the full HomoloGene data file from NCBI (ftp://ftp.
ncbi.nlm.nih.gov/pub/HomoloGene/current) and matching the species GeneIDs to the 
human homologs using an Entrez ID conversion script in R in order to compare the model 
systems. Only the homologs present in all model species were used for further analysis 
which resulted in 7828, 7825, 7623 and 8855 Entrez ID for mouse, rat, human and zebrafish, 
respectively. 
Gene expression analysis. 
Single gene expression. To ensure that an equal number of genes were compared between 
the different treatment/condition groups, the top-500 ranked genes based on Log2 
fold-change (Log2FC) were used. This analysis was performed because of differences in 
the power between the experimental designs. 
Single gene overlap. Per model, the unique genes found above in the “Single gene 
expression” were compiled. Similarity between these lists was visualized by means of a 
heatmap as well as Principal Component Analysis (PCA). 
Pathway analysis. Each of the lists compiled in the section “single gene overlap” were 
submitted to MetaCore from Thomsom Reuters and pathways having a p-value of < 0.05 
were identified. 
Biplot. Biplot representation of the pathway was done to display information on both 
the samples and the variables of the data matrix. In a biplot the samples are displayed 
as points, whereas the variables of the datamatrix are displayed as vectors. The biplot 
was generated using the “ade4” package in R (http://pbil.univ-lyon1.fr/ade4/home.
php?lang=eng)173,174 with an in-house R script based on the ggplot2 R-package175 
function, with minor changes that helped improve graphical representation.


























































































































































AMD High 60 25 10 7 2000 200 7
 Medium 20 1 3.3 1.4 600 60 1.4
 Low 6.7 0 1.1 0.28 200 20 0.28
APAP High 300 10000 660 5000 1000 1000 10000
 Medium 225 1000 220 1000 600 600 3000
 Low 168.75 0 73.3 200 300 300 1000
CsA High 26.7 50 6 6 300 100 6
 Medium 8.9 10 3 1.2 100 30 1.2
 Low 3 0 1 0.24 30 10 0.24
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Model-dependent gene expression changes. Changes in gene expression may be 
informative regarding how different models react to xenobiotic treatment. Therefore, to 
ensure equal numbers of differentially expressed genes (DEGs) for all 161 treatment 
conditions, we decided to use the top-500 ranked genes to determine the overlap 
between the conditions on single gene level and identify similarities between groups (Fig. 
2, Supplementary Figure 1). Based on this stringent selection model dependent changes 
were observed; as expected the greatest amount of overlap was found within a model. 
Additionally, within a model, the different dose and time points of a given compound 
tend to overlap. Yet different compounds tend to overlap less within a model. Furthermore, 
when comparing a model to the other models, there is no difference in the overlap. 
Therefore, to identify whether common regulated genes were found across all models a 
gene overlap comparison was performed.
Gene overlap across models. Our goal was to determine the feasibility of the ZFE to pick 
relevant transcriptomics changes that mimic other more standard models. Therefore we 
determined the overlap at the single gene level between ZFE and all other models. Per 
model, we used the unique genes across the top-500 of each treatment/condition group; 
since per compound (AMD, APAP and CSA) we had several concentration/doses the total 
DEGs for the analysis typically 500 genes per model. Because conceptually the ZFE shares 
likely similarities with the in vivo models as well as with the in vitro models, a separation 
was made between in vivo and in vitro. More single DEGs were found to be in common 
across all the different in vivo models per compound (22 AMD, 14 APAP, 19 CsA) than in the 
in vitro model comparison (5 AMD, 11 APAP, 5 CsA) (Fig. 3A) (Supplementary Table 2). For 
both the in vivo and in vitro comparisons of AMD and CsA, ZFE shared most genes with the 
mouse model. Yet for APAP, there was not much difference in overlap between the 
pair-wise comparisons. Furthermore, to identify whether there were common genes 
altered across hepatotoxic states, the common genes identified from the above overlap 
were compared across compounds. Almost all compound specific changes across species 
were unique. Only one gene, CYP8B1, was found in common in vivo across AMD, APAP, and 
CsA, but no genes were found in common from the in vitro studies (Figure 3B). 
Concordance identified at the pathway level. Next overrepresented pathways were 
determined using the unique top-500 ranked gene list for each model species to identify 
whether there were common pathways induced after reference compound exposure 
(Supplementary Table 3). Also here a separation between in vivo and in vitro models was 
made (see Fig. 4). Highest concordance for in vivo pathway activation was observed 
between rat and mouse; only several pathways overlapped between ZFE and rat and 
mouse, with mouse given the highest concordance with ZFE for CsA. Overlap for all the in 
vivo models was observed for only several pathways: for AMD one pathway that was 
shared between all models, which was the “Regulation of metabolism – Bile acids 
regulation of glucose and lipid metabolism via FXR”. This pathway was also observed after 
exposure to APAP and CsA. Another pathway that was regulated after APAP exposure was 
the “Regulation of CFTR activity”. For CsA, the pathways “Transcription – Transcription 
regulation of amino acid metabolism” and the pathway “Signal transduction – cAMP 
signaling” were enriched (Fig. 4). 
For the in vitro comparison, at the pathway level ZFE correlated overall best with the 
mouse primary hepatocytes with respect to AMD and CsA. Overlapping pathways 
included the regulation of lipid metabolism (Supplementary Table 4). Interestingly, also in 
vitro APAP and CsA exposure resulted in the enrichment of the “Regulation of metabolism 
– bile acids regulation of glucose and lipid metabolism via FXR” pathway. After exposure 
Figure 2   Single gene overlap between all conditions.
The top-500 ranked genes, for all 161 treatment conditions, were used to determine the overlap 
between the conditions on single gene level and identify similarities between groups. All conditions 
included in this study are color coded. RIVS is rat in vivo single dosing, RIVR is rat in vivo repeated 
dosing, RPH is rat primary hepatocytes, MIV is Mouse in vivo liver, MPH is mouse primary hepatocytes, 
ZFE is zebrafish embryos and PHH is human primary hepatocytes. Red color represents more overlap 
whereas green color represents less overlap.
Figure&2&
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to AMD, this pathway was only observed in MPH, RPH and ZFE and not in HPH. However, 
HPH shared an enriched pathway with MPH and RPH, which was “Reproduction – 
Progesterone – mediated oocyte maturation” (Fig. 4) (Supplementary Table 3). 
Species/model differences for genes within the enriched pathway. Overlap on single 
gene level resulted in one gene overlapping between the compounds in the in vivo 
models. This gene is part of the “Regulation of lipid metabolism_FXR-dependent nega-
tive-feedback regulation of bile acids concentration” pathway. For the in vitro models no 
overlap was found. However, pathway analysis resulted in one pathway enriched across 
most compounds and models being the “Regulation of metabolism – Bile acids regulation 
of glucose and lipid metabolism via FXR” pathway. To gain further insight into this specific 
pathway, a biplot was created to determine the effect of gene expression changes on 
each model (Fig. 5). It was observed that the genes APOE, LXR-α and HNF3-β had the 
lowest effect signified by their placement on the intersection of the axes. Genes were 
separated into the four different clusters: 1-topleft) SHP, PPAR-α, and ME1; 2-topright) MTP, 
APOB, HNF3-γ, F16P, HNF4-α, and FXR; 3-bottomleft) NIPK, SCD, ACACA, SREBP1 (nuclear), 
Insulin processed, GSK3-β, PLTP, HNF3-β, and FKHR; 4-bottomright) PPCKC and G6PT. 
Models were also separated into the four different clusters: 1) RIVR_CsA, RIVR_AMD, HPH_
APAP, HPH_AMD, RIVS_CsA, MPH_APAP and RIVS_APAP; 2) RIVS_AMD, RPH_AMD, ZFE_
AMD, ZFE_APAP, ZFE_CsA, MIV_APAP; 3) HPH_CsA, RPH_CsA, MPH_AMD, MPH_CsA, 
RIVR_APAP, MIV_CsA and MIV_AMD; 4) RPH_APAP. Based on the gene expression changes, 
there was no separation between in vivo and in vitro models. The ZFE model treatments 
Figure 3   Venn diagrams of overlapping genes.
Unique top-500 genes for each model are compared between all species and overlap is presented 
in Venn diagrams. A. Gene overlap of compound dependent in vivo and in vitro models. B. Gene 






Figure 4   Venn diagrams of overlapping pathways.
Pathway overlap determined using venn diagrams. Pathways were based on the unique top-500 
ranked genes per model and compound. Pathways were determined using MetaCore, a pathway 












were found in close proximity to each other on the biplot, and ZFE_AMD shared close 
similarity with AMD treated RPH in vitro, RIVS in vivo, and HPH in vivo models. These data 
indicate that although in all models an effect on the same pathway was observed, the 
components that were changed within the pathway were rather model dependent than 
compound dependent.
Discussion
Hepatotoxic potential of compounds to which humans are exposed are traditionally 
determined using rodent studies including mice and rats. However, these studies rely on 
long term exposure of the animals, and in light of the 3Rs, there is a need for new 
alternative testing models. The zebrafish embryo is a potential alternative testing model, 
which combines the benefits of an in vivo model, namely the complete biological 
complexity including the interactions between tissues and cells49,54,95, with the 
advantages of an in vitro model, that is reduced animal discomfort and the ability for 
medium to high throughput testing. Here, we assessed the similarities of the zebrafish 
embryo model in relation to the traditionally used models including rat and mouse in vivo 
and in vitro to help in the identification of common hepatotoxic responses.  
The changes on single gene level give information about how the different models 
respond to the xenobiotic treatment. Based on single gene overlap, the overlap within a 
species regardless of compound exposure was greater than between species. This might 
suggest that, within the limits of the data used for this analysis, every species produces a 
unique gene expression signature regardless of time, dose and compound. Also, 
comparing one model to the other models we found no difference in gene overlap 
suggesting that no two models are more similar to each other than the rest. When the 
DEGs were restricted to each individual model and compared across compounds, more 
DEGs were found in common for the in vivo comparison than for the in vitro comparison. 
This suggests that in vivo models may be more similar in the way they react to xenobiotic 
treatment than in vitro models. Alternatively the isolation procedure and culture 
procedures between mouse, rat and human hepatocytes affects the differentiation status 
of the cells preventing an equivocal comparison. Intriguingly, ZFE shared more genes with 
the mouse in vivo and in vitro models in the AMD and CsA comparison suggesting a strong 
similarity between the ZFE and mouse models. 
CYP8B1 was identified in the in vivo models as a common gene altered in all hepatotoxic 
states. CYP8B1 is a cytochrome P450 family member that catalyzes numerous drug and lipid 
metabolizing reactions, and it is found in the pathway “Regulation of lipid metabolism_
FXR-dependent negative-feedback regulation of bile acids concentration”. The expression 
of CYP8B1 is directly controlled by a combination of bile acids and the FXR receptor 
and indirectly by the PPAR-α receptor176, supporting an important role of this gene in 
hepatotoxicity. 
Inter- and intra-species comparison based on single genes is complicated because 
biological meaning is based on lists of differentially expressed genes. Instead, pathway 
analysis offers functional interpretation of these genes to a common, and therefore a 
more easy to compare endpoint83. Most importantly, in both in vitro (APAP and CsA) and 
in vivo (AMD, APAP and CsA) models, one pathway “Regulation of metabolism – Bile acids 
regulation of glucose and lipid metabolism via FXR” was found to be commonly regulated. 
Figure 5   Biplot of the “Regulation of metabolism – Bile acids regulation of glucose and 
lipid metabolism via FXR” pathway.
This pathway was found enriched across most compounds and models, and a biplot was created to 
determine the effect of gene expression changes on each model. Arrows represent the different 























































































Bile acids are produced in the liver and aid in the adsorption of dietary lipids. Additionally, 
bile acids can activate various downstream signaling pathways including those of nuclear 
receptors, like the farnesoid X receptor (FXR), regulating bile acid and drug metabolism 
among others34,177. This pathway has been linked before to cholestatic liver diseases164,178, 
and it has been regulated after exposure to AMD and APAP. After in vivo exposure of APAP, 
the pathway “Regulation of CFTR activity” was found in common. The cystic fibrosis 
transmembrane conductance regulator (CFTR), which is a member of the ATP-binding 
cassette (ABC) transporter family, is found in epithelial cells and acts as a glutathione 
channel among other functions. Furthermore, CFTR maintains water-salt homeostasis on 
the cell surface and normal function of epithelia lining airways, intestinal tract, and liver80. 
CFTR is significantly upregulated after APAP exposure in the mouse liver179. Since Kuppfer 
cells are suggested to play an important role in the upregulation of CFTR, this explains 
why this pathway is not observed in the in vitro models after APAP exposure because of 
their lack of Kupffer cells180. 
After in vivo exposure of CsA, the pathways “Transcription – Transcription regulation of 
amino acid metabolism” and “Signal transduction – cAMP signaling” were enriched. 
Amino acid metabolism is altered in the in vivo mouse model from CsA treatment119, and 
cAMP signaling is important in many biological processes including the regulation of 
glycogen, sugar and lipid metabolism, which occurs in the liver80. From the AMD in vitro 
studies, the pathway “Reproduction – Progesterone – mediated oocyte maturation” was 
only observed in MPH, RPH and HPH and not in ZFE. Within HPH, this pathway contains 
genes that are generally responsible for cell growth, like p90RSK1 and PLK1, suggesting 
this pathway is important in liver cell function during xenobiotic exposure. 
To gain more insight into how each model alters this particular pathway, a so-called biplot 
(Fig. 5) was made to identify the behavior of the genes, which resulted in their separation 
into five clusters. Additionally, the connection between the genes in each cluster was 
analyzed by plotting their location within the pathway (Fig. 6). In general, separation of 
the genes can be identified by their placement within the pathway. The genes within a 
particular cluster tend to have an interaction between them in a linear fashion then being 
scattered randomly. SHP and ME1 are found in cluster 1 where ME1 is controlled upstream 
by SHP in the regulation of lipogenesis. From cluster 2, HNF4-α is upstream of F16P in the 
modulation of gluconeogenesis and also upstream of MTP and APOB in the regulation of 
lipid transport. From cluster 3, NIPK and insulin processed are upstream of FKHR and 
GSK3β in the regulation of glycogenolysis and gluconeogenesis.  Additionally, SREBP1 is 
upstream of ACACA and SCD in the regulation of lipogenesis, but is also separate from the 
cluster 1 genes in this regulation. From cluster 4, G6PT and PPCKC both modulate gluco-
neogenesis. Lastly, the genes found at the intersection of the axes (cluster 5 in Fig. 6), 
APOE, LXR-alpha and HNF3-beta, identify that the changes in gene expression are fairly 
similar among all models leading to these genes having the least effect and being 
randomly distributed throughout the pathway.
Figure 6   Diagram of the “Regulation of metabolism – Bile acids regulation of glucose 
and lipid metabolism via FXR” pathway from Metacore.
The relationship between the genes in each cluster from the biplot in Figure 5 was analyzed by 
plotting their location within the pathway (numbered genes on the figure correspond to the 











In conclusion, the ZFE model shares similarity at the pathway level after xenobiotic 
exposure with both in vivo and in vitro models, using three reference compounds that 
cover a variety of hepatotoxic phenotypes. Concordance on the pathway level identified 
a single pathway to be altered across all hepatotoxic phenotypes, although with variations 
producing model and compound dependent clustering. Comparison at the single gene 
level showed that there were model specific changes and that outside of a model the 
overlap was fairly similar across models suggesting that on the gene level concordance 
cannot be readily identified. Therefore, the ZFE could be used as a prescreen for 
hepatotoxic compounds as it shares biological complexity with in vivo models and ease 
of testing found in in vitro models. 
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Supplementary Figure 1   PCA plot of the samples used within this study.
PCA plot of all the samples used within this study. PCA was based on a distance matrix using the 
overlap of the top-500 ranked genes between the samples. Samples are color-coded similar to as in 
Figure 2, and the different compounds are represented by the different shapes. Percentages on the 
x- and y-axis indicate the explained variances for the two first principal axes. 








































Hepatotoxicity-related pathologies as induced by drugs and industrial chemicals are 
traditionally measured in in vivo rat studies by histopathology and clinical chemistry. A 
disadvantage of in vivo studies is that they require enormous numbers of animals, which 
according to regulatory study protocols need to be exposed to high doses of compounds 
during extended periods of time. Apart from ethical and economical considerations, there 
is a scientific drawback because of the discordance between the hepatotoxic effects in 
rodents and humans, limiting the relevance of the outcome of in vivo studies regarding 
the prediction of human health risks. For these reasons, in recent years much effort was 
dedicated to the development of alternative test methods, and the zebrafish embryo is 
such a promising novel alternative test system. The general hypothesis of the work 
presented in this thesis is that the zebrafish embryo provides a simple and effective 
alternative animal model for hepatotoxicity testing, reproducing the complexity and 
functionality of the mammal liver in vivo. The main purpose of our studies was to develop 
and evaluate the zebrafish embryo model as an alternative system in a mechanism based 
way, using toxicogenomics approaches as a tool.
Through the mechanisms identified in our studies we provide evidence that the zebrafish 
embryo is a representative model to predict human hepatotoxicity, hence this discussion 
will focus on the critical factors related to hepatotoxicity testing in this model. First, the 
toxicokinetic properties of the zebrafish embryo will be discussed and how these differ 
from the human situation. Next, the histopathological changes as observed in the adult 
zebrafish liver and zebrafish embryo will be reviewed. Further, the additional value of 
toxicogenomic techniques presented in this thesis in identifying the underlying molecular 
mechanisms of hepatotoxicity will be discussed. Finally, further perspectives and 
applicability of the model will be considered.
Toxicokinetics in the zebrafish embryo
For a valid prediction of toxicity from fish to the mammal situation it is essential to take 
toxicokinetics in the zebrafish embryo toxicokinetics into account. Generally, toxicokinetics 
captures information on the administration and absorption, distribution, metabolism or 
biotransformation and excretion (ADME) of a toxic compound in an organism181. 
First, absorption of xenobiotic compounds greatly differs between mammals and zebrafish 
embryos. The difficulty to translate toxicity data from zebrafish embryos to humans starts 
with the xenobiotic characteristics, whereby water soluble compounds such as 
paracetamol may have completely different uptake and distribution patterns compared 
to more lipophilic compounds such as cyclosporine A. Lipophilicity may partly explain 
differences in absorption efficiency between fish and mammals, in view of the different 
surfaces through which absorption takes place. In fish, a major route of absorption of a 









humans most xenobiotic compounds are mainly orally ingested. Therefore, the zebrafish 
gills can be considered as an important first-pass organ in addition to the liver, which is the 
single first pass organ in mammals/humans. The importance of gills as a first pass organ is 
underlined by the presence of CYP450184. In addition, an important issue related to 
absorption difference between lipophilic and hydrophilic compounds in exposure studies 
in zebrafish embryos is the barrier that is formed by the chorion (egg shell). However, here 
we circumvented this problem by exposing after hatching of the embryo, which is a 
relevant timing for hepatotoxicity studies in view of the presence of functional liver tissue 
in the embryo. 
After the administration and uptake of a compound, the distribution of a compound is 
responsible for inducing the toxicity in the target organs, and distribution modeling can 
therefore help to understand details of observed effects. In the zebrafish embryo, whole 
organism concentration studies are only beginning to emerge185, while information 
regarding distribution is presently extremely limited, excluding direct comparison 
between relevant concentration in the fish versus plasma concentration in humans. Here, 
xenobiotic compounds dissolved in DMSO were added to the exposure medium, and 
were taken up by the zebrafish embryo presumably by passive diffusion, mainly through 
gills and skin182. The biotransformation capacity of the gills might influence the distribution 
of parent compound concentration and its metabolites at the site of the liver, and is a 
factor that needs to be taken into account when comparing liver toxicity profiles between 
ZFE and mammals. Furthermore, the distribution through the body might be influenced 
by the presence of the yolk sac, which is the internal food supply in the zebrafish embryo 
essential for initial development. However, the yolk is a lipid rich compartment allowing 
hydrophobic compounds to accumulated here. This accumulation could then lead to an 
overestimation for the effective concentrations required to induce organ toxicity182. 
Regarding the biotransformation of xenobiotic compounds, expression of most 
metabolizing enzymes is already present in early developmental stages55,182. Furthermore, 
enzymes that are part of the metabolizing process are highly conserved compared to 
mammals182 and many orthologs are found in humans55,182. However, development of 
the ZFE is associated with stage dependent changes of expression levels of metabolizing 
enzymes, which might result in a different sensitivity to the xenobiotic compounds 
compared to mammals. This difference in sensitivity is further anticipated by the large 
evolutionary distance between humans and zebrafish, which is around 445 million 
years186. 
The final component in ADME is the excretion of the compound. However, excretion is 
not seen as a very important aspect in the zebrafish embryo model while the exposure is 
mainly static182,187. 
In future studies, it is imperative to improve characterization of the kinetic properties in 
fish to gain a better understanding of their influence on the development of hepatotoxicity. 
In this thesis, we have not measured the internal concentration of our compounds or their 
metabolites in the ZFE, but relied on the observed compound-induced phenotypic 
changes in the liver, which were suggestive for internal ZFE drug exposure. 
Identification of hepatotoxicity using histopathology 
Histopathology can be used to differentiate the three hepatotoxic phenotypes cholestasis, 
steatosis and necrosis. Cholestasis is a chronic condition and is phenotypically characterized 
by bile accumulation as a result of changes in intra- or extracellular bile flow or bile 
composition34. Steatosis may occur chronically as well and is characterized as an increase 
in cellular lipid content due to an increase in de novo synthesis of fatty acids or reduced 
lipid secretion or oxidation19. Necrosis is an acute condition and is characterized by cell 
death due to oxidative stress and/or mitochondrial damage leading to loss of cellular ATP 
levels4,33. The model compounds CsA, EE2 and CPZ induce cholestasis. AMD, TET and VPA 
induce steatosis in humans137. Finally, necrosis is induced by APAP, PQ and TAA1,4. 
In chapter 2, we showed that the zebrafish embryo demonstrates clear histopathological 
changes after xenobiotic exposure, but failed to display the classical cholestatic and necrotic 
phenotypes as observed in humans. To verify whether this difference was life stage dependent 
or represents a response difference between fish and mammals, the adult zebrafish was also 
exposed to the same reference hepatotoxicants. The adult zebrafish liver was found 
particularly sensitive to the development of cholestasis and displayed a phenotype similar 
to humans. Cholestasis could not be identified in the zebrafish embryo probably due to the 
underdevelopment of bile production mechanisms, in line with the observation that genes 
involved in the formation of bile ducts are first expressed at 48-hpf 126 and that onset of 
fully operational bile production in the embryo is only from 5-dpf onwards44. The observed 
steatosis in both zebrafish life stages was consistent with the nominal phenotype as 
observed in mammals. The necrotic phenotype was represented in both life stages as 
hepatocellular vacuoles, but no apparent apoptosis or necrosis was induced.
The onset of necrosis typically involves lipid peroxidation, which is especially the case for 
acetaminophen. Lipid peroxidation is generally coupled to the formation of reactive 
oxygen species (ROS) and is a result of oxidative stress in cells. The Nrf2 transcription factor 
plays a very important role in the defense against oxidative stress188. In the zebrafish 
embryos, the Nrf2 pathway was not identified as a critical reporter for most of our hepato-
toxicants. The Nrf2 pathway is conserved between humans and zebrafish and is even 
present in the zebrafish embryos. However, it has been shown that the nrf2 mutant 
zebrafish embryo is not sensitive to all ROS productions as is the case within the 
mammalian systems189, suggesting that alternative defense mechanisms are active. This 
explains why this pathway has not been found as critical in the zebrafish embryo. Overall, 
there are apparently species and life stage dependent apical phenotypes, suggesting that 
toxicity pathways diverge between life stages and species. This is in line with the conclusion 
that our toxicogenomic methods could not distinguish the nominal pathological classes 









Identification of hepatotoxicity using gene expression profiling
Histopathology is the classical method to verify toxic events, but it does not provide 
information about the underlying molecular mechanisms leading to hepatotoxicity, and 
thus may limit full comparison of effects between testing models. Our working hypothesis 
was that the underlying molecular mechanisms leading to a toxic phenotype might be 
conserved between humans and zebrafish embryos, and therefore be more informative 
than histopathology regarding the translation of effects. In case of zebrafish, 
toxicogenomics techniques, including transcriptomics and proteomics, were already 
applied mostly in the area of developmental and ecotoxicological toxicity in the zebrafish 
embryo53,66–70,187. However, the implementation of transcriptomics or proteomics in the 
zebrafish embryo for predicting hepatotoxicity had not been applied, and our initial 
results described in chapter 1 indeed supported that the application of toxicogenomics 
in hepatotoxicity appeared to be of great added value regarding better understanding of 
the underlying molecular mechanisms of toxicant induced effects.
Defining liver-associated transcripts
In rodent experiments, the liver is dissected and subjected to RNA isolation for the 
determination of gene expression changes, but the zebrafish embryo is too small for liver 
dissection.  Although sophisticated procedures such as micro-dissection can be applied 
to collect small amounts of liver material, this will hamper the throughput and robustness 
of the testing system. Therefore, we first determined whether liver-associated gene 
expression can be detected in the whole zebrafish embryo using whole body 
homogenates. In the zebrafish embryo, the liver accounts for only approximately 20% of 
the total body weight, and this relatively small proportion might limit the detectability of 
liver specific signals. Therefore, to ensure that we were able to determine liver-specific 
gene expression, whole embryo homogenates were compared to isolated adult zebrafish 
livers. This comparison was complicated by the necessity to use pools of 15 zebrafish 
embryos per sample meaning that the specific signal of the individual embryo is diluted, 
but on the other hand, the observed gene expression changes are more robust106. In this 
comparison we used next-generation sequencing, which is a relatively new technique, 
which can be used for mapping as well as quantifying transcriptomes. The advantage 
over the use of the traditional RNA arrays is that this technique provides a more sensitive 
and precise measure of transcript levels resulting from the relative low background signal 
and the absence of an upper limit of detection64. The results in chapter 2 support 
theadditional value of this still developing technique for toxicity testing. Furthermore, we 
confirmed through next generation sequencing that liver-associated gene expression is 
present in the whole zebrafish embryo and that hepatotoxicity-associated signals are 
detectable over the noise of other tissues, and that the whole zebrafish embryo can 
therefore be used as a proxy for the assessment of hepatotoxicity. Building on this premise, 
a detailed analysis of mechanisms of hepatotoxicity was conducted using RNA arrays as 
shown in chapter 3. This resulted in a better description of hepatotoxic responses and to 
the development of expression markers predictive for hepatotoxicity in humans. To assess 
the liver-specificity of the found markers, we assessed their location using in situ hydrization 
(data not shown), and could thus confirm liver specificity of eight marker genes . This 
supports that the small proportion of the liver and the pooling of the samples did not 
influence the liver associated gene expression. 
Analysis of gene expression resulted in markers for general hepatotoxicity, but specific 
phenotypes were not reflected, possibly due to suboptimal exposure concentrations and 
durations. Additional efforts to discriminate between nominal phenotypes using 
proteomics (chapter 4) produced a similar result, i.e. identification of general markers for 
hepatotoxicity but not for specific phenotypes. Furthermore, we observed that most of 
the expressed proteins were linked to a more general hepatotoxic stress response, possibly 
also related to the used concentrations and exposure durations.  On the other hand, we 
did not observe interference of yolk sac related proteins, which is a general problem in 
proteomics studies with zebrafish embryos, supporting robustness of the liver specific 
protein signals.  This suggests that deyolking of a 5-dpf old whole zebrafish embryo is not 
necessary which improves the throughput of the system when applying proteomics. 
Determination of hepatotoxic classes 
The reference compounds used in this thesis were selected to represent three different 
histopathological endpoints (cholestasis, steatosis or necrosis), but as described in 
chapter 1, within each class, individual compounds have unique underlying molecular 
mechanisms for these histopathological changes. In chapter 3 and 4, we identified 
markers for general hepatotoxicity, while the applied zebrafish toxicogenomics strategy 
was unable to discriminate between the hepatotoxic classes of interest. This is either due 
to species dependent differences in liver physiology or to experimental conditions. With 
regard to the latter, the selected exposure concentrations were based on the maximum 
tolerable concentration inducing no teratological deviations or death. It might be that this 
single concentration of the compounds was not optimal for unducing the specific 
hepatotoxic phenotypes; moreover, the exposure period might be too short to induce the 
specific phenotype. Alternatively, zebrafish specific responsiveness to xenobiotics  could 
be in line with deviating responses in other models, such as hepatoma-derived cell lines 
which strongly differ from the whole liver gene expression profile64,101. It should be noted 
that we only tested a set of nine compounds, and a more comprehensive range of 
compounds will probably generate more robust results. A first attempt was made to 
validate our markers by using an additional set of seven hepatotoxic compounds (not 
shown). Zebrafish embryos were exposed to this new set of model hepatotoxicants and 
compared to three old reference hepatotoxicants. After exposure, the expression of the 
markers genes obtained in chapter 2 and 3, were determined using qPCR. Most of the 









toxicants, confirming the validity of our markers. However, this additional exercise was not 
designed to improve class distinction, and only  a larger drug library screen in a more 
high-through put setting including more hepatotoxicants and non-hepatotoxicants may 
provide a better estimate whether the zebrafish embryo is able to discriminate between 
classes. 
Interspecies extrapolation
As mentioned above, the zebrafish embryos were able to determine the hepatotoxic 
potential of xenobiotic compounds. It is important to extrapolate the observations to 
mammalian species and where possible even to the human situation, to underpin major 
added value of the zebrafish embryos. Therefore, in chapter 2 and 5, we compared the 
zebrafish embryo to the in vivo mouse and rat liver, in vitro mouse and rat hepatocytes, 
and primary human hepatocytes using gene expression changes from experiments using 
a model compound for each hepatotoxic phenotype to identify commonalities. Three 
compounds, CsA, AMD, and APAP, were chosen for the comparison because of their 
relevance to human toxicity and the availability of reference data in the selected models. 
This comparison revealed that the zebrafish embryo shares similarities at the pathway 
level after xenobiotic exposure with both in vivo and in vitro models, with the highest 
concordance to the mouse model. One pathway which was shared between all models 
was the pathway “Regulation of metabolism – bile acids regulation of glucose and lipid 
metabolism via FXR”. While bile acids are important in the regulation of the normal liver, 
they also activate various signaling pathways including those of nuclear receptors34,177. In 
this particular pathway, it was observed that each species targeted a specific part 
suggesting species differences. Still, the common regulation of this particular pathway 
between all included species indicates its robustness. This supports that the zebrafish 
embryo model has a similar response to the hepatotoxicants as the traditionally used 
models and therefore, the zebrafish embryo could be used as a prescreen for hepatotoxic 
compounds. 
Optimization of the zebrafish embryo screening for high throughput
The studies presented in this thesis have shown the promise and applicability of the 
embryo model for the detection of hepatoxic potential of compounds. In the current 
work, the model was not optimized for high throughput screening. Optimization of the 
model can be achieved in multiple ways. First, the experimental setup including handling 
of the zebrafish embryos and the distribution of the xenobiotic compound of interest can 
be improved. The handling of the embryos can be automated by using an embryo sorting 
machine, for example the COPAS XL59,190. The distribution of the xenobiotic compound to 
the well plates can be improved by either using a multichannel pipette or automated by 
the use of a robotic liquid-handling machine59. Furthermore, the whole genome 
sequencing or the microarray technologies that we applied here provide highly detailed 
information, but are rather time consuming. Dedicated arrays or selected qPCR with 
marker genes for hepatotoxicity could improve the throughput of the screening. A 
drawback of these methods is that these still require time consuming RNA extraction, and 
have no informationt on the tissue distribution, i.e. liver expression, of marker genes. To 
overcome these drawbacks, another optimization could be to generate transgenic 
reporter zebrafish, which allows screening in high throughput manner. The technique of 
generation reporters is well developed for zebrafish, and could be applied for the markers 
from chapter 2 and 3. For this purpose, DNA constructs enabling the expression of a 
fluorescent protein after induction of the marker of hepatotoxicity should be designed 
and injected in wild type one cell stage zebrafish embryos. Selected of embryos which 
show the intended presence of the fluorescent protein are further raised to adulthood 
and paired to produce fluorescent embryos which can subsequently be used for screening 
purposes191. With the use of transgenic zebrafish embryos for hepatotoxicity testing, 
large drugs screens can be tested in a more high-throughput manner using COPAS or 
confocal microscopy which has been shown to be a valid approach for developmental 
toxicity screening192–194. Preliminary testing with one such a reporter fish, fabp10195,196, 
has been initiated.
Implementation of the zebrafish embryo in drug discovery process
The zebrafish embryo testing model fits into multiple stages of the drug discovery 
pipeline, ranging from lead and target identification to lead optimization and ADME 
studies193,197. Application of this model is attractive because it is relatively cheap, it 
contributes to reduction of animal experimentation, and relatively small amounts of the 
xenobiotic compounds are needed. The model can be incorporated easily into the 
existing tiered approach for the prediction of hepatotoxicity. Combining multiple in vitro 
screening models in a tiered approach could overcome the limitations of each individual 
in vitro model in the prediction of toxicity, and a in a series of models, they can complement 
each other for information regarding toxicity164,197. Presently, the earliest test models in 
such a tiered approach for hepatotoxicity are typically the in vitro hepatoma cell lines, for 
example HepG2 or HepaRG. Next, primary hepatocytes from either rat or human origin 
would be tested, to ensure incorporation of drug metabolism and transport capabilities as 
well as bioenergetics that are closer to the in vivo situation. Precision cut tissue slices, 
which provide an intact architecture similar to the organ of interest, provide an alternative 
method that can used next in the line of in vitro models164,197. Although all these models 
are suitable for the detection of hepatotoxic potential of compounds, the zebrafish 
embryo offers biological complexitity similar to in vivo models with the ease of testing as 
is possible with in vitro models. Therefore, the zebrafish embryo can be used to prioritize 
the compounds, which should be tested in an in vivo set-up, thereby contributing to the 









Current and future application of the zebrafish embryo 
The implementation of the zebrafish embryo as a model for hepatotoxicity testing 
requires a number of steps. Firstly, as mentioned above, the toxicokinetic parameters, 
which limit assessment of particular compounds in the zebrafish embryo model, should 
be characterized better. As discussed, a clear example in this respect is the yolk sac which 
might cause underestimation of the results obtained by the more lipophilic xenobiotics 
compounds. 
Here, we tested only nine compounds which are known to induce hepatotoxicity in 
humans. To validate the model further and determine the predictability of the model, a 
large screen of many hepatotoxicants needs to be performed. For practical reasons, we 
had to limit our studies to a single sub-lethal concentration of each compound, but 
obviously confirmation of concentration-dependent responses would improve robustness 
of the identified markers. As indicated, improvement of the throughput of testing could 
be achieved through the development of transgenic zebrafish. In addition, humanized 
transgenic fish that would express relevant biotransformation enzymes could further 
strengthen the zebrafish embryo system. 
The zebrafish embryo can be of added value to elucidate the underlying molecular 
mechanisms by using morpholino techniques to establish a knock down of genes of 
interest. Morpholinos allow the temporary knockdown of genes thus identifying their role 
in the involved toxic mechanism of hepatotoxicity. For example genes that were induced 
by any of our model compounds in the present study could be interrogated for 
involvement in the onset of the phenotypic hepatotoxic changes in the liver. In particular 
those genes that would then be functionally associated with the onset of hepatotoxicity 
and have translational relevance would be of the highest interest to serve as marker for 
hepatotoxicity liabilities of novel chemical entities. 
Conclusion
In this thesis we showed the applicability of the zebrafish embryo as an alternative model 
for hepatotoxicity testing using analysis of mechanisms through toxicogenomics. By 
applying a variety of toxicogenomics techniques, we were able to characterize specific 
responses. NGS revealed that hepatotoxicity-associated gene expression remains 
detectable even in non-tissue specific analysis in whole body zebrafish embryo 
homogenates. Gene and protein expression profiling resulted in the identification of a set 
of marker genes that could be linked to pathways and processes, which are associated 
with a general hepatotoxic response. Application of such markers will increase the 
throughput of the system. Finally, we showed that the zebrafish embryo model shares 
similarities with in vivo and in vitro models for hepatotoxicity, where the model has more 
commonality with the mouse in vivo and in vitro models than with the other models. 
Overall, the model has the advantages of the in vitro models with the biological 
complexicity of an in vivo response, and we thus anticipate that the zebrafish embryo can 
contribute to the 3R strategy by reducing, refining and replacing animal studies. Our 
observations support that this model can have added value in a tiered approach as a 
pre-screen for the detection of hepatotoxic potential of compounds. 
English Summary
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This thesis aims to establish whether the zebrafish embryo is a suitable alternative testing 
method for the prediction of hepatotoxic potential of compounds, thereby using 
toxicogenomic techniques. The goal was to establish improved alternative models to 
better predict human hepatotoxicity, thereby directly contributing to the reduction, 
refinement and replacement (3Rs) of animal experimentation. 
In chapter 1, liver toxicity was introduced as an important target to study adverse drug 
effects. Especially, in mammals and particularly for xenobiotics that rely on oral uptake, 
many compounds provoke the first sign of toxicity in the liver. This is due to its function as 
a first pass organ in metabolism of toxic compounds, resulting in exposure of liver cells, 
mainly hepatocytes, to potentially toxic parent compounds and reactive metabolites. 
Hepatotoxicity is the result of various underlying molecular mechanisms arising from 
different xenobiotic-induced toxic phenotypes, of which cholestasis, steatosis and necrosis 
are most frequently observed. Cholestasis is a chronic condition and is phenotypically 
characterized by bile accumulation as a result of changes in intra- or extracellular bile flow 
or bile composition34. Steatosis may occur chronically as well and is characterized as an 
increase in cellular lipid content due to an increase in de novo synthesis of fatty acids or 
reduced lipid secretion or oxidation19. Necrosis is an acute condition and is characterized by 
cell death due to oxidative stress4,33. Traditionally, the hepatotoxic potential of compounds is 
tested using rodent studies. The aim of this thesis is to investigate whether the zebrafish 
embryo model combined with toxicogenomic techniques can be proposed as a 
promising alternative high-throughput method for hepatotoxicity testing. 
In chapter 2, the applicability of the whole ZFE for hepatotoxicity testing was further 
underpinned by combining histopathology and next generation sequencing-based gene 
expression profiling. To this end, whole ZFE and adult zebrafish were exposed to a set of 
hepatotoxic reference compounds. Histopathology revealed compound and life-stage 
specific effects indicative of toxic injury in livers of whole ZFE and adult zebrafish. Next 
generation sequencing (NGS) was used to compare transcript profiles in pooled RNA 
samples of whole ZFE and livers of adult zebrafish. This revealed that hepatotoxicity- 
associated expression can be detected above the overall transcription noise in the whole 
embryo supporting the applicability of the whole ZFE model for compound-induced 
hepatotoxicity screening. 
In chapter 3, we hypothesized that the detailed analysis of underlying mechanisms of 
hepatotoxicity in ZFE contributes to the improved identification of hepatotoxic properties 
of new compounds and to the reduction of the number of rodents used for chemical 









induction of cholestasis, steatosis and necrosis, and two non-hepatotoxic controls. 
Histopathology revealed various specific morphological changes in the ZFE hepatocytes 
indicative of cell injury. Gene expression profiles of the individual compounds were 
generated using microarrays. Regulation of single genes and of pathways could be linked 
to hepatotoxic responses in general, but phenotype-specific responses could not be 
distinguished. Hepatotoxicity-associated pathways included xenobiotic metabolism and 
oxidoreduction related pathways. Overall analysis of gene expression identified a small set 
of potential biomarkers specific for a common hepatotoxicity response. 
To allow for verification of the histopathology, we applied another -omics technique, 
which was proteomics. Proteomics identified multiple markers for hepatotoxicity using 
the whole zebrafish embryo. Furthermore, we compared the gene expression results with 
the obtained proteomics results in chapter 4. Proteomics results showed that it is possible 
to identify markers after exposure to hepatotoxicants. These markers can be linked to 
enriched biological processes which are associated with hepatotoxicity. Furthermore, as 
observed in chapter 3, the zebrafish embryo is so far in our hands only able to 
distinguished general hepatotoxicity and not phenotype-specific hepatotoxicity. 
In chapter 5, the zebrafish embryo was compared with the traditionally used models, 
including mice and rats. The ZFE model shares similarity at the pathway level after 
xenobiotic exposure with both in vivo and in vitro models. Concordance on the pathway 
level identified a single pathway to be altered across all hepatotoxic phenotypes. This 
analysis also suggest that pathways are better suited as hepatotoxicity markers than single 
genes as each model was found to effect different genes within the same pathway. 
Comparing at the single gene level showed that there were model specific changes and 
that outside of a model the overlap was fairly similar across models suggesting that on the 
gene level concordance cannot be readily identified. The advantage of the ZFE is that is 
can be used as a pre-screen to determine hepatotoxic potential of compounds, providing 
a quick and easy high-throughput testing model. 
In chapter 6, we provided a general discussion of the obtained results including the 
assessment of the toxicokinetics parameters. Further, we addressed the limitations and 
strengths of this model. In addition, we provided the future perspectives of this model for 






















Mensen worden gedurende hun hele leven blootgesteld aan een veelheid van schadelijke 
stoffen, via zowel natuurlijke als artificiële wegen. Soms vindt blootstelling aan deze 
schadelijke stoffen onbewust plaats, zoals blootstelling via voedsel, door inademing of 
door opname via de huid, of  bewust wanneer men bijvoorbeeld een medicijn inneemt. 
Het gebruik van medicijnen kan leiden tot schade aan het lichaam, zeker wanneer er een 
te hoge dosering wordt ingenomen. Door middel van toxicologisch onderzoek probeert 
men de risico’s in te schatten van deze schadelijke stoffen. 
Bij toxicologisch onderzoek is de lever een belangrijk orgaan. Dit komt onder andere door 
de rol die de lever in het menselijk lichaam heeft. De lever komt als eerste in aanraking 
met giftige stoffen, nadat deze door de darm zijn opgenomen. Verder speelt de lever een 
rol in het omzetten van giftige stoffen naar mindere giftige stoffen die gemakkelijk door 
het lichaam zijn uit te scheiden. Dit proces verloopt normaal gesproken zonder problemen, 
maar soms kan deze omzetting van stoffen juist tot een giftiger product leiden waardoor 
de lever schade oploopt. 
Leverschade kan resulteren in een verscheidenheid aan histopathologische veranderingen, 
waarbij cholestase, steatose en necrose de drie belangrijkste afwijkingen zijn. Cholestase 
is te zien in de levercel als geel-oranje druppeltjes. Steatose wordt gekenmerkt door 
ophoping van vet in de levercel en wordt zichtbaar door middel van histopathologische 
kleuringen. Bij necrose is er sprake van versterf van levercellen, wat afhankelijk van het 
stadium zichtbaar is als verkleuring of verval van levercellen. Alle vormen van leverschade 
kunnen uiteindelijk resulteren in leverfalen.  
Om te kunnen voorspellen welke giftige stoffen tot leverschade leiden, wordt er gebruik 
gemaakt van zowel in vitro als in vivo modellen. Bij in vitro modellen analyseert men de 
effecten van schadelijke stoffen op cellijnen, schijfjes lever en primaire lever cellen. In vivo 
modellen richten zich op het testen van stoffen in dieren, en daarbij worden er voornamelijk 
muizen en ratten gebruikt. Aan deze in vivo dierstudies kleven een aantal ethische, 
economische en wetenschappelijke bezwaren. Er worden veel dieren gebruikt die voor 
langere tijd aan hoge doseringen van de giftige stoffen worden blootgesteld. Het belangrijkste 
bezwaar is echter dat de resultaten die met deze dierstudies worden behaald, lang niet altijd 
de situatie in de mens goed voorspellen. Dit wordt ook wel aangeduid als vals positieve of 
vals negatieve resultaten. Daardoor heeft het onderzoek de afgelopen jaren zich 
voornamelijk gefocust op de ontwikkeling van alternatieve testmethoden die de situatie 
in de mens beter kunnen voorspellen. 
Een mogelijk goed alternatief model is het zebravis embryo model. Dit model combineert 
verschillende voordelen, waarvan er één is dat deze embryo’s nog zo’n primitief zenuw- 
stelsel hebben dat niet wordt verwacht dat ze  pijn of ongerief kunnen ervaren. Zebravis 
















aan de drie V strategie (Vermindering, Vervanging en Verfijning van proefdiergebruik).
Normaal gesproken word het effect van de giftige stoffen bepaald door het bekijken van 
histopathologische veranderingen en meten van leverenzymen. Deze methoden geven 
echter geen informatie over het mechanisme dat leidt tot leverschade, terwijl juist dit 
moleculaire mechanisme mogelijkheden geeft om leverschade goed te voorspellen. Om dit 
onderliggende mechanisme te kunnen begrijpen, wordt er gebruik gemaakt van verschillende 
moleculaire technieken, gericht op analyse van met name gen- en eiwitexpressie.  
Dit proefschrift beschrijft hoe het zebravis embryo model in combinatie met gen - 
expressie analyse-technieken het beste gebruikt kan worden om leverschade in de mens 
te kunnen voorspellen. 
Samenvatting van de studies beschreven  
in dit proefschrift
Hoofdstuk 2 beschrijft twee technieken die gebruikt zijn om te bepalen of het zebravis 
embryo als alternatief model gebruikt kan worden bij de voorspelling van leverschade. 
Hierbij hebben we  veranderingen in extracten van het gehele embryo vergeleken met 
veranderingen in de lever van de volwassen zebravis, om de vraag te beantwoorden of 
effecten op de lever wel in het zebravis embryo gemeten kunnen worden. Allereerst 
hebben we met behulp van histologie gekeken of er daadwerkelijk morfologische 
veranderingen in de lever van zowel de volwassen zebravis als de embryo waargenomen 
kunnen worden. Hieruit kwam naar voren dat er leeftijd- en stofspecifieke veranderingen 
optraden in beide modellen. Daarna hebben we met behulp van next generation 
sequencing onderzocht of we in staat waren om genexpressie veranderingen in het 
embryo te kunnen waarnemen, omdat de lever maar in geringe plaats inneemt in het 
embryo. Na analyse kwam naar voren dat we in staat zijn om leverspecifieke veranderingen 
waar te nemen in het gehele embryo. 
Omdat we in staat waren lever- geassocieerde genexpressie te kunnen bepalen in het 
gehele embryo, hebben we in hoofdstuk 3 geanalyseeerd of het mogelijk is om op basis 
van genexpressie profielen (transcriptomics) onderscheid te maken tussen de verschillende 
typen leverschade. Voor deze studie hebben we gebruik gemaakt van dezelfde stoffen als 
in hoofdstuk 2, maar zijn de genexpressie profielen op een andere manier geanalyseerd, 
namelijk met behulp van microarrays. Het bleek dat in het zebravis embryo model op die 
manier de verschillende klassen van leverschade niet te onderscheiden zijn, omdat de 
genexpressie profielen van alle klassen veel overlappen. Wel bleek het mogelijk om 
genexpressie markers te identificeren die leverschade zouden kunnen voorspellen in de 
mens.
Omdat met genexpressie geen onderscheid gemaakt kon worden tussen de verschillende 
typen leverschade hebben we in hoofdstuk 4 gebruik gemaakt van een andere techniek, 
namelijk het meten van eiwitexpressie veranderingen (proteomics). Maar ook met deze 
techniek bleek het niet mogelijk om in het zebravis embryo model onderscheid te maken 
tussen de verschillende typen klassen van leverschade. Daarentegen waren we wel in 
staat om een kleine lijst met markers te selecteren die leverschade in de mens zouden 
kunnen voorspellen.  
Om echt de voorspellende waarde van het zebravis embryo model te kunnen definiëren, 
hebben we in hoofdstuk 5 een overkoepelende analyse uitgevoerd die de genexpressie 
profielen van de verschillende testmodellen voor leverschade vergelijkt. In plaats van 
alleen te kijken naar veranderingen in expressie van alleen genen, hebben we bestudeerd 
of groepen van genen, de zogenaamde pathways, veranderde na blootstelling. Uit deze 
vergelijking bleek dat het zebravis embryo model met betrekking tot gereguleerde 
pathways overlap heeft met zowel de in vivo als de in vitro modellen. Wanneer we alle 
modellen met elkaar vergelijken, zowel in vivo als in vitro, komt er één pathway naar voren 
die in alle modellen gereguleerd is.  
In de afsluitende discussie (hoofdstuk 6) van het proefschrift worden de voor- en nadelen 
van de gebruikte technieken beschouwd, en besproken welke aanvullende studies nodig 
zijn om het zebravisembryo model daadwerkelijk in te zetten voor het voorspellen van 
leverschade door chemische stoffen in de mens. Als slotconclusie wordt geconcludeerd 
dat het zebravis embryo model gebruikt kan worden als alternatief voor dierproeven bij 
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Supplementary Table 1
Concept Sum Cholestasis Necrosis Steatosis Max
DLAT 0,105669253 0,075439912 0,005487761 0,024741581 0,075439912
ABCC2 0,077013887 0,059428233 0,005082565 0,012503092 0,059428233
CYP7A1 0,089591041 0,058404153 0,007123153 0,024063732 0,058404153
CASP7 0,068513878 0,008636802 0,051599174 0,008277902 0,051599174
hmgb1 0,060479209 0,005607468 0,047319817 0,007551923 0,047319817
NR1H4 0,059509341 0,046385944 0,003026804 0,010096595 0,046385944
ADIPOQ 0,062472939 0,009134896 0,007845505 0,045492538 0,045492538
BCL2 0,061035451 0,008593643 0,044535566 0,007906242 0,044535566
SLCO1C1 0,054385055 0,04260197 0,002904114 0,008878971 0,04260197
SREBF1 0,0620065 0,013704743 0,005960525 0,042341229 0,042341229
SLC10A2 0,050060485 0,041890794 0,002339994 0,005829697 0,041890794
slc10a1 0,048767049 0,040859258 0,002002404 0,005905387 0,040859258
MTTP 0,055873889 0,010500532 0,004744735 0,040628622 0,040628622
FAS 0,057379473 0,009123832 0,03891766 0,009337983 0,03891766
CASP9 0,051490605 0,00653371 0,037912443 0,007044452 0,037912443
ANXA5 0,050925869 0,006237081 0,037873741 0,006815049 0,037873741
CYP8B1 0,047159228 0,035887965 0,002677058 0,008594205 0,035887965
AGXT2 0,062399663 0,018095136 0,008463845 0,035840681 0,035840681
FASLG 0,050953589 0,008522448 0,034139986 0,008291154 0,034139986
PPARA 0,057423495 0,015419781 0,007888278 0,034115437 0,034115437
CASP8 0,046544049 0,006266749 0,033743194 0,006534107 0,033743194
TNFSF10 0,047283791 0,006461546 0,032733891 0,008088356 0,032733891
BCL2L1 0,045185164 0,006388873 0,032475919 0,006320371 0,032475919
ADIPOR2 0,039930321 0,004846609 0,002866152 0,032217559 0,032217559
JAG1 0,039694384 0,03195867 0,002512847 0,005222866 0,03195867
DNTT 0,044375997 0,006255758 0,031688804 0,006431436 0,031688804
ABCC4 0,041712489 0,031682357 0,003264796 0,006765335 0,031682357
GGT1 0,058739889 0,031172252 0,005695994 0,021871642 0,031172252
FABP6 0,038181286 0,030617575 0,002039491 0,005524218 0,030617575
ADIPOR1 0,037684642 0,004346629 0,002950362 0,030387653 0,030387653
VPS33B 0,03448106 0,030334381 0,001184143 0,002962535 0,030334381
ACOX1 0,041716449 0,009044701 0,003520968 0,029150779 0,029150779
HBP1 0,036433827 0,003363358 0,028806382 0,004264088 0,028806382
GPATCH3 0,043840192 0,028778959 0,002853069 0,012208163 0,028778959
CIRH1A 0,034875907 0,028750676 0,001859005 0,004266228 0,028750676
UGT1A1 0,045257438 0,028064319 0,004773295 0,012419822 0,028064319
SFPQ 0,048192773 0,015613025 0,004788 0,027791747 0,027791747
ABCG5 0,042074256 0,027521077 0,003103841 0,011449339 0,027521077
ADFP 0,033044651 0,003688654 0,00266236 0,026693638 0,026693638
FASN 0,041606337 0,010148192 0,00521373 0,026244416 0,026244416
ABCG8 0,038630858 0,026150254 0,002783493 0,009697112 0,026150254
AIFM1 0,034080546 0,003527898 0,025849619 0,00470303 0,025849619
PPARG 0,04306988 0,008887263 0,008552227 0,025630391 0,025630391
PARP1 0,034437459 0,004169373 0,025604269 0,004663819 0,025604269
CYP3A4 0,055940114 0,021053389 0,00944177 0,025444956 0,025444956
CASP2 0,033359248 0,004090021 0,025314556 0,003954672 0,025314556
DGAT2 0,032043066 0,005136488 0,002244031 0,024662545 0,024662545
GPT2 0,045966722 0,014927394 0,006657721 0,024381608 0,024381608
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Supplementary Table 1  Continued
Concept Sum Cholestasis Necrosis Steatosis Max
XIAP 0,032255523 0,004228349 0,023416213 0,004610962 0,023416213
CYP1A1 0,049911678 0,017936408 0,00858312 0,02339215 0,02339215
jag1a 0,027385078 0,023124695 0,001624401 0,002635983 0,023124695
APAF1 0,030219667 0,003756397 0,022798733 0,003664537 0,022798733
GPT 0,041659337 0,01239166 0,006703541 0,022564135 0,022564135
SCD 0,032475173 0,007002905 0,00295036 0,02252191 0,02252191
CASP10 0,031575859 0,004469684 0,022499723 0,004606452 0,022499723
DIABLO 0,031049399 0,003709918 0,022362359 0,004977122 0,022362359
CFLAR 0,031918153 0,004809873 0,021988189 0,005120092 0,021988189
dgat1 0,028060596 0,004171592 0,002479491 0,021409514 0,021409514
CASP6 0,028183853 0,00381928 0,02132523 0,003039344 0,02132523
MCL1 0,032170791 0,006030846 0,021251496 0,004888448 0,021251496
VIPR1 0,031439044 0,006466684 0,003761836 0,021210522 0,021210522
UCP2 0,035706505 0,006824117 0,00767204 0,02121035 0,02121035
FADD 0,030821892 0,005090054 0,021062072 0,004669766 0,021062072
NR1I2 0,037313148 0,020762435 0,005245015 0,011305696 0,020762435
XRCC5 0,048392344 0,01924159 0,008398013 0,020752742 0,020752742
TNFRSF1A 0,036860697 0,006620295 0,020456534 0,009783869 0,020456534
tnfb 0,044520594 0,007519054 0,020302272 0,016699269 0,020302272
HNF1A 0,048218399 0,019955347 0,008419686 0,019843366 0,019955347
AQP8 0,027445087 0,019715747 0,002881121 0,00484822 0,019715747
FABP1 0,034598611 0,011019209 0,00391388 0,019665524 0,019665524
NR1H3 0,038704947 0,014066209 0,005043181 0,019595555 0,019595555
zgc:158371 0,030945756 0,008310882 0,003057135 0,019577738 0,019577738
RBP4 0,031877313 0,007494911 0,004879188 0,019503214 0,019503214
RIPK1 0,025423696 0,002608761 0,019347206 0,00346773 0,019347206
CTGF 0,033212196 0,008016778 0,005851786 0,019343631 0,019343631
LPIN1 0,025058595 0,003857077 0,00187868 0,019322839 0,019322839
APOB 0,037570022 0,011408326 0,006972171 0,019189526 0,019189526
adipoql2 0,024932278 0,004123997 0,001853973 0,018954308 0,018954308
ifn3 0,031407136 0,009136916 0,003346376 0,018923844 0,018923844
KLHL20 0,025708759 0,002857364 0,018885973 0,003965421 0,018885973
BLVRB 0,027435131 0,018821862 0,003161966 0,005451304 0,018821862
CIDEC 0,023659833 0,002490126 0,00235765 0,018812056 0,018812056
PEMT 0,02801092 0,006710683 0,002700171 0,018600066 0,018600066
LDHA 0,043637305 0,011814404 0,018361333 0,013461568 0,018361333
atp7b 0,033615317 0,011889859 0,003828626 0,017896832 0,017896832
TMEM30A 0,022028193 0,017752279 0,001752175 0,002523738 0,017752279
HNF4A 0,041129429 0,015616528 0,00785573 0,017657171 0,017657171
PRSS1 0,03302978 0,017508695 0,009131679 0,006389406 0,017508695
BIRC2 0,024949275 0,003646871 0,017405748 0,003896657 0,017405748
PNPLA2 0,022414861 0,002911551 0,002238363 0,017264946 0,017264946
FGF19 0,027127514 0,017255177 0,001887887 0,007984449 0,017255177
ACADL 0,023819951 0,004163025 0,002457517 0,01719941 0,01719941
ALDH2 0,028506346 0,00620342 0,005104705 0,017198221 0,017198221
HMGB2 0,023257989 0,003421158 0,017075146 0,002761686 0,017075146
DFFB 0,023612443 0,003317844 0,01691659 0,003378008 0,01691659
BLVRA 0,023062713 0,01687457 0,002087081 0,004101064 0,01687457
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GNPAT 0,023393609 0,004263772 0,002335872 0,016793964 0,016793964
MAPK8 0,031920541 0,007347827 0,01660703 0,007965685 0,01660703
G6PC 0,030762972 0,009994931 0,004217285 0,016550757 0,016550757
PDHX 0,022350101 0,016546109 0,001617638 0,004186353 0,016546109
BAX 0,023386002 0,003407412 0,016497386 0,003481202 0,016497386
Cyp2b10 0,031427596 0,016436847 0,003478998 0,011511752 0,016436847
SQSTM1 0,033328641 0,005772629 0,016417256 0,011138758 0,016417256
PSME3 0,020864666 0,001998459 0,002495453 0,016370753 0,016370753
BCS1L 0,022746054 0,016334401 0,001825698 0,004585956 0,016334401
TGFB1 0,034526296 0,009064811 0,009154524 0,016306962 0,016306962
GOT1 0,030751588 0,009404703 0,005074093 0,016272791 0,016272791
ENTPD2 0,021686478 0,016172193 0,002182854 0,003331431 0,016172193
CD81 0,02492677 0,005359821 0,003475744 0,016091206 0,016091206
CYB5A 0,03473004 0,013363705 0,005395612 0,015970723 0,015970723
MGC92741 0,029027721 0,009795703 0,003330093 0,015901925 0,015901925
BNIP3 0,022055592 0,003227175 0,015794465 0,003033953 0,015794465
KRT18 0,037396435 0,010717558 0,010888772 0,015790104 0,015790104
HNF1B 0,038111903 0,015772928 0,006786002 0,015552973 0,015772928
VEGFA 0,032956634 0,009097955 0,015749989 0,00810869 0,015749989
TAT 0,03454319 0,012827191 0,005981295 0,015734704 0,015734704
ONECUT1 0,03052704 0,015676341 0,003968638 0,010882061 0,015676341
HIF1A 0,029163299 0,00800684 0,015662777 0,005493682 0,015662777
TP53 0,035636984 0,011853149 0,015628177 0,008155658 0,015628177
PCK1 0,031706557 0,010997188 0,005163926 0,015545441 0,015545441
FECH 0,028193304 0,015301908 0,003130973 0,009760423 0,015301908
PPARGC1A 0,028814338 0,007493079 0,006074304 0,015246955 0,015246955
TFR2 0,024453809 0,006236985 0,002998946 0,015217877 0,015217877
MIB1 0,028292784 0,006619989 0,015216871 0,006455925 0,015216871
HMOX1 0,041445717 0,015163179 0,013389433 0,012893107 0,015163179
BMPER 0,020479662 0,003626294 0,001703037 0,015150331 0,015150331
LEPR 0,0253284 0,004935588 0,005291006 0,015101806 0,015101806
TMEM30B 0,017649939 0,014935248 0,001120503 0,001594189 0,014935248
AHR 0,031836182 0,010715636 0,006185695 0,014934851 0,014934851
RATCERP 0,0336731 0,013174264 0,00564872 0,014850115 0,014850115
XPR1 0,022100756 0,014750975 0,001548462 0,005801318 0,014750975
SLC17A5 0,025975481 0,007172962 0,004123068 0,014679451 0,014679451
ACACA 0,021395484 0,004392912 0,002381212 0,01462136 0,01462136
ACADM 0,021878643 0,004075392 0,003258889 0,014544361 0,014544361
NFS1 0,021899361 0,004464439 0,003054629 0,014380294 0,014380294
ENDOG 0,019517068 0,00211346 0,014328009 0,003075599 0,014328009
cdkn1a 0,02839379 0,007771789 0,014297138 0,006324864 0,014297138
MAPK14 0,031152397 0,008763671 0,014289556 0,008099171 0,014289556
AGFG1 0,019824354 0,002580235 0,014250232 0,002993888 0,014250232
CEBPA 0,030453065 0,009797923 0,006407595 0,014247547 0,014247547
MAP2K4 0,026101328 0,00586159 0,014159399 0,00608034 0,014159399
KRAS 0,030957714 0,009369169 0,014141153 0,007447392 0,014141153
LPL 0,030910455 0,008934553 0,007899185 0,014076717 0,014076717
HFE2 0,021908689 0,005368965 0,002572366 0,013967358 0,013967358
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Supplementary Table 1  Continued
Concept Sum Cholestasis Necrosis Steatosis Max
mapk8 0,027983427 0,006004318 0,013945263 0,008033846 0,013945263
MLYCD 0,01773577 0,002179631 0,001714337 0,013841802 0,013841802
PIK3CG 0,031432491 0,009305946 0,013794655 0,008331888 0,013794655
Oct-01 0,022415508 0,013731853 0,003222523 0,00546113 0,013731853
HGF 0,033095926 0,012791373 0,006613493 0,013691059 0,013691059
PPARD 0,02097626 0,003482133 0,003820982 0,013673146 0,013673146
LIPC 0,029702909 0,010502266 0,005543574 0,013657069 0,013657069
MYC 0,029281709 0,008713666 0,013643687 0,006924356 0,013643687
ACLY 0,022523088 0,005979786 0,002933711 0,013609591 0,013609591
SLCO4A1 0,016806575 0,013362893 0,001299644 0,002144038 0,013362893
ADH5 0,023087617 0,006043346 0,003731309 0,013312962 0,013312962
CRK 0,025748551 0,006500926 0,013275154 0,00597247 0,013275154
DmelCG3861 0,027328024 0,007669253 0,013178549 0,006480223 0,013178549
RAF1 0,026557527 0,006484465 0,006931248 0,013141815 0,013141815
tjp1 0,015545474 0,013027028 0,001011238 0,001507209 0,013027028
MDM2 0,029093042 0,009109273 0,012982607 0,007001163 0,012982607
FOXO1 0,025163382 0,006291558 0,005901 0,012970823 0,012970823
ATG5 0,017572628 0,002202801 0,012941201 0,002428627 0,012941201
PRKRIR 0,015710823 0,001632279 0,00114529 0,012933254 0,012933254
MAP1LC3A 0,018914178 0,002765334 0,01286324 0,003285605 0,01286324
MAPK1 0,032464631 0,01046966 0,012845321 0,009149651 0,012845321
GFER 0,027299328 0,008619265 0,005840884 0,012839179 0,012839179
SLC23A1 0,016969826 0,012802857 0,001644121 0,002522848 0,012802857
RXRB 0,024259202 0,012783087 0,003669822 0,007806293 0,012783087
RXRA 0,027782276 0,012761163 0,003819636 0,011201478 0,012761163
SLC22A7 0,021758072 0,012754619 0,002439743 0,006563711 0,012754619
MAPK11 0,027976003 0,007853746 0,012743211 0,007379047 0,012743211
HADHB 0,023525519 0,008007959 0,002869872 0,012647688 0,012647688
ASPSCR1 0,021471515 0,0125962 0,005902733 0,002972582 0,0125962
HMOX2 0,024094654 0,012448587 0,00563486 0,006011207 0,012448587
POR 0,028214144 0,009718726 0,00606595 0,012429467 0,012429467
MTHFR 0,02562429 0,00581557 0,00740474 0,01240398 0,01240398
CD36 0,025321567 0,007080521 0,005910512 0,012330534 0,012330534
GHR 0,029211026 0,010487233 0,006411711 0,012312081 0,012312081
SERPINE1 0,024628581 0,005979443 0,006378766 0,012270373 0,012270373
API5 0,016351219 0,012257269 0,002029005 0,002064946 0,012257269
TRAIL 0,021770967 0,003489736 0,012175872 0,006105358 0,012175872
IL10 0,029994518 0,008696327 0,012144284 0,009153906 0,012144284
SEPSECS 0,024295079 0,012085529 0,002514439 0,009695112 0,012085529
APOA1 0,0207518 0,004711499 0,00399787 0,012042432 0,012042432
LIPE 0,018377451 0,003182043 0,003192937 0,012002471 0,012002471
GNMT 0,021026932 0,006332406 0,002700348 0,011994178 0,011994178
SCARB1 0,027560173 0,011876814 0,00496066 0,010722697 0,011876814
RELA 0,025274077 0,006750236 0,011872988 0,006650853 0,011872988
NFKBIA 0,023749791 0,005797198 0,011863844 0,00608875 0,011863844
MAT1A 0,021962637 0,007120771 0,002995166 0,0118467 0,0118467
RNF7 0,01884741 0,002692109 0,011846173 0,004309129 0,011846173
C9orf3 0,015491753 0,002286068 0,001385057 0,011820628 0,011820628
Supplementary Table 1  Continued
Concept Sum Cholestasis Necrosis Steatosis Max
COL1A1 0,024066279 0,007663363 0,004724976 0,01167794 0,01167794
SOD2 0,02739279 0,006341274 0,011615956 0,009435559 0,011615956
CAST 0,020438122 0,004497664 0,011609449 0,004331008 0,011609449
ABCG2 0,020177564 0,01158277 0,004630657 0,003964137 0,01158277
ABCA1 0,028468257 0,010925477 0,006062501 0,011480279 0,011480279
VIM 0,026992368 0,007930084 0,011457288 0,007604996 0,011457288
FOXA2 0,025602154 0,00980739 0,004358126 0,011436638 0,011436638
EHHADH 0,020967282 0,006625546 0,002924709 0,011417027 0,011417027
SMAD2 0,023918748 0,006454806 0,006070317 0,011393625 0,011393625
WDR26 0,025986934 0,01137865 0,006387496 0,008220789 0,01137865
FOXE3 0,026381619 0,010293738 0,004722645 0,011365237 0,011365237
SHBG 0,027700087 0,008172066 0,008173291 0,01135473 0,01135473
SOCS1 0,020077337 0,004351029 0,004374156 0,011352152 0,011352152
SMAD7 0,02269466 0,006279146 0,00507803 0,011337484 0,011337484
HLA-DRB1 0,02612205 0,00745553 0,011322855 0,007343666 0,011322855
UCP3 0,02187326 0,004323154 0,006233111 0,011316994 0,011316994
HSD3B7 0,015171532 0,011298706 7,82E-04 0,003091293 0,011298706
CCDC6 0,020314105 0,011269399 0,004839968 0,004204737 0,011269399
SIRT1 0,021563865 0,004282773 0,006027154 0,011253938 0,011253938
NOTCH2 0,017253086 0,011232573 0,003118563 0,002901949 0,011232573
fgf21 0,018556805 0,005386142 0,001972406 0,011198258 0,011198258
ABHD5 0,014097907 0,00172406 0,001187289 0,011186558 0,011186558
mat2a 0,020196145 0,006057636 0,002959666 0,011178844 0,011178844
ACADS 0,017703975 0,004517278 0,002133949 0,011052748 0,011052748
CDC2 0,025367407 0,008024441 0,011049162 0,006293806 0,011049162
SOCS7 0,015677366 0,002342825 0,002308094 0,011026448 0,011026448
ELOVL6 0,015407526 0,002998615 0,001385874 0,011023037 0,011023037
OCLN 0,018720072 0,011016652 0,004121236 0,003582184 0,011016652
INS 0,025144149 0,006420076 0,007750246 0,010973826 0,010973826
IGFBP1 0,026227554 0,00907476 0,006222358 0,010930435 0,010930435
JUN 0,025010629 0,007635969 0,010907425 0,006467235 0,010907425
UROD 0,01971429 0,006031759 0,002777734 0,010904798 0,010904798
rxrga 0,022707826 0,010859312 0,003126233 0,00872228 0,010859312
ATG7 0,015807344 0,002102256 0,010844933 0,002860155 0,010844933
PPARGC1B 0,01855463 0,0050136 0,002703208 0,010837823 0,010837823
ACADVL 0,016470009 0,003538457 0,002166314 0,010765238 0,010765238
HADHA 0,022723211 0,010018039 0,001995165 0,010710007 0,010710007
NR5A2 0,020822095 0,010706359 0,005255265 0,00486047 0,010706359
MBD2 0,024617489 0,009620801 0,004296141 0,010700547 0,010700547
DDC 0,030310558 0,010085961 0,010689252 0,009535345 0,010689252
abcb3l2 0,014051754 0,010675858 0,001145562 0,002230335 0,010675858
MAPK3 0,028548514 0,009496857 0,010657417 0,00839424 0,010657417
G6PD 0,020211326 0,010644634 0,005010072 0,00455662 0,010644634
GPC3 0,02011111 0,00509334 0,004463585 0,010554185 0,010554185
ADRA2B 0,016404252 0,003594533 0,002260285 0,010549436 0,010549436
MAP2K1 0,026280683 0,008172674 0,010545855 0,007562153 0,010545855
CPT2 0,019630326 0,006059116 0,003065126 0,010506085 0,010506085
SDAD1 0,019355072 0,010487013 0,001943135 0,006924922 0,010487013
162



















Supplementary Table 1  Continued
Concept Sum Cholestasis Necrosis Steatosis Max
SLCO3A1 0,013669365 0,010459238 0,001304136 0,001905991 0,010459238
KRT8 0,025367884 0,010456328 0,005198249 0,009713307 0,010456328
PPP1R3C 0,022853142 0,010392411 0,006787655 0,005673075 0,010392411
CEBPB 0,026209027 0,008805877 0,007062452 0,010340697 0,010340697
ERBB2 0,02883878 0,010340378 0,010201171 0,008297231 0,010340378
CDKN1B 0,0248792 0,007998035 0,010322264 0,006558901 0,010322264
FLT1 0,022246571 0,006310704 0,010303729 0,005632139 0,010303729
or126-1 0,022517679 0,005152976 0,010299297 0,007065406 0,010299297
TP73 0,021288596 0,006283781 0,010298626 0,004706189 0,010298626
ADD1 0,023682488 0,009257686 0,004136428 0,010288375 0,010288375
TNNC1 0,019872447 0,004934718 0,010275212 0,004662518 0,010275212
itga2b 0,023629891 0,010255006 0,006998573 0,006376312 0,010255006
ADAM17 0,019318532 0,003539303 0,010218241 0,005560987 0,010218241
AGT 0,02728812 0,010209682 0,00865866 0,008419779 0,010209682
CD68 0,023753181 0,005981891 0,010183056 0,007588235 0,010183056
CDK2 0,025480891 0,008452711 0,010170162 0,006858018 0,010170162
EPHX1 0,022888599 0,00826272 0,004458632 0,010167248 0,010167248
Pnp1 0,024196813 0,009133171 0,004898556 0,010165086 0,010165086
KDR 0,022250498 0,006675374 0,010121336 0,005453788 0,010121336
KIT 0,020301972 0,005275846 0,010114 0,004912126 0,010114
ABCG1 0,021244468 0,007480102 0,003696286 0,010068079 0,010068079
GRAP2 0,022504104 0,006559567 0,010037411 0,005907126 0,010037411
PTGS2 0,025359506 0,008330947 0,010008347 0,007020213 0,010008347
DPAGT1 0,017164266 0,004266203 0,00289536 0,010002703 0,010002703
Supplementary Table 2
Concept Sum Brain Eye Heart Max
PAX6 0,178321943 0,022913222 0,140569324 0,0148394 0,140569324
SIX3 0,141870365 0,01567154 0,116627347 0,009571472 0,116627347
six3b 0,133513004 0,01326474 0,114330692 0,005917569 0,114330692
NKX2-5 0,131155327 0,006951189 0,014265265 0,109938867 0,109938867
GATA4 0,119178429 0,006391891 0,010700367 0,102086171 0,102086171
six6a 0,117921859 0,01256135 0,101633277 0,003727231 0,101633277
TBX5 0,11584647 0,005487368 0,027726691 0,08263241 0,08263241
GATA6 0,088820197 0,005249717 0,00959564 0,073974836 0,073974836
ZFPM2 0,088794149 0,00335001 0,013068723 0,072375416 0,072375416
EYA1 0,08824259 0,006215983 0,068925288 0,013101321 0,068925288
SIX1 0,089750901 0,008327516 0,068836522 0,012586864 0,068836522
VAX2 0,090695895 0,004744419 0,068345736 0,017605737 0,068345736
TBX20 0,085233591 0,003792624 0,013351319 0,068089651 0,068089651
GATA5 0,077895351 0,003146774 0,007228061 0,067520514 0,067520514
VAX1 0,079889186 0,007381369 0,059493494 0,013014324 0,059493494
DAB1 0,074998029 0,059293475 0,010185451 0,005519101 0,059293475
DACH1 0,077562876 0,012655557 0,059247098 0,005660218 0,059247098
VSX2 0,076123282 0,008164224 0,058703932 0,009255126 0,058703932
RELN 0,077823713 0,058193578 0,012041848 0,007588284 0,058193578
MYL7 0,062604882 0,003154815 0,005332639 0,054117424 0,054117424
MEF2C 0,069035895 0,008002068 0,007215631 0,053818199 0,053818199
RAX 0,066668369 0,005990172 0,052369375 0,008308824 0,052369375
SIX4 0,066366047 0,005530024 0,051422338 0,009413684 0,051422338
EAF2 0,055084154 0,001100045 0,051024867 0,00295924 0,051024867
MITF 0,06393414 0,005255749 0,048964265 0,009714129 0,048964265
IRX4 0,059788555 0,003167061 0,008632615 0,047988879 0,047988879
OTX2 0,094262525 0,02878294 0,046866905 0,01861268 0,046866905
EYA3 0,054065339 0,002812763 0,046522075 0,004730502 0,046522075
mef2ca 0,056918621 0,005001749 0,005485586 0,046431288 0,046431288
PROX1 0,069144674 0,011860002 0,046077012 0,011207656 0,046077012
CRYAA 0,053587563 0,004484663 0,044179551 0,00492335 0,044179551
SRF 0,057598684 0,005425971 0,008297033 0,043875681 0,043875681
MYL2 0,052577663 0,004240988 0,00454675 0,043789927 0,043789927
DMBX1 0,067832008 0,017208477 0,043393016 0,007230513 0,043393016
wnt11 0,070198424 0,005844284 0,021064411 0,043289726 0,043289726
WNT11 0,070253387 0,00585135 0,021113247 0,04328879 0,04328879
TBX3 0,068560131 0,004006329 0,021442098 0,043111701 0,043111701
wnt11 0,070103385 0,005952562 0,021061623 0,043089204 0,043089204
CDK5 0,055067398 0,043061133 0,006038619 0,005967648 0,043061133
SOX1 0,075169489 0,01233842 0,042511489 0,020319583 0,042511489
MYH6 0,054092713 0,006164146 0,006078841 0,041849726 0,041849726
AES 0,052372187 0,004985748 0,041345441 0,006040997 0,041345441
nppa 0,052520875 0,002180919 0,009267298 0,041072659 0,041072659
LRRC10 0,044885568 0,001325308 0,002594433 0,040965827 0,040965827
DACH2 0,052785467 0,006090651 0,040520912 0,006173904 0,040520912
PITX2 0,07998991 0,007150433 0,039893058 0,032946416 0,039893058
hopx 0,045636944 0,001978416 0,003982008 0,03967652 0,03967652
SOX2 0,076029941 0,011762438 0,039673298 0,024594208 0,039673298
164



















Supplementary Table 2  Continued
Concept Sum Brain Eye Heart Max
six2 0,05517618 0,004621344 0,039425987 0,011128848 0,039425987
SIX2 0,05517618 0,004621344 0,039425987 0,011128848 0,039425987
CDK5R2 0,045541085 0,038721235 0,003440829 0,003379022 0,038721235
CTCF 0,047221705 0,004501128 0,038721193 0,003999385 0,038721193
pax2a 0,063120492 0,012553503 0,038562609 0,012004382 0,038562609
MAF 0,04994427 0,00505733 0,038482288 0,006404654 0,038482288
MEF2D 0,055798467 0,009617308 0,00784199 0,03833917 0,03833917
PITX3 0,055921994 0,008077445 0,038269354 0,009575194 0,038269354
otx1l 0,06698294 0,037639449 0,020088836 0,009254652 0,037639449
eya4 0,04538827 0,003412652 0,037568666 0,004406954 0,037568666
NKX2-2 0,063139036 0,012279124 0,037403122 0,013456793 0,037403122
EOMES 0,060267769 0,013516373 0,037321223 0,009430175 0,037321223
MYEF2 0,055019524 0,008953787 0,008966454 0,037099285 0,037099285
ISL1 0,077418409 0,009697639 0,031026876 0,036693894 0,036693894
OLFM3 0,044368021 0,004928045 0,036399123 0,003040856 0,036399123
mef2b 0,044603784 0,005991912 0,002782786 0,035829087 0,035829087
TBX18 0,051387899 0,003048582 0,012655642 0,035683673 0,035683673
BFSP2 0,043155961 0,003528312 0,035635648 0,003992001 0,035635648
FOXC1 0,063333727 0,012053639 0,035447269 0,01583282 0,035447269
EAF1 0,038386859 0,001111476 0,035410508 0,001864875 0,035410508
NKX2-3 0,045547318 0,00303399 0,007121174 0,035392151 0,035392151
MAB21L2 0,046415213 0,00532077 0,035342341 0,005752102 0,035342341
BMP2 0,074442334 0,008676405 0,030556471 0,035209456 0,035209456
EMX2 0,066138677 0,019494217 0,035163632 0,011480829 0,035163632
SHH 0,07605724 0,017809118 0,035152873 0,023095253 0,035152873
ELP4 0,048270274 0,010565259 0,035148573 0,002556442 0,035148573
TBX4 0,052892078 0,003972127 0,014202544 0,034717405 0,034717405
DBX1 0,0493926 0,008270895 0,034697068 0,006424637 0,034697068
CDK5R1 0,041871481 0,034050861 0,004114853 0,003705767 0,034050861
gsh2 0,04946842 0,008919284 0,034032437 0,006516698 0,034032437
dyrk1aa 0,040136397 0,033909927 0,002974366 0,003252102 0,033909927
BDNF 0,050921854 0,033133779 0,009176592 0,008611482 0,033133779
EMX1 0,067901835 0,025410886 0,033115316 0,009375636 0,033115316
map1b 0,041389551 0,033070242 0,004212758 0,004106549 0,033070242
slc8a1a 0,03906348 0,003132934 0,003020789 0,032909758 0,032909758
CNKSR2 0,038777225 0,003942589 0,0328765 0,001958135 0,0328765
bmp7a 0,06064434 0,005086783 0,032789459 0,022768099 0,032789459
MECP2 0,044530712 0,032737361 0,006551348 0,005242004 0,032737361
ISL2 0,058784898 0,006464186 0,032696817 0,019623896 0,032696817
ATOH7 0,04434729 0,005779851 0,032416155 0,006151283 0,032416155
ALDH1A3 0,049356967 0,004982705 0,032254044 0,012120218 0,032254044
MYLPF 0,037528805 0,002634016 0,002693603 0,032201188 0,032201188
BMP4 0,072191142 0,009958062 0,030106348 0,032126728 0,032126728
GJA5 0,044666402 0,005254206 0,007305357 0,03210684 0,03210684
mesp1 0,04332763 0,003057487 0,008281343 0,0319888 0,0319888
OTX1 0,071658097 0,028336401 0,031592966 0,011728727 0,031592966
rc3 0,037628155 0,03134258 0,003386031 0,002899542 0,03134258
MEF2A 0,045554403 0,007263368 0,00696501 0,031326027 0,031326027
Supplementary Table 2  Continued
Concept Sum Brain Eye Heart Max
WNT7B 0,063460559 0,008227264 0,03118088 0,024052415 0,03118088
MIP26 0,037572999 0,002932955 0,031060736 0,003579308 0,031060736
ZFPM1 0,045669008 0,003030051 0,011592472 0,031046486 0,031046486
BARHL2 0,039026093 0,003503176 0,031041031 0,004481884 0,031041031
POU5F1 0,059299685 0,012491451 0,015791289 0,031016944 0,031016944
TBX1 0,051753845 0,00899995 0,012006022 0,030747875 0,030747875
GFAP 0,050052516 0,03035348 0,011980851 0,007718185 0,03035348
NRL 0,040873673 0,004896084 0,030012292 0,005965297 0,030012292
FGF8 0,074985333 0,016159748 0,029844517 0,028981069 0,029844517
dbx2 0,044370908 0,009551957 0,029763821 0,005055131 0,029763821
NKX6-1 0,047607213 0,008105194 0,029690779 0,009811242 0,029690779
BMP7 0,064983256 0,007817911 0,029592777 0,027572565 0,029592777
BMP10 0,04093951 0,002080864 0,009294992 0,029563652 0,029563652
QSOX1 0,050521735 0,007846194 0,029502586 0,013172955 0,029502586
ELL 0,032946594 0,001846564 0,029262511 0,001837519 0,029262511
MYH7 0,038419295 0,004272257 0,004950251 0,029196788 0,029196788
MEIS2 0,047619447 0,006859206 0,02907285 0,01168739 0,02907285
HMX1 0,039346017 0,004099694 0,028858175 0,006388147 0,028858175
SMO 0,05328599 0,009916445 0,02856085 0,014808696 0,02856085
ZIC2 0,049256913 0,012437338 0,02829927 0,008520305 0,02829927
FBLIM1 0,032188959 0,001365398 0,002535972 0,028287591 0,028287591
cmlc1 0,031222668 0,001151086 0,001845259 0,028226322 0,028226322
GLI1 0,051256716 0,010014968 0,027898233 0,013343517 0,027898233
disc1 0,03634996 0,027724347 0,00469909 0,003926522 0,027724347
FGFR1 0,058377851 0,009416889 0,021312542 0,027648422 0,027648422
DLX1 0,056612384 0,013838526 0,027593378 0,015180481 0,027593378
GBX2 0,058807906 0,016732653 0,027584914 0,01449034 0,027584914
PLP1 0,03692067 0,027554902 0,00493995 0,00442582 0,027554902
cxcl12a 0,044893011 0,012436565 0,00490571 0,027550738 0,027550738
FZD5 0,044416055 0,004986577 0,027543419 0,01188606 0,027543419
MEIS1 0,040830385 0,004958775 0,027391298 0,008480311 0,027391298
FOXE3 0,043705333 0,004926329 0,02739064 0,011388364 0,02739064
VLDLR 0,034854352 0,027235883 0,00381426 0,003804211 0,027235883
CRYBB2 0,032442637 0,00270538 0,02720431 0,002532945 0,02720431
SOX7 0,036506724 0,002653695 0,006656682 0,027196346 0,027196346
GLI3 0,053298395 0,012226133 0,027126459 0,013945804 0,027126459
TGIF1 0,045431446 0,011387736 0,027106441 0,00693727 0,027106441
GJA3 0,046109647 0,005238436 0,026928989 0,013942222 0,026928989
wnt2 0,060179651 0,008064431 0,025197949 0,02691727 0,02691727
GFM2 0,033138629 0,003685707 0,00256539 0,026887532 0,026887532
WNT1 0,061392847 0,014224196 0,02676771 0,02040094 0,02676771
BFSP1 0,034378961 0,004007753 0,026674243 0,003696967 0,026674243
PAFAH1B1 0,035960585 0,026474292 0,004688761 0,004797533 0,026474292
FGFR2 0,058963306 0,00985375 0,022727918 0,026381639 0,026381639
TNNT2 0,032926798 0,003472916 0,003143604 0,026310279 0,026310279
EN1 0,0576239 0,016632098 0,026278517 0,014713286 0,026278517
jarid2a 0,030356819 0,002452832 0,001778801 0,026125185 0,026125185
sox17 0,040689476 0,004891027 0,009704305 0,026094144 0,026094144
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KERA 0,034869812 0,003642897 0,025988516 0,005238399 0,025988516
ST8SIA2 0,037097566 0,025876889 0,006068415 0,005152261 0,025876889
TBR1 0,053038184 0,018898884 0,025826156 0,008313144 0,025826156
SOX3 0,042719733 0,008054777 0,025788568 0,008876388 0,025788568
NKX2-1 0,046325054 0,00894093 0,01169997 0,025684153 0,025684153
LHX2 0,054539438 0,009577774 0,025657777 0,019303887 0,025657777
MBP 0,035998113 0,025597471 0,005371406 0,005029237 0,025597471
TNNC1 0,032461237 0,003756149 0,003321753 0,025383335 0,025383335
FGF16 0,037439812 0,005542275 0,006594595 0,025302943 0,025302943
FXR1 0,038347255 0,025299991 0,008200328 0,004846936 0,025299991
FMR1 0,037486117 0,02523618 0,007881047 0,004368888 0,02523618
USP9X 0,035733059 0,006609781 0,025174655 0,003948622 0,025174655
WNT5B 0,053338371 0,006776334 0,025162138 0,021399901 0,025162138
MOGAT2 0,031827275 0,003459433 0,025136205 0,003231636 0,025136205
RYBP 0,029893968 0,002490263 0,025073768 0,002329938 0,025073768
wnt2b 0,049035594 0,006226124 0,025038552 0,017770917 0,025038552
HES1 0,055086743 0,01207773 0,024948425 0,018060589 0,024948425
RFX4 0,032660566 0,024928018 0,004694026 0,003038522 0,024928018
BARHL1 0,036062241 0,005752957 0,024912561 0,005396722 0,024912561
JARID2 0,038222723 0,006833288 0,006517717 0,024871717 0,024871717
IRX3 0,044584271 0,007712609 0,024821637 0,012050024 0,024821637
Mnpepl 0,029616041 0,024731512 0,00260208 0,00228245 0,024731512
LHX5 0,038766783 0,006216482 0,024697323 0,007852977 0,024697323
MOV10L1 0,02943725 0,001653069 0,00311855 0,02466563 0,02466563
WNT5A 0,053680688 0,007518694 0,024657597 0,021504396 0,024657597
SHOX2 0,037456013 0,004567843 0,008233335 0,024654836 0,024654836
QRSL1 0,030455885 0,002176684 0,003682479 0,024596723 0,024596723
BMP2K 0,030476553 0,001799168 0,024548864 0,004128521 0,024548864
HEY2 0,044127516 0,005736743 0,013861591 0,024529182 0,024529182
acta1b 0,027575837 0,001039336 0,002050466 0,024486035 0,024486035
NOTCH1 0,056757666 0,013034332 0,024459129 0,019264205 0,024459129
CUGBP2 0,034336235 0,003782853 0,006127221 0,02442616 0,02442616
MSI2 0,039115552 0,009795312 0,024186608 0,00513363 0,024186608
CRYAB 0,037196208 0,006379911 0,024152212 0,006664084 0,024152212
NES 0,056818299 0,024117543 0,016765688 0,015935069 0,024117543
wnt3l 0,048337616 0,005633234 0,018602809 0,024101573 0,024101573
ik:tdsubc_2b12 0,042899556 0,004967245 0,013859455 0,024072857 0,024072857
GJA1 0,047220107 0,00789789 0,015263161 0,024059056 0,024059056
RCVRN 0,033371031 0,005393403 0,02402826 0,003949369 0,02402826
FAM82A2 0,027533328 0,001613726 0,024018743 0,00190086 0,024018743
FGF19 0,042887799 0,006769323 0,024001575 0,012116902 0,024001575
NTF3 0,046850536 0,023985725 0,009189357 0,013675452 0,023985725
WRB 0,02851413 0,00117694 0,003353637 0,023983553 0,023983553
ROS1 0,031588215 0,003161279 0,023890754 0,004536182 0,023890754
CRYBA4 0,028498895 0,002622936 0,023858195 0,002017763 0,023858195
MSX2 0,050886989 0,006521304 0,023827489 0,020538197 0,023827489
lhx9 0,044708923 0,008117174 0,012774229 0,02381752 0,02381752
GJA8 0,034679476 0,003037003 0,023749851 0,007892623 0,023749851
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SALL4 0,038861264 0,003949093 0,011175396 0,023736773 0,023736773
C10orf97 0,028556654 0,002700439 0,002125974 0,023730242 0,023730242
MSX1 0,053728081 0,007533196 0,023686059 0,022508826 0,023686059
NLK 0,036519263 0,004439509 0,023604308 0,008475446 0,023604308
NKX2-8 0,044484258 0,004155898 0,016890421 0,023437938 0,023437938
hesx1 0,049895227 0,009634887 0,023432597 0,016827745 0,023432597
ASCL1 0,054272223 0,015907495 0,023428644 0,014936083 0,023428644
SIK1 0,028957779 0,001949921 0,003585171 0,023422686 0,023422686
fgf2 0,051920965 0,01423993 0,014392997 0,023288038 0,023288038
cyp26b1 0,039859537 0,007192183 0,023199149 0,009468207 0,023199149
CXCR4 0,040120531 0,010955157 0,005987118 0,023178255 0,023178255
BMPR2 0,047159161 0,004501385 0,019636406 0,023021369 0,023021369
GRIN1 0,037281398 0,023003917 0,005519285 0,008758196 0,023003917
cyp1b1 0,033091258 0,004410882 0,022927461 0,005752914 0,022927461
ST8SIA4 0,031684294 0,022918701 0,004507717 0,004257877 0,022918701
CDON 0,036375858 0,007605392 0,022785506 0,005984959 0,022785506
SMAD1 0,04817846 0,005973095 0,019450217 0,022755147 0,022755147
EP300 0,044398893 0,006472839 0,015262833 0,02266322 0,02266322
CYP26B1 0,039906535 0,00726112 0,022637604 0,010007811 0,022637604
NR2F2 0,045781989 0,00479003 0,022618656 0,018373304 0,022618656
RCN1 0,034977473 0,003663671 0,022615608 0,008698193 0,022615608
SOX9 0,047367927 0,008909498 0,022601361 0,015857067 0,022601361
CYP1B1 0,032787576 0,004458903 0,022561952 0,005766722 0,022561952
POSTN 0,031442791 0,003515699 0,005390816 0,022536277 0,022536277
GAP43 0,034558035 0,022516441 0,0067539 0,005287693 0,022516441
LIM2 0,030111955 0,002737294 0,022446238 0,004928424 0,022446238
PDLIM2 0,028293736 0,001371684 0,004512483 0,02240957 0,02240957
PAX3 0,052264906 0,008103669 0,022362836 0,0217984 0,022362836
EGFR 0,036054131 0,006920896 0,022316275 0,006816961 0,022316275
crx 0,031049853 0,005144442 0,02225418 0,003651232 0,02225418
WNT2B 0,042936482 0,005863449 0,022241546 0,014831487 0,022241546
ATE1 0,02794145 0,001395948 0,004307426 0,022238076 0,022238076
ALDH1A2 0,050024379 0,006788738 0,021075317 0,022160324 0,022160324
LHX1 0,045076795 0,007393114 0,022150259 0,015533422 0,022150259
ATP2A2 0,031287681 0,00442642 0,004721118 0,022140142 0,022140142
GLI2 0,041967671 0,007866989 0,022085879 0,012014804 0,022085879
zscn5a 0,025616581 0,001651678 0,001897557 0,022067346 0,022067346
mylk3 0,024548538 8,61E-04 0,001638854 0,022048549 0,022048549
WNT8A 0,04474207 0,005800274 0,01690616 0,022035637 0,022035637
EN2 0,052092474 0,019805849 0,022010936 0,010275689 0,022010936
WNT3 0,049606014 0,007756128 0,019855111 0,021994776 0,021994776
IHH 0,043540005 0,007312392 0,021968678 0,014258934 0,021968678
MOCS3 0,027472891 0,002833089 0,02193768 0,00270212 0,02193768
NEUROD1 0,035579193 0,006998828 0,021879413 0,006700952 0,021879413
MYL9 0,028713042 0,003295566 0,003542504 0,021874973 0,021874973
FABP7 0,04393116 0,016084607 0,021820116 0,006026438 0,021820116
TTN 0,027050497 0,002192772 0,003052867 0,021804857 0,021804857
mitfa 0,030560462 0,002279493 0,021784979 0,006495989 0,021784979
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GJB1 0,041288603 0,008516785 0,011018864 0,021752955 0,021752955
FGF10 0,048042748 0,007855693 0,018463977 0,021723081 0,021723081
actc1a 0,024923079 0,001307192 0,001893343 0,021722544 0,021722544
DKK1 0,040483549 0,005834496 0,013023512 0,021625543 0,021625543
MYOC 0,028429329 0,003958834 0,021593544 0,002876952 0,021593544
BMPR1A 0,045165718 0,004900517 0,018672443 0,021592756 0,021592756
NOTCH2 0,048108365 0,010510799 0,021589355 0,016008212 0,021589355
WNT8B 0,045234382 0,007471677 0,021581803 0,016180902 0,021581803
WT1 0,048053455 0,006406316 0,021545574 0,020101564 0,021545574
PDX1 0,043724023 0,008593513 0,021540211 0,013590298 0,021540211
PAFAH1B3 0,02403738 0,021491927 0,001461668 0,001083786 0,021491927
TLL1 0,033280242 0,004300124 0,007508491 0,021471625 0,021471625
FERMT2 0,026723983 0,002299919 0,003019597 0,021404467 0,021404467
GPR143 0,026142489 0,002720293 0,021347794 0,002074402 0,021347794
NTRK2 0,037401538 0,021343136 0,007148148 0,008910254 0,021343136
MAG 0,031912714 0,021315108 0,005646596 0,004951011 0,021315108
TBX6 0,040322423 0,005429581 0,013598496 0,021294348 0,021294348
PCDH21 0,029890001 0,001902653 0,006696494 0,021290853 0,021290853
NEUROG1 0,048326306 0,01491267 0,021272069 0,012141568 0,021272069
RBM15 0,030828165 0,001661747 0,021236146 0,007930271 0,021236146
MOV10 0,032241687 0,005406248 0,005600735 0,021234703 0,021234703
pbx2 0,031616744 0,004367194 0,021230006 0,006019545 0,021230006
HMGN3 0,026601138 0,002712062 0,021149996 0,002739079 0,021149996
PKNOX1 0,030171281 0,004406209 0,021051145 0,004713927 0,021051145
lrp6 0,045641918 0,008234733 0,016391866 0,021015318 0,021015318
APP 0,036498643 0,020971099 0,008429689 0,007097855 0,020971099
GNL3 0,025157336 0,0031654 0,02094908 0,001042857 0,02094908
CREBBP 0,041858677 0,005662455 0,015293505 0,020902715 0,020902715
TCF7L1 0,036089927 0,006045029 0,020689138 0,009355762 0,020689138
SOX11 0,039279487 0,009959121 0,02053006 0,008790307 0,02053006
s100b 0,027917126 0,020511336 0,003311971 0,004093819 0,020511336
BARX1 0,040349282 0,004263926 0,020510331 0,015575026 0,020510331
NDEL1 0,027513713 0,020468984 0,003855482 0,003189246 0,020468984
DKK2 0,0377452 0,003732664 0,020443763 0,013568773 0,020443763
nr2f5 0,040116522 0,004223669 0,020428028 0,015464826 0,020428028
PAFAH1B2 0,022537149 0,020394135 0,00114892 9,94E-04 0,020394135
LBX1 0,03728091 0,004705756 0,012200593 0,020374562 0,020374562
TCF3 0,045556389 0,010763823 0,014420898 0,020371667 0,020371667
ptc1 0,036177151 0,007233932 0,020331102 0,008612116 0,020331102
RGR 0,02499561 0,002294843 0,020307384 0,002393382 0,020307384
MSI1 0,040877145 0,012406702 0,020264287 0,008206157 0,020264287
IRX2 0,034057893 0,003929339 0,009864995 0,020263559 0,020263559
CTNNBL1 0,040574796 0,020213373 0,013535398 0,006826025 0,020213373
hes5 0,047472879 0,012523353 0,020162611 0,014786914 0,020162611
TFE3 0,027610516 0,002449294 0,020161509 0,004999714 0,020161509
HAND2 0,032965384 0,007185623 0,005703633 0,020076128 0,020076128
CHRD 0,046179812 0,006559904 0,019549224 0,020070686 0,020070686
SPON1 0,027971201 0,005251834 0,020061544 0,002657822 0,020061544
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HOMER3 0,028946461 0,006612483 0,020036593 0,002297385 0,020036593
SIAH2 0,027553787 0,002860683 0,020034364 0,00465874 0,020034364
RRH 0,022913512 0,001262244 0,02002279 0,001628478 0,02002279
AKR1B1 0,027673084 0,004139197 0,019984997 0,003548891 0,019984997
STRA6 0,031129818 0,003968036 0,019962034 0,007199748 0,019962034
Stra6 0,031129818 0,003968036 0,019962034 0,007199748 0,019962034
NEUROD2 0,032629546 0,019908753 0,007159667 0,005561124 0,019908753
NEUROD6 0,042239882 0,019870948 0,017678084 0,004690851 0,019870948
OLIG2 0,047951449 0,017439818 0,019830989 0,010680641 0,019830989
SCN1B 0,026604047 0,003850269 0,00298971 0,019764069 0,019764069
APLP2 0,033040363 0,019749105 0,007269941 0,006021316 0,019749105
OPN3 0,023138495 0,001908903 0,019747189 0,001482404 0,019747189
smad4 0,036347397 0,005640531 0,01099182 0,019715047 0,019715047
col18a1 0,026350018 0,003363547 0,019621445 0,003365026 0,019621445
RBPJ 0,039283674 0,006625412 0,019607717 0,013050544 0,019607717
WNT9A 0,042610437 0,004724476 0,019603079 0,018282881 0,019603079
CNKSR1 0,023457309 0,001683891 0,019553595 0,002219823 0,019553595
CDH2 0,043976985 0,00889714 0,015540349 0,019539495 0,019539495
FGFR4 0,047205739 0,008374338 0,0193252 0,019506201 0,019506201
WNT9B 0,041080143 0,005060593 0,019500227 0,016519322 0,019500227
MBNL1 0,041813411 0,003155207 0,019162123 0,019496081 0,019496081
pax2b 0,02850662 0,004228995 0,019492304 0,004785322 0,019492304
NUDT6 0,036553536 0,007955809 0,009109222 0,019488507 0,019488507
tbx6 0,03478289 0,004518766 0,010822453 0,01944167 0,01944167
NFATC1 0,032435082 0,005097486 0,007911894 0,019425702 0,019425702
fgf6a 0,045286931 0,007654507 0,018220379 0,019412045 0,019412045
SMAD4 0,036019776 0,005716284 0,010894592 0,0194089 0,0194089
WNT7A 0,045386795 0,007780789 0,019393143 0,018212861 0,019393143
LIFR 0,03461219 0,008033181 0,007215912 0,019363098 0,019363098
vcana 0,025733801 0,002339732 0,004043683 0,019350385 0,019350385
LHX3 0,039165303 0,006853398 0,019348466 0,012963441 0,019348466
CA4 0,02732351 0,019343049 0,003956516 0,004023946 0,019343049
SMYD1 0,040899627 0,003120169 0,01844253 0,019336926 0,019336926
DDC 0,03094116 0,019311999 0,006511254 0,005117909 0,019311999
bmp2a 0,038129434 0,003374986 0,01547545 0,019278999 0,019278999
fabp7a 0,038585715 0,014187615 0,019277694 0,005120405 0,019277694
MBNL3 0,029036237 0,001570699 0,019249557 0,008215981 0,019249557
MBNL2 0,029553423 0,001730771 0,01923841 0,008584242 0,01923841
WNT16 0,039581712 0,004942751 0,019186898 0,015452062 0,019186898
PLA2G7 0,0262738 0,019133144 0,003717397 0,003423258 0,019133144
nf1 0,035512049 0,009675354 0,006758718 0,019077978 0,019077978
PAX7 0,039025705 0,007060136 0,019052784 0,012912785 0,019052784
UTP6 0,022339279 0,001997804 0,00130654 0,019034935 0,019034935
hdac9b 0,025769532 0,002295088 0,004449755 0,019024689 0,019024689
hsf4 0,031734128 0,003040359 0,018972305 0,009721465 0,018972305
SMAD5 0,040730748 0,004291857 0,017468861 0,018970029 0,018970029
FKBP8 0,026642211 0,003350663 0,018967311 0,004324237 0,018967311
SNAI1 0,030459296 0,003514196 0,00798651 0,01895859 0,01895859
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RHO 0,0262239 0,003989129 0,01889785 0,003336922 0,01889785
GPR177 0,029663064 0,003224814 0,018894684 0,007543566 0,018894684
IGF1 0,03518175 0,018833438 0,006922584 0,009425729 0,018833438
SFRP2 0,037814047 0,005078703 0,018820071 0,013915272 0,018820071
OPTN 0,024622945 0,003207808 0,018814484 0,002600653 0,018814484
IRX5 0,033662569 0,003544987 0,011315394 0,018802188 0,018802188
HOXD4 0,033558287 0,005435137 0,01872565 0,009397501 0,01872565
ZEB2 0,031630773 0,004659844 0,008248496 0,018722435 0,018722435
TYRP1 0,028174592 0,003910425 0,018619237 0,005644929 0,018619237
KLF13 0,026842875 0,003053665 0,005176788 0,018612421 0,018612421
DTH 0,032772422 0,018565816 0,007943048 0,006263557 0,018565816
GDF6 0,03007577 0,00287334 0,018549187 0,008653243 0,018549187
OPN1LW 0,027268264 0,004462638 0,018543143 0,004262483 0,018543143
OPN1SW 0,025112189 0,003038872 0,018482902 0,003590415 0,018482902
SERPINF1 0,026187284 0,00337362 0,018467836 0,004345829 0,018467836
Choline acetylase 0,029375819 0,018466671 0,005648566 0,005260582 0,018466671
SATB2 0,031406388 0,007364576 0,018396017 0,005645794 0,018396017
wnt4a 0,033107743 0,004285261 0,018378763 0,010443718 0,018378763
BCAN 0,027115548 0,018345413 0,003535383 0,005234753 0,018345413
SMARCD3 0,027041711 0,003228566 0,005486916 0,01832623 0,01832623
HEY1 0,038651209 0,005225367 0,015105512 0,018320331 0,018320331
HEXIM1 0,023411497 0,002333456 0,002789239 0,018288803 0,018288803
FGF4 0,042261239 0,007174217 0,016802565 0,018284459 0,018284459
MYF5 0,037655018 0,007367682 0,012012752 0,018274585 0,018274585
SLC1A3 0,031689681 0,018266988 0,008276386 0,005146305 0,018266988
PLOD1 0,029539671 0,002367537 0,00890676 0,018265374 0,018265374
TAF15 0,023547957 0,003006751 0,018213704 0,002327502 0,018213704
DISP1 0,028158344 0,004789024 0,018158989 0,005210331 0,018158989
SYP 0,030561646 0,018158566 0,006757078 0,005646003 0,018158566
TBX15 0,028938714 0,002727619 0,008082073 0,018129022 0,018129022
wu:fc26c12 0,026800072 0,002485418 0,006198619 0,018116034 0,018116034
WDR5 0,035008095 0,003371911 0,013529398 0,018106788 0,018106788
HHIP 0,031413261 0,005447593 0,018094265 0,007871403 0,018094265
REST 0,03722759 0,008999273 0,018070311 0,010158006 0,018070311
GATA2 0,032912023 0,005543733 0,009367362 0,018000928 0,018000928
SLC8A1 0,022510771 0,001817217 0,002696897 0,017996656 0,017996656
GMNN 0,026835611 0,003031444 0,017958531 0,005845637 0,017958531
HTR1A 0,028134517 0,017956831 0,005270921 0,004906766 0,017956831
SFRS2 0,025862589 0,004167447 0,003757627 0,017937515 0,017937515
HOXB1 0,045214772 0,011115123 0,017937484 0,016162166 0,017937484
WNT10A 0,040485099 0,005235283 0,017352946 0,01789687 0,01789687
LHX6 0,034284171 0,00778266 0,017895922 0,008605588 0,017895922
FOXD3 0,038368028 0,005635334 0,014840214 0,01789248 0,01789248
PRPH2 0,026125636 0,00481883 0,01788964 0,003417165 0,01788964
LMX1B 0,035238206 0,008025343 0,017884083 0,009328779 0,017884083
SIP1 0,030403502 0,005208097 0,007333815 0,017861591 0,017861591
DCT 0,028093373 0,00403126 0,017852634 0,00620948 0,017852634
HMX3 0,032545973 0,004918173 0,017848912 0,009778887 0,017848912
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MYOG 0,035915717 0,007607698 0,010494675 0,017813344 0,017813344
NR4A3 0,027671095 0,006023973 0,017806312 0,00384081 0,017806312
FOXA2 0,036871966 0,006115178 0,012971281 0,017785506 0,017785506
TEAD1 0,025981484 0,003266837 0,004956739 0,017757908 0,017757908
DMAP1 0,022455761 0,001700591 0,017753863 0,003001306 0,017753863
lmx1b 0,034592327 0,007934612 0,017724352 0,008933361 0,017724352
BMP6 0,040415749 0,005353805 0,017347771 0,017714173 0,017714173
HSF2 0,03604297 0,006627713 0,011874769 0,017540487 0,017540487
SH3BGR 0,0204858 0,001525809 0,001424721 0,01753527 0,01753527
CRYBA2 0,022028303 0,002095886 0,017534441 0,002397975 0,017534441
CRIM1 0,023863098 0,00233609 0,017512414 0,004014593 0,017512414
NDRG4 0,032772548 0,010784803 0,004493768 0,017493977 0,017493977
FSTL3 0,02443908 0,002019652 0,004979007 0,017440421 0,017440421
RRBP1 0,021628475 0,001230671 0,002968061 0,017429743 0,017429743
ABAT 0,027868891 0,006297938 0,004182428 0,017388524 0,017388524
TFAP2A 0,033082996 0,005058646 0,017382235 0,010642115 0,017382235
C21orf33 0,033242159 0,005870156 0,017337438 0,010034564 0,017337438
SUFU 0,029701259 0,004836745 0,017335427 0,007529085 0,017335427
RORA 0,029929241 0,017334212 0,006157314 0,006437716 0,017334212
CITED2 0,030051166 0,003678972 0,00905381 0,017318385 0,017318385
SIK2 0,020864479 0,001129033 0,002451603 0,017283844 0,017283844
ADNP 0,036654517 0,017229578 0,006957201 0,01246774 0,017229578
GATA1 0,034144912 0,006430553 0,010489445 0,017224914 0,017224914
CAPN2 0,026927872 0,00471981 0,017205957 0,005002104 0,017205957
FOXL1 0,031560492 0,003992111 0,017189129 0,010379251 0,017189129
STAU2 0,023395022 0,003652158 0,017166938 0,002575926 0,017166938
FGF1 0,041954368 0,010068872 0,014771551 0,017113945 0,017113945
FGFR3 0,04164803 0,007493715 0,017105214 0,017049101 0,017105214
DLL1 0,043078557 0,009297848 0,016703363 0,017077346 0,017077346
CDH10 0,02237862 0,002806724 0,002523753 0,017048142 0,017048142
sox10 0,043510582 0,009680961 0,017013929 0,016815692 0,017013929
AGRN 0,032423157 0,009712216 0,016950836 0,005760106 0,016950836
NR2E3 0,026827853 0,005458677 0,016934511 0,004434664 0,016934511
PAX9 0,034347594 0,004990829 0,016932707 0,01242406 0,016932707
TYR 0,027361494 0,005284308 0,016928488 0,005148698 0,016928488
PRDX5 0,024428666 0,016889743 0,004256174 0,003282748 0,016889743
VEGFA 0,035975493 0,00736562 0,01173971 0,016870163 0,016870163
PSEN1 0,033355143 0,016851356 0,009233229 0,007270559 0,016851356
HOXA2 0,03780115 0,007770806 0,016832604 0,01319774 0,016832604
PAX1 0,033455823 0,004793974 0,01679441 0,011867437 0,01679441
SMARCA5 0,02704465 0,005594725 0,016771124 0,004678802 0,016771124
SEMA5A 0,037018549 0,009020081 0,016762271 0,011236198 0,016762271
htra1 0,024147389 0,004102218 0,016761044 0,003284126 0,016761044
NEUROD4 0,034431938 0,009919189 0,01674384 0,00776891 0,01674384
CDH6 0,033029556 0,006503333 0,016739894 0,009786331 0,016739894
cdh4 0,026430035 0,007962693 0,016734322 0,001733021 0,016734322
TRIM71 0,02620095 0,004451265 0,016670834 0,005078851 0,016670834
GRIA3 0,02558055 0,016659248 0,004417847 0,004503455 0,016659248
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UBE3C 0,022779178 0,002301598 0,00382996 0,01664762 0,01664762
GCM2 0,030937014 0,00437185 0,016630741 0,009934424 0,016630741
FZD8 0,033254877 0,005388604 0,016608278 0,011257996 0,016608278
PBX1 0,031933341 0,007220792 0,016599524 0,008113024 0,016599524
AGTPBP1 0,023945466 0,016584575 0,003973869 0,003387022 0,016584575
ror2 0,036457341 0,007957316 0,011925195 0,016574829 0,016574829
PDLIM1 0,021480916 0,001911543 0,003013647 0,016555725 0,016555725
JAG2 0,03663655 0,008263698 0,016551223 0,011821631 0,016551223
RGD1564874 0,025852228 0,004233568 0,016546538 0,005072122 0,016546538
NR2F1 0,034935329 0,006819474 0,016466304 0,01164955 0,016466304
VPS35 0,021668181 0,001944739 0,016459442 0,003264 0,016459442
RAX1 0,022780515 0,002583072 0,016456775 0,003740669 0,016456775
ZEB1 0,0293293 0,004879171 0,008001665 0,016448463 0,016448463
TLX1 0,035822429 0,004822973 0,014557193 0,016442262 0,016442262
TEK 0,028507879 0,005471453 0,006604484 0,016431941 0,016431941
ARX 0,025134906 0,016424782 0,004608551 0,004101573 0,016424782
S1PR1 0,027875559 0,006830073 0,004624784 0,016420702 0,016420702
GSK3B 0,038137432 0,012679706 0,009057949 0,016399777 0,016399777
dhh 0,028949333 0,005373812 0,016396522 0,007178999 0,016396522
HMGA1 0,023489391 0,002835158 0,004268177 0,016386057 0,016386057
DPYSL2 0,025818106 0,016380666 0,005084177 0,004353262 0,016380666
OPTC 0,021771511 0,001355217 0,016346772 0,004069523 0,016346772
SLC1A2 0,025853058 0,016337583 0,005574121 0,003941353 0,016337583
DLX5 0,039950721 0,009324478 0,014297298 0,016328947 0,016328947
CYP26A1 0,035233378 0,006220052 0,016311999 0,012701329 0,016311999
RCBTB1 0,026976412 0,004580154 0,00612142 0,016274839 0,016274839
MARCKS 0,023865871 0,016250152 0,0041315 0,003484219 0,016250152
couptf2 0,026613163 0,001755174 0,01624682 0,008611168 0,01624682
FBLN2 0,022096397 0,002725323 0,003127944 0,01624313 0,01624313
VSX1 0,02356755 0,003490475 0,016217204 0,00385987 0,016217204
CRIP2 0,020943526 0,001853887 0,002874339 0,0162153 0,0162153
klf4 0,031755593 0,005179514 0,010372138 0,016203941 0,016203941
CASP7 0,03252209 0,01616028 0,007923226 0,008438585 0,01616028
CRB1 0,022819938 0,003596754 0,01615378 0,003069405 0,01615378
GTF2A2 0,021201454 0,00343208 0,016137987 0,001631389 0,016137987
SIAH1 0,024883492 0,005402516 0,016134753 0,003346223 0,016134753
OLFML3 0,023403399 0,002346699 0,016083825 0,004972875 0,016083825
VANGL2 0,033708833 0,007632115 0,010003525 0,016073191 0,016073191
GAD1 0,027546477 0,016063257 0,006345623 0,005137597 0,016063257
NR2E1 0,037826721 0,016031435 0,016055693 0,005739594 0,016055693
GRIN2C 0,025719907 0,016027502 0,003926394 0,005766011 0,016027502
IRX1 0,032361884 0,004857722 0,011537533 0,015966628 0,015966628
JAG1 0,037655137 0,006485921 0,015956381 0,015212836 0,015956381
SLIT1 0,032865286 0,008679417 0,015911901 0,008273967 0,015911901
KLF4 0,031152926 0,005131635 0,010162172 0,01585912 0,01585912
EPHA7 0,030652264 0,007727077 0,015855166 0,007070022 0,015855166
NR5A2 0,032770127 0,006807629 0,01011076 0,01585174 0,01585174
BMPR1B 0,034774542 0,003957066 0,014993968 0,015823506 0,015823506
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PUM1 0,021061277 0,002710784 0,015820677 0,002529816 0,015820677
KIF7 0,02750233 0,004470164 0,01581176 0,007220406 0,01581176
PAX5 0,030613441 0,00688433 0,015810675 0,007918437 0,015810675
GATA3 0,031424776 0,006182012 0,009434126 0,015808638 0,015808638
WNT10B 0,035224374 0,005550469 0,015795552 0,013878355 0,015795552
COL15A1 0,020685846 0,00199672 0,015783168 0,002905957 0,015783168
FZD7 0,034988135 0,005061746 0,014145608 0,015780782 0,015780782
ATOH1 0,036266804 0,011134793 0,015745212 0,009386799 0,015745212
FRS2 0,036817517 0,006285037 0,015726012 0,01480647 0,015726012
AMH 0,027866181 0,006254137 0,005924802 0,015687242 0,015687242
FKBP1B 0,019860722 0,002350536 0,001823874 0,015686313 0,015686313
PDLIM5 0,021685233 0,002943723 0,003062631 0,015678881 0,015678881
CDH1 0,033298288 0,006741844 0,010895949 0,015660495 0,015660495
ID2 0,032632519 0,006541388 0,010458304 0,015632826 0,015632826
GRID2 0,022821186 0,015624526 0,003551426 0,003645234 0,015624526
PAX8 0,038313802 0,010195236 0,015563558 0,012555008 0,015563558
BMP5 0,034297388 0,004124276 0,014611974 0,015561138 0,015561138
SALL1 0,032592662 0,004181384 0,015539107 0,012872171 0,015539107
fgf8b 0,037987906 0,007986483 0,014479774 0,015521648 0,015521648
INVS 0,026709612 0,003867739 0,007352423 0,015489451 0,015489451
HMGN2 0,021236913 0,001856999 0,015472668 0,003907246 0,015472668
TSHR 0,023641333 0,015466246 0,003649649 0,004525438 0,015466246
SH3GL1 0,020463135 0,002015736 0,015422841 0,003024559 0,015422841
DPYSL3 0,027475325 0,01541293 0,008214423 0,003847972 0,01541293
RGD1562983 0,029274942 0,002952577 0,015404973 0,010917392 0,015404973
SLC8A3 0,023240611 0,005564627 0,002275715 0,015400268 0,015400268
cb85 0,035432674 0,006197253 0,013900258 0,015335165 0,015335165
tnni1 0,020021997 0,002142216 0,002545112 0,015334668 0,015334668
SFRS2IP 0,024176199 0,003310998 0,005537722 0,015327479 0,015327479
map-1 0,019812824 0,015320323 0,002756283 0,001736218 0,015320323
KDR 0,032817278 0,007154919 0,010355203 0,015307156 0,015307156
Hmx1 0,026897589 0,004362637 0,015301032 0,00723392 0,015301032
RS1 0,020335892 0,002999156 0,015278143 0,002058594 0,015278143
THOC4 0,03110561 0,004847798 0,011005467 0,015252344 0,015252344
SFRP1 0,034310289 0,005155457 0,015249536 0,013905295 0,015249536
ACVR1 0,033604175 0,003650241 0,015203028 0,014750907 0,015203028
HTT 0,030699525 0,015197397 0,009212536 0,006289592 0,015197397
jag1a 0,031741768 0,004791794 0,011783989 0,015165986 0,015165986
LRP5 0,033320662 0,00535752 0,015163559 0,012799583 0,015163559
PITX1 0,03411565 0,004622824 0,015136412 0,014356415 0,015136412
PUM2 0,023206649 0,003275648 0,01513148 0,00479952 0,01513148
UNC5C 0,028032605 0,008748188 0,015122823 0,004161594 0,015122823
CDX1 0,032780159 0,005327413 0,012331695 0,015121049 0,015121049
POU4F2 0,027431095 0,005184559 0,015089367 0,00715717 0,015089367
CABIN1 0,020668205 0,003462116 0,002143284 0,015062804 0,015062804
CRYBB1 0,018851593 0,001428558 0,015039532 0,002383503 0,015039532
SFRP5 0,029741278 0,003656108 0,01105785 0,015027319 0,015027319
SILV 0,021558011 0,003468896 0,015013504 0,003075612 0,015013504
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cb717 0,02261195 0,015009001 0,003072111 0,004530837 0,015009001
SMAD2 0,031090442 0,006140311 0,009954046 0,014996086 0,014996086
TFDP2 0,026963552 0,005000449 0,014982353 0,006980751 0,014982353
THRB 0,02945058 0,014958903 0,006260844 0,008230833 0,014958903
neurog3 0,030462997 0,006490286 0,014941471 0,009031239 0,014941471
LFNG 0,032872897 0,005027521 0,012913328 0,014932047 0,014932047
INHA 0,024257999 0,00523666 0,004092456 0,014928884 0,014928884
msi2b 0,02160823 0,004348342 0,014911721 0,002348168 0,014911721
rsp-4 0,024087558 0,004538281 0,004678965 0,01487031 0,01487031
NEFL 0,024356782 0,014868271 0,00538225 0,004106261 0,014868271
TAL1 0,031043317 0,006428419 0,009792597 0,014822301 0,014822301
FGF3 0,035463195 0,00652805 0,014794961 0,014140182 0,014794961
LEF1 0,036064152 0,007543026 0,01375417 0,014766954 0,014766954
zgc:92533 0,018685322 0,001930664 0,014745576 0,002009083 0,014745576
SMAD9 0,032157689 0,004119986 0,013319974 0,014717731 0,014717731
AHI1 0,021415832 0,014689419 0,003977914 0,002748497 0,014689419
wu:fc44a10 0,016965613 0,014687767 0,001213199 0,001064647 0,014687767
ZIC3 0,028039221 0,006010002 0,007350128 0,01467909 0,01467909
ric-4 0,023904586 0,014675458 0,005972588 0,003256539 0,014675458
PDXP 0,020160688 0,014671074 0,002745152 0,002744461 0,014671074
fyna 0,024556547 0,014668664 0,005273151 0,004614732 0,014668664
ALDOC 0,022663083 0,01466651 0,004210532 0,003786041 0,01466651
FGF7 0,035786059 0,00697851 0,014142133 0,014665414 0,014665414
Mcph1 0,019552499 0,014647883 0,002935203 0,001969413 0,014647883
crmp1 0,026006045 0,014638954 0,008306967 0,003060123 0,014638954
NGFR 0,027806574 0,01463879 0,006328964 0,006838821 0,01463879
GDNF 0,032394651 0,014635764 0,008997806 0,008761082 0,014635764
SEMA3A 0,03446313 0,014597205 0,009345179 0,010520745 0,014597205
FOXA3 0,022376288 0,002294042 0,00549563 0,014586617 0,014586617
CAPN3 0,026586853 0,002897632 0,014555245 0,009133977 0,014555245
NRG1 0,034913935 0,014551393 0,007147504 0,013215038 0,014551393
GAS1 0,024913676 0,004416236 0,014550937 0,005946503 0,014550937
SEMA6D 0,023202876 0,004513826 0,004171366 0,014517684 0,014517684
FOXG1 0,036280058 0,014516241 0,013260201 0,008503618 0,014516241
DYX1C1 0,019258969 0,014506509 0,002462406 0,002290054 0,014506509
DLG4 0,028168149 0,014476212 0,0081077 0,005584236 0,014476212
MEOX1 0,029061187 0,003440336 0,011172006 0,014448846 0,014448846
GPC4 0,031007295 0,014440415 0,009824303 0,006742578 0,014440415
MYL1 0,023054525 0,004752896 0,003873348 0,014428282 0,014428282
SNAP25 0,023838209 0,014412381 0,006064345 0,003361482 0,014412381
ARID4A 0,029966604 0,006499487 0,014395202 0,009071915 0,014395202
ETV1 0,026549919 0,005310648 0,014377884 0,006861387 0,014377884
FGF17 0,037167415 0,009342097 0,014360442 0,013464874 0,014360442
FOXP2 0,026262127 0,014348163 0,0063031 0,005610864 0,014348163
RUNX2 0,034668908 0,007565932 0,012793302 0,014309673 0,014309673
HCCS 0,024103709 0,001594409 0,00821048 0,01429882 0,01429882
CASD1 0,033131715 0,014281432 0,009332016 0,009518267 0,014281432
hsd3b 0,017926365 0,002046974 0,001623037 0,014256354 0,014256354
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DmelCG3861 0,036623374 0,009144784 0,013233503 0,014245087 0,014245087
BCKDHA 0,031827446 0,006955553 0,010632626 0,014239266 0,014239266
ASPM 0,019257573 0,014238895 0,003121394 0,001897286 0,014238895
HOXB5 0,032435112 0,005816368 0,01422852 0,012390224 0,01422852
sp8 0,030514419 0,008808886 0,014221653 0,00748388 0,014221653
JAM3 0,01767919 0,001714975 0,001742896 0,014221319 0,014221319
MAP3K3 0,019563753 0,002396552 0,00295149 0,014215711 0,014215711
Tnni2 0,018558858 0,001569089 0,00277795 0,014211819 0,014211819
LDB2 0,02649118 0,006209168 0,014190123 0,006091889 0,014190123
ybx1 0,026997792 0,008391784 0,004454804 0,014151205 0,014151205
SSR1 0,016846482 9,35E-04 0,001791314 0,014120314 0,014120314
FOS 0,031926282 0,014105567 0,008723301 0,009097416 0,014105567
RCAN1 0,023239369 0,006044106 0,003098494 0,014096768 0,014096768
TSC1 0,023438169 0,01409649 0,005824009 0,00351767 0,01409649
DCLK2 0,0190232 0,014093827 0,002383787 0,002545586 0,014093827
CSPG5 0,019794161 0,014070826 0,003200477 0,002522858 0,014070826
LUM 0,023654597 0,003906079 0,014052294 0,005696224 0,014052294
HES7 0,030119652 0,004286637 0,011786764 0,014046251 0,014046251
espl1 0,017473839 0,002466491 0,014030217 9,77E-04 0,014030217
HOXB6 0,030157553 0,005004209 0,014029088 0,011124256 0,014029088
INA 0,023379466 0,014020409 0,004825931 0,004533126 0,014020409
MAPK11 0,029773451 0,006764405 0,008990746 0,0140183 0,0140183
DLX6 0,033073124 0,008101313 0,010955147 0,014016664 0,014016664
frs2 0,033008941 0,005421648 0,013588333 0,013998961 0,013998961
S1PR2 0,022910045 0,005923903 0,002987187 0,013998956 0,013998956
ADRB1 0,021563575 0,003940655 0,003631527 0,013991393 0,013991393
HDAC4 0,020912757 0,003571735 0,003351678 0,013989345 0,013989345
MAPK14 0,031442191 0,007768661 0,009689124 0,013984405 0,013984405
cxcr4b 0,024290346 0,007226576 0,003101283 0,013962486 0,013962486
UNC5D 0,020226229 0,002652042 0,013942295 0,003631892 0,013942295
CPSF1 0,019836921 0,002604228 0,013938131 0,003294563 0,013938131
NPY 0,025144322 0,013920032 0,005814601 0,00540969 0,013920032
kdrl 0,028219357 0,006204035 0,008096629 0,013918693 0,013918693
GUCA1A 0,019695366 0,002805581 0,013912618 0,002977167 0,013912618
JMJD6 0,027201146 0,00202956 0,013902266 0,011269321 0,013902266
CDKL5 0,017617343 0,013893267 0,002090945 0,00163313 0,013893267
HOXB3 0,033053149 0,006431458 0,01386565 0,012756042 0,01386565
GRM1 0,021868473 0,013860768 0,003865248 0,004142458 0,013860768
ACVR2B 0,029473878 0,003387066 0,012232498 0,013854313 0,013854313
SP8 0,029903481 0,008692846 0,013840897 0,007369737 0,013840897
NRP1 0,033755403 0,010000843 0,009919253 0,013835308 0,013835308
MAB21L1 0,020500623 0,003479882 0,013823251 0,003197489 0,013823251
TAZ 0,0216686 0,00262303 0,013797378 0,005248191 0,013797378
HOXC6 0,029639676 0,0051094 0,013786235 0,010744041 0,013786235
ANGPT1 0,024791243 0,00480195 0,006205525 0,013783769 0,013783769
SEMA3C 0,033777244 0,006431435 0,013780337 0,013565473 0,013780337
E2F4 0,031565811 0,004777089 0,013761921 0,013026801 0,013761921
SFRS6 0,020353969 0,002697091 0,013761628 0,003895251 0,013761628
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Concept Sum Brain Eye Heart Max
CAMK2D 0,028858004 0,013706957 0,004778958 0,01037209 0,013706957
dab2 0,025440838 0,007294283 0,004441216 0,013705339 0,013705339
POU1F1 0,02751256 0,005243496 0,0136757 0,008593363 0,0136757
S100A1 0,02675426 0,009474046 0,003621861 0,013658353 0,013658353
FGF13 0,026146835 0,004796659 0,00769419 0,013655986 0,013655986
SMN 0,027462391 0,007930878 0,005888869 0,013642645 0,013642645
OCA2 0,019317685 0,002907387 0,013630069 0,002780228 0,013630069
SLC6A4 0,023962582 0,013626723 0,005759888 0,004575971 0,013626723
HSBP1 0,017838143 0,001823732 0,002409294 0,013605117 0,013605117
tfdp1 0,023875052 0,004180703 0,013597736 0,006096613 0,013597736
bmp1l 0,023061883 0,003425075 0,006051973 0,013584835 0,013584835
NUP155 0,019336769 0,002457127 0,013584566 0,003295077 0,013584566
DAB2 0,025306646 0,007390721 0,004336545 0,01357938 0,01357938
NKX3-2 0,029275129 0,00422223 0,011474904 0,013577996 0,013577996
EDN1 0,025691936 0,007062256 0,005058684 0,013570995 0,013570995
YY1 0,030087028 0,00455155 0,011967094 0,013568384 0,013568384
NDE1 0,017984258 0,013511463 0,002611888 0,001860906 0,013511463
HAS2 0,023289099 0,003306234 0,006476222 0,013506644 0,013506644
itpr3 0,020613879 0,001505994 0,005607498 0,013500386 0,013500386
MYOD1 0,026549457 0,005073984 0,00797536 0,013500112 0,013500112
SNAI2 0,029230297 0,005917116 0,009823906 0,013489275 0,013489275
PLS3 0,018136524 0,002171563 0,002478261 0,013486701 0,013486701
SP1 0,038106542 0,011464289 0,01347939 0,013162864 0,01347939
NOTCH3 0,029576397 0,007958272 0,013472552 0,008145572 0,013472552
JUN 0,031887095 0,007722368 0,010697273 0,013467453 0,013467453
tie1 0,021322558 0,003122476 0,004762748 0,013437333 0,013437333
ORAOV1 0,019127788 0,002292237 0,01343102 0,003404531 0,01343102
celsr3 0,029330978 0,013425452 0,007334842 0,008570683 0,013425452
celsr3 0,029330978 0,013425452 0,007334842 0,008570683 0,013425452
celsr3 0,029330978 0,013425452 0,007334842 0,008570683 0,013425452
IL6ST 0,025257755 0,005317484 0,006522339 0,013417932 0,013417932
STMN2 0,024590461 0,013407189 0,006153248 0,005030024 0,013407189
tnk2 0,020296764 0,013402266 0,003916809 0,002977688 0,013402266
PENK 0,02355504 0,013393764 0,005311193 0,004850085 0,013393764
MED12 0,022571838 0,005911142 0,013384626 0,003276069 0,013384626
RGL2 0,015781119 0,001051815 0,0133751 0,001354204 0,0133751
FBXW11 0,024825152 0,002892048 0,008563286 0,013369817 0,013369817
ETS1 0,026420418 0,004872913 0,008182867 0,013364638 0,013364638
TSC2 0,022531915 0,013361098 0,005085997 0,00408482 0,013361098
SCUBE2 0,018664571 0,001745898 0,013360276 0,003558396 0,013360276
HOXB4 0,031432685 0,006308527 0,011770285 0,013353873 0,013353873
egln1 0,01880216 0,003095153 0,002355293 0,013351715 0,013351715
RYK 0,033170372 0,007915219 0,013345683 0,011909471 0,013345683
FZD6 0,031941235 0,005760419 0,012835619 0,013345197 0,013345197
TFEC 0,01697777 0,0012284 0,013340035 0,002409335 0,013340035
HOXA1 0,03774805 0,013339927 0,012049295 0,012358826 0,013339927
SP4 0,025235513 0,006926743 0,004983618 0,013325153 0,013325153
FRZB 0,029798804 0,004198779 0,012292622 0,013307403 0,013307403
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DLL4 0,028079109 0,005324418 0,013279188 0,009475503 0,013279188
ALX4 0,02721924 0,004496201 0,013242791 0,009480249 0,013242791
LGSN 0,01844871 0,002072159 0,013235728 0,003140823 0,013235728
MYF6 0,027188977 0,004969757 0,008987451 0,013231769 0,013231769
FGF5 0,030902153 0,007080872 0,010640495 0,013180787 0,013180787
fzd10 0,02885174 0,005202943 0,013170234 0,010478564 0,013170234
CDT1 0,02220824 0,003146442 0,013161163 0,005900634 0,013161163
GDF7 0,023986097 0,003962819 0,013148184 0,006875095 0,013148184
FKTN 0,028619407 0,013142884 0,011609862 0,00386666 0,013142884
CNR1 0,020948699 0,013141536 0,003937376 0,003869786 0,013141536
FAF2 0,019875679 0,003489319 0,013134783 0,003251577 0,013134783
JUND 0,029466948 0,006505588 0,009835285 0,013126074 0,013126074
HIPK 0,022266088 0,004349268 0,013123476 0,004793343 0,013123476
HOXA13 0,030927008 0,006745349 0,013122489 0,011059171 0,013122489
HOXB7 0,029397763 0,005604667 0,013117663 0,010675433 0,013117663
IGFBP3 0,024781941 0,013117563 0,005124583 0,006539794 0,013117563
SMARCC1 0,023223152 0,013116916 0,004503919 0,005602318 0,013116916
SDC3 0,02356687 0,013097456 0,005105342 0,005364072 0,013097456
HMX2 0,02578089 0,004480037 0,013091681 0,008209173 0,013091681
FOSL2 0,021558952 0,003359932 0,01307747 0,005121551 0,01307747
KRAS 0,028609158 0,007694819 0,013053861 0,007860477 0,013053861
STAT3 0,032978207 0,007975871 0,01195048 0,013051857 0,013051857
PTN 0,024999058 0,013048065 0,005045979 0,006905014 0,013048065
KCND3 0,020675426 0,004591034 0,003038382 0,013046009 0,013046009
FLT1 0,027778957 0,006096534 0,008638455 0,013043968 0,013043968
DTX2 0,019339906 0,00255377 0,003765972 0,013020164 0,013020164
RTN1 0,028184287 0,012998228 0,0122654 0,002920659 0,012998228
STRN3 0,023178918 0,004553798 0,012979166 0,005645956 0,012979166
CUGBP1 0,022177629 0,003115355 0,006106529 0,012955744 0,012955744
SNTB1 0,019077947 0,002313275 0,01295098 0,003813692 0,01295098
ID1 0,028792636 0,005301036 0,010542097 0,012949503 0,012949503
OSR1 0,022635961 0,002766791 0,006940863 0,012928307 0,012928307
CAV3 0,019920174 0,003467359 0,003548463 0,012904353 0,012904353
dlc 0,022586869 0,004100046 0,005583416 0,012903408 0,012903408
SF1 0,026885195 0,005911376 0,00809032 0,012883499 0,012883499
TEF 0,025440948 0,006714763 0,005854281 0,012871905 0,012871905
fzd4 0,028716121 0,004678906 0,012860806 0,011176409 0,012860806
FHL2 0,019974228 0,002799867 0,004319644 0,012854718 0,012854718
SLC1A1 0,02187714 0,012846806 0,00535715 0,003673184 0,012846806
HMGA2 0,022776568 0,004107226 0,005824548 0,012844794 0,012844794
sox32 0,02151243 0,002985537 0,005683467 0,012843425 0,012843425
chad 0,018749543 0,001420793 0,004505531 0,012823218 0,012823218
HOXC8 0,030066898 0,006152252 0,012821128 0,011093517 0,012821128
ABRA 0,01605108 0,001454125 0,001782578 0,012814378 0,012814378
BEGAIN 0,017170172 0,01279256 0,003019998 0,001357615 0,01279256
odz4 0,018836502 0,003286083 0,012790965 0,002759454 0,012790965
HRSP12 0,017577918 0,003122024 0,012776389 0,001679504 0,012776389
WHSC2 0,016979417 0,002202141 0,002022517 0,01275476 0,01275476
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DRD2 0,022625184 0,012750722 0,00514065 0,004733812 0,012750722
TNC 0,028940432 0,00973233 0,006459798 0,012748304 0,012748304
NPR1 0,021250155 0,005042643 0,00347201 0,012735502 0,012735502
CDCA8 0,017981922 0,002348663 0,012734928 0,002898331 0,012734928
NOS1 0,023464534 0,012719828 0,005239613 0,005505093 0,012719828
MNX1 0,027422892 0,004681666 0,012693227 0,010048 0,012693227
SUZ12 0,02429188 0,004135777 0,007469423 0,01268668 0,01268668
BRUNOL4 0,018882571 0,002350539 0,003864352 0,01266768 0,01266768
KREMEN1 0,025226932 0,003592675 0,008969501 0,012664756 0,012664756
TBP 0,027931949 0,005232677 0,012660854 0,010038417 0,012660854
CDKN1C 0,031315155 0,008640643 0,012637526 0,010036986 0,012637526
NTRK1 0,025776831 0,012622953 0,006113362 0,007040516 0,012622953
JARID1C 0,022139974 0,012605106 0,003525241 0,006009627 0,012605106
ttf1 0,02182566 0,004332988 0,004891559 0,012601112 0,012601112
IGF1R 0,027501607 0,012582544 0,006803157 0,008115906 0,012582544
FEZ1 0,018929569 0,012581108 0,004177292 0,002171169 0,012581108
cxcr7 0,019728253 0,004918344 0,002236262 0,012573646 0,012573646
PBRM1 0,016762489 0,001859647 0,002339449 0,012563395 0,012563395
RGMA 0,019796047 0,002367097 0,01256149 0,004867459 0,01256149
fzd1 0,027238887 0,00508779 0,012559214 0,009591883 0,012559214
CALB1 0,021450944 0,012555632 0,005565157 0,003330155 0,012555632
DPYSL4 0,018551696 0,012551013 0,003215898 0,002784786 0,012551013
AQP4 0,025367374 0,012512331 0,008958562 0,003896481 0,012512331
thraa 0,0273272 0,012506755 0,004533028 0,010287418 0,012506755
CSRP3 0,022693003 0,003333288 0,006853189 0,012506525 0,012506525
GRIA2 0,021231804 0,012486351 0,004325589 0,004419866 0,012486351
B4GALT5 0,016996898 0,012463482 0,001754443 0,002778974 0,012463482
AXIN2 0,026795482 0,004686981 0,012458041 0,009650461 0,012458041
KCNQ1 0,021531066 0,004011982 0,005063225 0,012455859 0,012455859
ANKRD6 0,029043391 0,012454745 0,008076714 0,008511931 0,012454745
pdlim5 0,017581822 0,003248719 0,00188087 0,012452234 0,012452234
dab2ip 0,016099431 0,01245168 0,002320641 0,001327108 0,01245168
RTN4R 0,02097645 0,012425605 0,004693355 0,003857491 0,012425605
RXRA 0,023740586 0,003429689 0,012419671 0,007891225 0,012419671
HAPLN1 0,020967258 0,002953961 0,005602944 0,012410353 0,012410353
rdh5 0,016418457 0,001619581 0,012404072 0,002394804 0,012404072
MNAT1 0,020102356 0,012402695 0,004082029 0,00361763 0,012402695
NCOA6 0,027954236 0,003406503 0,012169469 0,012378263 0,012378263
FXR2 0,021534301 0,012367086 0,004962718 0,004204499 0,012367086
INHBA 0,026336057 0,005298851 0,008692531 0,012344675 0,012344675
CUL3 0,017927017 0,002548388 0,012330941 0,003047688 0,012330941
COL4A3BP 0,017381536 0,012329287 0,002418381 0,002633868 0,012329287
FGF20 0,027237153 0,004540041 0,010368519 0,012328592 0,012328592
HIF1A 0,029449396 0,008547682 0,00858015 0,012321564 0,012321564
OLIG1 0,032094527 0,012320993 0,012265993 0,007507541 0,012320993
GRSF1 0,018730681 0,012307075 0,002702353 0,003721254 0,012307075
FZD2 0,029627211 0,005158773 0,012294533 0,012173905 0,012294533
SYN2 0,021289611 0,006491005 0,012269783 0,002528824 0,012269783
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EGR1 0,033352427 0,011525875 0,012264174 0,009562379 0,012264174
EFHC1 0,016217604 0,012237656 0,001791013 0,002188936 0,012237656
NRCAM 0,025463898 0,01223696 0,007625617 0,005601321 0,01223696
POFUT1 0,026915599 0,003329966 0,011353225 0,012232407 0,012232407
wnt7 0,026505115 0,002912177 0,011410101 0,012182836 0,012182836
LECT1 0,019100199 0,002395584 0,012166083 0,004538531 0,012166083
WIF1 0,027539851 0,004881425 0,012150585 0,010507841 0,012150585
TCF21 0,0236059 0,003050771 0,008428642 0,012126487 0,012126487
ALDH8A1 0,021037577 0,002431559 0,012122727 0,006483291 0,012122727
FOXA1 0,028132938 0,004938465 0,011077486 0,012116987 0,012116987
si:ch211-251g8.3 0,026906988 0,00361504 0,012109617 0,011182331 0,012109617
WWTR1 0,019648496 0,0022222 0,005325384 0,012100912 0,012100912
rxrbb 0,03001425 0,006782646 0,012098746 0,011132859 0,012098746
ETS2 0,023399334 0,004580226 0,006720514 0,012098593 0,012098593
ST8SIA3 0,016377861 0,01209308 0,002250302 0,002034479 0,01209308
B4GALT7 0,016405363 0,001511919 0,012078188 0,002815254 0,012078188
si:rp71-1f1.4 0,016801817 0,002286308 0,002441903 0,012073607 0,012073607
BMP3 0,026950864 0,002985256 0,011892677 0,01207293 0,01207293
PES1 0,022324812 0,006631584 0,012069649 0,003623579 0,012069649
KCND2 0,022462411 0,006835218 0,003563014 0,012064179 0,012064179
TNNI2 0,019725714 0,001683393 0,005984104 0,012058217 0,012058217
Sep-06 0,017653491 0,003518623 0,002076802 0,012058067 0,012058067
TGFBR1 0,022790259 0,004215968 0,00652744 0,012046851 0,012046851
MAOB 0,019965474 0,012044987 0,004182639 0,003737848 0,012044987
zgc:111879 0,0270721 0,003746467 0,012031493 0,01129414 0,012031493
UBE3A 0,021492414 0,012029309 0,004860605 0,004602499 0,012029309
ACVR2A 0,026313435 0,003886923 0,01041008 0,012016433 0,012016433
MAF1 0,016181411 0,001303353 0,012016298 0,002861761 0,012016298
EVX1 0,0297828 0,00577837 0,012007727 0,011996704 0,012007727
ELK4 0,020955987 0,003487631 0,005462835 0,012005521 0,012005521
ACVRL1 0,023142371 0,002229172 0,008922367 0,011990832 0,011990832
FBLN1 0,01908052 0,003365323 0,003731949 0,011983248 0,011983248
GINS2 0,01482001 0,001100057 0,011967501 0,001752452 0,011967501
RUNX1 0,028094005 0,005240671 0,011965125 0,010888208 0,011965125
FOXF1 0,028732453 0,005381271 0,011400802 0,011950379 0,011950379
sox8 0,030116592 0,006747425 0,011420126 0,011949042 0,011949042
MAPK1 0,032518253 0,009185283 0,011411195 0,011921776 0,011921776
SPRY1 0,025441699 0,004695326 0,008829241 0,011917131 0,011917131
COL8A2 0,015595082 0,001670392 0,011911413 0,002013278 0,011911413
NDUFS3 0,015418398 0,001458236 0,002050252 0,01190991 0,01190991
DVL2 0,027590407 0,006177828 0,00950432 0,01190826 0,01190826
GREM2 0,021774625 0,002618048 0,011892759 0,007263818 0,011892759
CAMK4 0,023255365 0,011890912 0,004144514 0,00721994 0,011890912
IGF2 0,029472457 0,011886984 0,007125702 0,01045977 0,011886984
PTF1A 0,028809046 0,006380484 0,010549088 0,011879474 0,011879474
PSEN2 0,024744043 0,011876749 0,007399545 0,00546775 0,011876749
e2f5 0,02646165 0,004992279 0,011872484 0,009596886 0,011872484
CXCR7 0,019098772 0,004799192 0,002429124 0,011870456 0,011870456
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ELF3 0,019090069 0,002686205 0,01186149 0,004542375 0,01186149
IGFBP1 0,023045633 0,011858264 0,005079665 0,006107704 0,011858264
STAT1 0,030756373 0,007324194 0,011852513 0,011579667 0,011852513
igfbp5a 0,022025153 0,011848204 0,004148253 0,006028696 0,011848204
SLC45A2 0,015211837 0,001385514 0,011841472 0,001984851 0,011841472
SP3 0,029970556 0,009022091 0,009109033 0,011839432 0,011839432
G3BP1 0,015769241 0,002285369 0,011829966 0,001653908 0,011829966
nkx2.1a 0,022990908 0,004341044 0,006853727 0,011796138 0,011796138
DRD3 0,019311575 0,011789444 0,0041631 0,00335903 0,011789444
DRD1 0,020322526 0,011777631 0,004521411 0,004023484 0,011777631
GRIA4 0,021983063 0,011768375 0,006071991 0,004142698 0,011768375
col15a1 0,015126006 0,001205967 0,011761891 0,002158147 0,011761891
ZIC1 0,029825179 0,011749265 0,009523488 0,008552426 0,011749265
WNK1 0,016821906 0,002488704 0,002587784 0,011745418 0,011745418
GRIK1 0,018149827 0,011738543 0,003128287 0,003282997 0,011738543
igfbp5 0,023831867 0,011733324 0,005985801 0,006112741 0,011733324
VIM 0,032025564 0,011715782 0,009033917 0,011275866 0,011715782
IDH1 0,02110433 0,002143266 0,011710007 0,007251057 0,011710007
MSTN 0,021291915 0,003434619 0,006155927 0,01170137 0,01170137
ADCYAP1 0,022265378 0,011691582 0,005256859 0,005316938 0,011691582
MYOZ1 0,015169119 0,00145435 0,002024139 0,01169063 0,01169063
MYCN 0,023800751 0,005765296 0,006344897 0,011690558 0,011690558
MAFB 0,031107293 0,008891026 0,011686402 0,010529865 0,011686402
BMP1 0,025259797 0,005732143 0,007842976 0,011684676 0,011684676
SUMO3 0,017804723 0,002296445 0,00382483 0,011683448 0,011683448
POU3F1 0,024512034 0,011681798 0,006467603 0,006362633 0,011681798
ERBB4 0,030699907 0,009081923 0,009936379 0,011681605 0,011681605
YWHAE 0,021634424 0,011680358 0,003831961 0,006122106 0,011680358
CDC2 0,030075682 0,011679228 0,010008704 0,008387751 0,011679228
GJD2 0,030187918 0,009847653 0,008661267 0,011678998 0,011678998
NUMB 0,024463698 0,006972192 0,011675021 0,005816485 0,011675021
Sep-02 0,015958214 0,002463649 0,00182506 0,011669506 0,011669506
SMYD2 0,016603341 0,001223181 0,003720794 0,011659367 0,011659367
arpp19b 0,013933877 0,011658436 0,001117634 0,001157806 0,011658436
ENO2 0,022991421 0,011653886 0,005917678 0,005419857 0,011653886
SLC26A5 0,019210577 0,003995389 0,011650956 0,003564232 0,011650956
ACTN2 0,019777933 0,005506837 0,002627426 0,011643671 0,011643671
ERBB2 0,028687511 0,009590258 0,011639825 0,007457427 0,011639825
HOXA11 0,025496678 0,004272185 0,011636368 0,009588126 0,011636368
DNAJC5 0,018600238 0,00506813 0,011635893 0,001896216 0,011635893
VANGL1 0,028685778 0,007055359 0,010003632 0,011626787 0,011626787
myhz1 0,022538608 0,002622744 0,008289385 0,011626478 0,011626478
mbp 0,017758362 0,011621123 0,003277539 0,002859699 0,011621123
AGT 0,025434235 0,007836647 0,005978355 0,011619232 0,011619232
CLDN11 0,018889353 0,011618506 0,002887344 0,004383502 0,011618506
TRH 0,021743553 0,011614918 0,005103466 0,005025167 0,011614918
GJB6 0,022542806 0,006134848 0,004813332 0,011594627 0,011594627
DCDC2 0,015696645 0,011594283 0,002100576 0,002001787 0,011594283
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PURA 0,020694524 0,011592613 0,003620117 0,005481794 0,011592613
GBX1 0,025626857 0,006098072 0,011591109 0,007937675 0,011591109
tfap2c 0,021514937 0,002275156 0,00765601 0,011583771 0,011583771
IGFBP2 0,022761183 0,011583738 0,004539007 0,006638437 0,011583738
cyp19a1b 0,024594855 0,01157569 0,005734116 0,007285048 0,01157569
SORBS3 0,017407494 0,001472511 0,004362819 0,011572164 0,011572164
TSPAN3 0,013725227 0,011562628 0,00106423 0,001098368 0,011562628
POU3F2 0,027748229 0,007762995 0,011550419 0,008434814 0,011550419
foxi1 0,021074278 0,003327285 0,011529833 0,006217161 0,011529833
IFT88 0,02356036 0,003925902 0,008121098 0,011513359 0,011513359
SOX5 0,024781005 0,004260216 0,01148247 0,009038319 0,01148247
CASQ2 0,015649283 0,001797996 0,002374364 0,011476923 0,011476923
ABLIM1 0,019591548 0,003546614 0,011475618 0,004569315 0,011475618
ACVR1B 0,023477152 0,003524012 0,008486668 0,011466472 0,011466472
POLA1 0,015918037 0,002500403 0,011458636 0,001958998 0,011458636
AHR 0,02682594 0,00645542 0,008916561 0,011453959 0,011453959
FGF18 0,028451322 0,005869244 0,011138273 0,011443805 0,011443805
TRDN 0,013934673 0,001209298 0,001290911 0,011434463 0,011434463
MT-1 0,018340591 0,011413642 0,003671249 0,0032557 0,011413642
CACNB2 0,01543266 0,001834074 0,00218599 0,011412595 0,011412595
m17 0,020678351 0,004657541 0,004610199 0,01141061 0,01141061
th2 0,027946135 0,009422041 0,007114259 0,011409836 0,011409836
pld1a 0,018233869 0,003897059 0,002944136 0,011392675 0,011392675
CYP19A1 0,024097512 0,011378011 0,006154307 0,006565195 0,011378011
zgc:171463 0,021030108 0,011374061 0,004864787 0,00479126 0,011374061
tnnt1 0,014785297 0,001430213 0,002004563 0,011350521 0,011350521
BBS5 0,015835902 0,001300451 0,011346893 0,003188558 0,011346893
BBS5 0,015835902 0,001300451 0,011346893 0,003188558 0,011346893
SOX6 0,025990961 0,004851758 0,011345433 0,009793769 0,011345433
HSF1 0,024492584 0,005740338 0,007425329 0,011326918 0,011326918
SP7 0,025147876 0,004185982 0,009655778 0,011306116 0,011306116
NR2F6 0,025216129 0,003093144 0,011303599 0,010819386 0,011303599
HNF1A 0,027529277 0,005937436 0,010303909 0,011287932 0,011287932
HCN2 0,019400531 0,005390371 0,002728457 0,011281702 0,011281702
ROBO2 0,029855415 0,009311443 0,009267137 0,011276835 0,011276835
NCAM1 0,025020501 0,007932664 0,005815191 0,011272647 0,011272647
PRDM1 0,021840006 0,003750222 0,01126909 0,006820695 0,01126909
KIAA0712 0,016869577 0,011267795 0,002913654 0,002688126 0,011267795
TGFB1 0,026090164 0,007485843 0,007340909 0,011263411 0,011263411
FOXH1 0,022558298 0,003004644 0,008302626 0,011251029 0,011251029
PLXNA1 0,024201237 0,006900161 0,006062925 0,011238151 0,011238151
COL2A1 0,023807982 0,005207506 0,011228832 0,007371645 0,011228832
BHLHE40 0,020322725 0,003283826 0,011226484 0,005812416 0,011226484
MOBKL3 0,02340967 0,001778817 0,011220734 0,010410119 0,011220734
dkk3 0,024561878 0,003632248 0,011219018 0,009710613 0,011219018
NEGR1 0,018849356 0,011215153 0,005372308 0,002261896 0,011215153
gdf5 0,025170237 0,00371275 0,011214849 0,010242638 0,011214849
DTNBP1 0,017993564 0,011209527 0,002918474 0,003865564 0,011209527
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PAH 0,01963564 0,011194037 0,004717222 0,003724381 0,011194037
NR4A2 0,026823627 0,011180746 0,008370427 0,007272453 0,011180746
CASP9 0,024798874 0,011178628 0,006661987 0,006958258 0,011178628
DYNC1H1 0,022432288 0,011172893 0,009250736 0,002008659 0,011172893
EGR2 0,031703524 0,011167363 0,009903363 0,010632798 0,011167363
SLC2A3 0,022996781 0,011153606 0,004986665 0,006856509 0,011153606
LAMA1 0,025599806 0,003608608 0,011142091 0,010849107 0,011142091
CKM 0,019269627 0,003318912 0,004814912 0,011135803 0,011135803
LDB1 0,028085334 0,006184399 0,010768679 0,011132257 0,011132257
HTR2C 0,019371163 0,011106766 0,004274588 0,003989809 0,011106766
TGFBR2 0,022036517 0,004570047 0,006364066 0,011102405 0,011102405
ANGPT2 0,021169093 0,004244511 0,005827526 0,011097057 0,011097057
DYRK2 0,022145012 0,011071575 0,004476258 0,00659718 0,011071575
DLX3 0,026172755 0,004387285 0,010715709 0,011069761 0,011069761
MAPK7 0,021845844 0,00585645 0,004920088 0,011069305 0,011069305
NR1H3 0,021882486 0,004605759 0,011060539 0,006216188 0,011060539
HLF 0,017516773 0,011057135 0,003431388 0,00302825 0,011057135
TGFB3 0,022951346 0,005148163 0,006766232 0,011036951 0,011036951
HOXA10 0,025449008 0,005240739 0,011031882 0,009176387 0,011031882
EHF 0,015400069 0,001673769 0,01103033 0,00269597 0,01103033
CDK2 0,029502016 0,010283798 0,011029515 0,008188702 0,011029515
DIO2 0,024957422 0,009766858 0,00416136 0,011029205 0,011029205
PLK2 0,017624861 0,003097519 0,011021727 0,003505614 0,011021727
PRICKLE2 0,028202863 0,008849234 0,008360162 0,010993468 0,010993468
CHRNA7 0,019228347 0,010988195 0,004020162 0,00421999 0,010988195
BMPER 0,021018596 0,002721925 0,007314935 0,010981737 0,010981737
PHOX2B 0,025862986 0,006533439 0,008354096 0,010975452 0,010975452
VRK1 0,016240073 0,001905882 0,003362578 0,010971613 0,010971613
ACP1 0,015326801 0,002742138 0,010965659 0,001619005 0,010965659
BACE1 0,018756788 0,010939894 0,004103211 0,003713683 0,010939894
TGFB2 0,025844857 0,004870738 0,010932367 0,010041752 0,010932367
DZIP1 0,018121487 0,00263238 0,010915131 0,004573976 0,010915131
SEMA3D 0,017649869 0,003135654 0,003600154 0,010914061 0,010914061
GRIK4 0,01696069 0,010907918 0,002612213 0,003440559 0,010907918
WFDC1 0,014746926 0,001127825 0,010901903 0,002717197 0,010901903
DACT2 0,022516709 0,003183476 0,008447649 0,010885584 0,010885584
ACTA2 0,015657233 0,00162739 0,00314618 0,010883664 0,010883664
SLC2A1 0,026026735 0,009822871 0,005320816 0,010883048 0,010883048
MAP2K1 0,028599216 0,007696963 0,010868666 0,010033587 0,010868666
DLGAP1 0,018698346 0,010839235 0,004907831 0,00295128 0,010839235
TNR 0,021560866 0,010834058 0,004445893 0,006280916 0,010834058
SMAD7 0,02298218 0,00433423 0,00781447 0,01083348 0,01083348
SIM2 0,022629229 0,01082384 0,006520514 0,005284875 0,01082384
PSMA6 0,02219975 0,0042959 0,007107464 0,010796386 0,010796386
RPL15 0,015105269 0,001421602 0,002895624 0,010788042 0,010788042
GMFB 0,017264787 0,010787338 0,004166591 0,002310859 0,010787338
TNMD 0,016472537 0,001586909 0,010784575 0,004101053 0,010784575
MLC1 0,024634434 0,010776517 0,003241122 0,010616795 0,010776517
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SLC1A6 0,019518673 0,010772222 0,006076378 0,002670072 0,010772222
PTPN11 0,026504502 0,005995029 0,010757795 0,009751677 0,010757795
MYT1 0,022656487 0,006709289 0,010752483 0,005194715 0,010752483
TSC22D1 0,023430377 0,00947229 0,010750663 0,003207423 0,010750663
STK11 0,019337757 0,003651616 0,010749324 0,004936817 0,010749324
HOXB9 0,024995033 0,004876613 0,010744512 0,009373907 0,010744512
MYC 0,029243855 0,008346933 0,010738471 0,010158451 0,010738471
HOXD12 0,021809865 0,003811043 0,010735887 0,007262935 0,010735887
SOX21 0,020010134 0,004541848 0,010730659 0,004737627 0,010730659
CTF4 0,028085219 0,007341555 0,010014155 0,010729509 0,010729509
FOXI1 0,021207333 0,003387112 0,010702886 0,007117336 0,010702886
rdh10b 0,01847749 0,010690546 0,004189322 0,003597621 0,010690546
foxd1 0,022358369 0,004190183 0,010687631 0,007480555 0,010687631
NRP2 0,028461004 0,009122972 0,008653774 0,010684258 0,010684258
PIK3CG 0,030581363 0,00935734 0,010543412 0,010680611 0,010680611
HRC 0,013590302 0,001395599 0,001515931 0,010678772 0,010678772
PTK2 0,026489791 0,008283154 0,007530077 0,010676559 0,010676559
FOXM1 0,022615703 0,004740977 0,007200429 0,010674296 0,010674296
IFT20 0,016044006 0,002216495 0,003155757 0,010671754 0,010671754
RBL1 0,024263646 0,005821131 0,010656111 0,007786404 0,010656111
id3 0,024634747 0,005509242 0,008477814 0,010647691 0,010647691
PCTK1 0,01432375 0,010647633 0,002143833 0,001532284 0,010647633
RAB23 0,020173553 0,004147874 0,010645035 0,005380646 0,010645035
SEMA3F 0,02727071 0,01063462 0,006471369 0,010164722 0,01063462
HNF4A 0,027400419 0,006232531 0,01054153 0,010626358 0,010626358
NKX6-2 0,026366962 0,008738926 0,010617754 0,007010281 0,010617754
KLF2 0,019475274 0,003154055 0,005728361 0,010592858 0,010592858
ROR1 0,025423301 0,010589206 0,007156205 0,007677892 0,010589206
gys1 0,013261279 0,001601791 0,001074197 0,010585291 0,010585291
ADCYAP1R1 0,01862699 0,010579362 0,003957714 0,004089914 0,010579362
CDC25B 0,021109341 0,004536255 0,010577149 0,005995936 0,010577149
CAMKK1 0,0149774 0,010566498 0,002512593 0,00189831 0,010566498
nr4a2b 0,026002729 0,010554458 0,007733877 0,007714393 0,010554458
MAPK3 0,02984681 0,009115186 0,010178811 0,010552813 0,010552813
GRB2 0,023775905 0,006095263 0,010544382 0,007136261 0,010544382
PROM1 0,026743777 0,00854675 0,007652776 0,01054425 0,01054425
MYL6 0,017845755 0,003577768 0,003729943 0,010538045 0,010538045
DICER1 0,024951741 0,003963124 0,010460372 0,010528244 0,010528244
SPAG5 0,018324845 0,002859844 0,010507771 0,004957228 0,010507771
UNCX 0,019503018 0,003104448 0,005904962 0,010493608 0,010493608
bmp3 0,022840263 0,002459429 0,009892813 0,01048802 0,01048802
B3GAT1 0,025095861 0,007925735 0,006695847 0,01047428 0,01047428
SCRIB 0,020245533 0,003270928 0,006500852 0,010473754 0,010473754
NKD1 0,02512805 0,004291694 0,010467272 0,010369084 0,010467272
CNTN2 0,023950806 0,010452344 0,008229627 0,005268836 0,010452344
MET 0,023005784 0,00549722 0,007062747 0,010445817 0,010445817
PLXNB3 0,018442458 0,010440651 0,00285767 0,005144137 0,010440651
POU2F1 0,023712747 0,004824847 0,008448933 0,010438967 0,010438967
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TSHZ1 0,017668152 0,0030529 0,01043788 0,004177372 0,01043788
ALCAM 0,018618267 0,00405588 0,004141824 0,010420563 0,010420563
NCAPG 0,015957067 0,001904431 0,003632796 0,01041984 0,01041984
NXNL1 0,012692794 7,86E-04 0,010411536 0,00149526 0,010411536
GSK3A 0,022142041 0,008212884 0,003518555 0,010410604 0,010410604
MAGI2 0,019859364 0,005413611 0,010403762 0,004041991 0,010403762
prkar1a 0,015374902 0,002136062 0,002835218 0,010403622 0,010403622
PLK4 0,015597959 0,001931649 0,003265386 0,010400924 0,010400924
NPC2 0,022236453 0,006455311 0,010388397 0,005392745 0,010388397
MAPK8 0,027404157 0,007758571 0,010381517 0,00926407 0,010381517
DYRK3 0,014588271 0,010364504 0,002044579 0,002179189 0,010364504
SPARC 0,024571795 0,004231037 0,010364107 0,009976652 0,010364107
SPARCL1 0,022986814 0,004450919 0,008174353 0,010361542 0,010361542
STAR 0,020861112 0,005615819 0,004884723 0,010360571 0,010360571
CCND2 0,026303662 0,007196867 0,008759859 0,010346936 0,010346936
mbd1 0,019527487 0,010343633 0,005301421 0,003882434 0,010343633
FAT1 0,019893762 0,005464042 0,010322406 0,004107313 0,010322406
GIPC3 0,021377692 0,003209758 0,010322404 0,00784553 0,010322404
dclk1 0,015150169 0,0103159 0,002203284 0,002630985 0,0103159
GDF2 0,02284239 0,002587446 0,009939726 0,010315218 0,010315218
MYG 0,020355692 0,005493263 0,00455009 0,01031234 0,01031234
CEBPB 0,025337679 0,005931802 0,009094568 0,010311309 0,010311309
FZD3 0,029970258 0,009379516 0,010284593 0,010306149 0,010306149
PPP5C 0,016451316 0,004051986 0,002099357 0,010299973 0,010299973
FABP1 0,020200295 0,005058439 0,004850589 0,010291267 0,010291267
FYN 0,019499611 0,010287933 0,004812593 0,004399086 0,010287933
PAXIP1 0,016621273 0,002400834 0,010279773 0,003940665 0,010279773
PDGFA 0,026347516 0,006640857 0,010260097 0,009446561 0,010260097
twist2 0,021246029 0,002891863 0,008097658 0,010256507 0,010256507
otx5 0,021491261 0,005379558 0,010252162 0,005859542 0,010252162
TNNC2 0,015430113 0,002575921 0,002602623 0,010251568 0,010251568
phox2a 0,022316368 0,005265228 0,006802252 0,010248889 0,010248889
DMRT1 0,023483692 0,004908331 0,008339282 0,010236078 0,010236078
GRK1 0,014809219 0,001788721 0,010230248 0,00279025 0,010230248
HDAC6 0,019175863 0,004334256 0,004616028 0,010225579 0,010225579
RGS5 0,018754421 0,00299991 0,005534122 0,010220388 0,010220388
HOXB8 0,023306273 0,004355024 0,010211311 0,008739938 0,010211311
DLG3 0,017987119 0,010209955 0,004478328 0,003298835 0,010209955
lin28 0,023005994 0,004079864 0,008717823 0,010208307 0,010208307
DKK3 0,023535099 0,003842817 0,010208278 0,009484004 0,010208278
DNAJB9 0,013781803 0,001812618 0,001774216 0,010194968 0,010194968
XRCC5 0,024417987 0,005441897 0,008787648 0,010188441 0,010188441
L1CAM 0,018919507 0,010173927 0,004518682 0,004226897 0,010173927
F11R 0,017068934 0,003289243 0,010161594 0,003618095 0,010161594
tcf3 0,024634151 0,005993428 0,008492455 0,010148269 0,010148269
SOSTDC1 0,021549366 0,002809158 0,010143472 0,008596735 0,010143472
CDX4 0,023610182 0,004156285 0,009311346 0,010142552 0,010142552
ADSSL1 0,013238929 0,001321552 0,001781843 0,010135534 0,010135534
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NPAS4 0,013785467 0,010133391 0,001671966 0,001980111 0,010133391
MMP2 0,022435257 0,006559132 0,005759762 0,010116363 0,010116363
ELAVL4 0,019894816 0,010115225 0,005851009 0,003928581 0,010115225
ihhb 0,018336684 0,003450368 0,010106972 0,004779343 0,010106972
APLNR 0,016909763 0,002458544 0,004348863 0,010102356 0,010102356
SPI1 0,025301853 0,005968076 0,009236389 0,010097389 0,010097389
FZD9 0,023770584 0,005320288 0,010081746 0,008368551 0,010081746
ITGB1 0,025427431 0,008076439 0,007276592 0,0100744 0,0100744
nedd8 0,015012197 0,002011081 0,010073671 0,002927445 0,010073671
SLC32A1 0,020012105 0,010066601 0,006719578 0,003225925 0,010066601
SMARCA2 0,021933643 0,004976143 0,010066156 0,006891344 0,010066156
FOXO3 0,020970454 0,004706187 0,006203481 0,010060787 0,010060787
GARS 0,022024408 0,003235361 0,008748321 0,010040726 0,010040726
mchr2 0,012919294 0,001858224 0,001024445 0,010036625 0,010036625
col9a1 0,014241372 0,0019612 0,010031328 0,002248844 0,010031328
EFNA5 0,025266789 0,009901202 0,01002959 0,005335998 0,01002959
TUBA1A 0,020413084 0,010028994 0,006165692 0,004218399 0,010028994
ATXN1 0,022125777 0,007886863 0,010023311 0,004215603 0,010023311
GPX4 0,018180132 0,010016657 0,004549958 0,003613517 0,010016657
CDK4 0,027606985 0,009785376 0,010012372 0,007809238 0,010012372
ENO3 0,015005909 0,002476247 0,002521595 0,010008067 0,010008067
zgc:110164 0,018886177 0,002967048 0,005912496 0,010006633 0,010006633
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Sum Cholestasis Necrosis Steatosis Max
ABCC2 44,82557696 14,92890273 0,077013887 0,059428233 0,005082565 0,012503092 0,059428233
ABCC4 9,324918909 17,31227095 0,041712489 0,031682357 0,003264796 0,006765335 0,031682357
ABCG5 8,227333663 5,889999226 0,042074256 0,027521077 0,003103841 0,011449339 0,027521077
ABCG8 16,73607996 3,416021008 0,038630858 0,026150254 0,002783493 0,009697112 0,026150254
ACADM 239,4903964 125,8165362 0,021878643 0,004075392 0,003258889 0,014544361 0,014544361
ACADS 38,37813334 22,95076745 0,017703975 0,004517278 0,002133949 0,011052748 0,011052748
ACADVL 115,2226426 65,60680926 0,016470009 0,003538457 0,002166314 0,010765238 0,010765238
ACOX1 91,44284995 39,90439619 0,041716449 0,009044701 0,003520968 0,029150779 0,029150779
ADD1 8,890479253 23,21992742 0,023682488 0,009257686 0,004136428 0,010288375 0,010288375
ADH5 185,9726784 107,3427021 0,023087617 0,006043346 0,003731309 0,013312962 0,013312962
ADIPOR2 23,90921391 45,77604023 0,039930321 0,004846609 0,002866152 0,032217559 0,032217559
ADRA2B 1,104650512 3,951360682 0,016404252 0,003594533 0,002260285 0,010549436 0,010549436
AGT 377,0012398 23,61386123 0,02728812 0,010209682 0,00865866 0,008419779 0,010209682
APAF1 2,803194208 6,435978406 0,030219667 0,003756397 0,022798733 0,003664537 0,022798733
API5 8,339437574 33,9956096 0,016351219 0,012257269 0,002029005 0,002064946 0,012257269
APOA1 5368,123544 1268,492767 0,0207518 0,004711499 0,00399787 0,012042432 0,012042432
APOB 242,1716426 21,39642033 0,037570022 0,011408326 0,006972171 0,019189526 0,019189526
ATG5 6,09118839 10,65827261 0,017572628 0,002202801 0,012941201 0,002428627 0,012941201
ATG7 1,196703827 4,049285585 0,015807344 0,002102256 0,010844933 0,002860155 0,010844933
BCL2 0,95678364 4,442045097 0,061035451 0,008593643 0,044535566 0,007906242 0,044535566
BCS1L 1,547084928 6,643677531 0,022746054 0,016334401 0,001825698 0,004585956 0,016334401
BIRC2 12,10309739 33,45166888 0,024949275 0,003646871 0,017405748 0,003896657 0,017405748
BLVRB 27,27104596 22,4778521 0,027435131 0,018821862 0,003161966 0,005451304 0,018821862
BMPER 0,001 9,227547986 0,020479662 0,003626294 0,001703037 0,015150331 0,015150331
CASP2 1,175373738 6,300164642 0,033359248 0,004090021 0,025314556 0,003954672 0,025314556
CASP6 4,056175271 4,350155253 0,028183853 0,00381928 0,02132523 0,003039344 0,02132523
CASP8 3,032239959 4,281990814 0,046544049 0,006266749 0,033743194 0,006534107 0,033743194
CASP9 1,419193514 6,323288363 0,051490605 0,00653371 0,037912443 0,007044452 0,037912443
CAST 10,31751332 52,29798187 0,020438122 0,004497664 0,011609449 0,004331008 0,011609449
CD36 6,288256716 70,46346231 0,025321567 0,007080521 0,005910512 0,012330534 0,012330534
CD81 9,528793203 238,5779886 0,02492677 0,005359821 0,003475744 0,016091206 0,016091206
CDK2 2,543544816 8,979739389 0,025480891 0,008452711 0,010170162 0,006858018 0,010170162
CDKN1B 11,38727393 37,18383469 0,0248792 0,007998035 0,010322264 0,006558901 0,010322264
CEBPA 9,121480044 16,98361489 0,030453065 0,009797923 0,006407595 0,014247547 0,014247547
CEBPB 63,04305331 31,99001321 0,026209027 0,008805877 0,007062452 0,010340697 0,010340697
CFLAR 2,992572402 5,853770503 0,031918153 0,004809873 0,021988189 0,005120092 0,021988189
CIRH1A 12,00911533 12,02633604 0,034875907 0,028750676 0,001859005 0,004266228 0,028750676
CPT2 19,76413574 14,01319778 0,019630326 0,006059116 0,003065126 0,010506085 0,010506085
CRK 7,209310662 22,65269365 0,025748551 0,006500926 0,013275154 0,00597247 0,013275154
CTGF 1,922007197 39,38037706 0,033212196 0,008016778 0,005851786 0,019343631 0,019343631
CYB5A 263,4268918 107,6954326 0,03473004 0,013363705 0,005395612 0,015970723 0,015970723
DDC 4,963320937 10,3268003 0,030310558 0,010085961 0,010689252 0,009535345 0,010689252
DFFB 1,657687715 3,782372125 0,023612443 0,003317844 0,01691659 0,003378008 0,01691659
DGAT2 58,74214147 23,9670907 0,032043066 0,005136488 0,002244031 0,024662545 0,024662545
DLAT 3,921573888 14,09515255 0,105669253 0,075439912 0,005487761 0,024741581 0,075439912
DPAGT1 11,02363831 9,546879365 0,017164266 0,004266203 0,00289536 0,010002703 0,010002703
EHHADH 65,05138954 7,170441641 0,020967282 0,006625546 0,002924709 0,011417027 0,011417027





Sum Cholestasis Necrosis Steatosis Max
ELOVL6 57,89943202 20,70040554 0,015407526 0,002998615 0,001385874 0,011023037 0,011023037
EPHX1 75,45824173 12,00644431 0,022888599 0,00826272 0,004458632 0,010167248 0,010167248
ERBB2 6,951416382 4,742550064 0,02883878 0,010340378 0,010201171 0,008297231 0,010340378
FABP6 0,001 149,7185745 0,038181286 0,030617575 0,002039491 0,005524218 0,030617575
FADD 6,167302297 7,595666486 0,030821892 0,005090054 0,021062072 0,004669766 0,021062072
FAS 0,681434485 1,359948928 0,057379473 0,009123832 0,03891766 0,009337983 0,03891766
FASLG 0,117812232 0,001 0,050953589 0,008522448 0,034139986 0,008291154 0,034139986
FASN 4,02739947 10,76606294 0,041606337 0,010148192 0,00521373 0,026244416 0,026244416
FECH 1,458594967 2,816107342 0,028193304 0,015301908 0,003130973 0,009760423 0,015301908
FGF19 0,122142023 0,968768834 0,027127514 0,017255177 0,001887887 0,007984449 0,017255177
FLT1 1,839201017 1,309551888 0,022246571 0,006310704 0,010303729 0,005632139 0,010303729
FOXA2 22,79098457 4,506487217 0,025602154 0,00980739 0,004358126 0,011436638 0,011436638
FOXE3 0,327230763 2,447602834 0,026381619 0,010293738 0,004722645 0,011365237 0,011365237
GFER 4,937207523 8,49887181 0,027299328 0,008619265 0,005840884 0,012839179 0,012839179
GGT1 0,001 0,721100276 0,058739889 0,031172252 0,005695994 0,021871642 0,031172252
GNMT 143,4323997 34,16008257 0,021026932 0,006332406 0,002700348 0,011994178 0,011994178
GNPAT 1,470753512 4,688973719 0,023393609 0,004263772 0,002335872 0,016793964 0,016793964
GOT1 63,8266418 99,22935225 0,030751588 0,009404703 0,005074093 0,016272791 0,016272791
GPC3 0,001 2,571735874 0,02011111 0,00509334 0,004463585 0,010554185 0,010554185
GPT2 0,393747944 6,62471783 0,045966722 0,014927394 0,006657721 0,024381608 0,024381608
HADHA 51,25144087 13,961273 0,022723211 0,010018039 0,001995165 0,010710007 0,010710007
HFE2 3,229190927 2,303597352 0,021908689 0,005368965 0,002572366 0,013967358 0,013967358
HMGB2 31,96692829 272,4247087 0,023257989 0,003421158 0,017075146 0,002761686 0,017075146
HMOX1 16,95985439 12,15940931 0,041445717 0,015163179 0,013389433 0,012893107 0,015163179
HNF1A 7,886318781 2,902018634 0,048218399 0,019955347 0,008419686 0,019843366 0,019955347
HNF4A 49,06556047 9,954180886 0,041129429 0,015616528 0,00785573 0,017657171 0,017657171
HSD3B7 74,68288492 14,37781683 0,015171532 0,011298706 0,000782 0,003091293 0,011298706
IL10 0,001 0,001 0,029994518 0,008696327 0,012144284 0,009153906 0,012144284
INS 0,657444807 3,746820763 0,025144149 0,006420076 0,007750246 0,010973826 0,010973826
JUN 13,79269365 45,61784692 0,025010629 0,007635969 0,010907425 0,006467235 0,010907425
KDR 1,813695297 2,362934557 0,022250498 0,006675374 0,010121336 0,005453788 0,010121336
KLHL20 1,881012559 7,321126624 0,025708759 0,002857364 0,018885973 0,003965421 0,018885973
KRAS 3,488570042 20,34409521 0,030957714 0,009369169 0,014141153 0,007447392 0,014141153
KRT18 466,5976757 165,3483625 0,037396435 0,010717558 0,010888772 0,015790104 0,015790104
KRT8 493,6805144 404,8514515 0,025367884 0,010456328 0,005198249 0,009713307 0,010456328
LDHA 9,142657629 181,3878948 0,043637305 0,011814404 0,018361333 0,013461568 0,018361333
LEPR 2,558063202 3,550204497 0,0253284 0,004935588 0,005291006 0,015101806 0,015101806
LIPC 212,95974 0,418143157 0,029702909 0,010502266 0,005543574 0,013657069 0,013657069
LPIN1 30,20772955 49,16458362 0,025058595 0,003857077 0,00187868 0,019322839 0,019322839
MAP1LC3A 32,32884316 52,73154608 0,018914178 0,002765334 0,01286324 0,003285605 0,01286324
MAP2K1 7,707091218 19,34897855 0,026280683 0,008172674 0,010545855 0,007562153 0,010545855
MAP2K4 1,793811449 4,584121875 0,026101328 0,00586159 0,014159399 0,00608034 0,014159399
MAPK1 3,283224037 16,69665826 0,032464631 0,01046966 0,012845321 0,009149651 0,012845321
MAPK3 2,849759018 3,166575029 0,028548514 0,009496857 0,010657417 0,00839424 0,010657417
MAT1A 598,328758 101,9681742 0,021962637 0,007120771 0,002995166 0,0118467 0,0118467
MBD2 4,184226714 4,011231641 0,024617489 0,009620801 0,004296141 0,010700547 0,010700547
MDM2 5,878038889 15,71224445 0,029093042 0,009109273 0,012982607 0,007001163 0,012982607
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Sum Cholestasis Necrosis Steatosis Max
NFS1 8,652978931 13,47661614 0,021899361 0,004464439 0,003054629 0,014380294 0,014380294
NOTCH2 3,837263455 9,710167419 0,017253086 0,011232573 0,003118563 0,002901949 0,011232573
NR1H4 16,04568011 2,659726401 0,059509341 0,046385944 0,003026804 0,010096595 0,046385944
NR1I2 12,29845316 8,184744036 0,037313148 0,020762435 0,005245015 0,011305696 0,020762435
NR5A2 14,93647739 3,599706097 0,020822095 0,010706359 0,005255265 0,00486047 0,010706359
ONECUT1 0,083673889 0,425580115 0,03052704 0,015676341 0,003968638 0,010882061 0,015676341
PARP1 2,485717839 17,6605449 0,034437459 0,004169373 0,025604269 0,004663819 0,025604269
PCK1 27,91625839 76,34542805 0,031706557 0,010997188 0,005163926 0,015545441 0,015545441
POR 3,2356716 21,55966249 0,028214144 0,009718726 0,00606595 0,012429467 0,012429467
PPARG 24613,6446 2528,198403 0,04306988 0,008887263 0,008552227 0,025630391 0,025630391
PPARGC1B 5,678718194 8,483471535 0,01855463 0,0050136 0,002703208 0,010837823 0,010837823
PRKRIR 1,766266266 7,581362174 0,015710823 0,001632279 0,00114529 0,012933254 0,012933254
PSME3 8,507929815 17,98376848 0,020864666 0,001998459 0,002495453 0,016370753 0,016370753
RBP4 3275,754367 699,926721 0,031877313 0,007494911 0,004879188 0,019503214 0,019503214
RNF7 21,242118 60,80971782 0,01884741 0,002692109 0,011846173 0,004309129 0,011846173
SCARB1 1,997037262 12,62886017 0,027560173 0,011876814 0,00496066 0,010722697 0,011876814
SCD 2,431507673 0,925601328 0,032475173 0,007002905 0,00295036 0,02252191 0,02252191
SDAD1 25,92869434 17,45438429 0,019355072 0,010487013 0,001943135 0,006924922 0,010487013
SEPSECS 8,730270026 3,24451775 0,024295079 0,012085529 0,002514439 0,009695112 0,012085529
SERPINE1 19,67664234 7,190450593 0,024628581 0,005979443 0,006378766 0,012270373 0,012270373
SFPQ 15,74344349 74,80480799 0,048192773 0,015613025 0,004788 0,027791747 0,027791747
SHBG 346,884657 11,77683501 0,027700087 0,008172066 0,008173291 0,01135473 0,01135473
SLC10A2 0,169245438 6,529313252 0,050060485 0,041890794 0,002339994 0,005829697 0,041890794
SLC23A1 1,509281158 4,692434969 0,016969826 0,012802857 0,001644121 0,002522848 0,012802857
SLCO1C1 0,142235827 3,09574504 0,054385055 0,04260197 0,002904114 0,008878971 0,04260197
SLCO3A1 0,475099028 4,620845608 0,013669365 0,010459238 0,001304136 0,001905991 0,010459238
SLCO4A1 0,001 3,835557912 0,016806575 0,013362893 0,001299644 0,002144038 0,013362893
SMAD2 3,781409926 12,28375512 0,023918748 0,006454806 0,006070317 0,011393625 0,011393625
SMAD7 5,847674514 10,21192594 0,02269466 0,006279146 0,00507803 0,011337484 0,011337484
SOCS1 3,334390683 4,271036601 0,020077337 0,004351029 0,004374156 0,011352152 0,011352152
SOCS7 0,093646613 7,137940767 0,015677366 0,002342825 0,002308094 0,011026448 0,011026448
SOD2 71,26165447 77,20095537 0,02739279 0,006341274 0,011615956 0,009435559 0,011615956
SQSTM1 55,56137115 31,03552352 0,033328641 0,005772629 0,016417256 0,011138758 0,016417256
SREBF1 11,27778401 12,00100437 0,0620065 0,013704743 0,005960525 0,042341229 0,042341229
TAT 306,6853912 30,86567388 0,03454319 0,012827191 0,005981295 0,015734704 0,015734704
TFR2 81,72260335 2,871331277 0,024453809 0,006236985 0,002998946 0,015217877 0,015217877
TMEM30A 9,237611566 25,5132471 0,022028193 0,017752279 0,001752175 0,002523738 0,017752279
TNFRSF1A 1,072399556 0,664767203 0,036860697 0,006620295 0,020456534 0,009783869 0,020456534
TNNC1 0,001 5,181196031 0,019872447 0,004934718 0,010275212 0,004662518 0,010275212
TP53 5,843986963 15,30868189 0,035636984 0,011853149 0,015628177 0,008155658 0,015628177
TP73 0,001 0,789306777 0,021288596 0,006283781 0,010298626 0,004706189 0,010298626
UROD 5,269735587 9,671257507 0,01971429 0,006031759 0,002777734 0,010904798 0,010904798
VIM 0,21470073 64,53292452 0,026992368 0,007930084 0,011457288 0,007604996 0,011457288
VIPR1 0,001 1,06088157 0,031439044 0,006466684 0,003761836 0,021210522 0,021210522
VPS33B 3,15450443 4,810771849 0,03448106 0,030334381 0,001184143 0,002962535 0,030334381
XIAP 9,660739561 19,05401865 0,032255523 0,004228349 0,023416213 0,004610962 0,023416213






Sum Brain Eye Heart Max
ABAT 49,94653841 67,90229578 0,027868891 0,006297938 0,004182428 0,017388524 0,017388524
ACP1 0,001 0,274059831 0,015326801 0,002742138 0,010965659 0,001619005 0,010965659
ACTA2 9,814040215 138,769799 0,015657233 0,00162739 0,00314618 0,010883664 0,010883664
ACTN2 0,001 12,21774858 0,019777933 0,005506837 0,002627426 0,011643671 0,011643671
ACVR1B 1,215293162 20,78808439 0,023477152 0,003524012 0,008486668 0,011466472 0,011466472
ACVR2A 2,971192873 16,41577059 0,026313435 0,003886923 0,01041008 0,012016433 0,012016433
ACVRL1 1,265737226 7,08665736 0,023142371 0,002229172 0,008922367 0,011990832 0,011990832
ADCYAP1R1 0,001 7,752555621 0,01862699 0,010579362 0,003957714 0,004089914 0,010579362
ADNP 0,001 8,445057708 0,036654517 0,017229578 0,006957201 0,01246774 0,017229578
ADRB1 0,001 2,674851847 0,021563575 0,003940655 0,003631527 0,013991393 0,013991393
ADSSL1 0,058174225 22,44692468 0,013238929 0,001321552 0,001781843 0,010135534 0,010135534
AES 1,728698297 13,14584342 0,052372187 0,004985748 0,041345441 0,006040997 0,041345441
AGT 377,0012398 23,61386123 0,025434235 0,007836647 0,005978355 0,011619232 0,011619232
AHI1 0,287226245 5,254688115 0,021415832 0,014689419 0,003977914 0,002748497 0,014689419
AKR1B1 33,88513639 52,01606334 0,027673084 0,004139197 0,019984997 0,003548891 0,019984997
ALDH1A2 1,951904822 27,46067055 0,050024379 0,006788738 0,021075317 0,022160324 0,022160324
ALDH8A1 28,34145823 7,460762201 0,021037577 0,002431559 0,012122727 0,006483291 0,012122727
ALX4 0,001 3,334935908 0,02721924 0,004496201 0,013242791 0,009480249 0,013242791
AMH 0,187191618 0,001 0,027866181 0,006254137 0,005924802 0,015687242 0,015687242
ANGPT1 0,289918028 2,364037525 0,024791243 0,00480195 0,006205525 0,013783769 0,013783769
ANGPT2 0,001 0,349517717 0,021169093 0,004244511 0,005827526 0,011097057 0,011097057
ANKRD6 2,133676261 10,30558677 0,029043391 0,012454745 0,008076714 0,008511931 0,012454745
APLP2 8,616560571 51,41967469 0,033040363 0,019749105 0,007269941 0,006021316 0,019749105
AQP4 0,001 3,205675511 0,025367374 0,012512331 0,008958562 0,003896481 0,012512331
ARX 0,001 6,385849508 0,025134906 0,016424782 0,004608551 0,004101573 0,016424782
ASPM 1,1778774 4,58924719 0,019257573 0,014238895 0,003121394 0,001897286 0,014238895
ATOH7 0,001 3,418239995 0,04434729 0,005779851 0,032416155 0,006151283 0,032416155
AXIN2 1,971469813 12,05349415 0,026795482 0,004686981 0,012458041 0,009650461 0,012458041
B4GALT5 0,112959246 1,087069606 0,016996898 0,012463482 0,001754443 0,002778974 0,012463482
B4GALT7 2,949424538 3,752006922 0,016405363 0,001511919 0,012078188 0,002815254 0,012078188
BARHL2 0,001 15,010992 0,039026093 0,003503176 0,031041031 0,004481884 0,031041031
BARX1 0,001 2,703660868 0,040349282 0,004263926 0,020510331 0,015575026 0,020510331
BBS5 0,635307302 7,179673433 0,015835902 0,001300451 0,011346893 0,003188558 0,011346893
BBS5 0,635307302 7,179673433 0,015835902 0,001300451 0,011346893 0,003188558 0,011346893
BCAN 0,001 7,774925379 0,027115548 0,018345413 0,003535383 0,005234753 0,018345413
BCKDHA 17,66933571 32,74910796 0,031827446 0,006955553 0,010632626 0,014239266 0,014239266
BDNF 0,331162461 10,40999382 0,050921854 0,033133779 0,009176592 0,008611482 0,033133779
BHLHE40 17,33660929 94,11987701 0,020322725 0,003283826 0,011226484 0,005812416 0,011226484
BMP10 0,453083965 0,001 0,04093951 0,002080864 0,009294992 0,029563652 0,029563652
BMP2K 3,948499941 11,12759943 0,030476553 0,001799168 0,024548864 0,004128521 0,024548864
BMP3 0,21721407 10,41946676 0,026950864 0,002985256 0,011892677 0,01207293 0,01207293
BMP4 0,234683699 7,735018164 0,072191142 0,009958062 0,030106348 0,032126728 0,032126728
BMP6 3,672384019 1,871512289 0,040415749 0,005353805 0,017347771 0,017714173 0,017714173
BMPER 0,001 9,227547986 0,021018596 0,002721925 0,007314935 0,010981737 0,010981737
CALB1 0,001 10,25326012 0,021450944 0,012555632 0,005565157 0,003330155 0,012555632
CAMK4 0,066337339 14,42950007 0,023255365 0,011890912 0,004144514 0,00721994 0,011890912
CAMKK1 1,041088599 3,932922904 0,0149774 0,010566498 0,002512593 0,00189831 0,010566498
190
























Sum Brain Eye Heart Max
CASD1 1,365759923 11,76528472 0,033131715 0,014281432 0,009332016 0,009518267 0,014281432
CASP9 1,419193514 6,323288363 0,024798874 0,011178628 0,006661987 0,006958258 0,011178628
CASQ2 0,001 45,3296218 0,015649283 0,001797996 0,002374364 0,011476923 0,011476923
CAV3 0,001 44,62854274 0,019920174 0,003467359 0,003548463 0,012904353 0,012904353
CDCA8 0,61201068 3,487563479 0,017981922 0,002348663 0,012734928 0,002898331 0,012734928
CDH1 36,16465206 25,14712463 0,033298288 0,006741844 0,010895949 0,015660495 0,015660495
CDH10 0,05673588 4,898837338 0,02237862 0,002806724 0,002523753 0,017048142 0,017048142
CDH2 33,66852547 48,25474004 0,043976985 0,00889714 0,015540349 0,019539495 0,019539495
CDH6 0,001 16,22155486 0,033029556 0,006503333 0,016739894 0,009786331 0,016739894
CDK2 2,543544816 8,979739389 0,029502016 0,010283798 0,011029515 0,008188702 0,011029515
CDK5 1,657295872 8,842439896 0,055067398 0,043061133 0,006038619 0,005967648 0,043061133
CDKL5 0,045562833 6,332708518 0,017617343 0,013893267 0,002090945 0,00163313 0,013893267
CDKN1C 0,132513771 13,28391133 0,031315155 0,008640643 0,012637526 0,010036986 0,012637526
CDON 2,763599212 17,03908584 0,036375858 0,007605392 0,022785506 0,005984959 0,022785506
CDT1 0,615924279 3,966051746 0,02220824 0,003146442 0,013161163 0,005900634 0,013161163
CDX4 0,001 0,333015931 0,023610182 0,004156285 0,009311346 0,010142552 0,010142552
CEBPB 63,04305331 31,99001321 0,025337679 0,005931802 0,009094568 0,010311309 0,010311309
CHRNA7 0,090515201 0,818269985 0,019228347 0,010988195 0,004020162 0,00421999 0,010988195
CLDN11 0,682326183 4,80773387 0,018889353 0,011618506 0,002887344 0,004383502 0,011618506
CNKSR1 0,182236597 4,091742696 0,023457309 0,001683891 0,019553595 0,002219823 0,019553595
CNKSR2 0,001 2,395869013 0,038777225 0,003942589 0,0328765 0,001958135 0,0328765
CNR1 0,001 3,105092844 0,020948699 0,013141536 0,003937376 0,003869786 0,013141536
COL15A1 0,720588156 2,683672135 0,020685846 0,00199672 0,015783168 0,002905957 0,015783168
CPSF1 2,604800977 10,41073765 0,019836921 0,002604228 0,013938131 0,003294563 0,013938131
CRB1 0,001 4,356881023 0,022819938 0,003596754 0,01615378 0,003069405 0,01615378
CRIM1 0,391860267 6,413216078 0,023863098 0,00233609 0,017512414 0,004014593 0,017512414
CRIP2 0,915333839 16,56622343 0,020943526 0,001853887 0,002874339 0,0162153 0,0162153
CRYAA 0,222656688 33,58203991 0,053587563 0,004484663 0,044179551 0,00492335 0,044179551
CRYBA4 0,001 873,3472541 0,028498895 0,002622936 0,023858195 0,002017763 0,023858195
CRYBB1 0,330277781 1509,347559 0,018851593 0,001428558 0,015039532 0,002383503 0,015039532
CRYBB2 0,001 0,184757245 0,032442637 0,00270538 0,02720431 0,002532945 0,02720431
CSPG5 0,001 74,63589159 0,019794161 0,014070826 0,003200477 0,002522858 0,014070826
CSRP3 0,147852854 0,58758264 0,022693003 0,003333288 0,006853189 0,012506525 0,012506525
CTCF 10,11250724 37,69599009 0,047221705 0,004501128 0,038721193 0,003999385 0,038721193
CUGBP1 10,07415721 24,7189911 0,022177629 0,003115355 0,006106529 0,012955744 0,012955744
CUGBP2 0,842112033 41,037351 0,034336235 0,003782853 0,006127221 0,02442616 0,02442616
CUL3 7,634667507 25,09951872 0,017927017 0,002548388 0,012330941 0,003047688 0,012330941
CYP1B1 0,001 1,036466106 0,032787576 0,004458903 0,022561952 0,005766722 0,022561952
CYP26A1 0,001 4,45059342 0,035233378 0,006220052 0,016311999 0,012701329 0,016311999
CYP26B1 0,324580077 14,64047465 0,039906535 0,00726112 0,022637604 0,010007811 0,022637604
DAB1 0,087556021 6,816930358 0,074998029 0,059293475 0,010185451 0,005519101 0,059293475
DAB2 1,569110337 11,72857576 0,025306646 0,007390721 0,004336545 0,01357938 0,01357938
DACT2 0,151399561 1,831855475 0,022516709 0,003183476 0,008447649 0,010885584 0,010885584
DCLK2 0,001 3,938997655 0,0190232 0,014093827 0,002383787 0,002545586 0,014093827
DCT 0,001 19,88847528 0,028093373 0,00403126 0,017852634 0,00620948 0,017852634
DDC 4,963320937 10,3268003 0,03094116 0,019311999 0,006511254 0,005117909 0,019311999
DICER1 3,743504156 9,510715699 0,024951741 0,003963124 0,010460372 0,010528244 0,010528244





Sum Brain Eye Heart Max
DIO2 270,7054943 1,319378666 0,024957422 0,009766858 0,00416136 0,011029205 0,011029205
DISP1 0,865648237 2,46793803 0,028158344 0,004789024 0,018158989 0,005210331 0,018158989
DKK3 4,607867364 9,260588444 0,023535099 0,003842817 0,010208278 0,009484004 0,010208278
DLG3 5,356590917 31,7419335 0,017987119 0,010209955 0,004478328 0,003298835 0,010209955
DLGAP1 0,001 2,780908147 0,018698346 0,010839235 0,004907831 0,00295128 0,010839235
DLL4 2,789265568 6,394114685 0,028079109 0,005324418 0,013279188 0,009475503 0,013279188
DMAP1 1,88124798 9,237368686 0,022455761 0,001700591 0,017753863 0,003001306 0,017753863
DMRT1 0,040508252 0,001 0,023483692 0,004908331 0,008339282 0,010236078 0,010236078
DPYSL2 0,301720605 55,83895573 0,025818106 0,016380666 0,005084177 0,004353262 0,016380666
DPYSL3 0,475004642 71,45944774 0,027475325 0,01541293 0,008214423 0,003847972 0,01541293
DPYSL4 0,001 15,28542067 0,018551696 0,012551013 0,003215898 0,002784786 0,012551013
DRD1 0,001 0,043903674 0,020322526 0,011777631 0,004521411 0,004023484 0,011777631
DRD3 0,001 2,567957457 0,019311575 0,011789444 0,0041631 0,00335903 0,011789444
DVL2 1,751265935 4,673075863 0,027590407 0,006177828 0,00950432 0,01190826 0,01190826
DYNC1H1 15,40278886 42,22917477 0,022432288 0,011172893 0,009250736 0,002008659 0,011172893
DYRK2 2,235686376 14,90825081 0,022145012 0,011071575 0,004476258 0,00659718 0,011071575
DYX1C1 0,110798488 0,502227768 0,019258969 0,014506509 0,002462406 0,002290054 0,014506509
DZIP1 0,048571411 5,348626062 0,018121487 0,00263238 0,010915131 0,004573976 0,010915131
E2F4 2,887628002 11,48898586 0,031565811 0,004777089 0,013761921 0,013026801 0,013761921
EAF1 3,712922451 15,01463299 0,038386859 0,001111476 0,035410508 0,001864875 0,035410508
EAF2 5,93317924 11,74774063 0,055084154 0,001100045 0,051024867 0,00295924 0,051024867
EDN1 0,257013475 2,484479166 0,025691936 0,007062256 0,005058684 0,013570995 0,013570995
EFHC1 0,171014483 2,814407825 0,016217604 0,012237656 0,001791013 0,002188936 0,012237656
EGFR 0,721681364 4,759598308 0,036054131 0,006920896 0,022316275 0,006816961 0,022316275
EGR1 32,65271858 34,0689472 0,033352427 0,011525875 0,012264174 0,009562379 0,012264174
EHF 0,315126963 1,434982918 0,015400069 0,001673769 0,01103033 0,00269597 0,01103033
ELAVL4 0,001 71,26329942 0,019894816 0,010115225 0,005851009 0,003928581 0,010115225
ELF3 6,880102229 11,13006945 0,019090069 0,002686205 0,01186149 0,004542375 0,01186149
ELK4 0,820818431 1,527527181 0,020955987 0,003487631 0,005462835 0,012005521 0,012005521
ELL 7,421488733 7,405358387 0,032946594 0,001846564 0,029262511 0,001837519 0,029262511
ELP4 0,902220837 4,743590017 0,048270274 0,010565259 0,035148573 0,002556442 0,035148573
EMX1 0,001 2,591705592 0,067901835 0,025410886 0,033115316 0,009375636 0,033115316
EMX2 0,001 3,328183919 0,066138677 0,019494217 0,035163632 0,011480829 0,035163632
ENO2 0,001 80,45595729 0,022991421 0,011653886 0,005917678 0,005419857 0,011653886
ENO3 370,6639876 181,557777 0,015005909 0,002476247 0,002521595 0,010008067 0,010008067
EPHA7 0,571327048 2,550290641 0,030652264 0,007727077 0,015855166 0,007070022 0,015855166
ERBB2 6,951416382 4,742550064 0,028687511 0,009590258 0,011639825 0,007457427 0,011639825
ETS2 10,79508164 16,11005405 0,023399334 0,004580226 0,006720514 0,012098593 0,012098593
ETV1 0,001 4,50100164 0,026549919 0,005310648 0,014377884 0,006861387 0,014377884
EVX1 0,001 1,148655723 0,0297828 0,00577837 0,012007727 0,011996704 0,012007727
EYA1 0,001 9,464126139 0,08824259 0,006215983 0,068925288 0,013101321 0,068925288
EYA3 2,780171117 7,527101699 0,054065339 0,002812763 0,046522075 0,004730502 0,046522075
F11R 20,13999102 38,22290299 0,017068934 0,003289243 0,010161594 0,003618095 0,010161594
FAM82A2 5,183820784 10,35201675 0,027533328 0,001613726 0,024018743 0,00190086 0,024018743
FAT1 4,641989719 12,38838643 0,019893762 0,005464042 0,010322406 0,004107313 0,010322406
FBLN1 0,718050189 12,54872242 0,01908052 0,003365323 0,003731949 0,011983248 0,011983248
FBLN2 2,019849116 8,741177099 0,022096397 0,002725323 0,003127944 0,01624313 0,01624313
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Sum Brain Eye Heart Max
FERMT2 8,516861912 7,658143561 0,026723983 0,002299919 0,003019597 0,021404467 0,021404467
FEZ1 0,001 67,17791161 0,018929569 0,012581108 0,004177292 0,002171169 0,012581108
FGF1 0,001 1,995420087 0,041954368 0,010068872 0,014771551 0,017113945 0,017113945
FGF13 1,232944541 9,798715242 0,026146835 0,004796659 0,00769419 0,013655986 0,013655986
FGF16 0,001 1,290003027 0,037439812 0,005542275 0,006594595 0,025302943 0,025302943
FGF17 0,039268083 0,088346493 0,037167415 0,009342097 0,014360442 0,013464874 0,014360442
FGF19 0,122142023 0,968768834 0,042887799 0,006769323 0,024001575 0,012116902 0,024001575
FGF3 0,001 0,114686389 0,035463195 0,00652805 0,014794961 0,014140182 0,014794961
FGF4 0,001 0,446217554 0,042261239 0,007174217 0,016802565 0,018284459 0,018284459
FGF5 0,001 0,001 0,030902153 0,007080872 0,010640495 0,013180787 0,013180787
FGF7 0,001 0,32384422 0,035786059 0,00697851 0,014142133 0,014665414 0,014665414
FGFR3 0,001 9,766216293 0,04164803 0,007493715 0,017105214 0,017049101 0,017105214
FGFR4 19,43235693 12,71319867 0,047205739 0,008374338 0,0193252 0,019506201 0,019506201
FKBP8 8,783768151 2,434637716 0,026642211 0,003350663 0,018967311 0,004324237 0,018967311
FKTN 3,07489347 7,708860268 0,028619407 0,013142884 0,011609862 0,00386666 0,013142884
FLT1 1,839201017 1,309551888 0,027778957 0,006096534 0,008638455 0,013043968 0,013043968
FMR1 4,767917567 18,60426765 0,037486117 0,02523618 0,007881047 0,004368888 0,02523618
FOS 16,33840179 26,30186985 0,031926282 0,014105567 0,008723301 0,009097416 0,014105567
FOXA1 17,40991629 5,003019215 0,028132938 0,004938465 0,011077486 0,012116987 0,012116987
FOXA2 22,79098457 4,506487217 0,036871966 0,006115178 0,012971281 0,017785506 0,017785506
FOXA3 17,82174628 5,111711684 0,022376288 0,002294042 0,00549563 0,014586617 0,014586617
FOXD3 0,001 7,951313457 0,038368028 0,005635334 0,014840214 0,01789248 0,01789248
FOXE3 0,327230763 2,447602834 0,043705333 0,004926329 0,02739064 0,011388364 0,02739064
FOXF1 0,508435863 6,578017807 0,028732453 0,005381271 0,011400802 0,011950379 0,011950379
FOXH1 0,146187226 0,884702139 0,022558298 0,003004644 0,008302626 0,011251029 0,011251029
FOXI1 0,001 0,391060675 0,021207333 0,003387112 0,010702886 0,007117336 0,010702886
FOXL1 0,578164034 4,611797732 0,031560492 0,003992111 0,017189129 0,010379251 0,017189129
FOXP2 1,079462835 13,47316067 0,026262127 0,014348163 0,0063031 0,005610864 0,014348163
FRS2 3,867193339 9,233402394 0,036817517 0,006285037 0,015726012 0,01480647 0,015726012
FRZB 0,119205529 5,835486962 0,029798804 0,004198779 0,012292622 0,013307403 0,013307403
FXR1 7,578846921 32,18782634 0,038347255 0,025299991 0,008200328 0,004846936 0,025299991
FZD2 2,514349456 19,85591956 0,029627211 0,005158773 0,012294533 0,012173905 0,012294533
FZD3 0,186837642 9,544880002 0,029970258 0,009379516 0,010284593 0,010306149 0,010306149
FZD9 0,001 7,581459957 0,023770584 0,005320288 0,010081746 0,008368551 0,010081746
G3BP1 13,64505635 41,23903146 0,015769241 0,002285369 0,011829966 0,001653908 0,011829966
GAD1 0,024837381 103,8669596 0,027546477 0,016063257 0,006345623 0,005137597 0,016063257
GATA3 0,120959457 32,24167861 0,031424776 0,006182012 0,009434126 0,015808638 0,015808638
GATA4 14,79096764 2,962223171 0,119178429 0,006391891 0,010700367 0,102086171 0,102086171
GATA5 1,703895059 6,941785532 0,077895351 0,003146774 0,007228061 0,067520514 0,067520514
GBX1 0,001 4,325944368 0,025626857 0,006098072 0,011591109 0,007937675 0,011591109
GBX2 0,001 6,267840267 0,058807906 0,016732653 0,027584914 0,01449034 0,027584914
GCM2 0,001 3,92058267 0,030937014 0,00437185 0,016630741 0,009934424 0,016630741
GDF7 0,001 0,484503106 0,023986097 0,003962819 0,013148184 0,006875095 0,013148184
GDNF 0,001 1,667391746 0,032394651 0,014635764 0,008997806 0,008761082 0,014635764
GFAP 0,061571011 123,9791003 0,050052516 0,03035348 0,011980851 0,007718185 0,03035348
GINS2 0,937634664 6,093897237 0,01482001 0,001100057 0,011967501 0,001752452 0,011967501
GLI3 0,06485703 1,148804816 0,053298395 0,012226133 0,027126459 0,013945804 0,027126459





Sum Brain Eye Heart Max
GMFB 0,642704794 17,16527008 0,017264787 0,010787338 0,004166591 0,002310859 0,010787338
GMNN 2,733159614 5,197771099 0,026835611 0,003031444 0,017958531 0,005845637 0,017958531
GNL3 15,66153159 25,22773242 0,025157336 0,0031654 0,02094908 0,001042857 0,02094908
GPC4 10,41296405 18,52245953 0,031007295 0,014440415 0,009824303 0,006742578 0,014440415
GPR143 0,050233361 4,383610293 0,026142489 0,002720293 0,021347794 0,002074402 0,021347794
GPR177 5,570758805 26,22975168 0,029663064 0,003224814 0,018894684 0,007543566 0,018894684
GRB2 11,3887493 34,29655007 0,023775905 0,006095263 0,010544382 0,007136261 0,010544382
GREM2 0,177561017 1,310745605 0,021774625 0,002618048 0,011892759 0,007263818 0,011892759
GRID2 2,265890141 7,063026065 0,022821186 0,015624526 0,003551426 0,003645234 0,015624526
GRIK4 0,001 2,825551332 0,01696069 0,010907918 0,002612213 0,003440559 0,010907918
GRIN2C 5,527925391 2,770178948 0,025719907 0,016027502 0,003926394 0,005766011 0,016027502
GRSF1 11,45004981 12,31858483 0,018730681 0,012307075 0,002702353 0,003721254 0,012307075
GSK3A 8,460724304 39,2923593 0,022142041 0,008212884 0,003518555 0,010410604 0,010410604
GSK3B 8,508615284 21,1665384 0,038137432 0,012679706 0,009057949 0,016399777 0,016399777
GUCA1A 0,149461422 0,678723241 0,019695366 0,002805581 0,013912618 0,002977167 0,013912618
HAND2 2,442204284 7,501800013 0,032965384 0,007185623 0,005703633 0,020076128 0,020076128
HAS2 0,001 0,806569937 0,023289099 0,003306234 0,006476222 0,013506644 0,013506644
HCCS 7,909060535 15,0427202 0,024103709 0,001594409 0,00821048 0,01429882 0,01429882
HCN2 0,001 6,090658057 0,019400531 0,005390371 0,002728457 0,011281702 0,011281702
HDAC4 0,669858295 4,29746294 0,020912757 0,003571735 0,003351678 0,013989345 0,013989345
HDAC6 1,699251951 4,232109283 0,019175863 0,004334256 0,004616028 0,010225579 0,010225579
HEY1 0,187135214 12,34825105 0,038651209 0,005225367 0,015105512 0,018320331 0,018320331
HEY2 0,001 2,679518409 0,044127516 0,005736743 0,013861591 0,024529182 0,024529182
HHIP 23,45351308 13,98703503 0,031413261 0,005447593 0,018094265 0,007871403 0,018094265
HMGA2 1,416742718 16,02344623 0,022776568 0,004107226 0,005824548 0,012844794 0,012844794
HMGN3 8,518741552 111,1314753 0,026601138 0,002712062 0,021149996 0,002739079 0,021149996
HMX1 0,001 5,885777072 0,039346017 0,004099694 0,028858175 0,006388147 0,028858175
HMX2 0,001 4,428895589 0,02578089 0,004480037 0,013091681 0,008209173 0,013091681
HMX3 0,001 5,272990866 0,032545973 0,004918173 0,017848912 0,009778887 0,017848912
HNF1A 7,886318781 2,902018634 0,027529277 0,005937436 0,010303909 0,011287932 0,011287932
HNF4A 49,06556047 9,954180886 0,027400419 0,006232531 0,01054153 0,010626358 0,010626358
HRC 0,001 70,09602787 0,013590302 0,001395599 0,001515931 0,010678772 0,010678772
HSBP1 19,72095685 80,94110001 0,017838143 0,001823732 0,002409294 0,013605117 0,013605117
HSF1 2,698800278 6,424773977 0,024492584 0,005740338 0,007425329 0,011326918 0,011326918
HSF2 4,813000703 30,76293422 0,03604297 0,006627713 0,011874769 0,017540487 0,017540487
HTT 3,099221506 7,48572182 0,030699525 0,015197397 0,009212536 0,006289592 0,015197397
ID1 26,76364573 172,5041557 0,028792636 0,005301036 0,010542097 0,012949503 0,012949503
IDH1 59,95124959 102,4082866 0,02110433 0,002143266 0,011710007 0,007251057 0,011710007
IFT20 3,779374182 6,116270177 0,016044006 0,002216495 0,003155757 0,010671754 0,010671754
IFT88 1,009135963 5,238938382 0,02356036 0,003925902 0,008121098 0,011513359 0,011513359
IGF1 43,10004265 1,473651308 0,03518175 0,018833438 0,006922584 0,009425729 0,018833438
IGFBP3 3,462869268 6,745648165 0,024781941 0,013117563 0,005124583 0,006539794 0,013117563
IL6ST 10,33603071 7,954064431 0,025257755 0,005317484 0,006522339 0,013417932 0,013417932
INVS 4,120526088 1,789820528 0,026709612 0,003867739 0,007352423 0,015489451 0,015489451
ISL1 0,001 28,11875357 0,077418409 0,009697639 0,031026876 0,036693894 0,036693894
JAG2 0,438992148 5,193054873 0,03663655 0,008263698 0,016551223 0,011821631 0,016551223
JAM3 1,888920597 11,99808963 0,01767919 0,001714975 0,001742896 0,014221319 0,014221319
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Sum Brain Eye Heart Max
JMJD6 2,685939265 4,470756489 0,027201146 0,00202956 0,013902266 0,011269321 0,013902266
JUN 13,79269365 45,61784692 0,031887095 0,007722368 0,010697273 0,013467453 0,013467453
JUND 0,001 0,001 0,029466948 0,006505588 0,009835285 0,013126074 0,013126074
KCND2 0,001 5,464793076 0,022462411 0,006835218 0,003563014 0,012064179 0,012064179
KCND3 0,001 6,561966164 0,020675426 0,004591034 0,003038382 0,013046009 0,013046009
KCNQ1 0,063063873 0,425980392 0,021531066 0,004011982 0,005063225 0,012455859 0,012455859
KDR 1,813695297 2,362934557 0,032817278 0,007154919 0,010355203 0,015307156 0,015307156
KERA 0,001 10,41581553 0,034869812 0,003642897 0,025988516 0,005238399 0,025988516
KIF7 0,995773766 1,479006404 0,02750233 0,004470164 0,01581176 0,007220406 0,01581176
KLF4 0,096408748 3,9208502 0,031152926 0,005131635 0,010162172 0,01585912 0,01585912
KRAS 3,488570042 20,34409521 0,028609158 0,007694819 0,013053861 0,007860477 0,013053861
LAMA1 0,027598803 1,245585434 0,025599806 0,003608608 0,011142091 0,010849107 0,011142091
LECT1 0,001 110,0453689 0,019100199 0,002395584 0,012166083 0,004538531 0,012166083
LEF1 0,222098359 12,71198919 0,036064152 0,007543026 0,01375417 0,014766954 0,014766954
LFNG 2,93029436 24,07676481 0,032872897 0,005027521 0,012913328 0,014932047 0,014932047
LGSN 0,034436675 22,62954074 0,01844871 0,002072159 0,013235728 0,003140823 0,013235728
LHX2 0,001 8,104327194 0,054539438 0,009577774 0,025657777 0,019303887 0,025657777
LHX3 0,001 5,437823662 0,039165303 0,006853398 0,019348466 0,012963441 0,019348466
LHX5 0,001 11,61808359 0,038766783 0,006216482 0,024697323 0,007852977 0,024697323
LHX6 0,329022146 4,894335471 0,034284171 0,00778266 0,017895922 0,008605588 0,017895922
LRP5 9,55827004 8,08270374 0,033320662 0,00535752 0,015163559 0,012799583 0,015163559
LRRC10 0,001 0,181168974 0,044885568 0,001325308 0,002594433 0,040965827 0,040965827
LUM 0,001 33,73023464 0,023654597 0,003906079 0,014052294 0,005696224 0,014052294
MAB21L1 0,001 0,23349922 0,020500623 0,003479882 0,013823251 0,003197489 0,013823251
MAB21L2 0,001 0,290919093 0,046415213 0,00532077 0,035342341 0,005752102 0,035342341
MAF 1,67006787 8,265438618 0,04994427 0,00505733 0,038482288 0,006404654 0,038482288
MAF1 3,725801822 21,30770996 0,016181411 0,001303353 0,012016298 0,002861761 0,012016298
MAG 0,001 14,6543759 0,031912714 0,021315108 0,005646596 0,004951011 0,021315108
MAGI2 0,181715394 3,392510188 0,019859364 0,005413611 0,010403762 0,004041991 0,010403762
MAP2K1 7,707091218 19,34897855 0,028599216 0,007696963 0,010868666 0,010033587 0,010868666
MAP3K3 0,875014708 3,533687292 0,019563753 0,002396552 0,00295149 0,014215711 0,014215711
MAPK1 3,283224037 16,69665826 0,032518253 0,009185283 0,011411195 0,011921776 0,011921776
MAPK3 2,849759018 3,166575029 0,02984681 0,009115186 0,010178811 0,010552813 0,010552813
MAPK7 0,801969157 4,266808397 0,021845844 0,00585645 0,004920088 0,011069305 0,011069305
MBNL2 7,167607765 17,80839704 0,029553423 0,001730771 0,01923841 0,008584242 0,01923841
MBNL3 8,215643286 4,459002991 0,029036237 0,001570699 0,019249557 0,008215981 0,019249557
MBP 0,001 62,57889193 0,035998113 0,025597471 0,005371406 0,005029237 0,025597471
MECP2 1,253996463 3,867230228 0,044530712 0,032737361 0,006551348 0,005242004 0,032737361
MED12 3,904928007 12,22696921 0,022571838 0,005911142 0,013384626 0,003276069 0,013384626
MEF2A 3,250976505 9,03906792 0,045554403 0,007263368 0,00696501 0,031326027 0,031326027
MEF2D 2,957955635 20,81839889 0,055798467 0,009617308 0,00784199 0,03833917 0,03833917
MEIS1 3,484331406 60,29355779 0,040830385 0,004958775 0,027391298 0,008480311 0,027391298
MEOX1 0,001 4,792653921 0,029061187 0,003440336 0,011172006 0,014448846 0,014448846
MET 3,796023275 1,621460949 0,023005784 0,00549722 0,007062747 0,010445817 0,010445817
MLC1 0,001 4,947088759 0,024634434 0,010776517 0,003241122 0,010616795 0,010776517
MMP2 3,024165567 53,50840358 0,022435257 0,006559132 0,005759762 0,010116363 0,010116363
MNAT1 1,457300888 3,614034042 0,020102356 0,012402695 0,004082029 0,00361763 0,012402695





Sum Brain Eye Heart Max
MNX1 0,001 1,194358827 0,027422892 0,004681666 0,012693227 0,010048 0,012693227
MOBKL3 17,01411059 53,21555707 0,02340967 0,001778817 0,011220734 0,010410119 0,011220734
MOCS3 1,250627725 2,633857247 0,027472891 0,002833089 0,02193768 0,00270212 0,02193768
MOGAT2 1,419869861 20,13636617 0,031827275 0,003459433 0,025136205 0,003231636 0,025136205
MSI1 0,036656473 26,57337253 0,040877145 0,012406702 0,020264287 0,008206157 0,020264287
MYCN 0,064764253 28,30876927 0,023800751 0,005765296 0,006344897 0,011690558 0,011690558
MYEF2 10,25744045 52,67398706 0,055019524 0,008953787 0,008966454 0,037099285 0,037099285
MYF5 0,10955695 2,72658096 0,037655018 0,007367682 0,012012752 0,018274585 0,018274585
MYF6 0,001 2,801001021 0,027188977 0,004969757 0,008987451 0,013231769 0,013231769
MYH6 0,001 1,211217357 0,054092713 0,006164146 0,006078841 0,041849726 0,041849726
MYL2 0,043362958 1,93486003 0,052577663 0,004240988 0,00454675 0,043789927 0,043789927
MYL7 0,001 23,23823196 0,062604882 0,003154815 0,005332639 0,054117424 0,054117424
MYOD1 0,001 7,565919954 0,026549457 0,005073984 0,00797536 0,013500112 0,013500112
MYOG 0,001 10,16171058 0,035915717 0,007607698 0,010494675 0,017813344 0,017813344
NCAM1 0,42564454 30,4676532 0,025020501 0,007932664 0,005815191 0,011272647 0,011272647
NCAPG 0,442910486 7,439837955 0,015957067 0,001904431 0,003632796 0,01041984 0,01041984
NCOA6 3,578061935 12,07585777 0,027954236 0,003406503 0,012169469 0,012378263 0,012378263
NDRG4 0,151694655 69,66701908 0,032772548 0,010784803 0,004493768 0,017493977 0,017493977
NDUFS3 36,72588929 81,96022945 0,015418398 0,001458236 0,002050252 0,01190991 0,01190991
NEFL 0,452379996 17,07970738 0,024356782 0,014868271 0,00538225 0,004106261 0,014868271
NEGR1 1,378089596 28,1468591 0,018849356 0,011215153 0,005372308 0,002261896 0,011215153
NES 0,1223334 2,862736052 0,056818299 0,024117543 0,016765688 0,015935069 0,024117543
NEUROD2 0,001 4,86428368 0,032629546 0,019908753 0,007159667 0,005561124 0,019908753
NEUROD4 0,001 24,0383338 0,034431938 0,009919189 0,01674384 0,00776891 0,01674384
NEUROG1 0,001 4,690995108 0,048326306 0,01491267 0,021272069 0,012141568 0,021272069
NFATC1 0,078189992 2,702508522 0,032435082 0,005097486 0,007911894 0,019425702 0,019425702
NGFR 0,001 3,049183357 0,027806574 0,01463879 0,006328964 0,006838821 0,01463879
NKD1 0,001 8,81418349 0,02512805 0,004291694 0,010467272 0,010369084 0,010467272
NOS1 0,492681508 4,025648746 0,023464534 0,012719828 0,005239613 0,005505093 0,012719828
NOTCH2 3,837263455 9,710167419 0,048108365 0,010510799 0,021589355 0,016008212 0,021589355
NOTCH3 3,249245705 13,43488182 0,029576397 0,007958272 0,013472552 0,008145572 0,013472552
NPAS4 0,001 11,95693855 0,013785467 0,010133391 0,001671966 0,001980111 0,010133391
NPC2 81,17849944 41,06881673 0,022236453 0,006455311 0,010388397 0,005392745 0,010388397
NPY 0,001 7,958421715 0,025144322 0,013920032 0,005814601 0,00540969 0,013920032
NR2E1 0,11474164 3,570693686 0,037826721 0,016031435 0,016055693 0,005739594 0,016055693
NR2E3 0,001 4,345278425 0,026827853 0,005458677 0,016934511 0,004434664 0,016934511
NR2F2 18,55433771 44,00904835 0,045781989 0,00479003 0,022618656 0,018373304 0,022618656
NR4A3 0,238701645 6,391050771 0,027671095 0,006023973 0,017806312 0,00384081 0,017806312
NR5A2 14,93647739 3,599706097 0,032770127 0,006807629 0,01011076 0,01585174 0,01585174
NRG1 0,117149781 3,944520793 0,034913935 0,014551393 0,007147504 0,013215038 0,014551393
NRL 0,001 0,856143472 0,040873673 0,004896084 0,030012292 0,005965297 0,030012292
NTF3 0,001 2,355433772 0,046850536 0,023985725 0,009189357 0,013675452 0,023985725
NTRK1 0,037434555 1,082099313 0,025776831 0,012622953 0,006113362 0,007040516 0,012622953
NUMB 1,856799246 2,936364249 0,024463698 0,006972192 0,011675021 0,005816485 0,011675021
NUP155 5,290005652 10,65871139 0,019336769 0,002457127 0,013584566 0,003295077 0,013584566
NXNL1 0,001 4,344629007 0,012692794 0,000786 0,010411536 0,00149526 0,010411536
OCA2 0,001 2,004478991 0,019317685 0,002907387 0,013630069 0,002780228 0,013630069
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Sum Brain Eye Heart Max
OLFM3 0,001 5,638382535 0,044368021 0,004928045 0,036399123 0,003040856 0,036399123
OLIG1 0,001 2,600853564 0,032094527 0,012320993 0,012265993 0,007507541 0,012320993
OLIG2 0,557215154 6,401674055 0,047951449 0,017439818 0,019830989 0,010680641 0,019830989
OPN3 0,001 3,914704221 0,023138495 0,001908903 0,019747189 0,001482404 0,019747189
OPTC 0,001 0,001 0,021771511 0,001355217 0,016346772 0,004069523 0,016346772
OPTN 7,478053422 8,676961721 0,024622945 0,003207808 0,018814484 0,002600653 0,018814484
ORAOV1 1,053110171 2,882716357 0,019127788 0,002292237 0,01343102 0,003404531 0,01343102
OSR1 0,266146292 3,733027177 0,022635961 0,002766791 0,006940863 0,012928307 0,012928307
OTX2 0,001 23,93195857 0,094262525 0,02878294 0,046866905 0,01861268 0,046866905
PAFAH1B3 9,116063963 22,16129442 0,02403738 0,021491927 0,001461668 0,001083786 0,021491927
PAH 507,7014651 42,56210369 0,01963564 0,011194037 0,004717222 0,003724381 0,011194037
PAX5 0,001 0,733615452 0,030613441 0,00688433 0,015810675 0,007918437 0,015810675
PAX8 0,001 3,292288362 0,038313802 0,010195236 0,015563558 0,012555008 0,015563558
PAX9 0,001 6,126981808 0,034347594 0,004990829 0,016932707 0,01242406 0,016932707
PAXIP1 1,782323531 8,179981453 0,016621273 0,002400834 0,010279773 0,003940665 0,010279773
PBRM1 1,230900385 8,884419937 0,016762489 0,001859647 0,002339449 0,012563395 0,012563395
PCDH21 0,182236597 8,113540291 0,029890001 0,001902653 0,006696494 0,021290853 0,021290853
PDLIM1 9,965596329 20,70394949 0,021480916 0,001911543 0,003013647 0,016555725 0,016555725
PDLIM2 26,68166231 16,99931986 0,028293736 0,001371684 0,004512483 0,02240957 0,02240957
PDX1 0,139635456 6,250570635 0,043724023 0,008593513 0,021540211 0,013590298 0,021540211
PENK 7,944316847 9,257787946 0,02355504 0,013393764 0,005311193 0,004850085 0,013393764
PHOX2B 0,001 10,92146759 0,025862986 0,006533439 0,008354096 0,010975452 0,010975452
PITX1 0,001 10,2876001 0,03411565 0,004622824 0,015136412 0,014356415 0,015136412
PITX2 0,001 9,860184943 0,07998991 0,007150433 0,039893058 0,032946416 0,039893058
PITX3 0,001 6,356020296 0,055921994 0,008077445 0,038269354 0,009575194 0,038269354
PLK2 3,43145351 11,74596059 0,017624861 0,003097519 0,011021727 0,003505614 0,011021727
PLK4 0,233810071 2,843917862 0,015597959 0,001931649 0,003265386 0,010400924 0,010400924
PLS3 40,68621325 35,06912035 0,018136524 0,002171563 0,002478261 0,013486701 0,013486701
POFUT1 5,693431882 6,347539421 0,026915599 0,003329966 0,011353225 0,012232407 0,012232407
POLA1 0,730106156 5,975395653 0,015918037 0,002500403 0,011458636 0,001958998 0,011458636
POSTN 1,856635792 214,1122089 0,031442791 0,003515699 0,005390816 0,022536277 0,022536277
POU1F1 0,001 0,150832831 0,02751256 0,005243496 0,0136757 0,008593363 0,0136757
POU3F1 0,001 24,80016068 0,024512034 0,011681798 0,006467603 0,006362633 0,011681798
POU3F2 0,001 23,30705718 0,027748229 0,007762995 0,011550419 0,008434814 0,011550419
POU4F2 0,001 15,91107889 0,027431095 0,005184559 0,015089367 0,00715717 0,015089367
POU5F1 0,001 0,111208138 0,059299685 0,012491451 0,015791289 0,031016944 0,031016944
PRDX5 37,48983175 93,13832513 0,024428666 0,016889743 0,004256174 0,003282748 0,016889743
PRICKLE2 0,914281671 7,02797009 0,028202863 0,008849234 0,008360162 0,010993468 0,010993468
PROX1 32,75766565 13,91109147 0,069144674 0,011860002 0,046077012 0,011207656 0,046077012
PSEN1 5,430928045 17,80768748 0,033355143 0,016851356 0,009233229 0,007270559 0,016851356
PSEN2 8,020869628 13,51203063 0,024744043 0,011876749 0,007399545 0,00546775 0,011876749
PTF1A 0,065271165 1,17458602 0,028809046 0,006380484 0,010549088 0,011879474 0,011879474
PTN 0,001 35,5017142 0,024999058 0,013048065 0,005045979 0,006905014 0,013048065
PTPN11 0,061475624 0,346087425 0,026504502 0,005995029 0,010757795 0,009751677 0,010757795
PUM1 12,75417588 39,544775 0,021061277 0,002710784 0,015820677 0,002529816 0,015820677
PURA 0,001 0,001 0,020694524 0,011592613 0,003620117 0,005481794 0,011592613
QRSL1 1,089904194 2,983494717 0,030455885 0,002176684 0,003682479 0,024596723 0,024596723





Sum Brain Eye Heart Max
RAB23 3,08124102 7,435013515 0,020173553 0,004147874 0,010645035 0,005380646 0,010645035
RBL1 1,028628259 4,080218423 0,024263646 0,005821131 0,010656111 0,007786404 0,010656111
RBM15 3,329692971 17,3997476 0,030828165 0,001661747 0,021236146 0,007930271 0,021236146
RCAN1 0,043503621 13,72848991 0,023239369 0,006044106 0,003098494 0,014096768 0,014096768
RCBTB1 1,062292223 5,515120587 0,026976412 0,004580154 0,00612142 0,016274839 0,016274839
RCN1 4,10902954 10,38872864 0,034977473 0,003663671 0,022615608 0,008698193 0,022615608
RELN 2,238880025 8,541471341 0,077823713 0,058193578 0,012041848 0,007588284 0,058193578
REST 4,139456395 4,137689017 0,03722759 0,008999273 0,018070311 0,010158006 0,018070311
RFX4 0,001 6,102626111 0,032660566 0,024928018 0,004694026 0,003038522 0,024928018
RGL2 2,359018848 2,999628095 0,015781119 0,001051815 0,0133751 0,001354204 0,0133751
RGMA 0,15932258 33,18677561 0,019796047 0,002367097 0,01256149 0,004867459 0,01256149
RGR 1,428584433 25,82418704 0,02499561 0,002294843 0,020307384 0,002393382 0,020307384
RHO 0,001 1047,52691 0,0262239 0,003989129 0,01889785 0,003336922 0,01889785
ROS1 0,694632567 2,411795481 0,031588215 0,003161279 0,023890754 0,004536182 0,023890754
RPL15 1412,099778 1342,087686 0,015105269 0,001421602 0,002895624 0,010788042 0,010788042
RRBP1 96,93814099 22,43625128 0,021628475 0,001230671 0,002968061 0,017429743 0,017429743
RRH 0,001 1,773128579 0,022913512 0,001262244 0,02002279 0,001628478 0,02002279
RS1 0,001 94,43785667 0,020335892 0,002999156 0,015278143 0,002058594 0,015278143
RTN4R 0,091304577 4,690212659 0,02097645 0,012425605 0,004693355 0,003857491 0,012425605
RUNX1 0,318536093 0,589877869 0,028094005 0,005240671 0,011965125 0,010888208 0,011965125
S100A1 0,001 1,271321824 0,02675426 0,009474046 0,003621861 0,013658353 0,013658353
S1PR1 1,633738998 37,37989561 0,027875559 0,006830073 0,004624784 0,016420702 0,016420702
S1PR2 1,038016607 6,251304975 0,022910045 0,005923903 0,002987187 0,013998956 0,013998956
SALL4 0,230608498 1,756664512 0,038861264 0,003949093 0,011175396 0,023736773 0,023736773
SATB2 0,276942668 4,199908065 0,031406388 0,007364576 0,018396017 0,005645794 0,018396017
SCRIB 10,22669764 16,59987184 0,020245533 0,003270928 0,006500852 0,010473754 0,010473754
SCUBE2 3,178426123 5,40696092 0,018664571 0,001745898 0,013360276 0,003558396 0,013360276
SEMA3C 0,467232552 3,86748743 0,033777244 0,006431435 0,013780337 0,013565473 0,013780337
SEMA3D 0,001 10,19122866 0,017649869 0,003135654 0,003600154 0,010914061 0,010914061
SEMA5A 0,153187667 12,77637655 0,037018549 0,009020081 0,016762271 0,011236198 0,016762271
SEMA6D 1,004676231 5,728200858 0,023202876 0,004513826 0,004171366 0,014517684 0,014517684
Sep-02 8,727769305 38,8715866 0,015958214 0,002463649 0,00182506 0,011669506 0,011669506
Sep-06 21,46827776 47,80612654 0,017653491 0,003518623 0,002076802 0,012058067 0,012058067
SF1 19,05672221 49,25518657 0,026885195 0,005911376 0,00809032 0,012883499 0,012883499
SFRP2 0,001 24,90187974 0,037814047 0,005078703 0,018820071 0,013915272 0,018820071
SFRP5 1,128184834 7,231419816 0,029741278 0,003656108 0,01105785 0,015027319 0,015027319
SFRS2 34,60406492 80,86499094 0,025862589 0,004167447 0,003757627 0,017937515 0,017937515
SFRS2IP 6,316398757 14,25617269 0,024176199 0,003310998 0,005537722 0,015327479 0,015327479
SHOX2 0,001 4,33424422 0,037456013 0,004567843 0,008233335 0,024654836 0,024654836
SIAH1 2,527028041 12,62700467 0,024883492 0,005402516 0,016134753 0,003346223 0,016134753
SIM2 0,001 0,282452037 0,022629229 0,01082384 0,006520514 0,005284875 0,01082384
SIP1 4,713807975 17,90121079 0,030403502 0,005208097 0,007333815 0,017861591 0,017861591
SLC1A2 0,172055774 241,5271847 0,025853058 0,016337583 0,005574121 0,003941353 0,016337583
SLC1A6 0,001 10,46189849 0,019518673 0,010772222 0,006076378 0,002670072 0,010772222
SLC26A5 14,98929245 11,22948514 0,019210577 0,003995389 0,011650956 0,003564232 0,011650956
SLC2A3 0,001 36,30970074 0,022996781 0,011153606 0,004986665 0,006856509 0,011153606
SLC32A1 0,001 50,17296399 0,020012105 0,010066601 0,006719578 0,003225925 0,010066601
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Sum Brain Eye Heart Max
SLC45A2 0,001 10,39871153 0,015211837 0,001385514 0,011841472 0,001984851 0,011841472
SLC8A3 0,001 2,133080683 0,023240611 0,005564627 0,002275715 0,015400268 0,015400268
SMAD1 3,194402753 11,49029548 0,04817846 0,005973095 0,019450217 0,022755147 0,022755147
SMAD2 3,781409926 12,28375512 0,031090442 0,006140311 0,009954046 0,014996086 0,014996086
SMAD5 6,383774208 11,06490054 0,040730748 0,004291857 0,017468861 0,018970029 0,018970029
SMAD7 5,847674514 10,21192594 0,02298218 0,00433423 0,00781447 0,01083348 0,01083348
SMAD9 2,330748508 4,565295856 0,032157689 0,004119986 0,013319974 0,014717731 0,014717731
SMARCA2 7,768984464 8,388147115 0,021933643 0,004976143 0,010066156 0,006891344 0,010066156
SMARCA5 2,897241825 28,1819187 0,02704465 0,005594725 0,016771124 0,004678802 0,016771124
SMARCC1 3,885395849 19,43207653 0,023223152 0,013116916 0,004503919 0,005602318 0,013116916
SMO 0,347805332 5,998736907 0,05328599 0,009916445 0,02856085 0,014808696 0,02856085
SNAI2 0,411716805 10,89893469 0,029230297 0,005917116 0,009823906 0,013489275 0,013489275
SORBS3 1,24368577 6,054329134 0,017407494 0,001472511 0,004362819 0,011572164 0,011572164
SOSTDC1 0,001 0,001 0,021549366 0,002809158 0,010143472 0,008596735 0,010143472
SOX2 0,037960559 40,24171434 0,076029941 0,011762438 0,039673298 0,024594208 0,039673298
SOX3 0,001 22,65939335 0,042719733 0,008054777 0,025788568 0,008876388 0,025788568
SOX5 6,032395148 17,42892397 0,024781005 0,004260216 0,01148247 0,009038319 0,01148247
SOX6 2,115175793 8,634271029 0,025990961 0,004851758 0,011345433 0,009793769 0,011345433
SOX7 0,173670959 7,055741389 0,036506724 0,002653695 0,006656682 0,027196346 0,027196346
SP1 4,863155092 6,988514653 0,038106542 0,011464289 0,01347939 0,013162864 0,01347939
SP3 1,339982609 2,965527186 0,029970556 0,009022091 0,009109033 0,011839432 0,011839432
SP4 1,508305026 10,00945883 0,025235513 0,006926743 0,004983618 0,013325153 0,013325153
SP7 1,088875956 1,366685927 0,025147876 0,004185982 0,009655778 0,011306116 0,011306116
SPARC 7,497442469 529,6407661 0,024571795 0,004231037 0,010364107 0,009976652 0,010364107
SPI1 2,394115247 2,134695372 0,025301853 0,005968076 0,009236389 0,010097389 0,010097389
SPRY1 0,593166866 6,556330739 0,025441699 0,004695326 0,008829241 0,011917131 0,011917131
SRF 2,058957854 3,945499817 0,057598684 0,005425971 0,008297033 0,043875681 0,043875681
SSR1 134,6232472 77,65727204 0,016846482 0,000935 0,001791314 0,014120314 0,014120314
ST8SIA2 0,001 0,605758643 0,037097566 0,025876889 0,006068415 0,005152261 0,025876889
ST8SIA3 0,085819484 1,114197534 0,016377861 0,01209308 0,002250302 0,002034479 0,01209308
ST8SIA4 0,394133768 2,733758396 0,031684294 0,022918701 0,004507717 0,004257877 0,022918701
STAR 0,001 4,56693969 0,020861112 0,005615819 0,004884723 0,010360571 0,010360571
STAT3 3,445328055 4,748615111 0,032978207 0,007975871 0,01195048 0,013051857 0,013051857
STAU2 30,77129316 108,643707 0,023395022 0,003652158 0,017166938 0,002575926 0,017166938
STRA6 0,054317628 11,37966192 0,031129818 0,003968036 0,019962034 0,007199748 0,019962034
STRN3 13,76889506 22,86182805 0,023178918 0,004553798 0,012979166 0,005645956 0,012979166
SUFU 5,143628754 10,04846901 0,029701259 0,004836745 0,017335427 0,007529085 0,017335427
SUMO3 10,43117861 37,87540994 0,017804723 0,002296445 0,00382483 0,011683448 0,011683448
TAL1 0,93478775 11,02413075 0,031043317 0,006428419 0,009792597 0,014822301 0,014822301
TAZ 13,53667548 15,19936429 0,0216686 0,00262303 0,013797378 0,005248191 0,013797378
TBP 3,599107253 10,64701691 0,027931949 0,005232677 0,012660854 0,010038417 0,012660854
TBX1 0,001 6,881548583 0,051753845 0,00899995 0,012006022 0,030747875 0,030747875
TBX15 0,051880452 7,665850066 0,028938714 0,002727619 0,008082073 0,018129022 0,018129022
TBX18 0,034162367 2,23393616 0,051387899 0,003048582 0,012655642 0,035683673 0,035683673
TBX20 0,001 1,74161118 0,085233591 0,003792624 0,013351319 0,068089651 0,068089651
TBX4 0,001 1,140360811 0,052892078 0,003972127 0,014202544 0,034717405 0,034717405
TBX5 0,001 0,687391589 0,11584647 0,005487368 0,027726691 0,08263241 0,08263241





Sum Brain Eye Heart Max
TBX6 0,001 0,58596379 0,040322423 0,005429581 0,013598496 0,021294348 0,021294348
TCF21 1,084782349 0,495744342 0,0236059 0,003050771 0,008428642 0,012126487 0,012126487
TEF 14,44398893 129,9691718 0,025440948 0,006714763 0,005854281 0,012871905 0,012871905
TFAP2A 0,001 39,6120371 0,033082996 0,005058646 0,017382235 0,010642115 0,017382235
TFDP2 0,588786039 10,78982381 0,026963552 0,005000449 0,014982353 0,006980751 0,014982353
TFEC 0,54340143 1,053321681 0,01697777 0,0012284 0,013340035 0,002409335 0,013340035
TGFB3 2,913512847 23,69910341 0,022951346 0,005148163 0,006766232 0,011036951 0,011036951
TGFBR2 4,30011566 12,85094577 0,022036517 0,004570047 0,006364066 0,011102405 0,011102405
TGIF1 1,623360955 15,82300163 0,045431446 0,011387736 0,027106441 0,00693727 0,027106441
THRB 6,744940035 10,09017565 0,02945058 0,014958903 0,006260844 0,008230833 0,014958903
TLL1 0,183353651 1,268579925 0,033280242 0,004300124 0,007508491 0,021471625 0,021471625
TLX1 0,035549727 0,35586723 0,035822429 0,004822973 0,014557193 0,016442262 0,016442262
TNC 0,177467401 25,53137032 0,028940432 0,00973233 0,006459798 0,012748304 0,012748304
TNNC1 0,001 5,181196031 0,032461237 0,003756149 0,003321753 0,025383335 0,025383335
TNR 0,60820812 7,446018094 0,021560866 0,010834058 0,004445893 0,006280916 0,010834058
TRH 0,044392114 8,271010384 0,021743553 0,011614918 0,005103466 0,005025167 0,011614918
TRIM71 1,462774004 7,091027754 0,02620095 0,004451265 0,016670834 0,005078851 0,016670834
TSC2 5,298525091 12,20748343 0,022531915 0,013361098 0,005085997 0,00408482 0,013361098
TSC22D1 3,025131377 101,2552853 0,023430377 0,00947229 0,010750663 0,003207423 0,010750663
TSHZ1 1,425642173 13,80279004 0,017668152 0,0030529 0,01043788 0,004177372 0,01043788
TYR 0,001 9,869129137 0,027361494 0,005284308 0,016928488 0,005148698 0,016928488
UBE3A 5,14766264 13,12516435 0,021492414 0,012029309 0,004860605 0,004602499 0,012029309
UBE3C 2,489172886 7,371468954 0,022779178 0,002301598 0,00382996 0,01664762 0,01664762
UNCX 0,084755772 6,070700188 0,019503018 0,003104448 0,005904962 0,010493608 0,010493608
UTP6 3,903721448 11,84939882 0,022339279 0,001997804 0,00130654 0,019034935 0,019034935
VANGL1 0,92226061 12,72827737 0,028685778 0,007055359 0,010003632 0,011626787 0,011626787
VAX1 0,001 5,181228213 0,079889186 0,007381369 0,059493494 0,013014324 0,059493494
VAX2 0,001 1,139340336 0,090695895 0,004744419 0,068345736 0,017605737 0,068345736
VIM 0,21470073 64,53292452 0,032025564 0,011715782 0,009033917 0,011275866 0,011715782
VLDLR 4,505635922 22,57418871 0,034854352 0,027235883 0,00381426 0,003804211 0,027235883
VPS35 10,75184581 33,54539121 0,021668181 0,001944739 0,016459442 0,003264 0,016459442
VRK1 0,253644877 2,480634771 0,016240073 0,001905882 0,003362578 0,010971613 0,010971613
VSX1 0,099340643 30,97668351 0,02356755 0,003490475 0,016217204 0,00385987 0,016217204
VSX2 0,001 7,527211602 0,076123282 0,008164224 0,058703932 0,009255126 0,058703932
WDR5 4,044860306 22,84207463 0,035008095 0,003371911 0,013529398 0,018106788 0,018106788
WIF1 1,523094039 14,13239473 0,027539851 0,004881425 0,012150585 0,010507841 0,012150585
WNT1 0,139012655 2,127333835 0,061392847 0,014224196 0,02676771 0,02040094 0,02676771
WNT10A 0,001 0,546100783 0,040485099 0,005235283 0,017352946 0,01789687 0,01789687
WNT10B 0,155328284 0,705505338 0,035224374 0,005550469 0,015795552 0,013878355 0,015795552
WNT11 0,001 0,576577337 0,070253387 0,00585135 0,021113247 0,04328879 0,04328879
WNT16 0,001 2,964726318 0,039581712 0,004942751 0,019186898 0,015452062 0,019186898
WNT3 0,001 1,002739496 0,049606014 0,007756128 0,019855111 0,021994776 0,021994776
WNT5A 0,001 0,664529189 0,053680688 0,007518694 0,024657597 0,021504396 0,024657597
WNT5B 1,420832097 6,685050361 0,053338371 0,006776334 0,025162138 0,021399901 0,025162138
WNT7A 0,001 8,515785713 0,045386795 0,007780789 0,019393143 0,018212861 0,019393143
WNT8A 0,046716692 0,105347864 0,04474207 0,005800274 0,01690616 0,022035637 0,022035637
WNT8B 0,001 1,278948113 0,045234382 0,007471677 0,021581803 0,016180902 0,021581803
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Sum Brain Eye Heart Max
WNT9B 0,001 1,751351269 0,041080143 0,005060593 0,019500227 0,016519322 0,019500227
WRB 0,160509953 0,820179494 0,02851413 0,00117694 0,003353637 0,023983553 0,023983553
WWTR1 4,989699404 6,757915227 0,019648496 0,0022222 0,005325384 0,012100912 0,012100912
XRCC5 2,220057407 5,065974978 0,024417987 0,005441897 0,008787648 0,010188441 0,010188441
ZEB1 1,914216382 7,031041044 0,0293293 0,004879171 0,008001665 0,016448463 0,016448463
ZFPM1 2,914772039 2,836054324 0,045669008 0,003030051 0,011592472 0,031046486 0,031046486
ZIC1 0,001 31,34187397 0,029825179 0,011749265 0,009523488 0,008552426 0,011749265
ZIC3 0,001 20,73239204 0,028039221 0,006010002 0,007350128 0,01467909 0,01467909
Supplementary Table 5



































































TranscriptID ZFE_GeneID Mouse_GeneID ZFE_CsA_C1 ZFE_CsA_C2 ZFE_CsA_C3 ZFE_CsA_C4 ZFE_CsA_C5 aZFL CsA_01_C_1 CsA_02_C_1 CsA_03_C_1 CsA_04_C_1 CsA_05_C_1 CsA_06_L_1 CsA_07_L_1 CsA_08_L_1 CsA_09_L_1 CsA_11_M_1 CsA_12_M_1 CsA_13_M_1 CsA_14_M_1 CsA_15_M_1 CsA_16_H_1 CsA_17_H_1 CsA_18_H_1 CsA_19_H_1 CsA_20_H_1 CsA_21_C_4 CsA_22_C_4 CsA_23_C_4 CsA_24_C_4 CsA_25_C_4 CsA_26_L_4 CsA_27_L_4 CsA_28_L_4 CsA_29_L_4 CsA_30_L_4 CsA_31_M_4 CsA_32_M_4 CsA_33_M_4 CsA_34_M_4 CsA_36_H_4 CsA_37_H_4 CsA_38_H_4 CsA_39_H_4 CsA_40_H_4 CsA_41_C_11 CsA_42_C_11 CsA_43_C_11 CsA_44_C_11 CsA_45_C_11 CsA_46_L_11 CsA_47_L_11 CsA_48_L_11 CsA_49_L_11 CsA_50_L_11 CsA_51_M_11 CsA_52_M_11 CsA_53_M_11 CsA_54_M_11 CsA_55_M_11 CsA_56_H_11 CsA_57_H_11 CsA_58_H_11 CsA_59_H_11 CsA_60_H_11
13003871 30144 22423 -0,202392 -0,493617 -0,273244 -0,441142 -0,549005 -0,2591235 0,05785765 -0,070105384 -0,02482802 -0,058569144 0,0956449 -0,11211123 -0,204823182 0,226364881 -0,243634359 -0,161159569 -0,124452085 -0,324 0,526 0,015 -0,104 -0,230 -0,103 -0,186 -0,067 -0,259 0,141 0,070 0,045 0,003 0,116 0,032 0,062 0,041 0,008 0,096 -0,026 0,116 -0,119 -0,002 0,181 0,127 0,091 -0,025 -0,196 -0,172 0,006 0,136 0,226 0,084 -0,205 -0,057 0,116 -0,181 -0,014 -0,075 0,299 0,068 -0,046 0,070 -0,011 0,124 0,137 -0,023
13110453 81583 54419 0,487805 0,404225 0,333043 0,481648 0,5112 0,5093255 0,097709111 0,08557761 -0,257492765 -0,02452872 0,098734765 -0,072154986 -0,084545279 0,014350783 0,164960844 -0,176130954 0,185512104 -0,107 -0,038 0,030 -0,210 0,089 -0,075 -0,217 0,185 -0,101 0,289 0,057 0,075 -0,320 -0,001 -0,074 -0,219 -0,147 -0,198 0,053 -0,159 0,102 0,033 0,052 0,031 0,079 -0,015 -0,119 0,134 -0,177 0,016 -0,136 0,163 0,026 0,165 -0,081 0,145 -0,180 0,184 -0,080 0,185 -0,017 0,285 -0,008 -0,077 0,309 -0,110 -0,083
13305252 335494 71665 0,442363 0,752296 0,490159 0,698706 0,629938 -0,5890005 -0,04894975 -0,135289724 0,096880546 0,028683856 0,058675074 0,137923491 0,0331383 -0,006888815 0,10290374 0,09102672 0,058386681 0,143 0,317 -0,118 0,070 0,048 0,104 -0,098 -0,021 0,187 -0,117 -0,046 -0,006 -0,018 0,040 -0,029 -0,108 -0,202 0,067 -0,060 0,103 0,128 0,131 -0,004 -0,068 -0,171 -0,069 0,054 -0,028 0,122 -0,107 -0,028 0,041 -0,091 -0,084 0,007 0,099 -0,057 0,107 0,075 -0,107 0,095 -0,013 0,051 0,094 -0,032 0,168 0,068
13283206 378479 14964 -0,885064 -2,230631 -1,254029 -0,868238 -2,064966 1,621455 0,049809716 -0,067085749 0,047055869 -0,077510196 0,047730364 -0,007823771 -0,076723975 -0,080796104 -0,041924024 -0,093989402 -0,03999117 0,077 -0,053 -0,046 -0,062 -0,025 0,083 -0,026 -0,022 -0,071 0,021 -0,072 0,109 0,013 0,076 0,126 0,224 0,076 0,069 0,061 0,046 0,033 -0,003 0,059 0,014 -0,095 0,032 0,015 -0,088 0,179 0,115 -0,096 -0,111 0,004 -0,096 -0,165 -0,225 -0,190 -0,174 -0,202 -0,243 -0,115 -0,121 -0,194 0,008 -0,134 0,207 -0,227
13284362 378479 14964 -0,885064 -2,230631 -1,254029 -0,868238 -2,064966 1,621455 0,049809716 -0,067085749 0,047055869 -0,077510196 0,047730364 -0,007823771 -0,076723975 -0,080796104 -0,041924024 -0,093989402 -0,03999117 0,077 -0,053 -0,046 -0,062 -0,025 0,083 -0,026 -0,022 -0,071 0,021 -0,072 0,109 0,013 0,076 0,126 0,224 0,076 0,069 0,061 0,046 0,033 -0,003 0,059 0,014 -0,095 0,032 0,015 -0,088 0,179 0,115 -0,096 -0,111 0,004 -0,096 -0,165 -0,225 -0,190 -0,174 -0,202 -0,243 -0,115 -0,121 -0,194 0,008 -0,134 0,207 -0,227
13131516 393530 53311 0,277255 0,90484 0,318033 0,60422 0,46505 0,1722305 0,133226438 -0,110572775 -0,065327684 -0,015469041 0,05814306 0,36726267 0,150882345 0,071098812 -0,010114565 -0,205090277 -0,321149351 -0,189 -0,031 0,072 -0,236 -0,252 0,417 0,119 -0,195 0,336 0,285 -0,206 -0,185 -0,230 0,388 -0,062 0,203 0,259 0,150 0,234 0,057 0,026 0,340 -0,233 0,072 -0,249 0,073 -0,008 0,074 -0,046 -0,238 0,039 0,172 -0,036 0,457 -0,039 -0,030 0,135 -0,130 0,215 -0,037 0,255 0,224 0,048 0,438 -0,276 0,001 -0,121
13113617 474325 13178 -0,769185 -0,647585 -0,584364 -0,427937 -0,211119 -0,8417785 0,006415477 0,213422855 -0,18143595 -0,027181145 -0,011221234 -0,029985388 0,155250114 -0,006269627 0,095971617 -0,143079255 0,111932904 -0,014 -0,131 0,167 0,029 -0,102 0,279 -0,003 0,053 0,008 -0,118 0,156 0,134 -0,180 0,014 -0,066 0,139 -0,053 0,024 0,051 -0,168 -0,276 0,165 0,066 0,126 -0,065 0,096 -0,137 -0,046 0,319 0,156 -0,244 -0,186 -0,389 -0,024 -0,400 -0,374 -0,276 -0,189 -0,339 -0,152 -0,435 -0,207 -0,149 -0,138 -0,133 -0,427 -0,179
13079367 492774 170823 -0,545197 -0,554926 -0,560557 -0,322014 -0,227127 -0,1797875 -0,343282882 0,268232408 -0,070971749 0,060530668 0,085491555 -0,15581164 0,307495422 0,012041558 0,075822933 0,068981869 0,064959225 0,486 -0,438 -0,010 0,096 -0,038 0,129 0,126 -0,082 0,248 -0,185 0,106 -0,125 -0,044 0,289 -0,258 -0,205 0,168 0,107 0,176 -0,178 0,018 -0,035 -0,067 0,027 -0,356 -0,105 -0,122 -0,117 -0,031 0,231 -0,122 0,038 -0,202 -0,141 -0,025 0,127 0,090 -0,135 -0,148 -0,270 -0,055 -0,149 0,093 0,054 -0,098 0,066 -0,114
13152298 494036 68016 0,519397 0,630466 0,266743 0,47097 0,371837 0,042008 0,021765976 -0,104013536 0,155591137 -0,132758499 0,059414922 0,125169028 -0,067554712 0,107473727 0,063286819 0,063424844 -0,008199632 0,033 0,094 0,144 -0,058 -0,203 0,052 0,186 -0,025 -0,011 0,067 -0,129 0,232 -0,159 0,016 -0,112 0,141 0,132 0,208 0,021 0,016 -0,067 -0,170 -0,043 0,117 0,015 -0,227 -0,111 -0,056 0,068 0,064 -0,085 0,009 -0,024 -0,107 -0,068 -0,055 0,153 -0,082 0,121 0,109 -0,072 0,057 0,001 0,034 0,006 0,060 0,124
13283630 541319 12925 0,302382 0,227114 0,422399 0,675729 0,47825 -0,566397 0,158298699 -0,055555703 -0,131418506 0,057179309 -0,028503798 0,1334611 0,150253636 -0,01797534 0,053101131 0,220579812 0,278965952 0,408 0,311 0,333 0,331 0,480 0,267 0,045 0,308 -0,216 -0,135 0,377 -0,096 0,070 -0,012 0,210 0,118 0,109 -0,123 -0,254 0,223 -0,007 -0,162 -0,035 0,179 0,078 0,120 0,082 -0,216 0,042 0,423 -0,025 -0,224 -0,041 -0,387 -0,211 -0,129 0,095 0,037 -0,282 0,017 0,029 -0,425 -0,251 -0,083 -0,050 0,163 -0,071
12964078 550569 59310 0,5278415 0,5549205 0,3810315 0,5798515 0,4631605 0,2599035 -0,076866388 0,023078722 0,00464142 0,027506075 0,021640172 0,166621496 0,026009635 0,054300439 0,124728591 0,062610762 -0,08368925 0,429 -0,020 -0,192 -0,115 0,038 0,208 -0,045 0,080 -0,004 -0,138 -0,006 0,125 0,024 -0,301 0,161 -0,080 0,139 -0,071 0,220 0,068 0,294 0,056 0,037 0,097 0,036 -0,026 0,018 -0,119 -0,013 0,140 -0,118 0,110 -0,126 -0,045 0,368 0,095 0,121 0,054 -0,249 0,069 -0,063 0,139 -0,002 0,348 -0,114 -0,045 0,087
13081404 553336 216152 -0,542924 -0,253451 -0,222699 -0,496319 -0,542862 0,218988 0,143722456 -0,159833206 0,178925696 -0,160208258 -0,002606686 0,074255895 -0,241782959 -0,053825948 -0,573462787 -0,201999448 -0,286741647 0,168 0,306 0,050 -0,167 -0,316 -0,056 -0,264 0,059 -0,099 0,052 -0,032 0,038 0,040 0,055 -0,163 -0,097 0,063 -0,009 0,270 0,033 0,266 0,094 0,277 0,070 0,714 0,069 0,082 -0,228 -0,295 -0,222 0,595 0,152 0,281 -0,072 -0,129 0,197 -0,386 -0,469 -0,427 -0,060 -0,016 -0,100 -0,074 -0,055 -0,027 -0,172 -0,459
13094209 553543 13116 0,651351 0,475638 0,46391 0,277795 0,512897 -0,089556 -0,090739756 0,256577711 -0,076123095 0,07851136 -0,168226218 -0,093847028 -0,052872915 0,161554135 0,145364621 0,27893755 0,397020063 -0,036 0,026 0,222 0,172 0,335 -0,020 0,281 0,129 0,114 -0,095 -0,059 0,024 0,016 -0,196 -0,267 -0,251 0,028 -0,164 -0,001 -0,053 0,155 -0,227 0,140 0,086 -0,473 0,167 -0,232 0,077 -0,025 -0,275 -0,097 0,319 0,114 0,080 -0,132 0,191 0,243 -0,114 0,184 0,670 0,279 0,172 0,365 0,276 0,104 0,415 0,601
13054773 554103 12866 0,114273 0,555591 0,593705 0,565034 0,4568 0,2138275 0,093935222 0,061228918 -0,083962775 -0,014613019 -0,056588344 -0,01969527 0,03913283 -0,016484962 -0,005032954 -0,000608767 -0,055950227 0,007 0,006 0,043 0,051 -0,026 0,043 -0,061 -0,013 0,014 0,007 0,006 -0,006 -0,021 0,003 0,008 -0,039 -0,051 -0,000 -0,021 -0,042 -0,099 0,057 -0,012 -0,001 0,063 0,075 0,001 0,037 -0,102 0,061 0,064 -0,059 0,038 0,051 0,033 -0,046 0,082 0,029 -0,002 0,011 0,009 0,003 0,050 0,018 0,002 -0,025 0,079
13065823 560115 16949 0,3747515 0,5145025 0,2590325 0,7679475 0,6953505 0,612996 -0,10974215 0,000151601 0,104562581 0,040953897 -0,03592593 0,393897824 0,13269258 0,189655728 0,178145359 0,036719525 0,095163394 0,021 -0,137 0,093 0,116 0,133 -0,348 0,194 -0,347 0,282 -0,080 0,141 -0,276 -0,067 -0,141 0,317 0,015 0,358 -0,129 -0,057 0,380 -0,241 -0,080 -0,233 0,169 -0,359 -0,032 0,089 0,146 0,073 0,006 -0,162 -0,062 0,102 0,432 0,013 -0,077 0,288 -0,271 -0,208 0,057 -0,202 -0,047 -0,030 0,112 -0,137 0,268 0,098
13234461 561287 74145 -0,716307 -0,486624 -0,716973 -0,390164 -0,462106 -0,0347705 0,088718511 0,054273573 0,06937364 -0,156973604 -0,055392123 0,025583168 0,213170478 -0,002428126 0,105550504 0,117710344 -0,113731088 0,036 -0,033 0,410 0,076 0,122 -0,374 0,045 -0,230 0,095 0,222 -0,041 -0,228 -0,049 0,121 0,156 -0,142 0,212 -0,072 -0,110 -0,050 -0,108 0,126 0,066 0,019 -0,025 -0,266 0,386 0,041 0,026 0,190 -0,103 -0,154 -0,175 0,404 0,052 -0,144 0,034 -0,206 -0,014 -0,246 -0,284 0,390 -0,126 0,153 -0,142 -0,098 0,205
12956364 564383 242022 0,637787 0,846888 0,966453 0,940433 1,008885 -0,2860905 -0,180045345 0,035064788 -0,033463053 -0,027508924 0,205952534 -0,013494376 0,041260754 0,103369928 0,167292988 -0,034436963 0,074865097 0,146 -0,115 -0,124 0,046 0,051 -0,212 -0,088 0,166 -0,105 -0,092 0,126 0,048 0,023 0,058 0,133 0,099 -0,158 -0,050 0,029 -0,127 -0,186 -0,048 -0,114 -0,116 0,129 0,071 -0,161 0,118 -0,027 -0,000 -0,089 -0,001 0,145 0,025 -0,007 0,176 0,204 0,226 0,132 0,412 0,045 0,243 0,103 0,263 -0,044 -0,140 0,136
13034897 571184 211482 -0,4095035 -0,6042265 -0,5993245 -0,4424615 -0,5817115 0,416319 0,080248436 -0,11758983 0,139712736 -0,213206384 0,110835045 -0,092359177 -0,09099233 0,019104596 -0,152705464 -0,131350561 0,212793186 -0,075 -0,034 -0,127 0,059 -0,100 -0,141 0,002 -0,051 0,040 0,109 -0,048 -0,034 -0,067 -0,037 0,068 0,104 0,013 -0,068 -0,001 0,178 -0,030 -0,286 0,061 0,061 -0,101 -0,176 0,111 -0,130 -0,058 -0,214 0,097 0,306 -0,071 -0,139 0,015 -0,031 -0,004 -0,201 0,060 -0,195 -0,029 -0,201 -0,130 -0,250 -0,183 -0,018 -0,067
13278988 572183 18679 0,695956 0,791756 0,412596 1,072473 0,74914 0,5758485 -0,162442578 -0,365774945 -0,041421461 0,130750238 0,438888743 -0,129190989 -0,029980187 0,098469188 0,136730984 0,097130934 0,126341895 -0,208 -0,651 0,175 0,195 0,162 0,021 0,308 0,038 0,193 0,162 0,066 -0,118 -0,303 -0,280 0,014 0,069 -0,956 -0,090 0,086 -0,182 -0,423 -0,389 -0,237 0,234 -0,241 0,344 -0,104 -0,120 0,254 -0,034 0,003 -0,103 -0,073 -0,122 -0,591 -0,360 -0,286 -0,227 0,110 -0,072 -0,596 -0,073 0,291 -0,018 0,280 -0,385 0,223
13200912 791610 14080 0,3503155 0,1684505 0,4078565 0,4850535 0,6159035 -0,24775 0,112201991 0,123962595 -0,056796215 -0,013352734 -0,166015639 0,123997812 -0,067713854 0,068349878 0,062001673 0,036622376 -0,05518621 -0,026 0,034 0,142 0,131 0,032 -0,067 -0,013 -0,008 -0,058 0,124 -0,046 0,073 -0,094 0,148 0,070 -0,001 0,093 0,062 0,177 -0,080 0,024 0,084 0,080 0,037 0,223 0,178 0,217 0,191 -0,148 -0,128 0,008 0,077 0,083 0,119 0,087 0,128 0,064 0,050 0,106 0,082 0,033 0,069 0,252 -0,016 -0,003 -0,012 0,248
13036819 100000322 64177 0,606221 1,709899 0,866182 0,897898 1,1636 0,0754655 0,00800186 -0,113134733 -0,088581121 0,206396816 -0,012682824 0,378908977 0,001649315 -0,019161991 0,015930079 -0,067503353 -0,159106499 0,122 0,525 -0,343 0,039 -0,149 -0,058 -0,058 0,136 -0,074 -0,018 -0,014 0,281 -0,176 0,022 0,129 0,322 -0,028 -0,019 -0,028 0,142 0,012 -0,172 0,382 0,160 0,359 -0,006 -0,139 -0,006 -0,038 -0,084 -0,087 0,214 0,055 -0,005 0,132 -0,049 -0,222 0,205 -0,017 -0,105 0,224 0,023 0,126 0,230 -0,297 0,117 -0,078
13166102 100073335 104582 -0,728183 -0,30249 -0,556249 -0,390703 -0,676573 0,145974 0,199352026 -0,135980628 -0,036530967 -0,012591086 -0,014249347 0,000851151 -0,278886106 -0,287220766 0,024982295 -0,007552102 0,314738212 -0,221 0,045 -0,059 -0,269 0,017 -0,374 -0,209 0,285 0,136 -0,067 -0,055 0,019 -0,033 -0,067 -0,203 0,211 -0,102 -0,261 0,056 -0,005 0,075 -0,251 -0,103 -0,027 -0,127 -0,200 0,164 -0,285 0,137 -0,099 0,022 0,225 0,060 0,048 0,193 0,252 -0,173 -0,083 0,096 0,201 0,077 0,047 -0,050 -0,010 0,010 0,160 -0,093
13153157 100124599 140781 0,472492 0,868807 0,551368 0,84333 0,705466 0,511235 -0,003978496 -0,090197946 0,047347165 -0,048554405 0,09538368 0,223690476 0,309768815 0,05984867 0,028800351 0,039573917 -0,027257332 0,240 -0,039 -0,137 0,097 0,203 0,288 0,763 -0,136 0,135 -0,055 0,125 -0,103 -0,102 -0,215 0,071 0,039 0,135 -0,178 0,109 -0,097 -0,240 -0,034 -0,329 -0,012 0,296 -0,158 -0,034 0,259 -0,051 0,099 -0,358 0,051 0,377 0,343 -0,114 -0,087 0,295 0,269 0,226 0,105 0,033 0,209 0,030 0,441 0,166 -0,036 0,112
12992494 335859 14104 -0,362356 -0,386481 -0,245179 -0,432966 -0,797939 -0,762153 -0,155701714 0,632349574 -0,187089602 -0,331663222 0,042104964 0,41527505 0,002420435 0,427500973 -0,136222067 0,434612428 0,359951077 0,454 -0,676 0,408 0,601 0,718 1,449 -0,360 1,072 -0,026 -0,386 1,107 0,396 -1,090 -1,312 -1,277 -1,235 -0,896 -1,486 -0,268 -0,702 -0,973 -1,057 0,105 0,198 -1,022 0,439 -1,497 -0,247 -0,287 -0,792 1,019 0,307 0,535 -0,074 -0,228 0,631 -0,004 -0,166 -0,042 1,279 0,352 -0,106 -0,692 -0,569 0,514 0,789 -0,040
13176029 378721 14904 -1,735606 -1,550183 -0,983129 -1,081322 -1,488407 -0,207051 0,28558547 -0,154642735 -0,103740343 0,050854572 -0,078056962 -0,069946453 -0,179598063 -0,225703554 -0,085705375 -0,112211797 -0,097590947 -0,162 0,311 -0,098 -0,166 -0,074 -0,063 -0,101 -0,315 -0,091 -0,239 -0,027 0,026 0,331 0,011 0,025 -0,112 -0,055 -0,075 -0,170 -0,062 0,109 -0,143 -0,081 -0,078 -0,012 -0,048 0,017 -0,082 0,045 -0,226 0,163 0,100 -0,091 0,004 -0,028 0,007 -0,016 -0,072 0,062 -0,122 0,115 0,194 -0,150 -0,046 0,134 0,040 0,029
13223058 568527 16979 0,3188675 0,3381485 0,5973935 0,6809075 0,2986065 0,451721 -0,107922143 -0,206606119 0,042578086 0,072956347 0,198993827 0,251892772 0,032754733 -0,041763045 -0,010725167 0,146046759 -0,045752585 0,291 0,140 -0,145 -0,190 0,223 -0,002 0,209 0,016 -0,073 0,172 -0,041 -0,048 -0,010 0,174 0,296 -0,056 -0,212 0,054 -0,067 -0,046 0,111 -0,031 0,084 -0,301 -0,192 -0,051 -0,033 -0,066 0,100 -0,051 -0,039 0,057 0,054 0,031 0,041 0,210 -0,026 -0,028 0,083 0,027 -0,039 0,212 0,103 0,000 0,062 -0,106 -0,102
13048660 692064 18222 -0,4332075 -0,4268095 -0,5583265 -0,6322795 -0,9201365 0,188312 -0,070668404 0,01639467 -0,137190833 0,151170106 0,040294462 0,001622771 0,137008951 -0,030055983 0,057825435 0,215391278 0,081224135 0,051 0,062 0,277 0,032 -0,025 -0,014 0,134 0,601 0,104 -0,154 0,171 -0,230 0,110 -0,055 0,273 -0,074 -0,049 0,090 0,014 -0,072 0,289 0,017 0,046 0,028 0,070 0,350 -0,056 0,165 0,129 -0,105 -0,015 -0,174 0,089 0,031 -0,293 0,180 -0,045 0,052 -0,285 0,150 0,137 0,040 -0,138 -0,225 0,129 0,206 0,026
13109885 445250 50877 0,248273 0,802071 0,406888 0,76368 0,56946 -0,161587 0,015963268 0,171750559 -0,149673178 0,017744907 -0,055785553 -0,193409926 -0,183691322 0,072051957 0,001443024 0,043333052 -0,082686564 0,049 -0,031 -0,014 0,149 -0,092 -0,051 -0,278 -0,072 -0,084 0,032 0,316 -0,038 -0,225 -0,084 -0,034 -0,249 -0,146 -0,106 -0,111 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 555206 50877 0,248273 0,802071 0,406888 0,76368 0,56946 -0,161587 0,015963268 0,171750559 -0,149673178 0,017744907 -0,055785553 -0,193409926 -0,183691322 0,072051957 0,001443024 0,043333052 -0,082686564 0,049 -0,031 -0,014 0,149 -0,092 -0,051 -0,278 -0,072 -0,084 0,032 0,316 -0,038 -0,225 -0,084 -0,034 -0,249 -0,146 -0,106 -0,111 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 780844 50877 0,248273 0,802071 0,406888 0,76368 0,56946 -0,161587 0,015963268 0,171750559 -0,149673178 0,017744907 -0,055785553 -0,193409926 -0,183691322 0,072051957 0,001443024 0,043333052 -0,082686564 0,049 -0,031 -0,014 0,149 -0,092 -0,051 -0,278 -0,072 -0,084 0,032 0,316 -0,038 -0,225 -0,084 -0,034 -0,249 -0,146 -0,106 -0,111 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 793046 50877 0,248273 0,802071 0,406888 0,76368 0,56946 -0,161587 0,015963268 0,171750559 -0,149673178 0,017744907 -0,055785553 -0,193409926 -0,183691322 0,072051957 0,001443024 0,043333052 -0,082686564 0,049 -0,031 -0,014 0,149 -0,092 -0,051 -0,278 -0,072 -0,084 0,032 0,316 -0,038 -0,225 -0,084 -0,034 -0,249 -0,146 -0,106 -0,111 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 100000684 50877 0,248273 0,802071 0,406888 0,76368 0,56946 -0,161587 0,015963268 0,171750559 -0,149673178 0,017744907 -0,055785553 -0,193409926 -0,183691322 0,072051957 0,001443024 0,043333052 -0,082686564 0,049 -0,031 -0,014 0,149 -0,092 -0,051 -0,278 -0,072 -0,084 0,032 0,316 -0,038 -0,225 -0,084 -0,034 -0,249 -0,146 -0,106 -0,111 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13176029 336812 65019 -1,735606 -1,550183 -0,983129 -1,081322 -1,488407 -0,207051 0,185409436 0,004815352 -0,115888967 -0,014999102 -0,059336721 0,087282394 0,065256562 0,149181891 0,192255059 -0,021108689 -0,180489467 -0,120 0,065 0,013 -0,116 0,046 0,196 -0,240 -0,131 0,058 0,128 -0,192 0,040 -0,034 0,055 0,083 0,049 -0,082 0,206 0,320 -0,053 -0,023 0,252 0,157 0,025 -0,002 -0,202 0,071 -0,113 0,016 0,124 -0,043 0,015 0,215 0,070 0,083 0,098 -0,227 -0,098 -0,009 -0,184 -0,037 -0,074 0,204 -0,049 -0,090 0,060 0,099
13071605 100329433 67469 0,249227 0,525937 0,471702 0,692404 0,333244 -0,1663795 0,464090666 -0,209510726 -0,113299373 -0,189302122 0,048021556 -0,063462165 -0,206707265 -0,292406594 -0,027325752 0,144966046 -0,031522546 0,052 0,126 0,017 -0,020 0,148 -0,222 0,315 -0,006 -0,008 0,152 -0,064 0,171 -0,251 -0,030 0,349 0,155 -0,164 -0,028 -0,220 -0,032 -0,286 0,151 0,076 0,030 0,422 0,119 0,264 0,044 0,088 -0,005 -0,026 -0,101 0,021 0,352 0,038 0,020 0,207 0,053 0,110 -0,161 -0,019 -0,228 0,159 0,008 -0,040 -0,202 -0,158
13223058 415249 70047 0,3188675 0,3381485 0,5973935 0,6809075 0,2986065 0,451721 0,055943212 0,183071305 0,183309912 -0,184552983 -0,23777145 -0,036974576 0,132478092 -0,083765087 -0,006137339 0,045032576 0,007532754 0,130 -0,541 -0,190 -0,020 -0,006 -0,050 -0,381 -0,116 -0,054 -0,091 0,042 0,105 -0,002 -0,198 -0,097 0,116 -0,477 0,024 -0,057 -0,111 -0,156 -0,266 -0,094 0,013 -0,201 -0,441 -0,200 -0,014 0,141 -0,022 0,053 -0,157 0,017 0,106 -0,080 -0,225 0,195 0,349 -0,105 0,189 0,072 -0,005 0,315 -0,425 -0,033 0,095 -0,066
13071605 791138 72415 0,249227 0,525937 0,471702 0,692404 0,333244 -0,1663795 -0,087878505 0,047875138 -0,000156118 0,015546277 0,024613207 0,925317376 -0,116905208 -0,243395965 -0,05272336 -0,041977181 -0,258775052 0,639 0,336 -0,187 0,013 0,051 -0,154 -0,056 -0,113 -0,135 0,166 0,271 -0,316 0,013 -0,071 0,318 0,574 0,310 0,247 0,176 0,232 0,046 -0,092 0,186 -0,142 0,053 0,011 -0,005 -0,020 -0,009 0,219 -0,001 -0,188 -0,232 -0,024 0,022 -0,073 0,154 0,020 0,280 0,123 -0,002 -0,108 0,154 -0,013 0,201 0,234 0,137
13176029 437026 73293 -1,735606 -1,550183 -0,983129 -1,081322 -1,488407 -0,207051 -0,070269865 -0,059057439 0,031780539 -0,076429815 0,173976577 -0,177198324 -0,162405798 -0,110859522 -0,037022612 0,030510034 0,005857277 0,016 -0,184 -0,181 -0,011 0,050 -0,148 0,023 -0,029 0,042 0,045 -0,179 0,015 0,077 0,147 -0,145 0,010 0,079 -0,150 -0,281 -0,145 0,219 -0,036 -0,010 -0,044 -0,148 -0,018 -0,054 -0,070 -0,022 0,004 0,136 -0,048 -0,090 0,064 -0,009 -0,117 0,052 -0,144 -0,275 -0,161 -0,173 -0,010 0,153 0,016 0,037 -0,156 -0,191
13280104 553445 75732 0,468533 0,85854 0,530088 0,415316 0,493642 -0,023891 -0,037042149 -0,097650597 0,090938921 0,020957711 0,022796112 -0,008266259 -0,16841699 -0,131382576 -0,05701402 -0,086985819 0,097216356 -0,184 0,406 0,070 -0,022 0,070 0,314 -0,274 0,385 -0,103 -0,208 0,041 0,082 0,189 0,267 0,019 0,073 0,135 0,005 -0,075 0,057 0,011 0,245 -0,129 0,104 0,187 0,210 -0,186 -0,061 0,136 0,054 -0,048 -0,082 -0,055 0,045 0,087 0,262 -0,148 0,007 -0,136 -0,119 0,022 0,017 0,015 -0,340 0,112 0,022 0,187
13048660 334455 97827 -0,4332075 -0,4268095 -0,5583265 -0,6322795 -0,9201365 0,188312 -0,066951612 0,161990191 0,026308407 -0,036532137 -0,084814847 -0,193533585 -0,204369965 -0,406486719 -0,279886058 -0,004351111 -0,150364283 -0,299 -0,216 0,089 -0,246 -0,167 0,052 -0,321 -0,086 0,275 -0,158 0,089 -0,259 0,052 0,146 0,088 -0,047 -0,145 0,022 0,022 -0,295 0,242 0,083 -0,058 0,299 0,198 0,073 -0,029 -0,040 0,078 0,101 -0,293 0,153 -0,141 0,104 0,085 0,287 0,184 -0,109 -0,187 0,308 0,082 -0,086 0,097 0,266 0,252 -0,254 0,340
13176029 406635 105835 -1,735606 -1,550183 -0,983129 -1,081322 -1,488407 -0,207051 -0,122940173 0,125104756 -0,25706693 0,170941157 0,083961193 0,372616121 0,165512173 0,44876172 0,299608778 0,160841526 0,214886847 0,415 0,169 0,232 0,277 0,269 0,292 0,333 0,123 0,324 0,062 -0,143 -0,159 -0,084 -0,048 -0,089 0,305 0,267 -0,162 -0,111 -0,206 -0,113 0,160 -0,370 -0,277 -0,104 -0,191 0,002 -0,119 -0,216 -0,047 0,234 0,149 0,315 0,198 0,035 -0,011 0,071 0,141 0,145 0,027 -0,121 0,077 -0,065 0,062 -0,020 -0,083 0,002
13223058 100333566 232288 0,3188675 0,3381485 0,5973935 0,6809075 0,2986065 0,451721 -0,438945095 0,365219773 -0,123193366 0,359205296 -0,162286608 0,433364362 -0,083558715 -0,262970333 0,018402715 0,773399373 0,699980364 0,062 -0,153 0,376 0,433 -0,637 0,180 -0,846 0,532 0,102 -0,019 0,594 -0,041 -0,635 -0,424 -0,277 -0,922 -0,619 -0,812 -0,790 -0,264 -0,250 -0,256 0,038 -0,514 -1,119 0,488 -0,498 -0,272 -0,500 0,406 0,112 0,253 -0,378 -0,016 -0,351 0,122 -0,735 0,074 0,186 0,435 -0,069 -0,108 0,074 0,253 0,516 0,550 0,473
13071605 323365 100040970 0,249227 0,525937 0,471702 0,692404 0,333244 -0,1663795
13103533 30733 -1,1732018 -0,513069 -0,460112 -0,581411 -0,32109 -0,055904
13149335 100124621 -0,832527 -0,758598 -0,487658 -0,686713 -0,400825 -0,2117805
13108001 100136851 -0,286971 -0,410512 -0,484425 -0,503558 -0,455494 -0,1578735
13168252 100137108 1,152169 1,109029 0,480781 0,421349 1,184601 -0,0900815
13300520 100148409 0,462583 0,859696 0,918119 0,376967 0,625568 0,635497
13024318 100149324 -0,7624145 -0,3170415 -0,6865215 -0,2739085 -0,6383935 -0,2770055
13106669 100150294 -0,343677 -0,461186 -0,344101 -0,626498 -0,87161 -0,565908
12988489 100538165 0,549699 0,828137 0,623532 0,503771 0,534346 0,0921685
13287022 100004883 -0,356771 -0,433107 -0,511798 -0,391137 -0,504585 -0,5943025
13271005 100005575 -0,4704265 -0,8449595 -0,7157095 -0,4854985 -0,9459795 0,318522
13115203 797431 -0,78794 -0,700089 -0,433847 -0,248362 -0,690636 -0,400418
13031162 798527 0,535675 0,57285 0,615937 0,714429 0,857358 0,25629
13282574 326706 -0,5447785 -0,4771905 -0,6040745 -0,6536435 -0,2378195 -0,03969
13284122 326706 -0,5447785 -0,4771905 -0,6040745 -0,6536435 -0,2378195 -0,03969
13218627 790940 0,305683 0,476406 0,376756 0,400269 0,602545 0,435753
12976741 791213 -0,128711 -0,641837 -0,340338 -0,425044 -0,498207 -0,6748915
13043707 560526 -0,247932 -0,394274 -0,587718 -0,571003 -0,46077 -0,168377
13008652 555334 -0,301029 -0,758465 -0,867434 -1,36513 -1,363258 0,8606725
13049400 559427 0,526567 0,482467 0,324405 0,675258 0,324929 -0,053496
13092976 550371 0,379921 0,597878 0,422762 0,394646 0,537735 0,1737675
13181059 436801 0,568796 0,948333 0,461188 0,370841 0,244328 0,2117265
13261534 445222 -0,26093 -0,616846 -0,509804 -0,678381 -0,789329 -0,460568
13078348 336038 0,292775 0,627167 0,235366 0,498335 0,654735 -0,2044905
12971056 393511 -1,681193 -2,156234 -1,996144 -2,488381 -2,022008 0,4283755
13008742 403309 269295 -1,024995 -0,98147 -1,137205 -1,096485 -1,448919 -0,0996135
12947809 406356 0,834604 1,208438 0,844445 0,952509 0,726933 0,621199
13305278 415164 238880 0,599933 0,700872 0,549721 0,273886 0,465054 0,0395105
13222673 317679 56505 -0,4126645 -0,4162045 -0,3595775 -0,7144065 -0,3729105 -0,8789725
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Supplementary Table 6  Continued
TranscriptID CsA_13_M_1 CsA_14_M_1 CsA_15_M_1 CsA_16_H_1 CsA_17_H_1 CsA_18_H_1 CsA_19_H_1 CsA_20_H_1 CsA_21_C_4 CsA_22_C_4 CsA_23_C_4 CsA_24_C_4 CsA_25_C_4 CsA_26_L_4 CsA_27_L_4 CsA_28_L_4 CsA_29_L_4 CsA_30_L_4 CsA_31_M_4 CsA_32_M_4 CsA_33_M_4 CsA_34_M_4 CsA_36_H_4 CsA_37_H_4 CsA_38_H_4 CsA_39_H_4 CsA_40_H_4 CsA_41_C_11 CsA_42_C_11 CsA_43_C_11 CsA_44_C_11 CsA_45_C_11 CsA_46_L_11 CsA_47_L_11 CsA_48_L_11 CsA_49_L_11 CsA_50_L_11 CsA_51_M_11 CsA_52_M_11 CsA_53_M_11 CsA_54_M_11 CsA_55_M_11 CsA_56_H_11 CsA_57_H_11 CsA_58_H_11 CsA_59_H_11 CsA_60_H_11
13003871 -0,323863642 0,526362124 0,015000589 -0,104037329 -0,229771238 -0,102618564 -0,186216621 -0,067123135 -0,259025487 0,140559897 0,070359565 0,044977517 0,003128507 0,115907704 0,032494581 0,061528135 0,041198908 0,007969002 0,095547223 -0,026 0,116 -0,119 -0,002 0,181 0,127 0,091 -0,025 -0,196 -0,172 0,006 0,136 0,226 0,084 -0,205 -0,057 0,116 -0,181 -0,014 -0,075 0,299 0,068 -0,046 0,070 -0,011 0,124 0,137 -0,023
13110453 -0,107033825 -0,038495439 0,030327319 -0,209580832 0,088718592 -0,074896852 -0,216604483 0,184687038 -0,100953089 0,288516786 0,056769776 0,075451623 -0,319785099 -0,000888231 -0,07368912 -0,218607616 -0,147105088 -0,198139835 0,052732434 -0,159 0,102 0,033 0,052 0,031 0,079 -0,015 -0,119 0,134 -0,177 0,016 -0,136 0,163 0,026 0,165 -0,081 0,145 -0,180 0,184 -0,080 0,185 -0,017 0,285 -0,008 -0,077 0,309 -0,110 -0,083
13305252 0,142626991 0,316669067 -0,118102007 0,070168854 0,047535366 0,103871182 -0,098331859 -0,021268456 0,187303047 -0,116552809 -0,046073306 -0,006183433 -0,018493497 0,040428339 -0,0291998 -0,107911865 -0,201851379 0,067263159 -0,060414336 0,103 0,128 0,131 -0,004 -0,068 -0,171 -0,069 0,054 -0,028 0,122 -0,107 -0,028 0,041 -0,091 -0,084 0,007 0,099 -0,057 0,107 0,075 -0,107 0,095 -0,013 0,051 0,094 -0,032 0,168 0,068
13283206 0,077342187 -0,053470937 -0,046110266 -0,06244859 -0,025146649 0,083333108 -0,025709178 -0,022394159 -0,070567177 0,020879525 -0,072337078 0,108831473 0,013193257 0,075978556 0,126497524 0,223801539 0,075807937 0,069000229 0,060985954 0,046 0,033 -0,003 0,059 0,014 -0,095 0,032 0,015 -0,088 0,179 0,115 -0,096 -0,111 0,004 -0,096 -0,165 -0,225 -0,190 -0,174 -0,202 -0,243 -0,115 -0,121 -0,194 0,008 -0,134 0,207 -0,227
13284362 0,077342187 -0,053470937 -0,046110266 -0,06244859 -0,025146649 0,083333108 -0,025709178 -0,022394159 -0,070567177 0,020879525 -0,072337078 0,108831473 0,013193257 0,075978556 0,126497524 0,223801539 0,075807937 0,069000229 0,060985954 0,046 0,033 -0,003 0,059 0,014 -0,095 0,032 0,015 -0,088 0,179 0,115 -0,096 -0,111 0,004 -0,096 -0,165 -0,225 -0,190 -0,174 -0,202 -0,243 -0,115 -0,121 -0,194 0,008 -0,134 0,207 -0,227
13131516 -0,188862198 -0,030581978 0,072054858 -0,236273149 -0,252013248 0,416796937 0,11920216 -0,194530244 0,335861408 0,285072196 -0,206216252 -0,184880103 -0,229837247 0,387907119 -0,061928731 0,203194933 0,258721912 0,149652036 0,234266157 0,057 0,026 0,340 -0,233 0,072 -0,249 0,073 -0,008 0,074 -0,046 -0,238 0,039 0,172 -0,036 0,457 -0,039 -0,030 0,135 -0,130 0,215 -0,037 0,255 0,224 0,048 0,438 -0,276 0,001 -0,121
13113617 -0,014072525 -0,131290646 0,167184013 0,029472631 -0,102049995 0,278848273 -0,002872492 0,053422142 0,007713454 -0,117758816 0,156070539 0,134410673 -0,180435852 0,013501609 -0,065754487 0,138723727 -0,053151325 0,024495848 0,050912013 -0,168 -0,276 0,165 0,066 0,126 -0,065 0,096 -0,137 -0,046 0,319 0,156 -0,244 -0,186 -0,389 -0,024 -0,400 -0,374 -0,276 -0,189 -0,339 -0,152 -0,435 -0,207 -0,149 -0,138 -0,133 -0,427 -0,179
13079367 0,48556273 -0,437707368 -0,010434878 0,096267295 -0,038030543 0,128605865 0,125935761 -0,082382946 0,248140533 -0,18538293 0,106020065 -0,124985868 -0,043791798 0,288858676 -0,257966781 -0,205242964 0,168231691 0,106932473 0,17571276 -0,178 0,018 -0,035 -0,067 0,027 -0,356 -0,105 -0,122 -0,117 -0,031 0,231 -0,122 0,038 -0,202 -0,141 -0,025 0,127 0,090 -0,135 -0,148 -0,270 -0,055 -0,149 0,093 0,054 -0,098 0,066 -0,114
13152298 0,032912023 0,093579952 0,143556992 -0,05793123 -0,202791042 0,052042938 0,185629957 -0,025129314 -0,010809036 0,067098197 -0,129203284 0,232118187 -0,159204067 0,016127413 -0,111656439 0,140697944 0,131715134 0,207511624 0,020982083 0,016 -0,067 -0,170 -0,043 0,117 0,015 -0,227 -0,111 -0,056 0,068 0,064 -0,085 0,009 -0,024 -0,107 -0,068 -0,055 0,153 -0,082 0,121 0,109 -0,072 0,057 0,001 0,034 0,006 0,060 0,124
13283630 0,407651848 0,311319223 0,33315284 0,33075058 0,479525792 0,266617332 0,044925529 0,307683662 -0,215933356 -0,135166748 0,377043056 -0,096250929 0,07030798 -0,01231842 0,209888226 0,117513312 0,109493056 -0,122863179 -0,254033155 0,223 -0,007 -0,162 -0,035 0,179 0,078 0,120 0,082 -0,216 0,042 0,423 -0,025 -0,224 -0,041 -0,387 -0,211 -0,129 0,095 0,037 -0,282 0,017 0,029 -0,425 -0,251 -0,083 -0,050 0,163 -0,071
12964078 0,429086977 -0,019997421 -0,191601701 -0,114703071 0,038155647 0,208130638 -0,044616038 0,080469506 -0,004292579 -0,138304432 -0,006125399 0,124588369 0,02413404 -0,30145282 0,16070689 -0,079612904 0,138839589 -0,071257706 0,219754364 0,068 0,294 0,056 0,037 0,097 0,036 -0,026 0,018 -0,119 -0,013 0,140 -0,118 0,110 -0,126 -0,045 0,368 0,095 0,121 0,054 -0,249 0,069 -0,063 0,139 -0,002 0,348 -0,114 -0,045 0,087
13081404 0,168343788 0,306183332 0,049819735 -0,167045622 -0,31580185 -0,056325369 -0,264233147 0,058805928 -0,098819506 0,052269182 -0,031699334 0,037922119 0,040327541 0,054742113 -0,163031361 -0,096882919 0,06258302 -0,008548284 0,269882005 0,033 0,266 0,094 0,277 0,070 0,714 0,069 0,082 -0,228 -0,295 -0,222 0,595 0,152 0,281 -0,072 -0,129 0,197 -0,386 -0,469 -0,427 -0,060 -0,016 -0,100 -0,074 -0,055 -0,027 -0,172 -0,459
13094209 -0,035751769 0,026440913 0,22235434 0,172269171 0,334812057 -0,019548459 0,281492855 0,128941099 0,114306604 -0,094934777 -0,059416867 0,023961165 0,016083874 -0,196252386 -0,266725722 -0,250764066 0,027628026 -0,16410067 -0,000634955 -0,053 0,155 -0,227 0,140 0,086 -0,473 0,167 -0,232 0,077 -0,025 -0,275 -0,097 0,319 0,114 0,080 -0,132 0,191 0,243 -0,114 0,184 0,670 0,279 0,172 0,365 0,276 0,104 0,415 0,601
13054773 0,006974129 0,005554638 0,042656876 0,050818214 -0,025982668 0,042645128 -0,061330057 -0,012977652 0,013884526 0,00677338 0,006161768 -0,006105412 -0,02071426 0,00302414 0,007954276 -0,038975363 -0,051361038 -0,000299309 -0,021320968 -0,042 -0,099 0,057 -0,012 -0,001 0,063 0,075 0,001 0,037 -0,102 0,061 0,064 -0,059 0,038 0,051 0,033 -0,046 0,082 0,029 -0,002 0,011 0,009 0,003 0,050 0,018 0,002 -0,025 0,079
13065823 0,02068783 -0,136939626 0,092705592 0,116122889 0,13347806 -0,34774562 0,193796274 -0,347340234 0,282059233 -0,080314455 0,141294212 -0,275992301 -0,067046691 -0,14083432 0,316834778 0,014892083 0,358151586 -0,129370713 -0,056692238 0,380 -0,241 -0,080 -0,233 0,169 -0,359 -0,032 0,089 0,146 0,073 0,006 -0,162 -0,062 0,102 0,432 0,013 -0,077 0,288 -0,271 -0,208 0,057 -0,202 -0,047 -0,030 0,112 -0,137 0,268 0,098
13234461 0,036286478 -0,033087419 0,410379013 0,075873265 0,121641215 -0,373507567 0,045142871 -0,230372969 0,095105367 0,221821632 -0,040505624 -0,227878102 -0,048543275 0,120546602 0,155811992 -0,14202392 0,211541025 -0,072262205 -0,109665237 -0,050 -0,108 0,126 0,066 0,019 -0,025 -0,266 0,386 0,041 0,026 0,190 -0,103 -0,154 -0,175 0,404 0,052 -0,144 0,034 -0,206 -0,014 -0,246 -0,284 0,390 -0,126 0,153 -0,142 -0,098 0,205
12956364 0,145953588 -0,114851768 -0,123942338 0,046112465 0,050698908 -0,212324977 -0,08808741 0,165832643 -0,104894181 -0,092450201 0,126394313 0,047749303 0,023200767 0,058469066 0,132737914 0,098951563 -0,157892139 -0,049565894 0,029493864 -0,127 -0,186 -0,048 -0,114 -0,116 0,129 0,071 -0,161 0,118 -0,027 -0,000 -0,089 -0,001 0,145 0,025 -0,007 0,176 0,204 0,226 0,132 0,412 0,045 0,243 0,103 0,263 -0,044 -0,140 0,136
13034897 -0,075025826 -0,033747792 -0,126948721 0,058584279 -0,099741985 -0,141041123 0,002162557 -0,051435486 0,04019181 0,109016162 -0,048411583 -0,033978534 -0,066817858 -0,037301577 0,067692654 0,103543648 0,013219591 -0,068261954 -0,00093799 0,178 -0,030 -0,286 0,061 0,061 -0,101 -0,176 0,111 -0,130 -0,058 -0,214 0,097 0,306 -0,071 -0,139 0,015 -0,031 -0,004 -0,201 0,060 -0,195 -0,029 -0,201 -0,130 -0,250 -0,183 -0,018 -0,067
13278988 -0,208446538 -0,650832615 0,175277998 0,194972277 0,162187768 0,02134612 0,307888121 0,037843188 0,193240349 0,161768072 0,065661252 -0,117906636 -0,302763039 -0,28033847 0,013901734 0,068995397 -0,955898237 -0,089874837 0,086100927 -0,182 -0,423 -0,389 -0,237 0,234 -0,241 0,344 -0,104 -0,120 0,254 -0,034 0,003 -0,103 -0,073 -0,122 -0,591 -0,360 -0,286 -0,227 0,110 -0,072 -0,596 -0,073 0,291 -0,018 0,280 -0,385 0,223
13200912 -0,026143469 0,034238816 0,141909835 0,131248939 0,03163983 -0,067160295 -0,012729693 -0,007690818 -0,058242668 0,124298088 -0,045640767 0,073283155 -0,093697809 0,148239215 0,069931172 -0,000967437 0,093032956 0,061759404 0,177064838 -0,080 0,024 0,084 0,080 0,037 0,223 0,178 0,217 0,191 -0,148 -0,128 0,008 0,077 0,083 0,119 0,087 0,128 0,064 0,050 0,106 0,082 0,033 0,069 0,252 -0,016 -0,003 -0,012 0,248
13036819 0,121593197 0,524798672 -0,3428237 0,038518086 -0,148783111 -0,058259204 -0,057520507 0,136080165 -0,073674998 -0,017920884 -0,013773932 0,281213104 -0,175843289 0,021662228 0,129200515 0,321695337 -0,027533776 -0,018880563 -0,027722196 0,142 0,012 -0,172 0,382 0,160 0,359 -0,006 -0,139 -0,006 -0,038 -0,084 -0,087 0,214 0,055 -0,005 0,132 -0,049 -0,222 0,205 -0,017 -0,105 0,224 0,023 0,126 0,230 -0,297 0,117 -0,078
13166102 -0,220899698 0,045147719 -0,05889427 -0,268949776 0,016680365 -0,374360839 -0,208603577 0,284812763 0,135825225 -0,06699446 -0,054835983 0,018837913 -0,032832694 -0,06664196 -0,202985203 0,210920937 -0,101645535 -0,26104947 0,056371934 -0,005 0,075 -0,251 -0,103 -0,027 -0,127 -0,200 0,164 -0,285 0,137 -0,099 0,022 0,225 0,060 0,048 0,193 0,252 -0,173 -0,083 0,096 0,201 0,077 0,047 -0,050 -0,010 0,010 0,160 -0,093
13153157 0,240081483 -0,039358954 -0,136811042 0,09660335 0,20267645 0,287961464 0,762750957 -0,135564601 0,134845747 -0,055335799 0,125177904 -0,102725343 -0,10196251 -0,214907819 0,070580695 0,038796524 0,135288824 -0,178081316 0,109203403 -0,097 -0,240 -0,034 -0,329 -0,012 0,296 -0,158 -0,034 0,259 -0,051 0,099 -0,358 0,051 0,377 0,343 -0,114 -0,087 0,295 0,269 0,226 0,105 0,033 0,209 0,030 0,441 0,166 -0,036 0,112
12992494 0,454286049 -0,675978528 0,407842054 0,600943371 0,717864707 1,449031587 -0,360305328 1,072049761 -0,026072344 -0,386367935 1,106666492 0,395772242 -1,089998457 -1,311654643 -1,277239403 -1,234695909 -0,896499712 -1,486169245 -0,268310889 -0,702 -0,973 -1,057 0,105 0,198 -1,022 0,439 -1,497 -0,247 -0,287 -0,792 1,019 0,307 0,535 -0,074 -0,228 0,631 -0,004 -0,166 -0,042 1,279 0,352 -0,106 -0,692 -0,569 0,514 0,789 -0,040
13176029 -0,161956576 0,310877532 -0,097864751 -0,165780573 -0,074203301 -0,063095929 -0,101093545 -0,31526795 -0,091247033 -0,2387263 -0,02690479 0,025890917 0,330987209 0,010846297 0,025259468 -0,111952298 -0,055072259 -0,075452125 -0,170141219 -0,062 0,109 -0,143 -0,081 -0,078 -0,012 -0,048 0,017 -0,082 0,045 -0,226 0,163 0,100 -0,091 0,004 -0,028 0,007 -0,016 -0,072 0,062 -0,122 0,115 0,194 -0,150 -0,046 0,134 0,040 0,029
13223058 0,291014625 0,14021144 -0,145315389 -0,190171282 0,222667734 -0,001738821 0,208826792 0,016304533 -0,0727851 0,17189015 -0,041059467 -0,047866302 -0,010179281 0,174271305 0,296292851 -0,055720111 -0,211681461 0,053791928 -0,067439188 -0,046 0,111 -0,031 0,084 -0,301 -0,192 -0,051 -0,033 -0,066 0,100 -0,051 -0,039 0,057 0,054 0,031 0,041 0,210 -0,026 -0,028 0,083 0,027 -0,039 0,212 0,103 0,000 0,062 -0,106 -0,102
13048660 0,050869618 0,062289569 0,276819434 0,032100086 -0,02538487 -0,014041338 0,13401505 0,601136133 0,104050343 -0,154365943 0,170595473 -0,230438095 0,110158219 -0,054944777 0,273180713 -0,074480229 -0,049191951 0,089825271 0,01355031 -0,072 0,289 0,017 0,046 0,028 0,070 0,350 -0,056 0,165 0,129 -0,105 -0,015 -0,174 0,089 0,031 -0,293 0,180 -0,045 0,052 -0,285 0,150 0,137 0,040 -0,138 -0,225 0,129 0,206 0,026
13109885 0,048884234 -0,030552448 -0,014003841 0,149125164 -0,092380332 -0,050721609 -0,27827237 -0,072148909 -0,083924439 0,031504296 0,315749102 -0,038028987 -0,225299973 -0,083638266 -0,034237568 -0,248959002 -0,146173622 -0,106369462 -0,11080573 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 0,048884234 -0,030552448 -0,014003841 0,149125164 -0,092380332 -0,050721609 -0,27827237 -0,072148909 -0,083924439 0,031504296 0,315749102 -0,038028987 -0,225299973 -0,083638266 -0,034237568 -0,248959002 -0,146173622 -0,106369462 -0,11080573 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 0,048884234 -0,030552448 -0,014003841 0,149125164 -0,092380332 -0,050721609 -0,27827237 -0,072148909 -0,083924439 0,031504296 0,315749102 -0,038028987 -0,225299973 -0,083638266 -0,034237568 -0,248959002 -0,146173622 -0,106369462 -0,11080573 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 0,048884234 -0,030552448 -0,014003841 0,149125164 -0,092380332 -0,050721609 -0,27827237 -0,072148909 -0,083924439 0,031504296 0,315749102 -0,038028987 -0,225299973 -0,083638266 -0,034237568 -0,248959002 -0,146173622 -0,106369462 -0,11080573 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 0,048884234 -0,030552448 -0,014003841 0,149125164 -0,092380332 -0,050721609 -0,27827237 -0,072148909 -0,083924439 0,031504296 0,315749102 -0,038028987 -0,225299973 -0,083638266 -0,034237568 -0,248959002 -0,146173622 -0,106369462 -0,11080573 -0,264 -0,046 -0,173 0,090 -0,059 0,118 -0,129 0,002 -0,137 0,145 -0,005 0,135 -0,139 0,160 -0,116 -0,081 -0,181 -0,058 -0,190 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13176029 -0,119855864 0,064750946 0,013388939 -0,116002538 0,04615139 0,196365524 -0,239541303 -0,131214216 0,057822174 0,127783019 -0,191634342 0,039720812 -0,033691664 0,055200248 0,082602226 0,048651376 -0,081502004 0,205835139 0,320187516 -0,053 -0,023 0,252 0,157 0,025 -0,002 -0,202 0,071 -0,113 0,016 0,124 -0,043 0,015 0,215 0,070 0,083 0,098 -0,227 -0,098 -0,009 -0,184 -0,037 -0,074 0,204 -0,049 -0,090 0,060 0,099
13071605 0,051736133 0,126139831 0,01681698 -0,020334419 0,148465697 -0,222378895 0,315102244 -0,005973953 -0,007569677 0,151708126 -0,063507457 0,170532428 -0,251163419 -0,029807134 0,34944994 0,155251701 -0,164423009 -0,028362755 -0,21966638 -0,032 -0,286 0,151 0,076 0,030 0,422 0,119 0,264 0,044 0,088 -0,005 -0,026 -0,101 0,021 0,352 0,038 0,020 0,207 0,053 0,110 -0,161 -0,019 -0,228 0,159 0,008 -0,040 -0,202 -0,158
13223058 0,129577911 -0,54094595 -0,190476754 -0,019637508 -0,00642818 -0,050210444 -0,380545958 -0,116131438 -0,054051771 -0,091036204 0,041852742 0,105293489 -0,002058257 -0,198089908 -0,096995472 0,11570156 -0,477475896 0,024452403 -0,057049455 -0,111 -0,156 -0,266 -0,094 0,013 -0,201 -0,441 -0,200 -0,014 0,141 -0,022 0,053 -0,157 0,017 0,106 -0,080 -0,225 0,195 0,349 -0,105 0,189 0,072 -0,005 0,315 -0,425 -0,033 0,095 -0,066
13071605 0,63885925 0,336120314 -0,187470993 0,013133139 0,050511004 -0,154202246 -0,055685824 -0,112650331 -0,135387239 0,166315181 0,271259863 -0,315556743 0,013368941 -0,071027585 0,318307283 0,573909994 0,31006873 0,246719551 0,175692972 0,232 0,046 -0,092 0,186 -0,142 0,053 0,011 -0,005 -0,020 -0,009 0,219 -0,001 -0,188 -0,232 -0,024 0,022 -0,073 0,154 0,020 0,280 0,123 -0,002 -0,108 0,154 -0,013 0,201 0,234 0,137
13176029 0,016492653 -0,18400238 -0,180665354 -0,011149736 0,050486602 -0,147856858 0,023163545 -0,028750406 0,041788056 0,045073697 -0,179190559 0,015155237 0,077173569 0,146550673 -0,144541837 0,010036013 0,079350596 -0,150349219 -0,281217412 -0,145 0,219 -0,036 -0,010 -0,044 -0,148 -0,018 -0,054 -0,070 -0,022 0,004 0,136 -0,048 -0,090 0,064 -0,009 -0,117 0,052 -0,144 -0,275 -0,161 -0,173 -0,010 0,153 0,016 0,037 -0,156 -0,191
13280104 -0,183930012 0,405906223 0,070182708 -0,021585152 0,069606034 0,31420219 -0,273822991 0,384568079 -0,103272891 -0,20811643 0,04106473 0,081533711 0,188790883 0,267082679 0,019332399 0,072716481 0,134743218 0,004585991 -0,074977659 0,057 0,011 0,245 -0,129 0,104 0,187 0,210 -0,186 -0,061 0,136 0,054 -0,048 -0,082 -0,055 0,045 0,087 0,262 -0,148 0,007 -0,136 -0,119 0,022 0,017 0,015 -0,340 0,112 0,022 0,187
13048660 -0,299293111 -0,215555953 0,089230925 -0,246236939 -0,166819643 0,052435601 -0,321136215 -0,085697659 0,275085108 -0,15771552 0,089326568 -0,258777766 0,052081611 0,146219644 0,087593814 -0,047391309 -0,144525088 0,022238456 0,021606599 -0,295 0,242 0,083 -0,058 0,299 0,198 0,073 -0,029 -0,040 0,078 0,101 -0,293 0,153 -0,141 0,104 0,085 0,287 0,184 -0,109 -0,187 0,308 0,082 -0,086 0,097 0,266 0,252 -0,254 0,340
13176029 0,41478713 0,169185615 0,232128671 0,277092308 0,269339624 0,292432118 0,33318025 0,123229867 0,324490943 0,061825611 -0,143119119 -0,159256663 -0,083940771 -0,048400219 -0,088616151 0,305096607 0,266963592 -0,161685605 -0,110858223 -0,206 -0,113 0,160 -0,370 -0,277 -0,104 -0,191 0,002 -0,119 -0,216 -0,047 0,234 0,149 0,315 0,198 0,035 -0,011 0,071 0,141 0,145 0,027 -0,121 0,077 -0,065 0,062 -0,020 -0,083 0,002


















































Supplementary Table 6  Continued
TranscriptID CsA_32_M_4 CsA_33_M_4 CsA_34_M_4 CsA_36_H_4 CsA_37_H_4 CsA_38_H_4 CsA_39_H_4 CsA_40_H_4 CsA_41_C_11 CsA_42_C_11 CsA_43_C_11 CsA_44_C_11 CsA_45_C_11 CsA_46_L_11 CsA_47_L_11 CsA_48_L_11 CsA_49_L_11 CsA_50_L_11 CsA_51_M_11 CsA_52_M_11 CsA_53_M_11 CsA_54_M_11 CsA_55_M_11 CsA_56_H_11 CsA_57_H_11 CsA_58_H_11 CsA_59_H_11 CsA_60_H_11
13003871 -0,026404528 0,116486894 -0,118826566 -0,001817666 0,180969526 0,127307407 0,091080787 -0,024541714 -0,196238095 -0,171916787 0,006013587 0,135959703 0,226181589 0,08429258 -0,204727095 -0,056781053 0,115706078 -0,180750054 -0,013833163 -0,075 0,299 0,068 -0,046 0,070 -0,011 0,124 0,137 -0,023
13110453 -0,158792049 0,102198553 0,033156648 0,052468476 0,031065043 0,078629246 -0,014965477 -0,118667174 0,133704529 -0,176918126 0,015977597 -0,135727553 0,162963557 0,025699732 0,165081842 -0,081362443 0,145147551 -0,180158302 0,184148828 -0,080 0,185 -0,017 0,285 -0,008 -0,077 0,309 -0,110 -0,083
13305252 0,102596874 0,127608083 0,131429146 -0,003845694 -0,068366447 -0,170688416 -0,068529347 0,054154649 -0,027599294 0,121831635 -0,106603407 -0,028245373 0,040616437 -0,090939399 -0,083511744 0,007250303 0,098672061 -0,057286232 0,107278544 0,075 -0,107 0,095 -0,013 0,051 0,094 -0,032 0,168 0,068
13283206 0,046002552 0,032630419 -0,002835226 0,058991038 0,014118017 -0,095327476 0,032087208 0,015223503 -0,087667142 0,17941064 0,115419465 -0,095895372 -0,111267592 0,004331041 -0,095823163 -0,164665556 -0,22533882 -0,1901241 -0,173986755 -0,202 -0,243 -0,115 -0,121 -0,194 0,008 -0,134 0,207 -0,227
13284362 0,046002552 0,032630419 -0,002835226 0,058991038 0,014118017 -0,095327476 0,032087208 0,015223503 -0,087667142 0,17941064 0,115419465 -0,095895372 -0,111267592 0,004331041 -0,095823163 -0,164665556 -0,22533882 -0,1901241 -0,173986755 -0,202 -0,243 -0,115 -0,121 -0,194 0,008 -0,134 0,207 -0,227
13131516 0,057349901 0,026055727 0,340337162 -0,233344593 0,072448756 -0,24934645 0,072686592 -0,007774229 0,073734252 -0,046029285 -0,238425458 0,038818046 0,171902445 -0,036262325 0,456979387 -0,039180689 -0,029810058 0,134865024 -0,12976281 0,215 -0,037 0,255 0,224 0,048 0,438 -0,276 0,001 -0,121
13113617 -0,168180075 -0,276453765 0,164705073 0,065703454 0,126373029 -0,064800145 0,096283202 -0,137162764 -0,045557412 0,319382006 0,155958118 -0,243826093 -0,185956622 -0,38931658 -0,0241136 -0,399883809 -0,374382137 -0,276499216 -0,189249234 -0,339 -0,152 -0,435 -0,207 -0,149 -0,138 -0,133 -0,427 -0,179
13079367 -0,17825775 0,018317116 -0,035196349 -0,066948271 0,026610449 -0,356114061 -0,104588617 -0,122495101 -0,116553604 -0,030905621 0,230720364 -0,121604256 0,038343119 -0,202298025 -0,141341591 -0,024922404 0,126769896 0,089510226 -0,134559745 -0,148 -0,270 -0,055 -0,149 0,093 0,054 -0,098 0,066 -0,114
13152298 0,015899022 -0,067055744 -0,16998336 -0,042581182 0,116613965 0,014599778 -0,226966365 -0,110652778 -0,055751855 0,067833329 0,063755705 -0,085188017 0,009350837 -0,023605216 -0,106536675 -0,06766927 -0,054784939 0,152951842 -0,081961977 0,121 0,109 -0,072 0,057 0,001 0,034 0,006 0,060 0,124
13283630 0,222801752 -0,006851268 -0,16190839 -0,035302797 0,179071733 0,078443568 0,119857974 0,081688315 -0,216327948 0,041614413 0,42331032 -0,024576498 -0,224020287 -0,040547492 -0,386511113 -0,210604476 -0,128887778 0,095347265 0,036630106 -0,282 0,017 0,029 -0,425 -0,251 -0,083 -0,050 0,163 -0,071
12964078 0,067719157 0,29390908 0,055951843 0,037297698 0,096992981 0,03607856 -0,026305243 0,017664285 -0,118672427 -0,013400975 0,140021515 -0,117858014 0,1099099 -0,125571935 -0,045266219 0,367947355 0,095196703 0,120557586 0,053527565 -0,249 0,069 -0,063 0,139 -0,002 0,348 -0,114 -0,045 0,087
13081404 0,033278857 0,265669415 0,093836769 0,276993897 0,070096547 0,71408859 0,069291741 0,082367145 -0,228353248 -0,295488411 -0,222389699 0,594545708 0,151685648 0,28056961 -0,072295261 -0,128909926 0,197145525 -0,386320194 -0,469015286 -0,427 -0,060 -0,016 -0,100 -0,074 -0,055 -0,027 -0,172 -0,459
13094209 -0,052678673 0,154582687 -0,226691044 0,140313617 0,086033869 -0,473019571 0,166604576 -0,232174064 0,077257814 -0,024562234 -0,274531576 -0,096707424 0,318543422 0,113716054 0,080155991 -0,131722784 0,190967213 0,243131008 -0,114425264 0,184 0,670 0,279 0,172 0,365 0,276 0,104 0,415 0,601
13054773 -0,042365526 -0,098938296 0,056797073 -0,012349542 -0,001040796 0,062958969 0,074589681 0,001134165 0,036500241 -0,102058854 0,061006489 0,063613912 -0,059061791 0,037627052 0,051360577 0,032708501 -0,045640366 0,082029101 0,029037885 -0,002 0,011 0,009 0,003 0,050 0,018 0,002 -0,025 0,079
13065823 0,380121374 -0,240710774 -0,079992675 -0,233442799 0,169155018 -0,359441697 -0,032329972 0,089134647 0,146451921 0,072738654 0,005572366 -0,162345665 -0,062417276 0,102124374 0,432352214 0,01322797 -0,076666947 0,287771865 -0,270739553 -0,208 0,057 -0,202 -0,047 -0,030 0,112 -0,137 0,268 0,098
13234461 -0,050373515 -0,108434089 0,126213298 0,065789274 0,019496116 -0,024568421 -0,265770992 0,385872857 0,040690864 0,026348713 0,190068317 -0,103406066 -0,15370183 -0,175335234 0,403593886 0,05160287 -0,143603925 0,03405471 -0,206072921 -0,014 -0,246 -0,284 0,390 -0,126 0,153 -0,142 -0,098 0,205
12956364 -0,127438644 -0,185913971 -0,047655597 -0,113523439 -0,11626672 0,128755375 0,071209924 -0,160531922 0,118047877 -0,026834418 -0,0004115 -0,089421802 -0,001380159 0,144780342 0,025088812 -0,007205222 0,176361108 0,203747247 0,226203143 0,132 0,412 0,045 0,243 0,103 0,263 -0,044 -0,140 0,136
13034897 0,17812029 -0,030197347 -0,285798292 0,06079939 0,060550991 -0,100557464 -0,176296536 0,11061974 -0,130213104 -0,058357962 -0,214157052 0,096689074 0,306039048 -0,071347372 -0,138610029 0,015309216 -0,030827512 -0,004355496 -0,200573941 0,060 -0,195 -0,029 -0,201 -0,130 -0,250 -0,183 -0,018 -0,067
13278988 -0,182145737 -0,423339731 -0,388565546 -0,236565021 0,233682486 -0,240546615 0,344246799 -0,10377802 -0,119707472 0,254248418 -0,034229218 0,002692499 -0,103004228 -0,073178158 -0,121586727 -0,591392089 -0,360406341 -0,286327981 -0,226860662 0,110 -0,072 -0,596 -0,073 0,291 -0,018 0,280 -0,385 0,223
13200912 -0,080121432 0,023571883 0,083699973 0,0801958 0,037209985 0,222832379 0,178232894 0,216670816 0,190888802 -0,147763116 -0,128415288 0,008082966 0,077206637 0,082841891 0,118573332 0,087438082 0,127518743 0,063590907 0,049764916 0,106 0,082 0,033 0,069 0,252 -0,016 -0,003 -0,012 0,248
13036819 0,141678184 0,01189394 -0,171878428 0,382253753 0,160406078 0,359263918 -0,005596089 -0,139306858 -0,006023788 -0,037625129 -0,083878655 -0,086925826 0,214453395 0,055478376 -0,005050577 0,13205955 -0,048850546 -0,221662738 0,204846353 -0,017 -0,105 0,224 0,023 0,126 0,230 -0,297 0,117 -0,078
13166102 -0,005309819 0,075089073 -0,251299689 -0,103302602 -0,02687861 -0,126876852 -0,199583515 0,163530108 -0,285345317 0,13702432 -0,09853988 0,021888047 0,224972827 0,059707308 0,048357106 0,192648917 0,251501672 -0,173042112 -0,083109388 0,096 0,201 0,077 0,047 -0,050 -0,010 0,010 0,160 -0,093
13153157 -0,09657014 -0,240070077 -0,034179142 -0,328594934 -0,011808156 0,295677906 -0,157507801 -0,033908699 0,259179873 -0,050908664 0,09859807 -0,357649742 0,050780463 0,377285395 0,343280236 -0,11378546 -0,086557405 0,294657045 0,269191531 0,226 0,105 0,033 0,209 0,030 0,441 0,166 -0,036 0,112
12992494 -0,701528682 -0,973120976 -1,056641629 0,104612696 0,198206544 -1,021897956 0,438887316 -1,49650315 -0,247060428 -0,287171971 -0,792120117 1,019036287 0,307316227 0,534845058 -0,073952422 -0,227532766 0,6313639 -0,003848634 -0,166352639 -0,042 1,279 0,352 -0,106 -0,692 -0,569 0,514 0,789 -0,040
13176029 -0,062211548 0,10857295 -0,143221203 -0,081072946 -0,078384174 -0,012407539 -0,048466233 0,017308543 -0,082177119 0,044634017 -0,225513209 0,162868524 0,100187788 -0,090846302 0,004326008 -0,028129443 0,007412006 -0,016473933 -0,071538946 0,062 -0,122 0,115 0,194 -0,150 -0,046 0,134 0,040 0,029
13223058 -0,045831203 0,111216606 -0,031006067 0,084207399 -0,300600142 -0,191634319 -0,051105344 -0,032769466 -0,06629649 0,100023853 -0,051497197 -0,03915911 0,056928943 0,053684041 0,031253665 0,041295424 0,210233288 -0,025566863 -0,028017468 0,083 0,027 -0,039 0,212 0,103 0,000 0,062 -0,106 -0,102
13048660 -0,072244061 0,289157895 0,017005662 0,045794088 0,027919601 0,069742114 0,349849434 -0,056272547 0,16475214 0,129212597 -0,10501229 -0,015134155 -0,173818291 0,088718168 0,030767308 -0,293116238 0,18010504 -0,04498848 0,051869959 -0,285 0,150 0,137 0,040 -0,138 -0,225 0,129 0,206 0,026
13109885 -0,26441684 -0,045747756 -0,173364339 0,089626117 -0,059087659 0,118109591 -0,128643989 0,001534397 -0,136604689 0,145275777 -0,005037963 0,135073296 -0,138706423 0,160450212 -0,116109431 -0,080713174 -0,181347445 -0,058176102 -0,190187844 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 -0,26441684 -0,045747756 -0,173364339 0,089626117 -0,059087659 0,118109591 -0,128643989 0,001534397 -0,136604689 0,145275777 -0,005037963 0,135073296 -0,138706423 0,160450212 -0,116109431 -0,080713174 -0,181347445 -0,058176102 -0,190187844 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 -0,26441684 -0,045747756 -0,173364339 0,089626117 -0,059087659 0,118109591 -0,128643989 0,001534397 -0,136604689 0,145275777 -0,005037963 0,135073296 -0,138706423 0,160450212 -0,116109431 -0,080713174 -0,181347445 -0,058176102 -0,190187844 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 -0,26441684 -0,045747756 -0,173364339 0,089626117 -0,059087659 0,118109591 -0,128643989 0,001534397 -0,136604689 0,145275777 -0,005037963 0,135073296 -0,138706423 0,160450212 -0,116109431 -0,080713174 -0,181347445 -0,058176102 -0,190187844 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13109885 -0,26441684 -0,045747756 -0,173364339 0,089626117 -0,059087659 0,118109591 -0,128643989 0,001534397 -0,136604689 0,145275777 -0,005037963 0,135073296 -0,138706423 0,160450212 -0,116109431 -0,080713174 -0,181347445 -0,058176102 -0,190187844 0,241 -0,015 -0,228 -0,282 -0,006 -0,256 -0,068 -0,032 0,056
13176029 -0,053102614 -0,023200165 0,252376439 0,157029168 0,02510542 -0,00219677 -0,201792048 0,070791642 -0,11253845 0,016130622 0,124133341 -0,042934232 0,015208717 0,214713321 0,069796429 0,082588315 0,097732735 -0,226706221 -0,097910115 -0,009 -0,184 -0,037 -0,074 0,204 -0,049 -0,090 0,060 0,099
13071605 -0,032187002 -0,285674821 0,150666988 0,076049975 0,029502825 0,421834368 0,118678449 0,263662987 0,043768172 0,087921656 -0,004538336 -0,026036819 -0,101114671 0,020784773 0,351555342 0,037682186 0,020484792 0,206717191 0,052578794 0,110 -0,161 -0,019 -0,228 0,159 0,008 -0,040 -0,202 -0,158
13223058 -0,111333812 -0,15565984 -0,265939107 -0,093772099 0,013306646 -0,201069448 -0,441488835 -0,200180521 -0,0144764 0,140537696 -0,022187638 0,053335401 -0,157209058 0,016569905 0,106329876 -0,079524605 -0,225135393 0,194598348 0,349271576 -0,105 0,189 0,072 -0,005 0,315 -0,425 -0,033 0,095 -0,066
13071605 0,232187252 0,046126596 -0,091625229 0,185710116 -0,141644598 0,053398538 0,010724349 -0,004886819 -0,020295091 -0,009215232 0,218608642 -0,000813263 -0,188285055 -0,231719299 -0,024241068 0,021638254 -0,072674179 0,153887463 0,020212192 0,280 0,123 -0,002 -0,108 0,154 -0,013 0,201 0,234 0,137
13176029 -0,144611075 0,21945563 -0,035535793 -0,00997022 -0,043705011 -0,14830564 -0,017782068 -0,053550881 -0,069777921 -0,021926985 0,003988711 0,136184257 -0,048468064 -0,090414499 0,064232792 -0,009304366 -0,117139544 0,052094167 -0,144174329 -0,275 -0,161 -0,173 -0,010 0,153 0,016 0,037 -0,156 -0,191
13280104 0,056601308 0,010908943 0,244868856 -0,129161323 0,104386381 0,187068801 0,209601741 -0,186247286 -0,060566446 0,136376795 0,054288382 -0,047709178 -0,082389552 -0,055283736 0,044688565 0,0867571 0,26187294 -0,147575212 0,007157721 -0,136 -0,119 0,022 0,017 0,015 -0,340 0,112 0,022 0,187
13048660 -0,295086857 0,242406623 0,082928131 -0,057781992 0,298981521 0,197597295 0,072770675 -0,028565751 -0,039537805 0,07797692 0,10126477 -0,292568444 0,152864556 -0,140982556 0,103792304 0,085327663 0,286874419 0,184029719 -0,108906688 -0,187 0,308 0,082 -0,086 0,097 0,266 0,252 -0,254 0,340
13176029 -0,205805611 -0,113429181 0,160042928 -0,369977305 -0,276967523 -0,104003454 -0,191417033 0,002296908 -0,1194282 -0,216222148 -0,047030359 0,233968156 0,148712549 0,314553532 0,197868991 0,035075015 -0,010523755 0,071332112 0,141293374 0,145 0,027 -0,121 0,077 -0,065 0,062 -0,020 -0,083 0,002


















































Supplementary Table 6  Continued
TranscriptID CsA_52_M_11 CsA_53_M_11 CsA_54_M_11 CsA_55_M_11 CsA_56_H_11 CsA_57_H_11 CsA_58_H_11 CsA_59_H_11 CsA_60_H_11
13003871 -0,074707624 0,298938244 0,068123096 -0,046002185 0,069862869 -0,010529149 0,123975456 0,136567407 -0,023114481
13110453 -0,080257004 0,184769125 -0,017222083 0,284906472 -0,008431517 -0,076597459 0,309155868 -0,109646657 -0,082853614
13305252 0,074680898 -0,107339958 0,094745868 -0,013215905 0,050554041 0,093522847 -0,032053433 0,16788184 0,068100019
13283206 -0,202288127 -0,243269595 -0,114528757 -0,121083899 -0,193866062 0,008017726 -0,134171402 0,206817835 -0,227469808
13284362 -0,202288127 -0,243269595 -0,114528757 -0,121083899 -0,193866062 0,008017726 -0,134171402 0,206817835 -0,227469808
13131516 0,215276952 -0,03687153 0,254691477 0,223654823 0,047693624 0,438114144 -0,275506838 0,001396447 -0,120781575
13113617 -0,338881101 -0,151932784 -0,435170683 -0,207309508 -0,148588376 -0,137640482 -0,133365413 -0,427227602 -0,179107727
13079367 -0,148178338 -0,269688355 -0,054663504 -0,148600164 0,092843622 0,053651132 -0,098077772 0,066382433 -0,11400303
13152298 0,12121716 0,108838424 -0,072369059 0,056521208 0,000795583 0,034488417 0,006161628 0,059583445 0,123581914
13283630 -0,281646334 0,016510395 0,029197417 -0,425022886 -0,25134127 -0,083268536 -0,050393395 0,162785883 -0,071458284
12964078 -0,24865474 0,068993628 -0,063322042 0,139345025 -0,001717273 0,347869483 -0,114006487 -0,045147455 0,086725277
13081404 -0,427021251 -0,059661478 -0,016171919 -0,100243111 -0,074417811 -0,055280476 -0,027157123 -0,172157953 -0,458727495
13094209 0,183735132 0,670057597 0,278912685 0,172488548 0,364708035 0,27556414 0,103737776 0,41488399 0,601262778
13054773 -0,00218492 0,010912402 0,008633772 0,003273997 0,049554259 0,018300656 0,002136663 -0,024986346 0,078792221
13065823 -0,208072956 0,057474133 -0,201745277 -0,047152471 -0,030157169 0,112025644 -0,137058608 0,268465739 0,097912517
13234461 -0,013732711 -0,246133975 -0,284368845 0,389883207 -0,126197973 0,152923939 -0,142361295 -0,097877889 0,204764668
12956364 0,132137869 0,411682304 0,045418705 0,243196521 0,103332992 0,262572837 -0,044302921 -0,139618838 0,135905732
13034897 0,060292482 -0,194851145 -0,028568071 -0,201363142 -0,129867951 -0,250297752 -0,183258635 -0,018331685 -0,067463014
13278988 0,109536999 -0,071992818 -0,595612299 -0,07323793 0,291349876 -0,018384468 0,280391815 -0,385036273 0,222896101
13200912 0,106111263 0,082057115 0,03276839 0,069323444 0,251688921 -0,016154977 -0,003403895 -0,01171703 0,247952629
13036819 -0,017264215 -0,105105372 0,224466239 0,023407991 0,126246882 0,229712037 -0,297223529 0,117176524 -0,077574509
13166102 0,096298223 0,201015565 0,076611096 0,046581551 -0,050077553 -0,009743276 0,010025897 0,160434342 -0,093118782
13153157 0,226431509 0,105148347 0,032864867 0,208784622 0,030455452 0,441041787 0,165805346 -0,036160615 0,111955439
12992494 -0,042156187 1,278868491 0,352167591 -0,106255293 -0,69226633 -0,569258119 0,513600642 0,788561608 -0,039918754
13176029 0,061763761 -0,12194529 0,114912514 0,194334802 -0,150180135 -0,045575681 0,134089103 0,040477256 0,02937827
13223058 0,082521301 0,027299388 -0,038779836 0,21157349 0,103366927 0,000151444 0,062293265 -0,106164404 -0,102347451
13048660 -0,284946136 0,150347976 0,136863129 0,04025026 -0,138082512 -0,225004278 0,129014975 0,206323606 0,026148458
13109885 0,240639074 -0,015470393 -0,228389667 -0,281850041 -0,005920744 -0,255644023 -0,06831785 -0,031977846 0,056001112
13109885 0,240639074 -0,015470393 -0,228389667 -0,281850041 -0,005920744 -0,255644023 -0,06831785 -0,031977846 0,056001112
13109885 0,240639074 -0,015470393 -0,228389667 -0,281850041 -0,005920744 -0,255644023 -0,06831785 -0,031977846 0,056001112
13109885 0,240639074 -0,015470393 -0,228389667 -0,281850041 -0,005920744 -0,255644023 -0,06831785 -0,031977846 0,056001112
13109885 0,240639074 -0,015470393 -0,228389667 -0,281850041 -0,005920744 -0,255644023 -0,06831785 -0,031977846 0,056001112
13176029 -0,009208352 -0,183597674 -0,036766057 -0,07439171 0,203738932 -0,048741313 -0,089928478 0,060415297 0,098578603
13071605 0,109732242 -0,161357794 -0,018647982 -0,227635571 0,159195741 0,008441771 -0,040478457 -0,202456247 -0,157701933
13223058 -0,105066533 0,189462493 0,07178124 -0,005042542 0,3150719 -0,425352099 -0,032571559 0,094558127 -0,06594176
13071605 0,27990231 0,122985782 -0,002341485 -0,108415633 0,154424966 -0,012676048 0,200988397 0,23415637 0,137306971
13176029 -0,275362615 -0,161023776 -0,172563607 -0,01021497 0,152550382 0,016223889 0,037388863 -0,156103507 -0,190861665
13280104 -0,135573018 -0,119081927 0,021548562 0,016620672 0,014762821 -0,339988153 0,111570214 0,021924792 0,187301387
13048660 -0,186903014 0,307530638 0,082113791 -0,086269068 0,096567963 0,265786011 0,251635217 -0,253508341 0,340138797
13176029 0,144724478 0,0272187 -0,121182032 0,077273182 -0,064557663 0,062209319 -0,019752371 -0,082798844 0,002013832










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 1  Dosing and time points in the models included in the comparison








Rat in vivo  
single dose
(RIVS)







primary hepatocytes  
(HPH)
Time 48 hours 1, 2, 4, 11 days 24, 48 hours 3, 6, 9, 24 hours 4, 8, 15, 29 days 2, 8, 24 hours 2, 8, 24 hours
Dose unit μM mg/kg μM mg/kg mg/kg μM μM
Compound
Amiodarone (AMD) doses 1.1 - 3.3 - 10 6.7 - 20 - 60 1 - 25 200 - 600 - 2000 20 - 60 - 200 0.28 – 1.4 - 7 0.28 – 1.4 - 7
Accession # GSE55618 GSE48126 E-MTAB-799 E-MTAB-800 E-MTAB-797 E-MTAB-798
Acetaminophen 
(APAP)
dose L-M-H 73.3 - 220 - 660 168.8 - 225 - 300 1000 - 10000 300 - 600 - 1000 300 - 600 - 1000 1000 - 3000 - 10000 200 - 1000 - 5000
 Accession # GSE55618 GSE51969 E-MTAB-799 E-MTAB-800 E-MTAB-797 E-MTAB-798
 
Cyclosporine A (CsA) dose L-M-H 1 - 3 - 6 3 - 8.9 - 26.7 10 - 50 30 - 100 - 300 10 - 30 - 100 0.24 - 1.2 - 6 0.24 - 1.2 - 6 
 Accession # GSE55618 GSE31540 E-MTAB-799 E-MTAB-800 E-MTAB-797 E-MTAB-798
Original publication Driessen et al., 2013; 
Driessen et al., 2014
Kienhuis et al., 2013; 
Vitins et al., 2014
Van Summeren  
et al., 2013
Noriyuki et al., 2012;  
Uehara et al., 2010
Noriyuki et al., 2012;  
Uehara et al., 2010
Noriyuki et al., 2012;  
Uehara et al., 2010
Noriyuki et al., 2012;  
Uehara et al., 2010
L-M-H, Low – Mid – High dose, respectively. 
There is no accession number for MPH while it is a in-house dataset
234




















Entrez_ID Gene_symbol Compound Condition
2 A2M AMD in_vivo
968 CD68 AMD in_vivo
1581 CYP7A1 AMD in_vivo
1582 CYP8B1 AMD in_vivo
1717 DHCR7 AMD in_vivo
1728 NQO1 AMD in_vivo
1891 ECH1 AMD in_vivo
1990 CELA1 AMD in_vivo
3171 FOXA3 AMD in_vivo
3484 IGFBP1 AMD in_vivo
4199 ME1 AMD in_vivo
6307 MSMO1 AMD in_vivo
9415 FADS2 AMD in_vivo
25987 TSKU AMD in_vivo
51316 PLAC8 AMD in_vivo
51703 ACSL5 AMD in_vivo
54677 CROT AMD in_vivo
54884 RETSAT AMD in_vivo
56898 BDH2 AMD in_vivo
57035 C1orf63 AMD in_vivo
84263 HSDL2 AMD in_vivo
220441 RNF152 AMD in_vivo
1962 EHHADH/ECHD AMD In_vitro
4239 MFAP4 AMD In_vitro
5649 RELN AMD In_vitro
9963 SLC23A1 AMD In_vitro
57715 SEMA4G AMD In_vitro
1581 CYP7A1 APAP in_vivo
1582 CYP8B1 APAP in_vivo
1647 GADD45A APAP in_vivo
1675 CFD APAP in_vivo
2643 GCH1 APAP in_vivo
2645 GCK APAP in_vivo
3303 HSPA1A APAP in_vivo
4323 MMP14 APAP in_vivo
4958 OMD APAP in_vivo
9099 USP2 APAP in_vivo
10110 SGK2 APAP in_vivo
51084 CRYL1 APAP in_vivo
Supplementary Table 2  Continued
Entrez_ID Gene_symbol Compound Condition
54884 RETSAT APAP in_vivo
55269 PSPC1 APAP in_vivo
2152 F3 APAP In_vitro
2289 FKBP5 APAP In_vitro
3303 HSPA1A APAP In_vitro
4320 MMP11 APAP In_vitro
4547 MTTP APAP In_vitro
5009 OTC APAP In_vitro
11069 RAPGEF4 APAP In_vitro
54463 FAM134B APAP In_vitro
55055 ZWILCH APAP In_vitro
64240 ABCG5 APAP In_vitro
123920 CMTM3 APAP In_vitro
1582 CYP8B1 CsA in_vivo
1595 CYP51A1 CsA in_vivo
1728 NQO1 CsA in_vivo
3484 IGFBP1 CsA in_vivo
4597 MVD CsA in_vivo
4837 NNMT CsA in_vivo
5313 PKLR CsA in_vivo
8835 SOCS2 CsA in_vivo
9601 PDIA4 CsA in_vivo
10110 SGK2 CsA in_vivo
10912 GADD45G CsA in_vivo
23423 TMED3 CsA in_vivo
25819 CCRN4L CsA in_vivo
26118 WSB1 CsA in_vivo
57546 PDP2 CsA in_vivo
57761 TRIB3 CsA in_vivo
64240 ABCG5 CsA in_vivo
83595 SOX7 CsA in_vivo
219972 MPEG1 CsA in_vivo
1039 CDR2 CsA In_vitro
1543 CYP1A1 CsA In_vitro
11069 RAPGEF4 CsA In_vitro
57761 TRIB3 CsA In_vitro
64240 ABCG5 CsA In_vitro
236




















RIVS AMD Pathways p<0.05
# Maps pValue
1 Regulation of metabolism_Bile acids regulation of glucose and lipid metabolism 
via FXR
8,189E-10
2 Cell cycle_Role of SCF complex in cell cycle regulation 1,182E-06
3 Development_Thromboxane A2 pathway signaling 2,707E-06
4 Development_Endothelin-1/EDNRA signaling 6,131E-06
5 Development_WNT signaling pathway. Part 2 6,131E-06
6 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 7,920E-06
7 Development_Role of IL-8 in angiogenesis 8,390E-06
8 Cell adhesion_Chemokines and adhesion 9,286E-06
9 Immune response_MIF-induced cell adhesion, migration and angiogenesis 1,053E-05
10 Immune response_MIF - the neuroendocrine-macrophage connector 1,053E-05
11 Transcription_ChREBP regulation pathway 1,117E-05
12 Development_Leptin signaling via PI3K-dependent pathway 1,291E-05
13 Regulation of lipid metabolism_Regulation of lipid metabolism via LXR, NF-Y and SREBP 1,397E-05
14 Reproduction_Progesterone-mediated oocyte maturation 2,183E-05
15 Development_Gastrin in cell growth and proliferation 2,959E-05
16 Immune response_IL-12-induced IFN-gamma production 6,935E-05
17 Immune response_IL-18 signaling 1,182E-04
18 Development_A3 receptor signaling 1,193E-04
19 Immune response_IL-6 signaling pathway 1,787E-04
20 G-protein signaling_Proinsulin C-peptide signaling 1,921E-04
21 Cytoskeleton remodeling_Cytoskeleton remodeling 2,034E-04
22 Regulation of lipid metabolism_Insulin regulation of fatty acid methabolism 2,082E-04
23 Putative pathways for stimulation of fat cell differentiation by Bisphenol A 2,209E-04
24 Cell cycle_Role of APC in cell cycle regulation 2,209E-04
25 Development_BMP signaling 2,709E-04
26 Cell cycle_ESR1 regulation of G1/S transition 2,709E-04
27 PGE2 pathways in cancer 2,987E-04
28 Immune response_IL-1 signaling pathway 3,070E-04
29 Development_Thrombopoietin-regulated cell processes 3,605E-04
30 G-protein signaling_Rap2A regulation pathway 4,172E-04
31 Development_Prolactin receptor signaling 4,500E-04
32 Regulation of CFTR activity (normal and CF) 4,500E-04
33 Cytoskeleton remodeling_Keratin filaments 4,773E-04
34 Development_EGFR signaling pathway 4,898E-04
35 Transport_Alpha-2 adrenergic receptor regulation of ion channels 4,905E-04
36 Development_WNT5A signaling 4,905E-04
37 wtCFTR and deltaF508 traffic / Membrane expression (normal and CF) 6,735E-04
38 Development_GM-CSF signaling 7,543E-04
39 Translation_Non-genomic (rapid) action of Androgen Receptor 9,288E-04
40 Development_G-CSF-induced myeloid differentiation 1,041E-03
41 Immune response_HMGB1 release from the cell 1,082E-03
42 Immune response_HMGB1/RAGE signaling pathway 1,122E-03
43 ENaC regulation in normal and CF airways 1,122E-03
44 Cytoskeleton remodeling_Reverse signaling by ephrin B 1,248E-03
Supplementary Table 3  Continued
RIVS AMD Pathways p<0.05
# Maps pValue
45 Transport_ACM3 in salivary glands 1,255E-03
46 Immune response_CCL2 signaling 1,272E-03
47 Development_VEGF signaling and activation 1,448E-03
48 Development_Transcription regulation of granulocyte development 1,485E-03
49 DNA damage_ATM/ATR regulation of G1/S checkpoint 1,485E-03
50 Immune response_MIF-mediated glucocorticoid regulation 1,505E-03
51 Development_S1P1 signaling pathway 1,664E-03
52 G-protein signaling_Regulation of CDC42 activity 1,755E-03
53 Normal and pathological TGF-beta-mediated regulation of cell proliferation 1,755E-03
54 Ca(2+)-dependent NF-AT signaling in cardiac hypertrophy 1,820E-03
55 Immune response_IL-33 signaling pathway 1,820E-03
56 Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins 1,844E-03
57 Immune response_IL-12 signaling pathway 1,861E-03
58 Apoptosis and survival_Beta-2 adrenergic receptor anti-apoptotic action 1,861E-03
59 Transcription_Androgen Receptor nuclear signaling 1,904E-03
60 Immune response_PGE2 signaling in immune response 1,904E-03
61 Signal transduction_Erk Interactions: Inhibition of Erk 2,060E-03
62 Neurophysiological process_ACM regulation of nerve impulse 2,170E-03
63 Reproduction_GnRH signaling 2,200E-03
64 Development_Growth hormone signaling via STATs and PLC/IP3 2,404E-03
65 Development_Beta-adrenergic receptors regulation of ERK 2,464E-03
66 Development_HGF signaling pathway 2,464E-03
67 Cytoskeleton remodeling_Neurofilaments 2,751E-03
68 Transcription_Transcription regulation of aminoacid metabolism 2,751E-03
69 Immune response_Histamine H1 receptor signaling in immune response 2,788E-03
70 Immune response_TLR5, TLR7, TLR8 and TLR9 signaling pathways 2,788E-03
71 G-protein signaling_G-Protein alpha-s signaling cascades 2,789E-03
72 Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 signaling 2,789E-03
73 Development_Alpha-2 adrenergic receptor activation of ERK 3,131E-03
74 Immune response_IL-2 activation and signaling pathway 3,143E-03
75 G-protein signaling_RhoB regulation pathway 3,146E-03
76 Development_Cross-talk between VEGF and Angiopoietin 1 signaling pathways 3,296E-03
77 DNA damage_ATM / ATR regulation of G2 / M checkpoint 3,296E-03
78 Cell cycle_Regulation of G1/S transition (part 2) 3,296E-03
79 Transcription_PPAR Pathway 3,465E-03
80 Apoptosis and survival_HTR1A signaling 3,532E-03
81 Immune response_Histamine signaling in dendritic cells 3,532E-03
82 Immune response_C5a signaling 3,532E-03
83 Signal transduction_cAMP signaling 3,697E-03
84 Transcription_Role of AP-1 in regulation of cellular metabolism 3,697E-03
85 Signal transduction_PKA signaling 3,957E-03
86 Some pathways of EMT in cancer cells 3,957E-03
87 Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 1 activity in 
lipogenic tissue
3,986E-03
88 Immune response_CD40 signaling 4,214E-03
238



















Supplementary Table 3  Continued
RIVS AMD Pathways p<0.05
# Maps pValue
89 Muscle contraction_Regulation of eNOS activity in endothelial cells 4,214E-03
90 Development_PACAP signaling in neural cells 4,224E-03
91 Development_FGF-family signaling 4,419E-03
92 Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation 4,806E-03
93 Apoptosis and survival_Role of PKR in stress-induced apoptosis 4,921E-03
94 Development_A1 receptor signaling 4,921E-03
95 Immune response_Oncostatin M signaling via JAK-Stat in mouse cells 4,965E-03
96 CFTR-dependent regulation of ion channels in CF 5,444E-03
97 Immune response_HSP60 and HSP70/ TLR signaling pathway 5,464E-03
98 Immune response_Fc epsilon RI pathway 6,051E-03
99 Regulation of lipid metabolism_PPAR regulation of lipid metabolism 6,143E-03
100 Apoptosis and survival_Lymphotoxin-beta receptor signaling 6,143E-03
101 Development_VEGF signaling via VEGFR2 - generic cascades 6,257E-03
102 Cell adhesion_Gap junctions 6,263E-03
103 Regulation of lipid metabolism_Insulin regulation of glycogen metabolism 6,685E-03
104 Chemotaxis_CCL2-induced chemotaxis 6,685E-03
105 Immune response_CD28 signaling 6,685E-03
106 Muscle contraction_Regulation of eNOS activity in cardiomyocytes 6,685E-03
107 Nicotine signaling in dopaminergic neurons, Pt. 2 - axon terminal 6,904E-03
108 Signal transduction_AKT signaling 6,904E-03
109 Apoptosis and survival_TNFR1 signaling pathway 6,904E-03
110 Development_A2A receptor signaling 6,904E-03
111 cAMP/ Ca(2+)-dependent Insulin secretion 6,904E-03
112 Apoptosis and survival_Role of IAP-proteins in apoptosis 7,227E-03
113 Immune response_ETV3 affect on CSF1-promoted macrophage differentiation 7,227E-03
114 Immune response_Role of PKR in stress-induced antiviral cell response 7,366E-03
115 Immune response_Oncostatin M signaling via JAK-Stat in human cells 7,380E-03
116 Impaired Lipoxin A4 signaling in CF 7,731E-03
117 Immune response_IL-5 signalling 7,731E-03
118 Cell cycle_Role of Nek in cell cycle regulation 8,291E-03
119 Neurophysiological process_Glutamate regulation of Dopamine D1A receptor signaling 8,628E-03
120 Development_Ligand-independent activation of ESR1 and ESR2 8,628E-03
121 Role of alpha-6/beta-4 integrins in carcinoma progression 8,628E-03
122 Signal transduction_Calcium signaling 8,628E-03
123 Cell cycle_Cell cycle (generic schema) 8,833E-03
124 Cell cycle_Chromosome condensation in prometaphase 8,833E-03
125 Cytoskeleton remodeling_Thyroliberin in cytoskeleton remodeling 9,458E-03
126 LRRK2 in neurons in Parkinson’s disease 9,458E-03
127 Cell cycle_Spindle assembly and chromosome separation 9,458E-03
128 Development_G-Proteins mediated regulation MAPK-ERK signaling 9,596E-03
129 Immune response_NF-AT signaling and leukocyte interactions 9,596E-03
130 Immune response_IL-17 signaling pathways 9,717E-03
131 Glycine, serine, cysteine and threonine metabolism 1,023E-02
132 Transcription_CREM signaling in testis 1,046E-02
133 Development_Thrombopoetin signaling via JAK-STAT pathway 1,046E-02
Supplementary Table 3  Continued
RIVS AMD Pathways p<0.05
# Maps pValue
134 Cell cycle_Role of 14-3-3 proteins in cell cycle regulation 1,046E-02
135 Regulation of lipid metabolism_Insulin signaling:generic cascades 1,064E-02
136 Development_TGF-beta-dependent induction of EMT via MAPK 1,064E-02
137 Development_PDGF signaling via MAPK cascades 1,064E-02
138 Chemotaxis_CCR4-induced chemotaxis of immune cells 1,073E-02
139 Mechanism of action of CCR4 antagonists in asthma and atopic dermatitis (Variant 1) 1,073E-02
140 CCR4-dependent immune cell chemotaxis in asthma and atopic dermatitis 1,073E-02
141 Oxidative stress_Role of ASK1 under oxidative stress 1,073E-02
142 Immune response_IL-22 signaling pathway 1,073E-02
143 Development_Role of CDK5 in neuronal development 1,073E-02
144 Glycine, serine, cysteine and threonine metabolism/ Rodent version 1,147E-02
145 Development_EPO-induced Jak-STAT pathway 1,212E-02
146 Cell adhesion_Plasmin signaling 1,212E-02
147 Transport_Macropinocytosis regulation by growth factors 1,258E-02
148 Development_Melanocyte development and pigmentation 1,296E-02
149 Transcription_CREB pathway 1,296E-02
150 Immune response_IL-9 signaling pathway 1,363E-02
151 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 1,365E-02
152 Development_A2B receptor: action via G-protein alpha s 1,425E-02
153 Proteolysis_Role of Parkin in the Ubiquitin-Proteasomal Pathway 1,427E-02
154 Development_Glucocorticoid receptor signaling 1,427E-02
155 Immune response_MIF-JAB1 signaling 1,427E-02
156 Immune response_IL-27 signaling pathway 1,427E-02
157 Mechanism of action of DGAT1 inhibitors in obesity and diabetes mellitus, type II 
(Variant 1)
1,427E-02
158 Triacylglycerol biosynthesis in obesity and diabetes mellitus, type II 1,427E-02
159 G-protein signaling_G-Protein alpha-12 signaling pathway 1,525E-02
160 Development_Delta-type opioid receptor mediated cardioprotection 1,525E-02
161 Development_Leptin signaling via JAK/STAT and MAPK cascades 1,647E-02
162 Cell cycle_Initiation of mitosis 1,647E-02
163 Cytoskeleton remodeling_ACM3 and ACM4 in keratinocyte migration 1,700E-02
164 Immune response_Human NKG2D signaling 1,700E-02
165 Development_Gastrin in differentiation of the gastric mucosa 1,700E-02
166 Development_IGF-1 receptor signaling 1,708E-02
167 Immune response_PGE2 common pathways 1,708E-02
168 Cell adhesion_ECM remodeling 1,708E-02
169 Muscle contraction_GPCRs in the regulation of smooth muscle tone 1,773E-02
170 Neurophysiological process_Dopamine D2 receptor transactivation of PDGFR in CNS 1,886E-02
171 Transcription_Receptor-mediated HIF regulation 1,888E-02
172 Cell adhesion_PLAU signaling 1,888E-02
173 Transcription_P53 signaling pathway 1,888E-02
174 G-protein signaling_Regulation of p38 and JNK signaling mediated by G-proteins 1,888E-02
175 Mucin expression in CF airways 2,002E-02
176 Membrane-bound ESR1: interaction with G-proteins signaling 2,028E-02
177 Immune response _IFN gamma signaling pathway 2,028E-02
240



















The full supplementary table can be requested by sending an email to marja.driessen@embl.de
Supplementary Table 3  Continued
RIVS AMD Pathways p<0.05
# Maps pValue
178 Immune response_BCR pathway 2,028E-02
179 Development_Neurotrophin family signaling 2,089E-02
180 G-protein signaling_G-Protein alpha-i signaling cascades 2,146E-02
181 Development_GH-RH signaling 2,304E-02
182 Development_VEGF-family signaling 2,304E-02
183 Airway smooth muscle contraction in asthma 2,387E-02
184 Immune response_Murine NKG2D signaling 2,532E-02
185 Development_Growth hormone signaling via PI3K/AKT and MAPK cascades 2,532E-02
186 Immune response_TLR2 and TLR4 signaling pathways 2,581E-02
187 Cytoskeleton remodeling_FAK signaling 2,581E-02
188 Apoptosis and survival_p53-dependent apoptosis 2,729E-02
189 Development_Angiotensin signaling via PYK2 2,775E-02
190 Regulation of metabolism_Role of Adiponectin in regulation of metabolism 2,775E-02
191 Immune response_HTR2A-induced activation of cPLA2 2,775E-02
192 Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 1 activity in 
keratinocytes
2,858E-02
193 Transcription_Transcription factor Tubby signaling pathways 2,858E-02
194 G-protein signaling_Rap2B regulation pathway 2,943E-02
195 Immune response_PGE2 in immune and neuroendocrine system interactions 3,031E-02
196 Neurophysiological process_Kappa-type opioid receptor in transmission of nerve 
impulses
3,052E-02
197 DNA damage_Brca1 as a transcription regulator 3,052E-02
198 Regulation of lipid metabolism_RXR-dependent regulation of lipid metabolism via 
PPAR, RAR and VDR
3,052E-02
199 Development_Osteopontin signaling in osteoclasts 3,052E-02
200 Development_Adiponectin signaling 3,302E-02
201 Cytoskeleton remodeling_Fibronectin-binding integrins in cell motility 3,398E-02
202 Development_Inhibition of angiogenesis by PEDF 3,398E-02
203 Immune response_IL-3 activation and signaling pathway 3,398E-02
204 Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of 
bile acids concentration
3,398E-02
205 Regulation of lipid metabolism_G-alpha(q) regulation of lipid metabolism 3,461E-02
206 Transcription_Role of VDR in regulation of genes involved in osteoporosis 3,461E-02
207 Development_GDNF family signaling 3,588E-02
208 Development_Angiotensin activation of Akt 3,588E-02
209 Muscle contraction_Oxytocin signaling in uterus and mammary gland 3,708E-02
210 Development_PDGF signaling via STATs and NF-kB 3,764E-02
211 Development_Angiotensin signaling via STATs 3,764E-02
212 Cell cycle_Start of DNA replication in early S phase 3,764E-02
213 Development_Alpha-1 adrenergic receptors signaling via cAMP 3,841E-02
214 Development_WNT signaling pathway. Part 1. Degradation of beta-catenin in the 
absence WNT signaling
3,841E-02
215 Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 2 activity in 
muscle
3,841E-02
Supplementary Table 3  Continued
RIVS AMD Pathways p<0.05
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216 Regulation of lipid metabolism_Regulation of fatty acid synthase activity in hepa-
tocytes
3,841E-02
217 Development_PIP3 signaling in cardiac myocytes 3,888E-02
218 Development_EGFR signaling via small GTPases 4,153E-02
219 Muscle contraction_Role of kappa-type opioid receptor in heart 4,153E-02
220 Muscle contraction_Relaxin signaling pathway 4,204E-02
221 Immune response_IL-15 signaling 4,236E-02
222 Immune response_Bacterial infections in normal airways 4,534E-02
223 Cell adhesion_Alpha-4 integrins in cell migration and adhesion 4,564E-02
224 Development_S1P1 receptor signaling via beta-arrestin 4,564E-02
225 Apoptosis and survival_Role of CDK5 in neuronal death and survival 4,564E-02
226 Immune response_CXCR4 signaling via second messenger 4,564E-02
227 Hypoxia-induced EMT in cancer and fibrosis 4,785E-02
228 Neurophysiological process_Corticoliberin signaling via CRHR1 4,880E-02
229 Development_TGF-beta receptor signaling 4,880E-02
230 Development_Angiopoietin - Tie2 signaling 4,996E-02
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Overlapping pathways between MPH and ZFE AMD
Blood coagulation_Blood coagulation
Protein folding and maturation_Angiotensin system maturation \ Human version
Cell adhesion_ECM remodeling
Regulation of metabolism_Bile acids regulation of glucose and lipid metabolism via FXR
Protein folding and maturation_Angiotensin system maturation \ Rodent version
Fructose metabolism
Phenylalanine metabolism/ Rodent version
Glycolysis and gluconeogenesis p. 1
Phenylalanine metabolism
Role of ZNF202 in regulation of expression of genes involved in atherosclerosis
Immune response_Alternative complement pathway
Fructose metabolism/ Rodent version
Tyrosine metabolism p.2 (melanin)
Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of bile acids 
concentration
Regulation of lipid metabolism_PPAR regulation of lipid metabolism
Glycolysis and gluconeogenesis (short map)
Propionate metabolism p.2
Histamine metabolism
Overlapping pathways between MPH and ZFE CsA
Blood coagulation_Blood coagulation
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling
Development_TGF-beta-dependent induction of EMT via SMADs
Immune response_Alternative complement pathway
Cell adhesion_ECM remodeling
Cell adhesion_Plasmin signaling




Regulation of lipid metabolism_PPAR regulation of lipid metabolism
Fructose metabolism/ Rodent version
Glycolysis and gluconeogenesis p. 1
Development_Growth hormone signaling via STATs and PLC/IP3
Glycolysis and gluconeogenesis (short map)
Regulation of lipid metabolism_Regulation of fatty acid synthesis: NLTP and EHHADH
Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of bile acids 
concentration
Regulation of lipid metabolism_Insulin regulation of glycogen metabolism
(L)-Alanine, (L)-cysteine, and (L)-methionine metabolism
(L)-Alanine, (L)-cysteine, and (L)-methionine metabolism / Human version

